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Asthma is increasingly recognised to be a heterogeneous 
disease with outcomes mediated by psychosocial and 
behavioural factors as well as by pathophysiological 
mechanisms. Inhaled corticosteroids (ICS) have long been the 
mainstay of treatment for asthma and poor ICS adherence has 
been shown to be associated with adverse outcomes. Despite 
this, poor ICS adherence has remained a persistent challenge 
for clinicians and patients with difficulties in both its 
measurement and management. 
In recent times, electronic monitoring has emerged as a gold 
standard for adherence measurement and a possible 
interventional tool for poor adherence. This thesis aimed to 
assess trial evidence for the use of electronic monitoring devices 
(EMDs) in asthma and assess whether there was adequate 
justification for their widespread clinical uptake.  
Methods 
Two literature reviews were conducted. The first was a 
systematic review and meta-analysis of the use of EMDs to 
measure adherence in adult asthma studies. The second was a 
review of the use of EMDs as interventional tools in both adults 
and children.  
A randomised controlled pilot study of adherence was 
conducted to investigate the effect of EMD-based feedback in a 
real-world study design. As part of this, testing data for based 
on previously published validation protocols were also 
presented. 
Finally, a series of semi-structured interviews were conducted 
to explore the experiences and perspectives of EMD users. 
Results 
The first literature review estimated population adherence to be 
64% of prescribed ICS doses. The second review demonstrated 
that EMD-based interventions were effective at improving 
adherence but that evidence of improvement in clinical 
outcomes was not consistent. 
Across all devices tested in the pilot study, 94% of actuation, 
installation and removal events were correctly detected pre-
study. Despite this, 12% of devices failed pre-study testing.  Of 
devices issued to study participants, a further 12% were found 
to have failed post-study.  
The pilot study of adherence found that the intervention group 
actuated 11% more of their prescribed ICS doses than the 
control group (p=0.319). An unexpected increase in 
exacerbations in the intervention group suggested that the 
relationship between adherence and outcomes may be more 
complex than previously thought. Across the whole study, 
greater frequency of short-acting beta-agonist (SABA) use was 
associated with poorer asthma control (p=0.003), lower 
asthma-related quality of life (p=0.001), lower percentage 
predicted forced expiratory volume in one second (FEV1, 
p=0.019) and an increased proportion of individuals suffering 
an exacerbation over the study period (p=0.038). 
Finally, in a qualitative study, participants described their desire 
to feel in control of their asthma. EMDs were generally 
acceptable and some reported impact on their awareness and 
behaviours. For others, there were frustrations around 
perceived technical faults and concerns about data reliability. 
Future desirability centred on the potential impact of EMDs in 
helping users take control of their asthma, including through 
integrating with other wearable technology and enhancing self-
monitoring. 
Conclusion 
Whilst inhaler monitoring technology holds significant promise 
in both identifying individuals with asthma who may benefit 
from targeted adherence intervention and as part of targeted 
adherence interventions, there remains concern with regards to 
their real-world reliability and inadequate evidence of their 
clinical benefit. This thesis puts forward considerations in both 
study and intervention design with the aim of building a better 
evidence base for their adoption into real-world use. 
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Chapter 1: Introduction 
1.1. Asthma: characterisation and management 
1.1.1. Epidemiology of asthma 
The Global Initiative for Asthma (GINA) guidelines state that 
asthma is, “a heterogeneous disease, usually characterized by 
chronic airway inflammation… defined by the history of 
respiratory symptoms such as wheeze, shortness of breath, 
chest tightness and cough that vary over time and in intensity, 
together with variable expiratory airflow limitation (1).” Like 
many attempts, this definition relies heavily on the clinical 
features of asthma. Other definitions lay greater emphasis on 
the underlying pathophysiology features of reversible airflow 
obstruction, airway hyper-responsiveness and airway 
inflammation (2). Crucially, however, there are discrepancies 
between clinical and pathophysiological features (3, 4). There 
is also an absence of a universal biomarker (5). Thus, whilst 
definitions such as the one above are commonly quoted, they 
are also agreed to be insufficient for determining diagnosis and 
management (2, 5-8). 
A recent study estimated the global prevalence of asthma at 
358.2 million people, a 12.6% increase between 1990 and 2015 
(9). Asthma UK have previously estimated that around 5.4 
million people are being treated for asthma in the United 
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Kingdom (1.1 million children and 4.3 million adults) (10). The 
Department of Health’s 2011 estimate was that treating asthma 
costs the NHS around £1 billion, not accounting for wider 
societal costs such as lost productivity. It also estimated that 
around 1000 people die from their asthma in the UK every year 
(11). In 2014, the National Review of Asthma Deaths (NRAD) 
published by the Royal College of Physicians found that asthma 
resulted in 65 000 hospital admissions between 2011 and 2012. 
It found 900 deaths met the inclusion criteria for asthma as the 
underlying cause and concluded that 65% of the 195 deaths 
eventually reviewed had “factors that could have avoided the 
death related to patients, their families and the environment…” 
One of these factors was poor adherence to asthma treatment 
(12).  
1.1.2. Characterising asthma 
The way asthma is understood is changing (13). A 2018 Lancet 
Commission argues that it is no longer adequate to describe the 
clinical syndrome without attempting to characterise the 
underlying mechanisms at play. The authors join others in 
advocating a move away from offering all patients with a 
diagnosis of asthma a common treatment pathway (5, 14, 15). 
In place of these models, they advocate an “era of asthma 
management, which accounts for the increasingly recognised 
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heterogeneity of asthma and offers precision management and 
targeted treatment on the basis of careful assessment of the 
characteristics of a patient’s disease.” (5)  
The concept of asthma as being more than a single entity is not 
new. Asthma was previously subdivided into “extrinsic asthma” 
(associated with an early age of onset and atopic features) and 
“intrinsic asthma” (older age of onset and an absence of allergic 
features) (16). This paradigm is now considered to be an 
oversimplification, however condensing the various known 
pathways into formal subgroups remains challenging (8).  
Unbiased techniques (such as cluster analysis and 
transcriptomics) are providing clues to phenotypes (“observable 
characteristics… [resulting] from interaction between… genes 
and the environment” (17)) that fit with emerging molecular 
pathways (18-20). However, these data also suggest that a 
significant proportion of individuals experience disease that is 
not easily explained. Haldar et al., for example demonstrated 
that some individuals with a high symptom burden experienced 
few exacerbations and had low inflammatory markers. In 
contrast, other individuals had a low symptom burden but 
frequent exacerbations and marked eosinophilia (3).  
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As acceptance of asthma’s biological complexity has grown, so, 
in turn, has the recognition that it interacts heavily with the 
individuals’ comorbidities, psychosocial status, behaviours and 
environment (5). The movement of treatment models towards 
personalisation is therefore not exclusive to molecular 
mechanisms (14, 15, 21). A ‘treatable traits’ model proposes 
that whilst atopy, for example, may be a key driver for disease 
in one person, smoking may be a key driver for disease in 
another and comorbid depression a key driver for poor control 
in yet another. As a result, there is a developing interest in 
characterising these disease-external factors in addition to 
characterising the disease itself. A recent post-hoc analysis of 
the Unbiased BIOmarkers in PREDiction of respiratory disease 
outcomes (U-BIOPRED) cohort (421 severe asthma, 88 
mild/moderate asthma) demonstrated the applicability of the 
treatable traits model both for biological phenotypes (such as 
atopy, fixed airflow obstruction and reversibility) and, 
importantly, for adherence (22). 
Guidelines from the British Thoracic Society and Scottish 
Intercollegiate Network (BTS/SIGN), GINA and the European 
Respiratory and American Thoracic Societies (ERS/ATS) are 
moving to reflect this new paradigm (1, 6, 21). They 
acknowledge that ‘non-disease’ factors impact the success of 
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pharmacological approaches. They further recommend the 
systematic targeting of these factors, particularly where there 
is apparent resistance to usual care. 
Summarily, as our understanding of asthma’s underlying 
pathophysiology evolves to account for its heterogeneity and 
complexity, an approach to asthma as a purely biological 
process appears increasingly obsolete. The centrality of 
searching for both prevention and cure, of greater aetiological 
understanding and of drug development is without debate. 
However, additional engagement with behavioural and 
psychosocial factors will prove important if progress in asthma 
outcomes is to be seen (5, 15, 23). 
1.1.3. Concepts in asthma diagnosis and management 
For a significant period of time, the diagnosis of asthma has 
been based on the presence of persistent symptoms and the 
ability to demonstrate reversible airflow obstruction (6). In the 
United Kingdom’s (UK) primary care system, a pragmatic 
approach is often taken, involving trials of treatment and 
observed response (6, 7). The response may either be 
subjective or objective with peak flow diaries and/or spirometry 
(6). However it is well recognised that this is a broad brush, 
with the NRAD in the UK noting that 10% of the 276 cases which 
were eventually reviewed for possible inclusion by the enquiry 
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were deemed unlikely to have ever had true asthma (12) and 
another study that a third of patients in primary care with an 
asthma diagnosis had no evidence of any physiological airway 
abnormality (reversibility or hyper-responsiveness) (4). 
Consequently, a system of supportive diagnostic features has 
developed where evidence of airway inflammation (sputum 
eosinophilia, serum eosinophilia and fractional exhaled nitric 
oxide [FENO]), airway hyper-responsiveness (e.g. methacholine 
challenge testing) or atopy (IgE levels, skin prick testing) may 
be included to fortify the case for diagnosis (6, 7).  
Whatever the journey to diagnosis, the treatment pathway has 
remained the same. Individuals are commenced on low-dose 
inhaled corticosteroids (ICS) and treatment is titrated in a step-
wise fashion with increasing doses or addition of adjuvant 
therapies depending on either response to treatment or new 
evidence of loss of control (6, 24). Traditionally, continuous oral 
corticosteroid therapy was used in severe disease which 
remained uncontrolled despite optimisation of other therapies. 
This came with a heavy side effect profile, particularly of 
metabolic disorders such as steroid-induced hyperglycaemia 
and osteoporosis (25). In recent years, however, the 
developing understanding of asthma’s varying underlying 
molecular mechanisms has begun to give rise to molecular-
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targeted therapies (5, 26), some of which had initially been 
discounted as ineffective because of the lack of targeting in 
early trials (27).  
Recent developments notwithstanding, ICS remains the 
mainstay of therapy in asthma (6) with a well-described role in 
controlling airway inflammation (28) and improving outcomes 
in asthma (29). National and international reports credit the fall 
in asthma mortality in the 1990s/2000s to the increased uptake 
in ICS (5, 9). It is therefore unsurprising that ICS underuse has 
been linked with poor outcomes in asthma, including increased 
risk of exacerbation, hospitalisation and mortality (12, 30-33). 
The wealth of evidence has led to clarified definitions of 
uncontrolled asthma which emphasise the importance of 
adherence assessment in this group of patients (21). The term 
‘difficult asthma’ is now preferred for asthma that remains 
uncontrolled despite apparently optimal standard therapy. This 
permits differentiation between inadequate medications 
adherence, for example, from truly refractory asthma. 
Furthermore, as clinical practice takes steps into the era of 
personalised medicine driven by the availability of high-cost, 
molecular-targeted therapies, both guideline groups and 
commissioners acknowledge that adherence management must 
play a greater role in the management of asthma (1, 6, 21, 34). 
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1.2. Concepts in adherence 
1.2.1. Defining adherence 
The World Health Organization’s (WHO) 2003 report defines 
adherence as, “the extent to which a person’s behaviour… 
corresponds with agreed recommendations from a health care 
provider” (35). Although the onus for directing behaviour is laid 
with the health professional, the report argues that there is an 
expectation of patient agreement. Adherence is thus 
differentiated from ‘compliance’, which implies unquestioning 
conformity.  
Adherence (or non-adherence) may be measured in several 
ways, dependent on its stage. Initiation (or primary non-
adherence) refers to whether the prescribed drug was ever 
commenced. Implementation (or secondary non-adherence) 
refers to whether the drug was taken as prescribed. Persistence 
(or tertiary non-adherence) refers to whether the drug was 
taken for the duration prescribed or prematurely stopped (35, 
36). The generally accepted metric of implementation 
adherence across contemporary studies is the amount of drug 
presumed taken as a proportion of the dose prescribed (37), 
often presented as a percentage.  
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In some adherence studies, adherence (including 
implementation adherence) is described in binary terms, i.e. 
adherence vs. non-adherence. This belies the fact that 
adherence is a continuum. Whilst some patients may take all or 
none of their medication as prescribed, most are more likely to 
take varying proportions of their prescribed doses (38). Steiner 
et al. argue that even the representation of adherence as a 
continuum is an oversimplification. Adherence behaviours, 
rather than being constant, may be interrupted in a calculated 
manner (a therapeutic break for example, where a patient takes 
no medication for a defined period of time but takes it as 
prescribed outside of this window), in a regular but unintended 
manner (e.g. shift patterns influencing when doses are missed) 
or accidentally, such that the pattern of use is as informative as 
the percentage of use (39, 40).  
Recommended levels of ‘good’ adherence tend to derive from 
the outcome sought, whether symptom control, disease control, 
reduction of future risk, or reduction of population risk. These 
parameters themselves depend both on the disease and the 
dose-response curve of the drug in question. In the case of 
human immunodeficiency virus (HIV), for example, studies 
suggest that a 95% adherence rate is required to achieve viral 
load suppression (35). In the case of hypertension, the 
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adherence level required for adequate disease control is likely 
to be lower (41).  
1.2.2. The problem of medications non-adherence 
In Decorum, the writer, thought to be Hippocrates, cautions, 
“Keep a watch also on the faults of the patients, which often 
make them lie about the taking of things prescribed. For 
through not taking disagreeable drinks, purgative or other, they 
sometimes die. What they have done never results in a 
confession, but the blame is thrown upon the physician” (37, 
42). Some 2500 years later, the dilemma of how to persuade 
the patient into better health persists (37). Estimates of non-
adherence range from 20-50% across chronic diseases (35, 37, 
43-45). These estimates are drawn from papers going back as 
far as the 1970s. A Cochrane review on ICS adherence by 
Normansell, Kew and Stovold suggested that, in studies 
examining education as an intervention, adherence rates in 
control participants were 46.7% when measured objectively 
and 57.1% when subjective measures were included (46). 
Despite decades of adherence intervention research, the rates 
of non-adherence to medications are not changing.  
Across chronic diseases overall, the evidence consistently 
suggests that poor adherence results in poorer outcomes for 
the patient and increased costs for healthcare systems (35, 38, 
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45). One review author quoted in a WHO report stated that, 
“Increasing the effectiveness of adherence interventions may 
have a far greater impact on the health of the population than 
any improvement in specific medical treatments” (35). In the 
United States, the cost of poor adherence to medication is 
thought to be approximately $100 billion per year (38). This 
may well be a conservative estimate (45). The risk remains that 
patients frequently come to harm, not because of a lack of 
scientific breakthrough, but because of a lack of uptake of 
existing interventions. The resultant hypothesis – that 
improving adherence will result in improved outcomes – is the 
basis of adherence research (37).  
1.2.3. The relationship between adherence and outcomes 
Of course, the relationship between adherence and outcomes is 
not straightforward. It is modified by the drug regimens 
involved, the way adherence is measured and the underlying 
disease (45). Furthermore, the fact a patient’s beliefs are 
contrary to their physician’s does not necessarily mean that 
they are wrong. One group of authors use the example of 
hypertension, where an estimated 19-43% achieve control 
despite reduced adherence, suggesting that treatment had 
been prescribed at a higher dose than required (39). Adherence 
will consequently only be a barrier to good outcomes where: 
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1. Prescribed treatment is appropriate to the outcome 
sought. For example, it has been speculated that, in a 
subset of individuals with a diagnosis of asthma but no 
evidence of steroid responsiveness, ICS may be ineffective 
(5, 8). Were this argument to be taken to its logical 
conclusion, ICS non-compliance in these individuals would 
not lead to worsened outcomes.  
2. Treatment is prescribed at the dose required to deliver 
the outcome sought. It has been proposed that many 
patients with asthma are over-treated with higher doses of 
inhaled corticosteroids than required for their level of 
pathology (47). Beasley’s group have previously shown that 
most of the effect of inhaled corticosteroid is likely to be 
achieved at 200 micrograms of fluticasone per day (roughly 
equivalent to 400 micrograms of beclometasone 
diproprionate [BDP]) (48). Beyond 500 micrograms of 
fluticasone (1000 micrograms of BDP), there is unlikely to 
be any additional benefit (49). Thus, poor adherence to 
overdosing regimes may not necessarily lead to worsened 
outcomes. 
3. Outcomes are influenced by factors other than the 
target disease. The role of comorbidities in asthma, 
particularly in severe disease, is well-recognised. Conditions 
such as bronchiectasis, inducible laryngeal obstruction or 
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gastro-oesophageal reflux may mimic asthma symptoms 
(15, 21). In these circumstances, increased adherence to 
higher doses of ICS will not contribute to better outcomes 
until the relevant comorbidity has been addressed. 
These factors impact the observed effectiveness of adherence 
interventions such that a difference in adherence may not 
necessarily equate to a difference in outcomes (45). 
Consequently, it may be more accurate to surmise that only 
where the appropriate drug is prescribed for the appropriate 
condition in the appropriate patient at the required dose will 
poor adherence be a true barrier to good outcomes. 
1.2.4. Overview of medications adherence in asthma 
Rates of inadequate ICS adherence in asthma are difficult to 
measure. Using a variety of means over the years, adherence 
has been quoted as ranging from as little as 22% to as high as 
63%, largely dependent on study design and context (50).  
Although electronic monitoring is increasingly seen as the gold 
standard (6), this is a more recent development (38, 51).  
In addition to difficulty measuring adherence, demonstrating 
the effect of poor adherence on clinical outcomes is complicated 
by challenges specific to the diagnosis and management of 
asthma. These challenges are the absence of a gold-standard 
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diagnostic test (6), difficulties in targeting certain treatments 
due to an incomplete understanding of underlying 
pathophysiological mechanisms and difficulties titrating 
treatment in the absence of biomarkers that correlate directly 
and consistently in a dose-responsive manner (48, 49). These 
challenges distinguish asthma from chronic conditions such as 
HIV and diabetes where there are clear diagnostic criteria and 
biomarkers which correlate directly with treatment response 
and outcomes (CD4 counts, capillary glucose, HbA1c).  
Williams et al. estimate (in an analysis of a cohort of 298 
predominantly African American participants) that 24.4% of 
exacerbations (oral steroids, emergency department [ED] visits 
and hospitalisations) may have been prevented by good ICS 
adherence. They further report that an estimated adherence 
level from their cohort of 75% was required to reduce the risk 
of exacerbations in uncontrolled (Asthma Control Test™ 
[ACT™] ≤19) asthma (32). Thus, whatever the challenges in 
diagnosis and treatment, there can be little doubt that 
encouraging higher levels of adherence in patients with asthma 
is central to improving outcomes (52). 
1.2.5. Barriers to adherence 
There has been a shift in recent times towards encouraging 
collaborative approaches for identifying and overcoming 
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barriers to adherence (39, 53). As a starting-point to 
understanding these barriers, a framework of intentional and 
unintentional non-adherence has been proposed (43). They are 
defined as follows: 
Intentional non-adherence: the patient decides not to take 
the medication or to take it in a way that differs from the 
recommendations… 
Unintentional non-adherence: the patient is prevented from 
implementing their intention to take the medication, as 
prescribed, by factors beyond their control… (53) 
Horne argues that the absence of conceptually differentiating 
between these distinct categories is part of the reason 
adherence interventions have had limited success to date (43, 
53). He instead advocates an approach which acknowledges 
that causes for poor adherence are complex and varied, an 
interaction between a person’s subconscious beliefs, outside 
factors and conscious decisions (43).  
An example framework for identifying intentional barriers would 
be the “necessity-concerns framework”. According to this 
framework, individuals are thought to balance their beliefs 
about their personal need for ICS against concerns they may 
have such as perceptions of modern medicine, steroids or side 
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effects (53, 54). This particular framework finds support in 
adherence literature, with concerns around ICS safety, side 
effects and tolerance in particular consistently appearing across 
multiple studies (54-62). However also important are 
individuals’ understandings of asthma as a chronic disease, of 
ICS and their person-level efficacy, readiness/motivation to 
take ICS, the influence of important others and trust in their 
physician (54-58, 60-62). An intervention that aims to modify 
beliefs on a larger scale requires such beliefs to be elicited and 
then targeted appropriately in a standardised manner (43, 62).  
Unintentional non-adherence can be divided into patient-related 
factors, prescribing factors and system-related factors. With 
regards to patient factors, non-modifiable risk factors such as 
age, sex, socioeconomic factors and race-ethnicity have a 
contentious position in the literature (43). Beyond adolescence, 
increasing age appears to be consistently associated with better 
adherence across diseases (35, 62, 63). Associations between 
adherence and sex are less clear. Some studies show an 
association between female sex and poor adherence (63, 64). 
A large meta-analysis, however, shows an association between 
female sex and better adherence (45). Yet other studies 
suggest that young males are more likely to be lost to follow-
up (62, 64).  
Page | 17  
 
The relationship between race-ethnicity is similarly unclear, 
having been shown to be mediated by personal beliefs and 
factors such as access to commercial health insurance, which 
are modifiable (56, 60, 62). Several authors therefore conclude 
that non-modifiable risk factors are unlikely to play a primary 
role in poor adherence and, where they do, this is likely to be 
mediated by risk factors (such as beliefs and socioeconomic 
factors) which are modifiable (43, 53, 62). 
Forgetfulness is a commonly-cited modifiable adherence barrier 
(38). In children, an ordered family routine has been shown to 
be associated with both good inhaler refill and electronically 
monitored adherence as well as with well-controlled asthma 
(65, 66). Foster et al. (2012) found a positive association 
between routines (“I have a fixed daily routine for taking my 
asthma medications”/”I keep it somewhere where I will 
remember to take it”) and electronically monitored adherence 
(54). More recently, real-time reminder technology has been 
shown to improve adherence to ICS (67-71). 
Somewhat unique to airways diseases is the role of technique 
in medication adherence. A recent meta-analysis of 144 studies 
estimated an overall prevalence of good technique in 31% of 
the population, acceptable technique in 41% of the population 
and poor technique in 31% of the population (72).  New 
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research is demonstrating that inhaler technique may 
independently modify outcomes in asthma (73, 74), making 
such a high prevalence of poor technique problematic. 
Modification of inhaler technique is further challenging as the 
literature would suggest healthcare professionals’ own 
understanding of inhaler technique is poor (75, 76). In addition 
to this, patients report that the time most healthcare providers 
are able to spend with them is often limited and infrequent (77), 
reducing the amount of time available to teach and reinforce 
technique.  
Other modifiable patient factors include poor recall or 
comprehension of consultations where the drug and drug 
regimen have been explained and other additional advice given 
(53, 78, 79). There is a possibility this may be related to poor 
health literacy (37). Effective communication from the clinician 
and reiteration of what has been discussed, potentially through 
multiple media, are central to modifying these barriers (37, 39). 
Finally, there is a probable role for comorbidities, in particular 
depression (12, 43, 45, 56).  
Several authors highlight the contribution of complex 
medication regimes to poor adherence (52, 78). Foster et al. 
reported that patients who forgot their evening doses had lower 
levels of adherence (54). Higher levels of device satisfaction, in 
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one study particularly related to physical characteristics, have 
also been associated with increased adherence (and improved 
outcomes) in asthma (80-82).  
In systems where there is a lack of universal healthcare 
coverage, patients with lower income may find their 
socioeconomic status to be a barrier to adherence (37, 62, 83).  
Systems may also present barriers to communication such as 
inadequate appointment time for addressing adherence and 
lack of continuity of care (35, 37).  
Overall, it is increasingly felt that silver-bullet solutions are 
unlikely to address the multifaceted nature of poor adherence. 
Comprehensive solutions addressing modifiable patient factors 
(including beliefs), disease/drug-specific factors and system 
factors are currently recommended to improve medications 
adherence and outcomes (35, 37). Some authors go even 
further, calling for a personalised approach to these factors (40, 
53). Evidence for the effectiveness of complex behavioural 
interventions over more simple interventions in asthma, 
however, remains weak (46). 
Research  tools which may assist with a more holistic approach 
to barriers in medication use include the Beliefs about Medicines 
Questionnaire (BMQ), which is based on a necessity-concerns 
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framework (84) and the Adherence Starts with Knowledge 
questionnaires (ASK-20 and ASK-12), which incorporates 
questions to draw out factors such as beliefs, affect, motivation 
and health literacy (85, 86). The Hospital Anxiety Depression 
Scale (HADS) is a well-accepted measure of symptoms of mood 
disorders (87) which are known to influence not only adherence 
but outcomes in asthma (12, 56, 88). Other tools include the 
Medication Adherence Report Scale for Asthma (MARS-A) and 
Morisky Medication Adherence Scale (MMAS), which specifically 
look for indicators of non-adherence, although are less 
concerned with the reasons for this (89, 90).    
1.2.6. Medication adherence: overuse 
Sometimes forgotten in the conversation around adherence is 
the overuse of both ICS and bronchodilators. This is more 
frequently seen in bronchodilator overuse, probably because 
patients gain comparatively rapid onset symptomatic relief 
(91).  However, bronchodilator overuse is an important risk 
factor for morbidity and mortality in asthma (92-94), most 
likely due to its role as a marker of poor asthma control (92, 
95, 96) and of poor ICS adherence (97). This is recognised by 
asthma guidelines, leading to guidelines no longer 
recommending separate prescription of long-acting beta 
agonist (LABA) and ICS and more recently removing the use of 
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a short-acting beta agonist (SABA)-only approach to mild 
asthma (6, 98). Despite this, the 2014 NRAD report shows 
evidence that high reliever use has not always been detected or 
responded to by patients and their clinicians (12). ICS overuse 
is also a recognised phenomenon (99-101).  
1.2.7. Adherence study design 
Many attempts have taken place over decades to find 
reproducible, sustainable interventions which are 
implementable in the real world but which also improve 
adherence and outcomes. There is some evidence that 
interventions do improve adherence (102, 103), however this 
is not consistent and is dependent on both the intervention 
(104) and the disease (102).  In their synthesis, Haynes et al. 
found a range of complex strategies including educational, 
behavioural and psychological strategies in varying 
combinations. Where interventions were demonstrated to be 
effective, the magnitude of the effect appeared outbalanced by 
the complexity of the intervention (103).  
Despite the logical presumption that improvements in 
adherence and consequent effects on outcomes would have cost 
savings implications, this has not been well demonstrated in the 
literature (102). This latter is of particular importance in asthma 
as the BTS guidelines, whilst recognising electronic monitoring 
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as the gold-standard for adherence measurement in research, 
suggest that this is not yet translatable into the clinical arena 
due to its excessive cost (6).  
In summary, adherence is not a concept that is easy to define. 
Poor adherence, primarily ICS underuse (and potentially 
including poor technique), is known to be associated with poor 
outcomes in asthma and SABA overuse is a marker of poor 
control. Reasons for poor adherence are complex and 
multifaceted. Adherence interventions should address them 
using a comprehensive approach which is both deliverable and 
clearly demonstrates effectiveness. 
1.2.8. Adherence in this thesis 
Unless otherwise specified, the term ‘adherence’ is generally 
taken to refer to implementation adherence in the literature and 
will be similarly used in this thesis. Adherence is generally taken 
to mean the proportion of expected doses measured as taken 
by the individual. This thesis uses the term ‘adherence’ 
recognising that it may describe a regime anywhere on a 
spectrum from clinician-imposed (compliance) to mutually 
agreed (concordance or shared decision-making). It recognises 
that these may confound the outcomes to be discussed, but also 
that the quality of healthcare team/patient interactions cannot 
be measured in a standardised way.  
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1.3. Hypothesis and aims of the thesis 
The introduction has demonstrated that asthma is a 
heterogeneous condition with ‘treatable traits’ which are not 
only pathophysiological but behavioural in nature. Whilst 
adherence has been clearly demonstrated to be one such trait, 
there is a paucity of evidence demonstrating that adherence 
interventions result in better clinical outcomes. Using the 
emerging gold-standard measure of electronic monitoring, this 
thesis will assess the performance of EMDs as adherence 
measures in asthma. It will also assess whether incorporating 
them into interventions targeting poor adherence results in 
improved adherence and clinical outcomes in asthma and 
whether this can be translated into real world settings for 
clinical use.  
Aims 
1. To review the available evidence on electronically 
monitored adherence in asthma, using it to estimate 
a population ICS adherence rate in asthma. 
There have been many attempts to assess adherence to asthma 
therapies. With EMDs mooted as the new gold-standard, 
Chapter 2 of this thesis reviews EMD studies, examining 
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precisely what these devices have been used to measure and 
how. In doing so, this thesis suggests considerations for the 
sorts of devices which should be used in future studies and how 
such use should be reported. Chapter 2 goes on to use the 
results of these studies to estimate a population adherence to 
ICS in asthma, examining the nature of these studies and the 
potential pitfalls of relying on them to reflect real-world 
adherence. 
2. To review existing evidence on whether adherence 
interventions incorporating EMDs lead to better 
outcomes in asthma. 
By conducting a systematic review with a more limited scope, 
Chapter 3 considers the effectiveness of interventions which use 
EMDs to increase ICS adherence in individuals with asthma, 
assessing whether success in improving adherence translates 
into improved clinical outcomes. Limitations of these studies are 
used as a foundation for methodological recommendations for 
future research in this area. 
3. To assess the validity of Smartinhaler™ devices in a 
trial setting.  
Smartinhaler™ (Adherium) devices are a brand of EMDs which 
have been commonly used and previously validated in the 
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literature. Chapter 4 summarises these validation studies. It 
then goes on to report the results of validation testing of these 
EMDs conducted as part of a pilot study, comparing the results 
to published data and considering the implications for real-
world use.  
4. To evaluate whether using EMDs as part of an 
adherence intervention improves outcomes in asthma.  
At the centre of this work, Chapter 5 presents a pilot study 
which assesses whether clinician feedback, informed by EMD-
derived adherence data, leads to improvements in adherence 
and clinical outcomes in asthma. It also describes the 
challenges of designing a study with real-world applicability.  
5. To understand user perspectives on using  
Smartinhaler™ technology. 
Pilot study participants were invited to describe their 
experiences of asthma, their treatment and study participation 
with the aim of developing an understanding of how these 
factors interacted with their unique experiences of using an 
EMD. Chapter 6 of this thesis presents findings from these 
interviews with implications for future EMD design, study design 
and real world application. 
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Chapter 2: Deriving a population 
adherence from electronic monitoring 
devices: A systematic review 
2.1. Introduction 
There are a broad range of estimates for adherence to inhaled 
corticosteroids (ICS), suggesting disparities in what is being 
measured, how it is being measured and who it is being 
measured in. This has the potential to handicap the coherent 
development of intervention design and construction of a body 
of evidence. Consequently, there is a need to identify where 
these disparities lie and how they may affect the evidence 
already in existence. Doing this would allow such factors to be 
considered in the development of new interventions.  
Adherence can been measured using subjective measures such 
as retrospective interviews, paper or electronic diaries, clinician 
estimates and validated questionnaires such as the Morisky 
Medication Adherence Scale (MMAS) or the Medication 
Adherence Report Scale for Asthma (MARS-A) (89, 90, 105). 
Questionnaires in particular have been shown to discriminate 
between good and poor adherence (90, 106). Despite this, 
subjective measures can suffer from a ‘social desirability’ bias, 
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driven by an individual’s desire not to be judged and resulting 
in under-reporting of non-adherence (105, 107, 108). 
Retrospective tools are also open to recall bias. Finally, all 
subjective measures are also open to manipulation by 
individuals who knowingly under- or over-report their ICS use.  
Increasingly, pharmacy records are being used to measure 
inhaler use to assess whether an individual is eligible for 
escalation of therapy (34). Prescription refills are routinely 
recorded in most healthcare data systems, allowing for a widely 
available estimation of adherence based on how often a 
prescribed medication is collected. In research, various 
calculations also attempt to account for irregular usage (105), 
however, prescription fills do not equate to usage and, by 
averaging adherence over time, fail to detect some patterns of 
poor adherence (51).  
Many ICS inhalers now incorporate dose counters. These can 
serve to remind an individual that a dose has been taken or that 
they require a new prescription. They can also inform 
investigators or clinicians that the inhaler is being actuated. 
Dose counters also fail to measure inhaler use patterns and 
inhalation. Underuse/overuse cycles, critical inhaler errors and 
dose dumping may therefore go undetected.  
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Direct measures such as blood prednisolone and cortisol assays 
do not have a useful equivalent for ICS. Directly observed 
therapy (DOTs) measures would be organisationally complex, 
time-consuming and expensive to deliver in an adult setting 
(46, 109, 110).  
Other methods used in the clinical trial setting include weighing 
canisters and electronic monitoring (51, 111). Fractional 
exhaled nitric oxide (FENO) levels have more recently been 
investigated as a means of distinguishing between lack of 
response to therapy and poor adherence (112). Each of these 
methods have limitations. Older generation EMDs share with 
both prescription data and canister weighing the inability to 
detect actual inhalation. Finally, FENO measurements in and of 
themselves are not specific to asthma/ICS adherence and so 
require a degree of skill to interpret and have generally been 
used in combination with electronic monitoring (112). 
The ideal measure of inhaler use would accurately detect inhaler 
actuations, assess quality of technique, measure how much 
drug is deposited in the airways and perhaps even assess how 
effective the dose has been with minimal invasiveness, 
discomfort or effort to the user. It would produce a clinically 
meaningful output not requiring great expenditure of time or 
skill for the user and clinical team to interpret. Such an ideal 
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measure does not yet exist. Electronic monitoring, however, is 
rapidly bridging the gap between the ideal and current methods 
of monitoring.  
In their ubiquitous form, electronic monitors detect, record and 
time-stamp inhaler actuations. Some devices go further, 
incorporating means of detecting inhalation and quantifying 
technique (74, 113). Thus, not only do electronic monitors have 
the potential to inform as to whether an individual has taken 
their medication, but also to provide objective, real-time 
information as to patterns and quality of inhaler use.  
This review examines studies where ICS adherence has been 
electronically monitored. It employs a working definition of 
adherence being the actuations recorded as a proportion of 
expected inhaler use. In light of the emerging role of electronic 
monitoring devices (EMDs) as the gold standard for adherence 
monitoring in ICS (6), this review asks what is meant by the 
term EMD and what they measure when they are reported as 
measuring adherence. The review goes on to offer an estimate 
of population adherence using electronic measurement alone.  
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2.2. Objectives 
1) To describe electronic monitoring methods for assessing 
adherence to inhaled corticosteroid therapy in adult asthma 
used in the literature in terms of: 
1. What is being measured 
2. How it is being measured  
3. How effectively it is being measured 
2) To determine the rate of ICS adherence described in the 




This chapter is drawn from a larger planned work aiming to look 
at adherence measurement across the spectrum of methods. 
The protocol for this is included in Appendix 2 and is registered 




Searches were conducted in April 2017. Studies were identified 
from the Cochrane Central Register of Controlled Trials 
(CENTRAL), MEDLINE group of databases, EMBASE, Web of 
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Science, SCOPUS, CINAHL, PsychINFO and IEEE Xplore. Grey 
literature searches were conducted using clinicaltrials.gov, 
BioMedCentral ISRCTN Registry and OpenGrey. Search terms 
were constructed with advice from the University of Nottingham 
Library services. The search terms deployed are shown below 
in Figure 2-1. 
Figure 2-1: Systematic review search terms 
 
Terms were designed to capture electronic monitoring of ICS 
from its inception through to the present day and terms 
reflected the changes in terminology since their first report in 
the early 1980s. Search terms also reflect the fact that this 
review forms the initial part of a planned broader study of 
different methods of adherence monitoring. 
2.3.2. Data management 
Titles and abstracts were managed using the Covidence online 
system (www.covidence.org, © 2017 Covidence, Melbourne). 
1. exp Asthma/ OR Asthma*.mp. 
2. (exp Nebulizers and Vaporizers/) OR (exp Asthma/dt) OR Inhal* 
OR Aerosol* OR Nebuli* 
1. AND 
2. (exp Patient Compliance/) OR Adher* OR Complian* OR 
Co?operat* OR Concord* OR Non?adher* OR Non?complian* OR 
Non?concord* OR Under?complian* OR Over?complian* OR 
Monitor* 
- OR -  
3. EMD OR Smartinhaler OR SmartTrack OR SmartTouch OR 
Nebulizer Chrono* OR Doser* OR Propeller OR MDILog OR 
Canister weigh* OR Prescription count* OR Refill count* OR Dose 
count* 
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Full texts were managed using EndNote X8 (Clarivate 
Analytics). Data extraction was conducted in Microsoft Excel 
(2016). Once checked, data were then imported into Stata 15 
(StataCorp. 2017. Stata Statistical Software: Release 15. 
College Station, TX: StataCorp LLC).  
2.3.3. Study eligibility 
Eligibility criteria were set a priori. Studies included randomised 
controlled trials (RCTs), quasi-experimental studies and cohort 
studies. This was in recognition of the fact that adherence, 
particularly in earlier studies, was studied as part of broader 
interventions. Included study populations were pre-defined as 
adults having asthma of any severity. The review was limited to 
studies targeting adults as behavioural factors and 
management are known to differ over the lifespan. During the 
course of the review, several key adult studies were identified 
that included adolescents aged 12-18. The decision was taken 
to include these studies. 
Due to the breadth of the review, the protocol was amended 
such that studies were required to specify the use of electronic 
monitors for ICS rather than both ICS and short-acting beta 
agonists (SABA). Comparators were permitted to include other 
objective methods of assessing adherence, subjective methods 
of assessing adherence or no assessment of adherence at all. 
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Outcomes of accuracy of methods of assessing adherence, 
change in self-management behaviours or change in clinical 
outcomes were of interest but not essential. 
2.3.4. Study selection 
Study selection at both the title and abstract stage was 
conducted by two independent reviewers. Disagreements were 
resolved by consensus. Initial screening of full texts was 
conducted by a single reviewer, however where it was felt that 
there was a possibility full texts might meet inclusion criteria, 
two independent reviewers again performed study selection 
with disagreements resolved either by consensus or by 
discussion with a third reviewer. Peer-reviewed publications 
were included in place of abstracts where the abstract had been 
included prior to article publication. Abstracts and full texts that 
were not in English were inspected using Google Translate. Any 
that were judged eligible for inclusion were to be referred for 
data extraction by someone fluent in that language.  
2.3.5. Data extraction 
Extraction was performed by two reviewers. Disagreements 
were resolved by consensus. Where consensus could not be 
found, disagreements were referred to a third reviewer. A third 
reviewer checked 10% of the studies included for validation 
purposes.  
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Data were extracted onto pre-designed forms. These were 
tested for usability and then further updated as the study 
progressed. The variables assessed included general study 
information, extraction of aspects of study design, how study 
samples were powered and how large the samples were, 
description of the study population, description of the devices 
and their characteristics, adherence and study quality. These 
forms are included below with shaded cells containing variables 
added during the course of the review. 
Table 2-1: Study information and design 
Fields Options (description in italics) 
Study ID [First author surname][Year] 
Reviewer Reviewer initials 
First author  
Year  
Study title  
Journal  




Multicentre Yes, no, unknown, n/a 




Comments For notes on study eligibility 
Setting – care 
sector 
Community (pharmacy or primary care), 
[dedicated] research centres, secondary/specialist 
care, mixed primary and secondary/specialist, n/a, 
not reported. Note this referred to where the 
study was conducted, not where participants were 
recruited from per se.  
Duration (weeks)  




Role of adherence Risk factor, outcome, outcome and risk factor, 
quality measure 
Inclusion criteria  
Exclusion criteria  
Comments  
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Table 2-2: Power calculations and sampling 
 Fields Options (description in italics) 
Adherence 
powered 
Yes, no, unclear – the authors indicate a power 
calculation to see an adherence outcome effect 
Effect size - 
adherence  
The adherence effect size being powered for 
Sample size – 
adherence 
The target sample size resulting from this 
Clinical outcomes 
powered 
Yes, no, unclear - the authors indicate a power 
calculation to see an effect on clinical outcomes 
Outcome measure 
(units) 
E.g. peak flow (L/min) 
Effect size - 
outcome 1 
The clinical outcomes effect size being powered for 
Sample size - 
outcome 1 
The resultant target sample size  
Effect size - 
outcome 2 
Effect size for a second clinical outcome  
Sample size - 
outcome 2 
The resultant target sample size  
Alpha  
Power  
Approached The number of people the authors specify as 
having been approached to participate  
Eligible 
 
The number of people the authors specify as 





The number of people the authors specify as 
having consented to be in the study overall and in 





The number of people the authors specify as 
having been randomised overall and in the 





The number of people the authors specify as 
having completed the study overall and in the 





The number of people the authors specify as 
including in the analysis overall and in the 
intervention and control groups 




Described - nil of note (loss to follow-up was >5% 
but those lost to follow-up did not differ 
significantly from the group who completed) 
Described - issues to note (loss to follow-up was 
>5% and those lost to follow-up differed 
significantly from the group who completed) 
Attrition <5% (loss to follow-up was <5%), not 
Described but intention to treat/whole population 
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 Fields Options (description in italics) 
analysis (loss to follow-up was not reported but 
there is evidence of an intention-to-treat analysis)  




loss to follow-up 
 
 
Table 2-3: Baseline characteristics 






For the overall study population and for each 
group where available with standard deviations  




Yes, no – baseline ethnicity data reported  




Proportion of population reported as black/black 
African/African American etc. 
Socio-economic 
status considered 
Yes, no – baseline socioeconomic data reported  
Did not graduate 
high school 
Proportion – educational attainment used as the 
most frequently occurring and standardised 
surrogate of socioeconomic status (SES) 
Only graduated 
high school 
Proportion – educational attainment used as the 
most frequently occurring and standardised 
surrogate of SES 
Completed 
further or higher 
education 
Proportion – educational attainment used as the 
most frequently occurring and standardised 
surrogate of SES 
Proportion 
exacerbation in 
the last year at 
baseline 
Low (0-33%), medium (34-66%), high (67-
100%), other, unreported – Proportion of 
population with an exacerbation in preceding 
twelve months (oral corticosteroid use, 
unscheduled GP* visits for asthma, ED† visits for 
asthma, hospitalisations for asthma). “Other” 
modes of reporting exacerbations included lifetime 
or rates.  
Proportion ED or 
hospital 
admission in the 
last year at 
baseline 







Population mean FEV1 percentage predicted and 
standard deviation 
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Fields Options (description in italics) 
Pre-study ICS 
dose (SD) 
Reported mean baseline ICS dose and standard 
deviation 
Study ICS The ICS supplied during the study if standardised 
and reported 
Study ICS dose The dose of ICS supplied during the study if 
standardised and reported 
Baseline reliever 
use measured 
Yes, no – the authors report a measure of reliever 





Yes, no – the authors report a validated measure 
of asthma control such as (but not limited to) 
ACT™§, ACQ¶, AQLQ# at baseline 
Mean ACT™ (SD) Mean baseline population asthma control test 
score (standard deviation) 
Mean ACQ7 (SD) Mean baseline population asthma control 




Yes, no – a study-constructed measure of asthma 
control with no previous external validation is 
reported by the authors  
Baseline 
differences 
Yes, no, unclear, n/a – reported baseline 






* General Practice/General Practitioner (GP)  
† Emergency Department (ED) 
‡ Forced expiratory volume in 1 second (FEV1) 
§ Asthma Control Test™ (ACT™) 
¶ Asthma Control Questionnaire (ACQ) 
# Asthma Quality of Life Questionnaire (AQLQ) 
 
Table 2-4: Devices 
Fields Options (description in italics) 
Name Device name 
Structure How the authors describe the device’s structure 
e.g. attached to the inhaler 
Date stamp The authors report device date stamps actuations* 
Time stamp The authors report device time stamps actuations* 
Detects 
inhalation 
The authors report device detects inhalation 
Assesses 
inhalation 








Actuations, days, actuations and days, proportion, 
other – the reported adherence outcome measure 
included for use. Actuations usually reported as 
mean actuations taken as a proportion of 
actuations prescribed. Days usually reported as 
mean percentage days ICS taken correctly as a 
proportion of study days. Proportion usually the 
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Fields Options (description in italics) 
percentage of the study population meeting a pre-




Adherence, non-adherence – results primarily 
reported in terms of adherence or in terms of non-
adherence 
 
Equation How electronically monitored adherence is 
calculated including the time period over which it 
is calculated (usually 12hrs or 24hrs then 
averaged out over the study period) 
Adherence 
summary statistic 
Mean, median, other, not reported 
Was adherence 
capped? 
Yes, no – the authors’ report on whether 
adherence was truncated to mitigate the effect of 
inappropriate overuse, usually capped at 100% 
Cap limit  
Validity comment Previously validated, commercially available, 
validation study, not validated, mixed, no 
comment on validity – author comments on 
previous validation of the EMD(s) used 
Device accuracy Authors’ comments on device accuracy 
Failure rate Proportion of EMD that malfunctioned during the 
course of the study 
Comparator (non-
EMD) adherence 




Have the authors commented on what they feel 
the particular strengths/limitations of their 
device(s) may be? 
Comments - other  
*Date/time stamps initially extracted as a combined variable and then separated over the 
course of the review 
 
Table 2-5: Results 







Pre-intervention adherence overall and per group 




Whole population adherence, usually reported 
over whole study period. This unadjusted value 





Whole population adjusted adherence e.g. capped 





Adjusted (if available) adherence for RCT 
intervention group over the measured study 
period.  
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Adjusted (if available) adherence for RCT control 
group over the measured study period. 
p-value/CI Reported p-value or confidence interval for any 
significant change in adherence 
Adherence cut-off 
(%) 






Proportion of study population reported as having 






The difference between baseline or peak 
adherence and adherence at the end of the study. 




None, canister weight, prescription record, dose 
counter, other objective, subjective, unclear -  any 








Yes, no – where clinical outcomes e.g. 
exacerbations/quality of life/FEV1 were reported, 
did the study demonstrate a statistically significant 
change related to a change in adherence? 
Comments  
 
2.3.6. Outcome measures 
1. Primary outcome: a population estimate of electronically 
monitored adherence. 
2. Secondary outcomes:  
a. A narrative synthesis of how the literature defines 
electronically monitored adherence  
b. Characteristics of devices used to measure adherence 
c. Reported EMD accuracy 
d. Comparison of electronically monitored adherence 
between intervention and control groups. 
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e. Comparison of electronically monitored adherence 
with other objective modes of adherence 
measurement 
For the purpose of the meta-analysis, adherence has been 
calculated as the proportion of expected inhaler puffs which 
were electronically recorded as actuated. The narrative 
synthesis details specifics of how this was done from study 
reports. 
2.3.7. Quality Assessment 
Risk of bias was assessed and reported descriptively by 
adapting the Cochrane Collaboration’s tool for RCTs (114) which 
examines five domains. Risk of selection bias was judged by 
reporting of random sequence generation and allocation 
concealment in RCTs. In the version adapted by this review for 
cohort studies, it looked for evidence of representative 
sampling. Performance bias assessed blinding of participants 
and personnel. This was adapted to incorporate blinding to EMD 
purpose and function. Detection bias looked for outcome 
assessment blinding. Attrition bias looked at the completeness 
of outcome data and extent of missing data. Finally, for RCTs, 
reporting bias looked for selective outcome reporting. The final 
score was out of seven for both RCTs and cohort studies. The 
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terms used and their definitions are included in Tables 2-6 and 
2-7 below. 
Table 2-6: Risk of bias (RCTs) 




Low – 1 
Unclear – u  
High – 0 




Low – 1 
Unclear – u  
High – 0 
Whether allocation was reported 






Double/ low - 1 
Single/ 
intermediate – 0.5 
Unblinded/high – 0 
Unclear – u 
Procedures reported for blinding 
participants and for blinding 
personnel to participant group.  
Blinding to 
EMD/function 
Double/ low – 1 
Single/ 
intermediate – 0.5 
Unblinded/high – 0 
Unclear – u 
Procedures reported for blinding 
participants to EMD function and 





Low – 1 
Unclear – u  
High – 0 




Low – 1 
Unclear – u  
High – 0 
Description of loss to follow-up 




Low – 1 
Unclear – u   
High – 0 
To what degree analysis was by 
intention to treat (ITT). If clear 
reason for ITT modification and 
<=5% participants excluded, a 
low risk score was considered. 
 
Table 2-7: Risk of bias (cohort studies) 
Fields Options Description 
Representative 
sampling 
Low – 2 
Intermediate - 1 
Unclear – u  
High – 0 
E.g. if the study was for a 
general asthma population, did 
the study recruit from the 
community? Have exclusion 
criteria been minimised? Were 
patients who did not enter the 
study markedly different to the 
sample population? 
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Low – 1 
Unclear - u 
High – 0 
Procedures reported for 
blinding participants and for 
blinding personnel to 
participant group.  
Blinding to 
EMD/function 
Double/ low - 1 
Single/ intermediate 
– 0.5 
Unblinded/ high – 0 
Unclear – u 
Procedures reported for 
blinding participants to EMD 
function and personnel 




Low – 1 
Unclear - u 
High – 0 
Procedures reported for 




Very low – 2 
Low – 1  
Unclear – u  
High – 0 
Description of loss to follow-up 
and missing data. If <=5% 
loss, score as very low risk. If 
5-15% loss and differences to 
remaining sample reported 
score as low risk. If 5-15% 
loss and differences to 
remaining sample not 
reported, score as low risk 
with an unreported element 
which may contribute to bias. 
If >15% loss, score as high 
risk. Specify “unclear” if 
unreported information may 
influence risk of bias. 
 
2.3.8. Data synthesis 
Narrative synthesis 
As not all review objectives and all studies could be included in 
a meta-analysis, a narrative synthesis is provided. This 
presents the following measures of adherence outcomes by 
study: 
1. Baseline adherence (%) 
2. Overall adherence (%) 
3. Adherence by group (%) 
4. p-values for RCTs where available 
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5. Change (decline) in adherence from study start to study 
end both overall and by group (%)  
6. Proportion of the study population deemed adherent (%) 
Separately described are the following: 
1. The studies themselves 
2. Study sampling (including numbers of participants 
recruited, randomised and analysed) 
3. Population characteristics (including age, sex, ethnicity 
and asthma control)  
4. Devices (including capabilities such as ability to date/time 
stamp and detect inhalation) 
5. How adherence is measured from study to study 
(including duration of data analysed, whether or not 
adherence was capped and whether or not overuse was 
reported).  
Finally, a narrative synthesis of the effect of RCT interventions 
on clinical outcomes is provided as this could not be examined 
by meta-analysis due to the disparate outcome measures. 
Meta-analysis – inclusion  
A meta-analysis of adherence at baseline, over the course of 
the study and compared between intervention and control 
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groups is also presented. Studies were included in the meta-
analysis as follows: 
1. Adequate summary data could be derived directly from the 
study report, or 
2. Adequate study data was provided such that summary data 
was calculable, or  
3. A reasonable estimate from available data could be made 
(e.g. where participant numbers analysed were not clearly 
reported, the number of participants who either completed 
the study or were randomised to the study were used to 
estimate this).  
For the meta-analysis, a random effects model was used, in 
expectation that there would be variation in the outcome 
measures due to study variations. The I2 statistic is also 
presented, acknowledging potential variations in population, in 
the types and capabilities of EMDs used, and in how adherence 
was defined and measured from study to study.  
Meta-analysis – adherence  
Population adherence estimates were obtained using two 
methods: 
1. Pooling baseline adherence in studies where this was 
available. 
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2. Pooling end of study adherence from cohort study 
populations and RCT control groups. 
An estimate of the effect of interventions on adherence was 
obtained from RCTs which could be included in the meta-
analysis. Individual study means and standard deviations (SD) 
were combined to give a standardised mean difference (SMD) 
and 95% confidence intervals. The SMD provides a pooled 
measure of effect which denotes a magnitude of effect from 0-
1.0. An SMD of 0.2 denotes a small effect size, 0.5 a moderate 
effect size and 0.8 a large effect size (115, 116). This allows for 
comparison of effect between disparate adherence measures. 
For reference, a mean difference in percentage adherence with 
95% confidence intervals has also been presented.  
Subgroup analyses were conducted to assess whether ethnicity, 
socioeconomic status and asthma severity had an effect on 
study-period adherence. To assess whether ethnicity 
proportions in studies had an effect on adherence, studies were 
split into binary groups based on whether they had a proportion 
≥50% of white participants. Similarly, studies reporting 
educational attainment were divided into studies reporting 
≥25% of participants not graduating high school and studies 
reporting <25% participants not having graduated high school. 
Difficult asthma was ascertained using two measures. First, a 
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percentage predicted forced expiratory volume in one second 
(FEV1) of <80% was used as this suggests evidence of a fixed 
airflow obstruction, a known marker of risk in asthma (6, 21). 
Secondly, asthma control scores signifying lack of control i.e.  
Asthma Control Test™ [ACT™]<20 and Asthma Control 
Questionnaire [ACQ]>1.5 were used as these are  often used 
as a benchmark for inclusion in clinical studies (21). 
Meta-analysis – comparator measures 
An estimate of the difference between study adherence 
obtained using EMDs and study adherence using other objective 
measures of adherence was derived. This meta-analysis again 
utilised the SMD as varying comparator methods were used by 
different studies. 
Meta-analysis – study quality and sensitivity 
Finally, studies were categorised into binary high- and low-
quality study groups, split by the median risk of bias score. 
Further analyses permitting no more than one area with an 
unclear risk of bias and separately not permitting any areas 
consistent with a high or unclear risk of bias were also 
undertaken. Sensitivity analysis was conducted to assess the 
impact of study quality on estimates of population adherence.  
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2.4.  Results 
Figure 2-2 provides the PRISMA flow diagram for this 
systematic review (117). Thirty-four papers were identified for 
analysis in this initial electronic monitoring sub-study (54, 56, 
60, 67, 68, 74, 88, 90, 99-101, 118-140).  
2.4.1. Description of studies 
General 
Due to the broad nature of this review, several papers are 
included which did not report data in the mode required for 
meta-analysis, but were still considered to be of narrative value 
(74, 88, 90, 100, 101, 119, 121, 123, 125, 126, 131, 132, 134, 
137, 139, 141). Where studies incorporated populations also 
reported elsewhere (e.g. D’Arcy et al., (142)), relevant findings 
from these auxiliary reports were incorporated into the 
narrative review.  
Studies were published between 1991 and 2019 in the United 
States (19 of the 34 papers), United Kingdom (UK), Australia, 
New Zealand, Republic of Ireland, Canada, Spain and The 
Netherlands (see Table 2-8). In one of these papers, two 
separate studies were reported (138). These are analysed 
separately (i.e. 35 studies from 34 papers). Of the 35 studies, 
18 were cohort studies and 17 RCTs. 
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Figure 2-2: Systematic review flow diagram 
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Thirteen studies were reported as multicentre and, of 25 studies 
reporting setting, 18 were conducted solely in research or 
specialist centres, signifying a smaller body of evidence directly 
generalizable to primary care. Study duration ranged from 2 – 
56 weeks, with a median duration of 10 weeks (interquartile 
range 6 – 24 weeks). 
Study designs varied considerably. Of the 18 cohort studies, 16 
were purely observational and two assessed study groups who 
had undergone a self-management intervention (136, 139). 
RCTs also varied with two studies which used ICS adherence as 
a quality rather than an outcome measure (101, 131) and 
studies which did consider it to be an outcome testing different 
categories of interventions. Some of these included behavioural 
interventions such as the use of audio-visual reminders (AVR) 
and feedback (67, 68, 99, 100, 118, 120, 121, 124-126, 141). 
Others tested drug regimes including dosing frequency and 
combination inhalers (122, 129, 133, 135).  
Management of control groups also differed between studies. 
Some control groups were reported as receiving usual care 
(100, 125), others received educational interventions (99, 
118), or, due to how the study groups had been structured, a 
mixture of usual care and a behavioural intervention (68). 
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Others received new inhalers, free inhalers or were reimbursed 
for the cost of their inhalers (67, 100, 118).  
Sampling and population 
Across the 35 studies, a total of 3478 participants were 
recruited, ranging from studies with ten participants to a study 
with 339 participants recruited. One thousand three-hundred 
and ninety-three of these participants were from cohort studies, 
whilst over half (n=2085) were from RCTs. Five studies were 
powered for adherence (see Table 2-8) and three for clinical 
outcomes (101, 132, 134). 
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Table 2-8: A systematic review of electronically monitored adherence: Study information 
 



















Apter1998 (119) USA   54     50     not described 
Apter2003 (56) USA   88     85     attrition <5% 
Apter2011 (118) USA 330 333 165 168 unclear unclear unclear not described 
Bender2010 
(120) 





Berg1997 (121)  USA   68 31 24 55 31 24 attrition <5% 
Bosley1994 (122) UK   102 51 51 72 36 36 described - 
issues to note 
Charles2007 (67) New 
Zealand 
100 110 55 55 90 44 46 not described 
Chmelik1994 
(139) 
USA         20     not described 
Cluley2001 (88) UK   103     66     described - 
issues to note 
Cohen2009 (90) USA   53     53     attrition <5% 
D'Arcy2014 (123) ROI   69     51     not described 
Foster2011 (54) Australia   100     85     not described 
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Foster2014 (68) Australia   143 76 67 129 67 62 not described 
Goeman2013 
(124) 


















USA   60     49     described - 
issues to note 
Lacasse2005 
(128) 
Canada 125 134     124     not described 
Le2008 (60) USA   86     86     attrition <5% 
Mann1992_a 
(129) 
USA   17     16 8 8 described - 
issues to note 
Mann1992_b 
(130) 
USA   10     10     attrition <5% 
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USA   15 7 8 15 7 8 attrition <5% 
McGann2008 
(132) 
USA   51     48     attrition <5% 
Onyirimba2003 
(100) 











Perrin2010 (133) New 
Zealand 
100 111 57 54 103 54 49 not described 
Plaza2016 (134) Spain   99     99     attrition <5% 
Rand2007 (135) USA   177 189 191 169       
Sulaiman2016_b 
(74) 
ROI         82     not described 
Sulaiman2018 
(99) 





  24     21     not described 
Weinstein2019 
(141) 
USA   50 27 23 39 19 20 not described 
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Wells2016 (137) USA         339     attrition <5% 
Yeung1994_s1 
(138) 
UK   10     10     not described 
Yeung1994_s2 
(138) 
UK   11     11     not described 
 
*Lost to follow-up/withdrawn/otherwise incomplete data
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Study mean/median ages ranged from 32.0 – 67.7 years (Table 
2-9). Studies reported between 26.7% to 85.0% female 
participants. Race and socioeconomic circumstances were only 
intermittently reported, with only seventeen studies reporting a 
measure of ethnicity and sixteen a measure of socioeconomic 
circumstances using a variety of measures and making 
comparison between studies challenging. Table 2-9 presents 
the most commonly used and easily comparable measures – 
percentage of the participant population reported to be of white 
or Afro-Caribbean ethnicity and the percentage of the 
participant population who did not graduate from high school. 
Eight studies reported exacerbations (defined as systemic 
steroid use or unscheduled service visits), ED attendances 
and/or hospitalisations in the preceding 12 months rates (see 
Table 2-9). Some studies reported these figures in other ways, 
for example mean hospital admission rates per person. 
Nineteen studies reported participant FEV1 at baseline and 20 
studies reported baseline subjective asthma control using a 
validated scoring system. Only five studies reported baseline 
reliever use.  
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Table 2-9: A systematic review of electronically monitored adherence: Baseline characteristics 
Study ID Mean age  Sex (% 
female) 
Ethnicity 
(% white ) 
Ethnicity 
(% Afro-


















Apter1998 (119) 46.0 74.0 42.0 22.0 32.0   75.0     
Apter2003 (56) 47.0 72.0   65.0     65.0     
Apter2011 (118) 49.0 72.0 20.0 68.0 17.0 medium  high  66.0   1.7 
Bender2010 (120) 41.6 64.0 58.0 20.0           
Berg1997 (121)  50.0 66.0 95.0   2.0         
Bosley1994 (122) 44.0 61.0         73.5     
Charles2007‡ (67)   54.6               
Chmelik1994 (139) 39.8 75.0       medium high        
Cluley2001 (88) 41.9 66.0               
Cohen2009 (90) 47.0 85.0 6.0 31.0 43.0         
D'Arcy2014 (123) 46.8 56.5               
Foster2011 (54) 47.6 58.0         82.8 19.9   
Foster2014 (68) 40.3 62.0       low  
 
77.1 14.6   
Goeman2013 (124) 67.7 72.4     2.4 low   73.7   1.4 
Janson2009 (126) 38.2 53.6   6.0   
 
 80.8     
Janson2010 (125) 50.0 68.4       low  low 81.3     
Krishnan2004 (127) 42.2 65.0 1.7 98.3   
 
high        
Lacasse2005 (128) 47.0 58.9         78.0   1.8 
Le2008 (60) 42.7 69.8 23.3 70.9 41.0         
Mann1992_a (129) 44.6 81.3               
Mann1992_b (130) 43.8 80.0               
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Study ID Mean age Sex (% 
female) 
Ethnicity 























32.5 26.7               
McGann2008 (132) 42.0 82.4 78.4       77.0     
Onyirimba2003 
(100) 
48.8 84.2     53.0   70.9     
Patel2013_c (101) 42.0 69.0 76.2     high   81.0   1.9 
Perrin2010 (133) 47.3 55.0         81.1   1.3 
Plaza2016 (134) 47.8 67.7     28.3   79.6     
Rand2007 (135) 35.2 69.5 80.8       93.9     
Sulaiman2016_b 
(74) 
54.8 59.0     42.0         
Sulaiman2018 (99) 49.2 64.0       high 
 
73.0 12.1   
vanderPalen1997 
(136) 
42.0 47.6               
Weinstein2019 (141) 40.0 60.7         72.8   2.3 
Wells2016 (137) 33.7 58.4 28.6 71.4     72.9 18.6   
Yeung1994_s1 (138) 38.0 40.0               
Yeung1994_s2 (138) 32.0 72.7               
 
* Proportions grouped as low (≤33%), medium (33-66%) or high (>66%) use of oral/systemic steroids in preceding 12 months for asthma exacerbation 
† Proportions grouped as low (≤15%), medium (15-30%) or high (>30%) ED attendance and/or hospital admission for asthma exacerbation 
‡ Ages given as medians for each group, no overall summary statistic 
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2.4.2. Devices 
Nine device brands were reported by studies in this review. 
These were the Doser (including the Doser Clinical Trials 
version, Doser CT), the INCA device, the MDI Chronolog, the 
MDI Log, the Nebulizer Chronolog, the Smartinhaler™, the 
Turbuhaler Inhalation Computer (TIC), the Diskus Adherence 
Logger (DAL) and the Electronic Diskhaler (see Table 2-10). The 
studies by Yeung et al. published an unbranded 
“electromechanical counter”. Three studies used a mixture of 
devices.  
There was variable reporting of how the EMD interacted with 
the inhaler (Table 2-10). Thirteen studies reported their EMD 
was attached to the inhaler, six that a standard metered dose 
inhaler (MDI) canister was inserted into the EMD and one that 
the EMD was integrated into the device, another specifying a 
concealed microchip. Of the studies using more than one device 
brand, one specified that one of the devices was a canister 
sleeve and two specified that their devices attached to the 
inhalers. 
Twenty-five studies clearly reported that the EMD(s) used 
provided a date stamp for actuations, 26 that they provided a 
time stamp for actuations, five that they detected inhalation 
and four that the EMD system was able to evaluate inhalation 
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technique (Table 2-10). Fourteen studies reported that at least 
one of the device models used was either previously validated 
and/or commercially available. Three were validation studies. 
The remaining 32 studies did not report any validation data 
(Table 2-10). Fifteen studies gave no report of device accuracy 
during the study period (see Table 2-10). Where device failure 
rates were reported (12 studies), the median failure rate was 
12.5% devices (interquartile range 7.6 – 15.2%). For the two 
brands in current use in the literature – the Smartinhaler™ and 
the INCA – reported failure rates were 12-13% and 6.5-9.81% 
respectively. 
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Table 2-10: A systematic review of electronically monitored adherence: Description of devices 

















no comment on 
validity 
  




no comment on 
validity 
  
Apter2011 (118) Diskus Adherence 
Logger; MDILog  


























Bosley1994 (122) Turbuhaler Inhalation 
Computer 
integrated  yes yes yes yes no comment on 
validity 
35.0 




no comment on 
validity 
  




no comment on 
validity 
  
Cluley2001 (88) No info concealed 
microchip 




no comment on 
validity 
  








no comment on 
validity 
  
D'Arcy2014 (123) INCA  attached not 
reported 
yes yes yes validation study 9.8 
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no comment on 
validity 
13.0 
Foster2014 (68) Smartinhaler™ 
(SmartTrack) 













no comment on 
validity 
  

















no comment on 
validity 
  

























no comment on 
validity 
  




no comment on 
validity 
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no comment on 
validity 
  















no comment on 
validity 
  
Patel2013_c (101) Smartinhaler™ “incorporated 
into all …MDIs 
dispensed” 


















no comment on 
validity 
  





INCA  attached yes yes yes yes previously 
validated 
6.5 
Sulaiman2018 (99) INCA  attached not 
reported 



















no comment on 
validity 
12.0 
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no comment on 
validity 
  
Yeung1994_s1 (138) electromechanical 
counter 




validation study   
Yeung1994_s2 (138) electromechanical 
counter 




validation study   
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2.4.3. Defining adherence 
At its most rudimentary, adherence was calculated over the 
whole study period. Some studies excluded data periods which 
were at risk of dose dumping. Some divided data into dosing 
periods (most commonly 24 hours) and calculated a daily 
adherence which was then averaged over the study period (see 
Table 2-11). To further limit the influence of dose dumping or 
periods of overuse masking periods of underuse, half of the 34 
studies reviewed placed a cap (usually 100% of expected 
doses) on adherence. Eighteen studies reported ICS overuse.  
Several studies used EMDs with technique-measuring 
capabilities. Some of these studies integrated technique into 
their adherence measurement, sometimes giving this figure 
alongside time-based adherence. Various studies used levels 
between 50-90% to define “good” adherence. From this, the 
studies divided their populations into adherent and non-
adherent groups (see Table 2-11). 
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Table 2-11: A systematic review of electronically monitored adherence: Definitions of adherence by study 


























Apter1998 (119) 6 5 recorded actuations/ 
prescribed actuations 
12 hrs 100% + 4 
actuations 
 mean yes 70 
Apter2003 (56) 6 6 recorded actuations/ 
prescribed actuations 
12 hrs 100%  mean yes   
Apter2011 (118) 24 24 recorded actuations/ 
prescribed actuations 
24 hrs 100%  mean no   
Bender2010 
(120) 




  mean no   
Berg1997 (121)  6* 8 
 
 100%  median no 80 




  mean yes 80 




100% 6 hrs mean/median yes   
Chmelik1994 
(139) 
5 1 recorded actuations/ 
protocol-defined actuations 
 110%  other yes 90 
Cluley2001 (88) 8 8 recorded actuations/ 
prescribed actuations 
8 weeks     no 70 
Cohen2009† (90) 12 4 percentage days ≥1 
actuation/30 days 
24 hrs 3.5 hours + 
unclear 
 
3.5 hrs mean  no 70 
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D'Arcy2014 (123) 12 12 cumulative number of 
correctly taken doses plotted 
against cumulative number 
of prescribed doses; slope 
compared to regression line 
of perfect adherence 
7 days   not reported no   




24 hrs  100%  mean no   
Foster2014 (68) 24 24 recorded actuations/ 
prescribed actuations 
   mean no   
Goeman2013 
(124) 




12 hrs    mean no 80 
Janson2009 
(126) 
24 18  recorded actuations/ 
prescribed actuations 
1 week  100% / 
24hrs 
 mean no 60 
Janson2010 
(125) 
52 52 recorded actuations/ 
prescribed actuations 
1 month 100%  mean no   
Krishnan2004 
(127) 
2 2 recorded actuations/ 
prescribed actuations 
 100%  mean no 50 
Lacasse2005‡ 
(128) 
12 12  recorded actuations/ 
prescribed actuations 
24 hrs 100%  mean yes 75 
Le2008 (60) 4 4 recorded actuations/ 
prescribed actuations 
4 weeks  100% / 24 
hrs 
 mean/median no   
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6 6 percentage days in study 
period actuations recorded 
were not equal to 8 
24 hrs 12 
actuations 
 mean yes   
Mann1992_b 
(130) 
9 9 recorded actuations/ 
prescribed actuations 
24 hrs   mean yes 100 
Mawhinney1991 
(131) 
4 4 days 8 actuations / total days 24 hrs   mean yes 75 (days) 
McGann2008 
(132) 
56 1.71  days prescribed number of 
actuations recorded/ 12 days 
24 hrs no cap  mean yes 80 
Onyirimba2003 
(100) 
10 10 recorded actuations/ 
prescribed actuations 
1 week 100%  mean yes   
Patel2013_c 
(101) 
24 24 proportion ≥0 actuation 




  mean yes   




 6 hrs§ mean yes 80 
Plaza2016 (134) 2 2 correctly taken actuations/ 
prescribed actuations 
 100%  mean  no 80 
Rand2007 (135) 48 36  recorded actuations/ 
prescribed actuations per 
subject averaged across 
subjects 
24 hrs   3 hrs§ mean yes   
Page | 68  
 




























4 4 cumulative drug exposure 
(area under the curve) 
4 weeks   mean   80 
Sulaiman2018 
(99) 
12 12 cumulative drug exposure 
(area under the curve) 
incorporating both critical 




  mean yes 80 
vanderPalen1997 
(136) 
6 6 recorded actuations/ 
prescribed actuations 
   mean yes 75 
Weinstein2019 
(141) 
12 12 recorded actuations/ 
prescribed actuations 
24 hrs 100  mean no 60 
Wells2016 (137) 6 6 recorded actuations/ 
prescribed actuations 
24 hrs   mean unreported   
Yeung1994_s1 
(138) 
2 2 recorded actuations/ 
prescribed actuations 
   mean yes 70 
Yeung1994_s2 
(138) 
3 3 recorded actuations/ 
prescribed actuations 
   mean yes 70 
 
* Duration of intervention rather than measurement 
† Common definition of adherence (i.e. recorded actuations/ prescribed actuations) used as a secondary definition 
‡ First and last days excluded from analysis 
§ Not used in primary measure of adherence 
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This review showed studies still used arbitrary thresholds of 
adherence to report sample proportions who had good 
adherence. These were, however, generally reported alongside 
summary measures of individual dose adherence. Finally, some 
studies used measures which precluded their comparison with 
other studies (101).  
2.4.4. Narrative adherence 
Adherence for each study (including those which could not be 
included in the meta-analysis) is presented in Table 2-12. 
Where the primary definition of adherence was not the 
proportion of actuations prescribed recorded as taken but this 
was calculated, the latter is presented. Also presented is change 
in adherence over the study period (reported by 14 studies) and 
the proportion of study population adherent.  
Control groups ranged from improvements in adherence over 
the study period of 7.2% to declines of 11%. Intervention 
groups ranged from an improvement in adherence of 19.3% to 
a decline of 13.8%. Where reported overall, change in 
adherence over the study period ranged from an improvement 
of 4% to a decline of 37.8%.  
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Apter2011 (118) 61.0 53.5 28.5   55.0 10.0 52.0 14.0 
 
  
Bender2010 (120)  56.8 18.3   64.5  49.1  0.003   
Berg1997 (121)   
  
  46.0 -6.0 23.0 11.0 0.043 16.4 
Bosley1994 (122)  63.5 33.6   67.0  60.0  
 
14.5 
Charles2007 (67)  76.8 24.8   88.0  66.0  
 
  











































Foster2014 (68)  60.0 30.1   73.0  46.0  <0.001   
Goeman2013 (124) 69.6 
  
  89.3 -19.3 76.4 -7.2 
 
  
Janson2009 (126) 81.5 
  
  77.0 5.0 73.0 7.0 
 
  






 0.160   





















Mann1992_a (129) 91.2 
  
  84.8 13.8 85.16 -2.5 0.001   


















































































Perrin2010 (133)  78.3 27.7   82.4  73.7  
 
54.4 



























Sulaiman2018 (99)  68.1 25.4   73.0 -10.0 63.0 4.0 0.010 45.0 
vanderPalen1997 
(136) 












































 *The proportion of each study population which achieved a threshold of ICS adherence pre-defined by each study 
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2.4.5. Clinical outcomes 
Fourteen RCTs using an adherence-based intervention with 
EMDs as their measure of adherence investigated clinical 
outcomes in addition to adherence outcomes. Only four 
reported an improvement in clinical outcomes. These included 
statistically significant differences in ACQ (124, 126, 141) as 
well as night-time awakenings (126), symptoms, oral 
corticosteroid (OCS) use and unscheduled service use (125).  
2.4.6. Electronically monitored estimates of population adherence 
by meta-analysis 
Two potential measures of population adherence are presented: 
1. Pooled study baseline adherence 
2. Pooled cohort and control group adherence 
Seven studies representing 962 participants gave a pooled 
baseline adherence estimate of 73.2% (95% CI 66.6-79.8, I2 
97.4%) as shown in Figure 2-3.  
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Figure 2-3: Meta-analysis of study adherence – estimate of electronically monitored 
population adherence using study baseline adherence 
 
Combining cohort and control group adherence from 19 studies 
representing data from 1365 participants gave a pooled 
estimate of 64.3% (95% CI 57.1-71.5%, I2 95.8%, see Figure 
2-4). 
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Figure 2-4: Meta-analysis of study adherence – estimate of electronically monitored 
population adherence using combined cohort and control group adherence  
 
2.4.7. RCTs: treatment effect on adherence 
Eight RCTs provided post-intervention between-group 
differences for meta-analysis. The overall SMD for adherence in 
intervention vs control groups was 0.5 (95% CI 0.2-0.8, I2 
75.8%), indicating that RCTs saw a moderate improvement in 
adherence in response to interventions (see also Figure 2-5). 
This represents a weighted mean difference (WMD) of 12.7% 
(95% CI 6.1 – 19.3%, I2 72.2%). 
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Figure 2-5: Meta-analysis of study adherence – between-group difference in 
adherence for RCTs 
 
2.4.8. Subgroup analyses 
Subgroup analyses looking at the effects of race, socioeconomic 
status and asthma severity (fixed airflow obstruction and 
asthma control) found no significant differences in adherence, 
although there was a signal towards fixed airflow obstruction 
affect cohort/control group adherence (Figure 2-6). It is also 
noted that only a few studies reported adequate relevant data 
for each of the subgroups, limiting the scope of the subgroup 
analyses. 
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Figure 2-6: Meta-analysis of study adherence - Subgroup analysis by airflow 
obstruction of cohort and control group adherence 
 
2.4.9. Comparison with other methods of adherence 
Only 13 studies reported use of a comparator measure of 
adherence. Of these, seven reported use of an objective 
comparator (canister weight and dose counter). One described 
the comparator (dose counter) as the gold standard (123). This 
study could not be included in the meta-analysis as there was 
no measure of variance reported.  
Three studies were eligible to be included in this paired analysis 
(see Figure 2-7). EMDs appeared to report a lower level of 
adherence than other objective methods of adherence 
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monitoring with an SMD of -0.5 (95% CI -0.9 to -0.2, I2 71.7%), 
p=0.029. 
Figure 2-7: Meta-analysis of electronically monitored adherence: EMD versus 
comparator 
 
2.4.10. Study quality and sensitivity analysis 
The main challenge across studies was blinding participants and 
study personnel to interventions where these were behavioural 
or where the use of an EMD was not covert. Other issues 
included lack of clarity with regards to whether personnel 
involved in outcome assessment also had access to EMD data 
and significant drop-out rates (see Tables 2-13 and 2-14).  
The median risk of bias score obtained from the modified quality 
assessment was 2.0 and the median number of unclear domains 
was two. A status of higher quality/lower risk of bias was 
therefore assigned to studies achieving a quality score of ≥2.0 
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with two or fewer unclear domains.  Overall, 19 studies (ten 
cohort and nine RCTs) were judged to be of higher quality/lower 
risk of bias by this definition (54, 56, 67, 68, 74, 90, 99, 101, 
120, 124-128, 130, 133, 134, 138).  
With the application of stricter criteria, the number of studies 
found to be high quality/low risk of bias reduced. Where high 
quality was defined as the median score of 2.0 with no unclear 
domains permitted, only four studies of the 35 met this 
standard (68, 120, 124, 125). Where high quality was defined 
by having no domains with a high or unclear risk of bias, only 
one of the 35 studies met this standard (125).  
Page | 79  
 
Table 2-13: A systematic review of electronically monitored adherence: Study quality assessment (RCTs) 







































low - 1 low - 1 unblinded/high 
- 0 
double-blind - 1 low - 1 low - 1 low - 1 6.0 0 
Berg1997 (121) low - 1 unclear - u unclear - u unclear - u unclear - u unclear - u low - 1 2.0 5 
Bosley1994 
(122) 
unclear - u unclear - u unblinded - 0 single-blind - 0.5 high - 0 high - 0 high - 0 0.5 2 
Charles2007 
(67) 
low - 1 low - 1 unblinded/high 
- 0 
single-blind - 0.5 unclear - u high - 0 high - 0 2.5 1 





low - 1 high - 0 high - 0 3.5 0 
Goeman2013 
(124) 





high - 0 low - 1 low - 1 5.0 0 
Janson2009 
(126) 
low - 1 unclear - u unblinded/high 
- 0 
single-blind - 0.5 low - 1 low - 1 low - 1 4.5 1 
Janson2010 
(125) 
low - 1 low - 1 double-blind - 1 single-
blind/intermediate 
- 0.5 
low - 1 low - 1 low - 1 6.5 0 
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low - 1 unclear - u unblinded/high 
- 0 





unclear - u unclear - u unblinded/high 
- 0 





unclear - u unclear - u unblinded/high 
- 0 
unclear - u unclear - u low - 1 high - 0 1.0 4 
Patel2013_c 
(101) 
low - 1 low - 1 unblinded - 0 unclear - u high - 0 low - 1 low - 1 4.0 1 
Perrin2010 
(133) 
low - 1 low - 1 unblinded/high 
- 0 
single-blind - 0.5 unclear - u low - 1 unclear - 
u 
3.5 1 
Rand2007 (135) low - 1 unclear - u unblinded/high 
- 0 





low - 1 unclear - u unblinded - 0 unblinded - 0 unclear - u high - 0 low - 1 2.0 2 
Weinstein2019 
(141) 
unclear - u unclear - u unblinded/high 
- 0 




*For the purpose of the meta-analysis, studies were considered high quality with a score of 2.0 or higher and two or fewer unclear domains. 
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Table 2-14: A systematic review of electronically monitored adherence: Quality assessment (cohort studies) 













Apter1998 (119) low - 2 low - 1 unclear - u  unclear – u low - 1 u 4.0 3 
Apter2003 (56) intermediate - 1 low - 1 unclear - u  unclear – u very low - 2 4.0 2 
Chmelik1994 (139) unclear - u low - 1 single/intermediate - 0.5 unclear – u unclear - u 1.5 3 
Cluley2001 (88) high - 0 unclear - u single blind - 0.5 unclear – u high - 0 0.5 2 
Cohen2009 (90) intermediate - 1 unclear - u unblinded/high - 0 unclear – u very low - 2 3.0 2 
D'Arcy2014 (123) intermediate - 1 high - 0 unblinded - 0 unclear – u high - 0 1.0 1 
Foster2011 (54) intermediate - 1 low - 1 single blind - 0.5 unclear – u low - 1 u 3.5 2 
Krishnan2004 (127) low - 2 high - 0 single/intermediate - 0.5 unclear – u high - 0 2.5 1 
Lacasse2005 (128) intermediate - 1 high - 0 unclear - u  low – 1 low - 1 3.0 1 
Le2008 (60) intermediate - 1 unclear - u unblinded/high - 0 unclear – u unclear - u 1.0 3 
Mann1992_b (130) high - 0 low - 1 unclear - u  unclear – u low - 1 2.0 2 
McGann2008 (132) low - 2 unclear - u unblinded - 0 unclear – u unclear - u 2.0 3 
Plaza2016 (134) intermediate - 1 unclear - u unclear - u  high – 0 very low - 2 3.0 2 
Sulaiman2016_b (74) low - 2 high - 0 unblinded - 0 unclear – u high - 0 2.0 1 
vanderPalen1997 (136) intermediate - 1 high - 0 unblinded/high - 0 unclear – u high - 0 1.0 1 
Wells2016 (137) low - 2 unclear - u unblinded/high - 0 unclear – u unclear - u 2.0 3 
Yeung1994_s1 (138) high - 0 unclear - u unblinded/high - 0 unclear – u very low - 2 2.0 2 
Yeung1994_s2 (138) high - 0 unclear - u single/intermediate - 0.5 unclear – u very low - 2 2.5 2 
 
*For the purpose of the meta-analysis, studies were considered high quality with a score of 2.0 or higher and two or fewer unclear domains. 
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Using the first definition of study quality where study quality 
was differentiated by median score/unclear domains, sensitivity 
analysis did not demonstrate a statistically significant difference 
between the overall study findings and findings in higher 
quality/lower risk of bias studies (Figures 2-8 and 2-9) i.e. study 
quality as defined by the median quality score/number of 
unclear domains did not significantly affect the findings of this 
meta-analysis.   
Figure 2-8: Meta-analysis of study adherence – sensitivity analysis of baseline 
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Figure 2-9:  Meta-analysis of study adherence – sensitivity analysis of electronically 
monitored end of study cohort and control group adherence by study quality (median 
score) 
 
Using the second, more stringent, definition of study quality 
where no unclear domains were permitted, there remained no 
effect on a population estimate by baseline adherence (Figure 
2-10). It did, however, have a significant effect on the 
population estimate of adherence by cohort studies/control 
groups (see Figure 2-11). Studies judged to be higher 
quality/lower risk of bias had a significantly lower adherence 
rate (47.8%, 95% CI 43.0 – 52.4%, I2 0.0%) than studies of 
lower quality/higher risk of bias (66.4%, 95% CI 59.0 – 73.9%, 
I2 95.6%) and as compared to the overall estimate (64.3%, 
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95% CI 57.1 – 71.5%, I2 95.8%). Furthermore, a signal 
towards studies of higher quality/lower risk of bias by this 
definition seeing a greater interventional study effect (SMD) 
when compared with lower quality/higher risk of bias studies 
was observed (Figure 2-12).  
Figure 2-10: Meta-analysis of study adherence – sensitivity analysis of baseline 
electronically monitored adherence by study quality (no unclear domains) 
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Figure 2-11: Meta-analysis of study adherence – sensitivity analysis of electronically 
monitored end of study cohort and control group adherence by study quality (no 
unclear domains) 
 
Figure 2-12: Meta-analysis of study adherence – sensitivity analysis of the SMD in 
interventional studies by study quality (no unclear domains) 
 




2.5.1. Overall study findings 
This review found 35 studies in 34 papers using EMDs to 
measure ICS adherence in a population of 3478 adults 
published up to and including 2017. Estimates of population 
adherence were drawn from a baseline adherence of 73.2% and 
cohort/control group adherence of 64.3%.  
Moderate EMD effectiveness in improving adherence behaviours 
was suggested by a weighted mean difference of 12.7% 
between intervention and control groups. That this led to an 
improvement in clinical outcomes was less clear, with only four 
out of fourteen studies reporting clinical benefit.  
2.5.2. How studies define and measure adherence 
As electronically measured adherence emerges as the gold 
standard of adherence monitoring, clarity of what is meant by 
adherence and how it is measured is required. The prime selling 
point of EMDs over alternative measures of adherence is their 
ability to remotely report detailed patterns of inhaler use, not 
just estimates of canister emptying. This review demonstrated 
important differences between the devices used in different 
studies which go beyond branding. On one end of the spectrum, 
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some devices which did not measure a date and/or time stamp 
were labelled as EMDs. On the opposite end of the spectrum 
were devices which incorporated not only a date and time stamp 
but also an assessment of inhalation quality. In order to provide 
adequate differentiation from other objective forms of 
adherence measurement, the presence of both a date and a 
time stamp should be minimum requirements for an EMD. This 
should be an important consideration in interpreting existing 
evidence and in selecting EMDs going forwards, both for 
research and for clinical practice.  
This review demonstrates a range of accuracies across devices 
and charts the emergence and fall from favour of various 
brands. Some of the more commonly used brands exhibited 
device failures. The possibility that as many as 10% of 
participants may have inaccurate results as a result of device 
malfunction is a matter for concern explored further in Chapter 
4. As new devices emerge onto the market, rigorous 
independent validation data must be a pre-requisite for clinical 
use. Furthermore, studies should be encouraged to reference 
device validation data as a marker of quality. This review 
suggests, however, that pre-existing validation data should not 
lead studies to neglect reporting in-study device accuracy. For 
comparison across the literature, device malfunctions should be 
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reported as a proportion of devices which failed after having 
been issued. Some of these failures may be minor and may not 
affect data integrity but should be reported regardless.  
In reviewing the evidence in adherence measurement, this 
review noted that the widely used surrogate marker of doses 
actuated as a proportion of doses prescribed neither indicates 
dose delivery nor effectiveness. Higher levels of adherence or 
overuse at specific periods (e.g. when symptomatic or before a 
study visit) may also mask underuse at other times. Some 
studies have employed devices capable of detecting drug 
inhalation and even inhalation technique. Others have adjusted 
for overuse by separating dosing periods truncating adherence 
at maximum expected usage. This heterogeneity in how 
adherence is defined and calculated is not new, but should be 
taken into account when comparing outcome measures (46).  
Ideal definitions of adherence are limited by device capabilities. 
There is as yet no available evidence that more complex 
measures are more clinically meaningful, although this would 
intuitively be the case. Until such evidence emerges, however, 
simple measures of temporal adherence which acknowledge 
patterns of overuse (accounting for windows of reduced airways 
anti-inflammatory cover) are likely to be adequate.  
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2.5.3. An EMD-derived estimate of population adherence in asthma 
Two estimates of population adherence were presented. 
Baseline adherence, being “pre-intervention”, should have 
provided the most accurate estimate of real-world population 
adherence. However, measured at the end of short run-in 
periods, the novelty of study participation and physical changes 
in inhaler device may have rendered it particularly susceptible 
to observer (Hawthorne) effect  (143).  
An estimate based on combined control/cohort groups provided 
a larger sample, however this estimate will also have been 
limited by Hawthorne effect. Further limitations to this estimate 
result from intrinsic study design differences. As already 
discussed, some cohort studies included behaviour-changing 
processes (e.g.  assessment of a self-management programme 
(136)) and some control groups received interventions over and 
above usual care (68, 99)).  
Both estimates are higher than previous estimates, particularly 
considering that most previous estimates are based on non-
EMD data (non-EMD data has consistently been shown to result 
in higher adherence estimates than EMD data (107, 108)). This 
may be explained by the requirement of study enrolment for 
provision of EMDs in both the RCTs and cohort studies included. 
Such a requirement sets these studies apart from, for example, 
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managed care database studies, which do not require active 
participation. Consequently participants are not aware that they 
are being observed and do not alter their behaviour. Not only 
does this mean EMD measures are susceptible to Hawthorne 
effect, they also share risks of selection bias as individuals with 
poor adherence may be less motivated to enrol or complete 
studies. Patchy reporting of race/ethnicity, socioeconomic 
status and baseline asthma control (see Table 2-9) may further 
limit their applicability to known at-risk populations.  
That the processes of trial enrolment and participation 
themselves likely impact on adherence is supported by the 
literature. Compliance in clinical trials of ICS from the 2000s 
tended to be reported at rates of over 80%, including when 
measured objectively (144, 145). This was in stark contrast 
with cross-sectional survey data from the same period, where 
even self-reported levels of good adherence (i.e. daily or as 
prescribed ICS use) ran as low as 27% (146-148). Similarly 
retrospective claims data showed that, in patients who 
persisted with therapy, adherence rates could be as low as 50% 
(33) and ICS persistence as low as 10% (33, 149).  
Of interest, sensitivity analysis suggested that studies with a 
lower risk of bias also provided a lower estimate for the 
combined cohort/control adherence than overall estimates 
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(47.8% vs 64.3%) with lower statistical heterogeneity, 
although this was not the case for baseline adherence (69.6% 
vs 73.2%). This further supports the argument that 
electronically monitored baseline adherence measured during a 
run-in period may be more susceptible to a Hawthorne effect 
than measurement over a longer study period. It also suggests 
that studies with a lower risk of bias (for example, better 
blinding practices) see a lower control group adherence rate 
that is closer to that of the general asthma population. These 
studies may consequently see a greater effect size from 
interventions. 
On the basis of the larger sample size and overall longer 
observation period, the combined cohort/control adherence 
estimate of 64.3% is likely to be the more useful measure of 
general population adherence. However, this is with the proviso 
that, for the reasons indicated, it is still likely to be an 
overestimate of real-world adherence, perhaps just as much as 
retrospective prescription data. This also has implications for 
what studies consider to be ‘baseline’ adherence and raises the 
question of whether true baseline adherence can truly be 
measurable using an EMD without truly covert monitoring (i.e. 
no study enrolment or change in inhaler device). As the vast 
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majority of inhalers do not incorporate such capabilities, this is 
not currently possible.  
2.5.4. Interventional studies 
This meta-analysis finds a significant difference between control 
and intervention group end of study adherence in RCTs. 
Adherence interventions ranged from speech recognition 
programmes to improve participant attitudes to their ICS to 
self-management programmes. As also noted by Normansell et 
al., this suggests that EMDs are an effective measure for 
detecting differences between good and poor adherence, 
important for both deployment in interventions and in clinical 
practice (46). The meta-analysis included studies using a range 
of EMDs, suggesting that effectiveness at this level is not 
necessarily dependent on more advanced EMD capabilities. It 
also suggests that, across a range of study designs, poor 
adherence does appear to be amenable to intervention. This 
should lend fresh impetus to addressing poor adherence in the 
clinical setting and to finding effective means of translating 
these potential gains to actual clinically meaningful changes for 
patients with poor adherence with potential benefit. This theme 
is explored in more detail in Chapter 3. 
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2.5.5. Heterogeneity and limitations of the review 
This review was designed to capture as much of the existing 
evidence as possible and determine what could be inferred from 
it to enable progress in the field. Thus its main strength is that 
it provides a comprehensive picture of the state of the art of 
EMDs. As a result of this, however, it has of necessity captured 
studies which have differed in purpose, design and conduct over 
a period of almost three decades. 
Examples of disparity in population beyond basic demographics 
included racial distribution, with some studies recruiting an 
overwhelmingly Caucasian population, whereas one study was 
98% Afro-Caribbean. In some studies, participants were more 
likely to have fixed airflow obstruction or have been hospitalised 
due to their asthma than others. Some of these factors are 
known to impact on both adherence (62) and adverse risk (21). 
Other areas of variation included what studies classed as EMDs, 
how the outcome of adherence was measured, how control 
groups were managed, and the nature of interventions. These 
factors have contributed to an extremely high level of 
heterogeneity, perhaps most clearly demonstrated in the meta-
analysis (I2 generally >75%).  Lower degrees of heterogeneity 
were primarily noted (including in subgroupings) where studies 
were interventional in nature and where studies were deemed 
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to have a lower risk of bias by more stringent criteria, 
suggesting that study design and conduct are key to obtaining 
representative and generalisable data. Thus, whilst such a high 
degree of heterogeneity is a limitation of this review, it also 
highlights disparities in how these studies, including 
interventional studies, are conducted and controlled. 
This impacts the confidence with which results of the meta-
analysis can be asserted. As discussed, control groups provided 
with new inhalers, reimbursement, additional educational and 
motivational interventions, as well as experimental study 
conditions are likely to inflate a supposedly baseline population 
adherence. More stringent definitions of adherence may offer 
lower adherence results, whilst less stringent definitions offer 
higher results, increasing the confidence intervals around the 
estimate. Biases in study conduct may reduce the confidence of 
any interventional effect size. Finally, behavioural interventions 
using (for example) motivational interviewing differ from 
testing dosing regimes.  
The nature of the evidence in this field as it stands is such that 
heterogeneity is inevitable. Attempts to minimise it would have 
led to more stringent inclusion criteria, reducing the breadth of 
the resulting data. Such a limited scope was not the aim of this 
review. However, the limitations which have been discussed are 
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important and the results of this review must be considered in 
light of them. 
 
2.6. Conclusion 
This review finds considerable differences between devices, 
device characteristics, definitions of adherence and study 
designs. Such widespread differences suggest a need for 
minimum standards in electronic monitoring of adherence.  
The review suggests that EMDs are an effective means of 
detecting the difference between good and poor adherence for 
interventional studies. This review further finds an electronically 
monitored adherence rate in the literature of 64.3%. Studies in 
this area are, however, noted to be vulnerable to selection bias 
and observer effect and so it is probable that this rate over-
estimates adherence in the asthma population as a whole.   
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Chapter 3: Electronic monitoring 
devices for improving adherence and 
clinical outcomes in asthma: A 
systematic review 
3.1. Introduction 
Adherence to inhaled corticosteroids (ICS) in asthma is thought 
to be poor. Chapter 2 exclusively used electronic monitoring to 
estimate a population adherence rate of 64% based on cohort 
studies and interventional study control groups. A subset of 
studies from a recent systematic review measuring average ICS 
adherence in adults with asthma suggested adherence levels 
between 22 and 63% (50). The upper limit fell to 50% in 
database studies where participants would not have been aware 
that their behaviour was being watched i.e. removing the 
Hawthorne Effect.  
Several factors have worked to support the increased 
prominence of identifying and modifying non-adherence. 
Firstly, it has been demonstrated that poor adherence to ICS 
and overuse of short-acting beta agonist (SABA) are associated 
with poor asthma outcomes, including risk of exacerbation, 
hospitalisation and death (30-32, 92, 150, 151). Secondly, due 
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to the advent of monoclonal antibody therapies with their 
associated increased cost and potential (if rare) adverse event 
profile, regulatory authorities now insist upon the measurement 
of adherence (5, 34). Thirdly, the advent of new inhaler 
technology makes objective monitoring more feasible.  
Beyond merely monitoring adherence, a new role for inhaler 
technology is emerging with stakeholders exploring its potential 
to effect behaviour change and facilitate care in asthma (152-
154). In Chapter 2, this thesis reviewed studies using electronic 
monitoring to measure adherence, but identified a need for in-
depth assessment of electronic monitoring device (EMD) 
effectiveness when used as a tool for intervention. This chapter 
addresses this need. Proposed mechanisms for EMD-mediated 
behaviour change include targeting causes of unintentional 
non-adherence (e.g. forgetfulness), and providing objective 
adherence data as a springboard for investigating and 
addressing underlying difficulties. It is also possible that the 
user’s knowledge that they are being observed may, at least 
temporarily, bring about improved compliance (the ‘Hawthorne 
Effect’ (155)). 
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3.2. Objectives 
1) Primary objective: to assess whether EMD-based 
behavioural interventions have been demonstrated to 
improve ICS adherence for individuals with asthma in 
controlled studies 
2) Secondary objectives: 
a) To assess whether improved adherence resulting from 
EMD-based behavioural interventions translated into 
improvements in clinical outcomes 
b) To examine the characteristics of studies where 
improved clinical outcomes were achieved in order to 
inform research in this area. 
3.3. Methods 
Medline, Scopus and Web of Science were searched by a single 
investigator for asthma studies using electronic monitors. 
Searches were completed July 2017 and updated January 2019. 
Due to the contemporary nature of the technology, no time 
limits were incorporated into the search criteria (see Figure 3-
1). Studies were included if they were controlled and 
improvement in adherence (i.e. measured comparison over 
time between the prescribed and actual dose of ICS) was either 
a primary or secondary objective. Studies for both adults and 
children were included.  
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Figure 3-1: Search terms 
 
Titles abstracts and full texts were assessed for eligibility. Data 
were extracted from the published full texts and 
supplements/study protocols where readily available for 
narrative synthesis. Data extracted included study design and 
a priori objectives, the nature and role of EMDs used, sample 
Medline 295 
((electronic and monitor* and asthma) or (inhaler and technology and (integrated and 
monitor)) or (asthmapolis or (doser and asthma) or (smartinhaler and tracker) or 
smarttrack or (turbuhaler and pneumotachograph) or (diskus and adherence and logger) 
or (inca and asthma) or (nebulizer and chronolog) or mdilog or smartmist or smarttouch or 
(propeller and asthma) or (Asthma and (smartdisk or smartturbo or smartflow or smartmat 
or smartspray)))).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
+1 (turbohaler and pneumotachograph).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms] 
 (discus and adherence and logger).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms] 
Scopus 511 
( TITLE-ABS-KEY ( ( electronic  AND monitor* )  AND  asthma ) )  OR  ( ( TITLE-ABS-KEY 
( inhaler  AND technology ) )  AND  ( integrated  AND monitor ) )  OR  ( TITLE-ABS-KEY 
( asthmapolis  OR  ( doser  AND  asthma )  OR  ( smartinhaler  AND tracker )  OR  
( smarttrack )  OR  ( turbuhaler  AND  pneumotachograph )  OR  ( diskus  AND adherence  
AND logger )  OR  ( inca  AND  asthma )  OR  ( nebulizer  AND chronolog )  OR  ( mdilog )  
OR  smartmist  OR  smarttouch  OR  ( propeller  AND  asthma ) ) )  OR  ( ALL ( asthma  
AND  ( smartdisk  OR  smartturbo  OR  smartflow  OR  smartmat  OR  smartspray ) ) ) 
+1 turbohaler and pneumotachograph 
discus and adherence and logger 
Web of Science 359 
TS=((electronic monitor* AND asthma) OR (inhaler technology AND (integrated monitor)) 
OR (asthmapolis OR (Doser AND Asthma) OR (Smartinhaler Tracker) OR SmartTrack OR 
(Turbuhaler AND pneumotachograph) OR (Diskus adherence logger) OR (INCA AND 
Asthma) OR (Nebulizer Chronolog) OR MDILog OR SmartMist OR SmartTouch OR (Propeller 
AND Asthma) OR SmartDisk OR SmartTurbo OR SmartFlow OR SmartMat OR SmartSpray)) 
OR TI=((electronic monitor* AND asthma) OR (inhaler technology AND (integrated 
monitor)) OR (asthmapolis OR (Doser AND Asthma) OR (Smartinhaler Tracker) OR 
SmartTrack OR (Turbuhaler AND pneumotachograph) OR (Diskus adherence logger) OR 
(INCA AND Asthma) OR (Nebulizer Chronolog) OR MDILog OR SmartMist OR SmartTouch 
OR (Propeller AND Asthma) OR SmartDisk OR SmartTurbo OR SmartFlow OR SmartMat OR 
SmartSpray)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=1900-2017 
+1 turbohaler and pneumotachograph 
discus and adherence and logger 
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size calculations and baseline population characteristics, with a 
particular focus on characteristics suggestive of a target 
population likely to benefit from EMD-based interventions. 
Outcome measures including measures of adherence, symptom 
control questionnaires, spirometry, and markers of 
exacerbation were also extracted. Author comments on EMD 
reliability and study limitations were noted.  
A meta-analytic synthesis was not conducted. As noted in 
Chapter 2, there was a significant degree of heterogeneity even 
between interventional studies. Even though this review was 
designed to have a narrower remit, it was still designed to 
capture a range of interventions, which would render a meta-
analysis susceptible to any of the same concerns as discussed 
regarding the interventional studies in Chapter 2. 
 
3.4. Results 
A flow diagram of included studies from the July 2017 search is 
shown below (Figure 3-2). Ten studies published between 2003 
and 2018 were identified from 1963 records screened: 1165 
screened from the initial search and 798 screened from 
bibliography searches (67-71, 99, 100, 118, 156, 157). From 
the January 2019 update, 271 new titles were identified, 33 of 
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which met the criteria for abstract screen and one of which met 
criteria for inclusion in this review (158).  
 
Figure 3-2: EMD as intervention - study flow 
 
Included studies had a combined population of 1510 
participants from Australia, the Netherlands, New Zealand, the 
Republic of Ireland, the United Kingdom and the United States 
of America. The studies lasted between ten weeks and twelve 
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months with a median duration of six months. Mean age ranged 
from 5.9 to 53.0 years. 
3.4.1. Study design 
Five of the studies reviewed were in adults only (68, 99, 100, 
118, 157), one (classified in this review as an adult study) 
recruited adults and adolescents (67) and the remaining five 
studies were in children (69-71, 156) (Table 3-1). Nine studies 
were reported as randomised controlled (67, 69-71, 99, 100, 
118, 156, 158), one as cluster-randomised, controlled (68) and 
one as cluster controlled (157) (Table 1). 
As with Chapter 2, significant heterogeneity is noted in the 
studies included in this review. Even accounting for population 
age (the review includes studies across the lifespan), there was 
significant heterogeneity in baseline reported ICS dose and in 
baseline adverse risk profile (i.e. lung function and exacerbation 
history). Table 3-1 further highlights differences in the kinds of 
interventions.  
The studies tested the following interventions: 
 EMD + reminder (67, 70, 71, 158) 
 EMD + feedback/behavioural intervention (100, 
118, 156) 
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 EMD + reminder + feedback/behavioural 
intervention (68, 69, 99, 157) 
Reminders were essentially integrated alarm systems which 
would sound in the event of missed doses. Feedback involved 
adherence discussions based on EMD-derived adherence data. 
Two studies tested more standardised, evidence-based 
behavioural research as part of the intervention. One tested a 
“problem solving approach”, individualised conversations 
successfully trialled in diabetes which involved addressing 
barriers with agreed solutions that were then evaluated and 
adapted (118). The second tested “personalised adherence 
discussions”, a form of motivational interviewing conducted by 
the patient’s own primary care practitioner who had been 
trained in the technique (68).  
There were also differences in EMDs and their capabilities. 
Adherium’s Smartinhaler™ was the most commonly used EMD 
brand, used in six of the studies (67-69, 71, 156, 157). These 
EMDs did not account for inhaler technique in adherence 
calculations as the INCA device does. Finally, again similar to 
the previous review, Table 3-1 demonstrates considerable 
variation in what is constitutes a ‘control’ group. 
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Adults 6 months (26 weeks) 
2 week run-in 
(baseline - week 2) 
Intervention initiation 
(week 2) 
3 months intervention 
(months 1, 2, 3) 
3 months observation 
(months 4, 5, 6) 
Problem solving (PS) intervention = 4x30 min 
sessions 
“Non-judgemental” feedback of ICS electronic 
monitoring device (EMD) data to inform PS 




Diskus Adherence Logger (DAL, 
developed by research group) 
MDI-Log (commercially available) 
Burgess (156) 2010 Australia Randomised 
controlled 
Children 4 months  
Baseline  
Months 1, 2, 3, 4 
Feedback of preventer EMD data to parent, 
child and physician, incorporated into 
management plan for following month 
EMD, no feedback Smartinhaler™ (commercially 
available, reference to validation 
study) 
Chan (71) 2015 New Zealand Randomised 
controlled 
Children 6 months  
Baseline 
Months 2, 4, 6 
EMD, audio-visual reminder (AVR) enabled EMD, no AVR SmartTrack Smartinhaler™ 
(commercially available, 
reference to reliability study) 





Baseline (-2 weeks), 
Weeks 0, 6, 12, 18, 24 
EMD, AVR enabled EMD, no AVR Smartinhaler™ (commercially 
available) 










Week 4  
Investigators:  
Week 1 
Months 2, 4, 6 
Inhaler reminders and feedback (IRF) group: 
EMD, AVR option enabled/online automated 
reports + GP feedback at four weeks/inter-
current review  
IRF + Personalised adherence discussions 
(PAD) group: 
EMD, AVR option enabled/online automated 
reports + GP feedback with personalised GP-
led PAD discussions 




reference to reliability study) 


























Children 1 month 
Baseline 
30 days 
EMD, Way to Health platform text messaging EMD, no text Propeller 




Adults 6 months 
Baseline, Intervention 




not completed, All - 
Month 6 
Initial visit with 1:1 counselling 
Two-weekly CARAT questionnaire with 
automated feedback/personalised feedback 
for low or deteriorating scores 
EMD + app reminder/visual app adherence 
feedback 
EMD + app/visual app adherence feedback + 









reference to validation data) 
using TurbuPlus platform 
(AstraZeneca) 




Children 12 months 
Baseline 
Months 3, 6, 9, 12 
EMD, AVR enabled + adherence feedback 
informing personalised management 
strategies 
EMD, no AVR 
or feedback - 
standard asthma 
review 
SmartTrack and SmartTurbo 
Smartinhaler™ (commercially 









Adults 10 weeks 
Baseline 
Days 7, 14, 21, 42, 70 
Direct feedback on ICS use by a “clinician 
investigator” 
EMD, usual care MDI Chronolog (commercially 
available) 




Adults 3 months  
Baseline 
Months 1, 2, 3 
EMD, direct (bio)feedback on inhaler use 





INCA (developed by research 
group, reference to validation 
studies) 




Children 12 months 
Baseline 
Months 3, 6, 9, 12 
EMD + tailored short messaging service  (SMS) 
reminders 






* Control of Allergic Rhinitis and Asthma Test (CARAT) 
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Six studies reported allocation concealment (67-71, 156) (see 
also Table 3-2). Methods of blinding reported included blinding 
participants to the study hypothesis (100) and fully covert 
monitoring either for all participants (67, 71) or for control 
participants/clinicians (68). They also included blinding the 
research team collecting participant data, delivering standard 
care or delivering interventions (68, 100). Three studies did not 
specify such blinding, but did specify that control participants’ 
adherence data was not looked at by study team in contact with 
the participant for the duration of the study (69, 156, 159). In 
one study, neither participants nor the research team had 
access to the data until the end of the intervention period, 
although it did not specify whether the team had access to data 
prior to other outcome measurement (158). One study only 
downloaded participant data once study visit procedures were 
complete (67). Only one study specified researcher blinding for 
any part of the analysis (159) (Table 3-2). 
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Apter (118) Use of a PS vs. standard asthma education (AE) 
“improves adherence and asthma-related health 
outcomes”. 
Blinded to hypothesis but 
not to (EMD) function 
 
Not reported Financial incentives ICS 
supplied if no insurance 
coverage or reimbursed if 
co-payment  
Burgess (156) “Measuring [preventer] adherence in children with 
unstable asthma and providing feedback [increases] 
adherence over the medium term.” 
Deliberate blinding not 
reported 
Study team delivering control management 
blinded to control adherence 
Not reported 
Chan (71) EMD with AVR improves adherence and asthma 
outcomes in school-age children following emergency 
department (ED) attendance for asthma exacerbation. 
Blinded to EMD 
function/study hypothesis 
(covert monitoring) 
Not reported Participants provided with 
inhalers 
Charles (67) An EMD with AVR improves ICS adherence in adult 
asthma. 
Blinded to EMD 
function/study hypothesis 
(covert monitoring) 
No intentional blinding reported, however 
data at each visit only downloaded after 
study participant had completed study 
procedures. 
Not reported 
Foster (68) Use of IRF, PAD incorporating Information-Motivation-
Behavioural skills model, or a combination of the two 
(IRF + PAD) improves adherence to combination  
ICS/long-acting beta agonist (LABA) inhaler and asthma 
control in poorly controlled, moderate-severe asthma 
compared with usual care (UC). 
 
Partially blinded- PAD/UC 
participants not informed of 
EMD function (covert 
monitoring). 
All participants blinded to 
study hypothesis.  
GPs randomised to a single intervention 
and blinded to other interventions. 
Minimal investigator involvement – study 
visits at baseline and 4 weeks conducted by 
GP. Investigator collecting telephone data 
blinded to study group. All other 
questionnaires via post. MiniWright Digital 
spirometer supplied to participants. 
 








Kenyon (158) A daily reminder text message intervention in a cohort 
of high risk children improves electronically monitored 
adherence following emergency department 
attendance or hospital admission for exacerbation of 
asthma. 
Participants in both arms 
provided with a “control” 
version of the app for data 
transmission purposes only. 
Blinding to purpose of EMD 
function not reported. 
 
Not reported. Study team unable to access 
data during intervention but unclear 
whether accessed prior to outcome data 
collection. 
$60 ($20 per survey at 
baseline, 30 days and 60 
days) 












Kuipers (157) “Prospective monitoring with patient-reported CARAT 
scores” informing “tailored pharmacists’ interventions” 
improves asthma control compared with usual care. 
Partially blinded to 
hypothesis 
Unblinded – all pharmacists have EMD data 
available but only intervention pharmacists 
to use, however control pharmacists did 
not have scheduled follow-up contact with 
participants. 
Not reported 
Morton (69) Use of EMD with AVR and feedback in the routine 
clinical setting with children with poorly controlled 
asthma would, “by addressing both the intentional and 
non-intentional adherence barriers”, increasing 
adherence rates “to a degree necessary to improve 
asthma control and clinical outcomes.” 





Use of “direct, non-judgemental clinician-to-patient 
feedback of inhaled steroid use” improves adherence 
compared with usual care. 
Blinded to study hypothesis, 
no blinding to EMD function 
Study staff delivering standard care blinded 
to study group for intervention visits. 
Clinicians blinded to control adherence 
data.  
ICS and salbutamol supplied 
to self-pay participants 
Sulaiman (99) “Visual (bio)feedback to the patient of their specific 
components of adherence [improves] adherence.”  
Not blinded to study 
hypothesis or EMD function 
but control group are 
blinded to own adherence 
data  
Automated adherence analysis; validated 
by two raters unaware of study group or 
clinical outcomes and uninvolved in clinical 
care. 
Salmeterol/fluticasone 
discus supplied by study 
team with INCA device 
loaded, exchanged monthly 
Vasbinder (70) EMD with tailored SMS reminders “[improves] 
adherence to ICS and… subsequently… asthma control, 
asthma-related quality of life and [reduces] asthma 
exacerbations” compared to EMD alone. 
Not blinded Not reported Not reported 
Page | 109  
 
Nine studies reported power calculations, five for adherence 
only (67, 70, 99, 118, 156), two for outcomes in asthma only 
(68, 69) and two for both (71, 157) (Table 3-3). Of note is the 
degree of variation in the ideal sample sizes required by these 
different power calculations. Four did not meet their recruitment 
targets (68, 70, 99, 118). Three studies reporting recruitment 
by group, study retention and primary analysis (i.e. intention to 
treat vs. per protocol) were fully powered for their intention to 
treat analysis (69, 71, 99). 
3.4.2. Population characteristics 
Most studies had majority female participants (67, 68, 70, 99, 
100, 118, 156, 157) as shown in Table 3-4. Three studies 
measured baseline adherence – one objectively (157), one 
subjectively (158) and one both objectively and subjectively 
(118), also shown in Table 3-4. Subjective asthma control was 
generally measured by validated questionnaire. Three of the 
four studies in children reporting use of the Childhood Asthma 
Control Test (C-ACT™) or Asthma Control Questionnaire (ACQ) 
showed baseline uncontrolled asthma (69, 71, 158). In adults, 
all four studies reporting control by questionnaire showed mean 
values consistent with uncontrolled asthma (68, 99, 118, 157).  
Page | 110  
 
Table 3-3: Review of EMD-based interventional studies – study power 





Effect size - Other Randomised/  
Allocated 
Completed 













Apter (118) 330 overall 10% - 333  Not reported Not reported Intention to 
treat (ITT) 
Not reported   








10% Schooldays missed 6 
day drop, asthma 
morbidity score 30% 
reduction 
220 213 (97) 108 105 ITT 110 IG / 110 CG 100 216 
Charles (67) 100 10% - 110 90 (82) 44 46 Apparent per 
protocol 
44 IG / 46 CG 82 90 
Foster (68) Over-recruit to 220 
(to allow for 15% 
attrition) 
- Improvement in 






PAD – 21 patients 
IRF – 35 patients 





21 PAD / 35 IRF / 
32 IRF + PAD / 41 
UC 
90 69 
Kenyon (158) - - - 41 32 (78) 15 17 Apparent per 
protocol 
15 IG / 17 CG  78  
Kuipers (157) 
 
Over-recruit to 80 (to 
allow for 5% 
attrition) 
15% CARAT: 4 
point 
difference 
80 68 (85) CARAT + TurbuPlus - 16 
CARAT only - 19 
TurbuPlus only - 16 
17 Not reported 39 EMD / 41 No 
EMD 
100 105 
Morton (69) 76 overall (over-
recruit to 90 to allow 
for 15% attrition) 
- ACQ: 0.5 90 77 (86) 39 38 ITT 47 IG / 42 CG 99 117 
Onyirimba 
(100) 
- - - 30 19 (63) 10 9 Apparent per 
protocol 
10 IG / 9 CG 63  
Sulaiman 
(99) 
200 10% - 218 
111 - IG 
107 - CG 
195 (89) 100 95 ITT 105 IG / 101 CG 94 103 
Vasbinder 
(70) 
110 per group 15% - 219 
108 - IG 
111 - CG 
209 101 108 ITT 101 IG / 108 CG 95 95 
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* Intervention group (IG) 
† Control group (CG) 
‡ Asthma Control Test™ (ACT™) 
Table 3-4: Review of EMD-based interventional studies – baseline characteristics 
First Author Mean Age Sex Asthma Control Asthma 
Quality of Life 
Mean FEV1 
(%Predicted) 
≥1 Exacerbation in 
previous 12 Months 





Apter (118) Overall: 49 (14) 
IG: 49 (13) 




IG: 122 (74%) 
CG: 119 (71%) 
Mean ACQ  
Overall: 1.67 









Overall: 172 (52%) 
IG: 86 (52%) 
CG: 86 (51%) 
Hospitalisation  
Overall: 103 (31%) 
IG: 52 (32%) 
CG: 51 (30%) 





P values not 
significant 
Burgess (156) IG: 9.1 
CG: 9.3 
Male  
IG: 11 (42.3%) 
CG: 7 (26.9%) 
Symptoms or 
reliever use ≥3x in 
last week 
IG: 10 (38.5%) 
CG: 8 (30.8%) 
Not measured IG: (72.9%) 
CG: (77.5%) 
Not measured Mean daily dose 
IG: 300 mcg 
(200-500) 
CG: 250 mcg 
(50-500) 
Not measured P values not 
significant 
Chan (71) IG: 8.9 
CG: 8.9 
Male 
IG: 55 (50%) 
CG: 58 (53%) 
Mean C-ACT™ 
IG: 18.8 / CG: 18.8 
Mean asthma 
morbidity score 
IG: 9.3 / CG: 9.2 
Not measured IG: (92%) 
CG: (90%) 
ED 
Overall: 100% (inclusion 
criterion) 
Not reported Not measured None reported 
Charles (67) Median  
IG: 39 (13-65) 
CG: 35 (15-64) 
Male  
IG: 28 (50.9%) 
CG: 22 (40%) 
Not measured Not measured PEF† 
IG: 434 / CG: 444 
Not measured Median daily dose 
IG: 500 mcg 
(100-2000) 
CG: 500 mcg 
(100-4000) 
Not measured Reported as nil 
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First Author Mean Age Sex Asthma Control Asthma 
Quality of Life 
Mean FEV1 
(%Predicted) 
≥1 Exacerbation in 
previous 12 Months 





Foster (68) Overall: 40.3 (15.2) 
PAD: 42.3 (15.6) 
IRF: 40.0 (13.7) 
IRF + PAD: 39.7 
(17.7) 











IRF + PAD: 14.1 
UC: 14.6 











Mean daily dose 
Overall: 718 mcg 
PAD: 722 mcg 
IRF: 704 mcg IRF + 
PAD: 777 mcg 
UC: 683 mcg 
Not measured Lower 
proportion of 




Kenyon (158) Overall: 5.9 (2.1) 
IG: 6.1 (2.1) 
CG: 5.8 (2.1) 
Male 
Overall: 22 (54%) 
IG: 12 (57%) 
CG: 10 (50%) 
Mean C-ACT™ 
Overall: 17.3 (4.4) 
IG: 17.8 (4.3) 
CG: 17.2 (4.6) 
Not measured Not measured Mean ED visits 
Overall: 1.0 (1.5) 
IG: 1.0 (1.5) 
CG: 1.0 (1.6) 
Mean hospitalisations 
Overall: 0.4 (0.7) 
IG: 0.3 (0.6) 
CG: 0.5 (0.8) 




IG: 65% (23%) 
CG: 62% (25%) 
Caregiver 
education level 
higher in control 
group  
Kuipers (157) EMI‡ vs. No 
IG: 44.08 (6.93) 
CG: 40.17 (12.71) 
EMI vs. No 
Female  
IG: 21 (53.8%) 
CG: 29 (70.1%) 
EMI vs. No 
CARAT lower airways 
IG: 12.95 / CG: 12.98 
CARAT total 
IG: 20.95 / CG: 20.73 
Not measured Not measured EMI vs. No 
Mean (range) No of OCS§ 
courses 6 months 
IG: 0.10 (0-2) 
CG: 0.12 (0-1) 





Mean age higher 
in IG (CARAT) 
group 
Morton (69) IG: 10.4 (2.9) 
CG: 10.2 (2.9) 
Male 
IG: 28 (60%) 
CG: 22 (52%) 
ACQ  






Previous 3 months: 
Number of OCS courses 
IG: 1.2 / CG: 1.2 
ED/GP visit  
IG: 1.9 / CG: 2.1 
Hospitalisation 
IG: 0.3 / CG: 0.2 
Mean dose  
IG: 697.9 mcg 
CG: 664.3 mcg 
Not measured Not reported 
Onyirimba (100) IG: 45 (11) 













IG: 2.3 / CG: 1.0 
IG: 946 mcg 
CG: 928 mcg 
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First Author Mean Age Sex Asthma Control Asthma 
Quality of Life 
Mean FEV1 
(%Predicted) 
≥1 Exacerbation in 
previous 12 Months 





Sulaiman (99) Overall: 49.2 
IG: 48.2 CG: 50.3 
Female 
Overall: 64% 










2.2 L (73.0%) 
IG: 2.2 L (75.1%) 
CG 2.1 L (70.8%) 
Number of OCS courses 
Overall: 3.9 
IG: 4.1 / CG: 3.8 
Proportion on 
500mcg ICS device 
Overall: 65% 
IG: 64% / CG: 65% 
Not measured P values not 
significant 
Vasbinder (70) IG: 7.8 (2.2) 
CG: 7.7 (2.1) 
Male 
IG: 59 (58.4%) 






IG: 39 (39.8%) 




Not measured Not measured Not reported 
directly as daily 
dose 
Not measured None reported 
 
* Asthma Quality of Life Questionnaire (AQLQ)  
† Peak expiratory flow (PEF) 
‡ Electronic monitoring of the intake of inhalation medication (EMI) 
§ Oral corticosteroid (OCS) 
¶ Proportion of days covered (PDC) 
# Paediatric Quality of Life Questionnaire (PAQLQ) 
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Eight studies reported baseline exacerbations. Two of the three 
paediatric studies reporting baseline exacerbations had 
populations which, on average, suffered at least one 
exacerbation within the three months preceding enrolment (69, 
71). Four adult studies reported exacerbations within the 
preceding year (99, 100, 118, 157), with the reported 
proportion of participants who had exacerbated ranging 
between 32% and 100% (Table 3-4). One adult study reported 
exacerbations in the preceding six months but had a mean rate 
of 0.10 oral corticosteroid (OCS) courses per intervention 
participant and 0.12 courses per control participant (157).  
3.4.3. Outcomes 
Adherence 
Adherence was generally measured as an average percentage 
of the doses taken over a specified period of time divided by the 
number of doses prescribed and capped at a maximum of 100% 
i.e. overuse of ICS was not included in the adherence measure 
(Table 3-5). Kuipers et al. used a prescription measure as their 
outcome adherence measure (157). Three studies specifically 
reported on ICS overuse (67, 99, 100). One study also assessed 
the quality of the dose taken (99). 
Eight studies reported absolute differences in average 
adherence between control and intervention arms, ranging 
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between 10% and 54% (Table 3-6). The largest differences 
were recorded by Chan et al. in children (71), and Onyirimba et 
al. in adults (100), described in Table 3-6. One study did not 
report an absolute difference but noted a four-fold higher 
adherence in their EMD group versus their non-EMD group 
(157). Only two of the eleven studies observed no improvement 
in adherence after use of an EMD as part of an adherence 
intervention (118, 158). However, one of these studies did find 
that participants with low social support, higher exposure to 
violence and low income did have a higher adherence in 
response to the intervention (118). 
Of studies reporting adherence over time, three showed decline 
(including a decay of any gains made in adherence) across both 
intervention and non-intervention arms (68, 71, 118). Two 
showed initial decline (over the first halves of a six and twelve 
month study respectively) and then stabilisation (67, 70). The 
remainder showed a separation between the intervention group 
and control groups, the former of which were able to maintain 
their gains in adherence (69, 99, 100, 156).  
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Primary Outcome Measure 
 
Secondary Outcome Measures 
 
Significant Primary Outcomes 
 
Significant Secondary Outcomes 
Apter(118) Adherence to ICS regimen 
prescribed by the patient’s 
physician 
= (number of actuations 
downloaded/number 
prescribed) x 100) 




4. ED/hospital for asthma 
5. ED/hospital for any cause 
Reduction in adherence by 10% in 
intervention group and 14% in control group 
(p=0.0004). 
Post-hoc better adherence with intervention 
if baseline low social support (p=0.003), high 
exposure to violence (p=0.007) and low 
income (p=0.03). 
Improved ACQ (p=0.002), mini-AQLQ (p<0.0001), 
first and second visit FEV1 (p<0.01) in both groups 
(no significant difference between groups). 
Post-hoc significant AQLQ improvement if baseline 
low CES-D* scores (p=0.007). 
Post-hoc significant FEV1 improvement if baseline 
low AQLQ (p=0.03) or numeracy (p=0.007). 
Burgess (156) Adherence to ICS =% of 
prescribed doses 
(midday/midnight for twice 
daily dosing) 
1. History of symptoms > twice in a 
week requiring reliever 
2. FEV1 % predicted 
NB Not specified in methodology 
Mean adherence 79% in active vs. 
57.9% in control (p<0.01). 
Control group adherence deteriorated 
slightly over study course, intervention group 
adherence rose (p<0.01). 
Symptom control as measured by reported reliever 
use significantly improved in both groups (p=0.02). 
FEV1 improved significantly in both groups - baseline 
75% to 85.2% (p<0.01). 
Chan (71) Adherence to ICS = degree 
of deviation from prescribed 
dose subtracted from 1 
(max 0% non- adherence) - 
measured midday/midnight 
School day absence 
(proportion of total number 
of possible schooldays 
missed) 
1. Asthma morbidity score 
2. C-ACT™ 
3. FEV1 % predicted 
4. ED attendance 
5. Caregiver work absence 
6. >=1 day 
7. Exacerbations 
8. Number of days of reliever use 
(electronically monitored) 
Median percentage adherence 84% in 
intervention vs. 30% in control (p<0.0001). 
Higher proportion in intervention group had 
adherence >70%. 
Fall in overall adherence in both groups at 
same rate. 
Greater improvement in asthma morbidity score in 
intervention group (2.0 vs. 1.2 point reduction, 
p=0.008). 
C-ACT™ significantly different at 2, 4 and 6 months 
(p<0.0001) although no significant improvement 
with time beyond 2 months. 
Improvement in reliever use (median 9.5% days 
intervention vs. 17.4% control, p=0.002). 
Difference in exacerbations at 0-2 months (7 vs. 26, 
p=0.015) but nil thereafter. 
Significant improvement in FEV1 in both groups 
(p=0.0003). 





Primary Outcome Measure 
 
Secondary Outcome Measures 
 
Significant Primary Outcomes 
 
Significant Secondary Outcomes 
Charles (67) Adherence to ICS (2 doses 6 
hours apart calculated as a 
proportion of prescribed 
doses % truncated at 100% - 
doses after midnight 
counted for previous day if 
before going to 
bed) 
1. >50%/80%/90% adherence 
2. Proportion of medication taken as 
prescribed in 2 week periods 
around appointments 
3. Proportion of medication taken as 
prescribed in 4 week periods 
between clinic assessments 
4. >50%, >80%, >90% 
5. PEF 
6. ACQ 
7. Rates of dose dumping 
In final 12 weeks, median adherence was 
93% intervention vs. 74% in control 
(p<0.0001). Mean values for the same period 
were 88% intervention vs. 66% in control. 
Taking >50% medication 95.5% intervention vs. 
71.7% control (p=0.003). 
Taking >80% medication 88.6% intervention vs. 
39.1% control (p<0.0001). 
Taking >90% medication 63.6% intervention vs. 
19.6% control (p<0.0001). 
Fall in overall adherence in both groups in first 12 
weeks, stable for next 12 weeks. 
Final 4 weeks, intervention group underestimated 
missed doses by mean of 3, control by mean 12.2 
(p=0.001). 
Dose dumping 10 occasions in intervention and 43 
occasions in control group (p=0.008). 




5. Prednisolone courses (severe 
exacerbations) 
ACT™ improvement all groups (overall mean 
change 4.5, p<0.0001, clinically meaningful 
threshold surpassed). 
Significantly higher adherence in both IRF vs. non 
IRF (73% vs. 46%, p<0.0001). 
Adherence decreased in all groups over time. 
Overall improvements in AQLQ (p<0.0001), anxiety 
(p=0.022), MARS-A (p=0.008). 
Kenyon (158) Feasibility  1. 30 day ICS adherence 
2. 30 day change in C-ACT™ 
  
Kuipers (157) CARAT 1. MARS-5§/ICS refill (PDC) adherence 
2. Exacerbations (pharmacy systemic 
steroid dispensing data) 
4.52 fold increase in refill adherence 
>80% in subgroup provided with EMD compared to 
no EMD (95% CI 1.56- 13.1). 





Primary Outcome Measure 
 
Secondary Outcome Measures 
 
Significant Primary Outcomes 
 
Significant Secondary Outcomes 
Morton (69) ACQ 1. FEV1 % predicted 
2. GP/ED asthma unplanned 
attendance 
3. Number of OCS courses reported 
4. Number of days of school due to 
asthma reported 
5. Reported beta agonist use 
6. BTS# level of asthma therapy 
7. Mini PAQLQ 
8. Adherence per 3 months (mean 
daily actual/prescribed x100) 
capped at 100% 
9. Parental BMQ** 
10. Parental IPQ†† 
ACQ decreased in both groups exceeding 
MID¶ by month 3 and maintained until 
month 12. 
Adherence 70% over 12m for intervention group vs. 
49% for controls (p≤0.001). 
Adherence maintained for 12 month period for 
adherence group but fell in controls. 
20 intervention participants vs. 6 controls had >80% 
adherence maintained for the 12 months. 
4 intervention participants vs. 11 controls had rates 
<30%. 
FEV1 improved in both arms with no sig diff 
between arms at 12m 
Intervention has lower event rate for OCS courses 
(p=0.008) and hospital admissions (p<0.001). 
Onyirimba 
(100) 
ICS adherence = mean 
weekly adherence 
(actuations/prescribed x 
100 for each day truncated 
to 100%) and percentage 
days overuse 
1. Daily albuterol electronically 
monitored (mean actuations/24h 
per week) 
2. Nighttime albuterol electronically 
monitored (mean nightly (1-5am) 
actuations per week) 
3. AQLQ 
4. FEV1 
Adherence comparable at wk 1 (61% 
vs. 51%) but separation at wk 2 (81% 
intervention vs. 47% control, p=0.003) 
maintained to the end of the study 
(p<0.0001). 
Control adherence declined to below 30% at 
wk 10, however from week 2 onwards, 
intervention group adherence maintained at 
>70%. 
AQLQ improved from baseline in both groups 
(p<0.05). 
Sulaiman(99) Rate of actual adherence at 
3 months (cumulative drug 
exposure in final month) 
Combined measure of asthma control 
generated from PEF, ACT™, AQLQ and 
adherence. 
Mean actual adherence 73% in intervention 
vs. 63% in controls (p≤0.01). 
Greater change in adherence over study 
period in intervention vs. control (p=0.02). 
Increase in intervention adherence over 
study period by 7.5% (p<0.01), fall in control 
group by 3.4% (p<0.01). 
52 (35%) uncontrolled overall with adherence <80%. 
40 (27%) uncontrolled with adherence >80%. 
0 cases of attempted dose dumping in intervention 
vs. 14 cases in control. 





Primary Outcome Measure 
 
Secondary Outcome Measures 
 
Significant Primary Outcomes 
 
Significant Secondary Outcomes 
Vasbinder (70) Temporal ICS adherence = 
proportion of prescribed 
doses recorded as taken 
within 6 hours (3 hours pre-, 
3 hours post-) of planned 
dose. 
1. C-ACT™ 




4. Costs (health and societal) 
Adherence was 69.3% in intervention vs. 
57.3% in control (95% CI for difference 6.7-
17.7%). 
Estimated treatment effect significant for 
both first and second 6 month periods but 
larger in first 6 months, adherence declined 




* Center for Epidemiologic Studies Depression (CES-D) Scale 
† Hospital Anxiety and Depression Scale (HADS) 
‡ Medication Adherence Report Scale for Asthma (MARS-A) 
§ Medication Adherence Report Scale (MARS) 
¶ Minimally important difference (MID) 
# British Thoracic Society (BTS) 
** Beliefs about Medicines Questionnaire (BMQ) 
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Table 3-6: Review of EMD-based interventional studies – summary of key adherence and clinical outcome findings and EMD performance  
First Author Difference in Adherence between 
Intervention and Control Groups 
Significant Asthma Outcomes EMD Pre-test and Study Performance 
Apter(118) 3% difference in means, not significant. Nil Monitor download failure  
Overall: 380 (20%) / Intervention: 18% / Control: 22% 
Burgess (156) 21% difference in means (p<0.01) Nil Not reported 
Chan (71) 54% difference in medians (p<0.0001) 52% 
difference in means 
Greater improvements in asthma morbidity score and 
ACT™ in intervention group over study period. Lower 
median reliever use in intervention group over study 
period. Lower patient-reported exacerbation rates in 
intervention group at two months; however this 
difference did not persist. 
Devices not returned  
Overall preventer: 16 (2%) 
Overall reliever: 65 (9%)  
Complete download available 
Overall preventer: 678 (all remaining)  
Overall reliever: 632 (all remaining) 
Charles (67) 19% difference in medians (p<0.0001) 22% 
difference in means 
Nil Not reported 
Foster (68) 27% difference in means (p <0.0001) Nil 5 devices failed in study, no data available for 6/143 due to device 
failures, 15 couldn’t be contacted to activate device, 8 lost device. 
Kenyon (158) 4% difference in adjusted means, not 
significant 
Nil 6 couldn’t be contacted to activate device; 3 had devices which only 
began to work after 30 day intervention period 
Kuipers (157) ICS refill >80% 4.52-fold (95% CI 
1.56-13.1) 
Nil Not reported 
Morton (69) 21% difference in means (p≤0.001) Fewer courses of OCS (p=0.008) and hospital admissions 
(p<0.001) in intervention group. 
Reported broken: Intervention: 23 (50%) / Control: 8 (19%) 
Objectively damaged: Intervention: 17 (37%) / Control: 2 (5%) 
Forgotten: Intervention: 10 (22%) / Control: 18 (43%)  
Lost: Intervention: 5 (11%) / Control: 2 (5%) 
Onyirimba (100) 34% difference in means week 2 (p=0.003) 
>40% study end (visual examination 
of graph) 
Nil Not reported 
Sulaiman(99) 10% difference in rates (p≤0.01) Nil Intervention group 12 device failures Control group 35 device failures 
(603 devices returned - see consort diagram - giving a failure rate of 
7.79%) 
Vasbinder (70) 12% mean (95% CI 6.7-17.7%) Nil Not reported 
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Asthma control 
At two months, Chan et al. reported a significant difference 
between study groups in parent-reported exacerbations, 
however this did not persist (71). Morton et al. reported a 
difference between study groups in OCS course and hospital 
admission event rates over the study period as shown in Table 
3-5 (69). Foster et al. reported an unadjusted difference 
between patients in the EMD groups vs. non-EMD groups 
experiencing severe exacerbation (measured by OCS courses) 
over the study period (11% vs. 28%, p=0.013). The adjusted 
value, however, was not statistically significant (p=0.06) (68). 
Three studies found a significant difference in asthma morbidity 
over the course of the follow-up period (see also Table 3-5). 
The first found a significant and clinically meaningful difference 
in both asthma morbidity score and C-ACT™ between 
intervention and control arms, although C-ACT™ plateaued at 
two months (71). Two others found significant and clinically 
meaningful improvements in reported asthma control across 
the study population over the course of the study, but no 
difference between control and intervention arms (68, 69).  
Several studies looked at reliever use as an outcome measure 
(69, 71, 100, 156), although only Chan et al. and Onyirimba et 
al. measured this objectively using EMDs (Table 3-5). Chan et 
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al. reported a significant difference in the median percentage of 
days of reliever use between groups over the study period (71); 
however, this did not have a significant interaction with time. 
Onyirimba et al. found no significant difference in reliever use 
between groups (100). 
In children, all three studies reporting baseline FEV1 (69, 71, 
156) showed an overall improvement in FEV1 across their study 
populations but no significant differences, including in degree of 
improvement in FEV1, between intervention and control groups. 
Of the four adult studies reporting percentage predicted FEV1 at 
baseline, only Apter et al. reported an improvement in FEV1 in 
a post-hoc sub-group analysis of participants with low baseline 
numeracy or AQLQ score (118). 
Devices 
Six studies reported problems with devices (68, 69, 71, 99, 118, 
158) - generally participants not returning or damaging their 
devices (Table 3-6). 
3.4.4. Study quality 
Tables 3-7 and 3-8 present an evaluation of study quality for 
this review. Only three studies (68, 69, 71) reported in all areas 
considered. One study (71) was judged to have a 
low/intermediate risk of bias in all of the areas considered. The 
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main areas of concern were blinding, loss to follow-up and 
device reliability. Also of concern were the number of areas 
which were not reported (see Tables 3-7 and 3-8). Strengths of 
the studies included that they were randomised (with the 
exception of one study (157)) and that they were generally 
analysed in line with the original allocation intention, making 
their findings more applicable in a real-world setting. 
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Table 3-7: Review of EMD-based interventional studies – study quality (design) 
Low risk of bias 
 Randomised at person- level 
 Allocation concealment 
 Subject blinded to study hypothesis and 
EMD function 
 All of interventions/standard care/data 
collection/analysis blinded 
Intermediate risk of bias 
 Randomised but not at person level 
 Subject blinded to hypothesis but not to 
EMD function; some subjects blinded to 
study hypothesis and/or EMD function 
 One or more (but not all) of 
interventions/standard care/data 
collection/analysis blinded 
Higher risk of bias 
 Not randomised 
 No allocation concealment 
 Subject aware of both EMD function 
and study hypothesis 
 Study team unblinded to all of 
interventions/standard care/data 
collection/analysis blinded 









Blinding - Subject (hypothesis and/or EMD 
Function) 
 
Blinding - Intervention Delivery and/or Data Collection 
Apter(118) Yes Not reported Partial Not reported 
Burgess (156) Yes Yes - sealed envelope Unblinded Partial - Control adherence blinded. 
Chan (71) Yes Yes - sealed envelope Full 
Partial - automated intervention delivery, data 
collection not reported. 
Charles (67) Yes Yes - sealed envelope Full 
Partial - automated intervention delivery, data 
collection not reported, adherence download post-
visits. 
Foster (68) Cluster-randomised 
Yes - method not 
elucidated 
Partial 
Partial - GPs blinded to alternative interventions, 
telephone data collection blinded, other data collection 
automated or postal; analysis blinding not reported. 
Kenyon (158, 160) Yes Not reported Unclear  Not reported 









Blinding - Subject (hypothesis and/or EMD 
Function) 
 
Blinding - Intervention Delivery and/or Data Collection 
Kuipers (157) No N/A Partial 
Partial - pharmacy staff have access to all EMD data 
but no mandatory interaction with controls until study 
end; each pharmacy allocated to CARAT or no CARAT. 
Morton (69) Yes 
Yes - independent code 
holder 
Unblinded 
Partial - control group clinicians blinded to adherence 
data when delivering clinical care. 
Onyirimba (100) Yes Not reported Partial 
Partial - standard care delivery blinded, clinicians 
blinded to control group adherence data but may still 
deliver clinical care without reported blinding to study 
group. 
Sulaiman(99) Yes Not reported Unblinded 
Partial - study team blinded to control group 
adherence data on data collection/intervention 
delivery visits. Automated data analysis, validation 
blinded. 
Vasbinder (70) Yes 
Yes - method not 
elucidated 
Unblinded Not reported 
 
Table 3-8: Review of EMD-based interventional studies – study quality (conduct and reporting) 
Low risk of bias 
 Power calculation reported 
 Baseline populations similar 
 ≤10% dropout rate 
 Intention to treat analysis 
 Analysis powered to detect 
outcomes 
 ≤10% device failure rate 
Intermediate risk of bias 
 Baseline populations differ, but this is 
reported 
 10-15% dropout rate 
 Per-protocol analysis only 
 Analysis not powered to detect 
outcomes 
Higher risk of bias 
 Baseline populations differ widely, not 
reported 
 >15% dropout rate 
 >10% device failure rate 
Not applicable/not reported 














Intention to Treat 
Analysis 
 
Powered to Detect 
Change in Adherence 
 
Powered to Detect 
Change in Outcomes 
 
Device Reliability 
Apter(118) Yes None reported Not reported Yes Not reported N/A >10% download 
failure 
Burgess (156) Yes None reported 100% Not reported Yes N/A Not reported 






None reported 81.8%  Apparent per-
protocol  
No N/A Not reported 
Foster (68) Yes Reported differences 71.7% GPs 
90.2% patients 
Yes N/A No <10% data 
unavailable due to 
loss/failure once 
activated 
Kenyon (158) N/A Reported differences 78% Apparent per-
protocol 
N/A N/A >10% data 
unavailable  
Kuipers (157) Yes Reported differences 85% Not reported Not explicit - 
apparent 
Not explicit - 
apparent 
Not reported 
Morton (69) Yes None reported 85.6% Yes N/A Yes >10% data 
unavailable - loss/ 
forgotten/ damage 
Onyirimba (100) No None reported 63.3% Apparent per-
protocol 
N/A N/A Not reported 
Sulaiman(99) Yes None reported 89.4% Yes Yes N/A <10% device failure 
rate 
Vasbinder (70) Yes None reported 95.4% Yes No N/A Not reported 
 




Eleven studies using EMD-based interventions with the aim of 
improving adherence and clinical outcomes were included in this 
review. Nine studies showed evidence of improved adherence; 
however, only two showed meaningful improvement in asthma-
related outcomes when adjusted for baseline factors. This is in 
keeping with current evidence which suggests that EMD-based 
interventions do improve adherence but only inconsistently 
impact on clinical outcomes (46, 161). Note is made of how 
different the studies are in design, recruited population samples 
and interventions employed. 
3.5.1. The impact of study population selection on study outcomes 
Whilst the studies reviewed do not represent a large cohort, 
there is a clear suggestion that interventions using EMDs are 
unlikely to carry clinically significant benefits at an individual 
level unless certain criteria are met. The two studies which did 
show improvements in clinical outcomes were both in children 
who had, on average, exacerbated at least once within the three 
months preceding recruitment (69, 71). Importantly, much of 
the literature linking asthma outcomes with adherence shows 
associations with exacerbation as defined by OCS use, 
emergency department (ED) visits and hospitalisation (30-32).  
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Another distinguishing factor of these two studies was the 
absence of the fixed airflow obstruction (FEV1 <80%) more 
commonly seen in adults who are at high risk of exacerbation. 
It is possible that this points to a comparatively lower burden 
of irreversible airway disease or a greater inflammatory 
component than in adults, perhaps rendering children more 
responsive to treatment with ICS than adults. It is also possible 
that this points to a greater behavioural component than in 
adults who may suffer more from intrinsic disease severity. If 
this were the case, exacerbations in these children may be more 
amenable to behavioural intervention.  
Appropriateness of baseline ICS dose should also be considered. 
Four of the studies in this review suggested that their 
participant population may have been over-treated at baseline 
(67, 68, 70, 100). In theory, this could mask potential clinical 
benefits where a critical threshold for dose response has already 
been superseded despite a lower frequency of inhaler usage. 
Notably, however, studies linking adherence to outcomes have 
not checked the appropriateness of baseline prescription and 
therefore the impact of any blunting effect from overtreatment 
on clinical outcomes remains unclear (31, 33, 151). 
Finally, there is a risk that participants are a self-selected group 
of motivated individuals. The three studies reporting baseline 
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adherence reported rates either at the higher end or above the 
higher end of the literature for adherence levels in asthma (50, 
118, 157). This is in keeping with the high population estimate 
found in Chapter 2. There are broader implications for such 
selection bias. Although it is unlikely that people with asthma 
taking 64% of their prescribed ICS dose (see Chapter 2) would 
be receiving the full benefit of their inhalers (32), it may be that 
a small improvement in adherence does not lead to significant 
measurable clinical response in the 6-12 month durations 
employed by most interventional studies. Thus, it is possible 
that in the studies with high baseline adherence and other 
studies with relatively high rates of adherence in the control 
group at study end (67, 99), any gains in treatment effect from 
the intervention have been masked.  
If real-world adherence is known to be poor and studies are 
potentially selecting for better adherence (162), this may 
explain in part why over a decade of interventional studies 
presented in this chapter have not seen consistent clinical 
improvements in outcomes. Thus, it may be that future RCTs 
attempting to show a change in clinical outcomes need to enrich 
for poor adherence in their population. This will involve finding 
innovative ways of engaging individuals who do not normally 
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engage with research but who stand to benefit the most from 
such interventions. 
3.5.2. Electronic monitoring devices 
Although less disparate than the EMD solutions noted in the 
previous chapter, there are again differences in the EMDs used, 
including more overt generational differences within the same 
brands. Points of variation included levels of validity and device 
capabilities (already discussed in depth in Chapter 2).  
EMDs used in the studies reviewed varied from validated, 
commercially available platforms to devices designed by local 
study teams. Failure rates were generally low where reported, 
in contrast to the rates reported in the wider literature (see 
Chapter 2). Use of a validated, reliable EMD is clearly essential 
to this area of research and real-world practice will rely on these 
factors to establish trust and maintain objectivity on the part of 
the clinician. 
One study found a disproportionate number of damaged devices 
returned by their intervention group (69). This highlights the 
possibility of a group that may be particularly resistant to 
engaging with EMD-based interventions. Such a group may 
require further characterisation in order for EMD researchers to 
be able to design effective interventions beyond what is offered 
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to the whole cohort (see Chapter 6).  Malfunction, damage and 
loss of devices risk rendering EMDs useless if neither clinicians 
nor patients trust them (their value lies in the reliability and 
objectivity of the data they provide and in low loss/damage 
rates). Having uncompromising quality standards in the former 
case and understanding the motivating factors for the latter will 
be important if a large clinical study is to be viable, but also if 
these devices are to be used in routine clinical practice. 
Whilst EMDs remain the best objective markers of temporal 
adherence available, this still does not guarantee drug delivery. 
Poor drug delivery may be intentional (known as dose dumping 
(69, 99)) and easily detectable by EMDs as multiple doses 
dumped at once, but harder to detect if spaced out at prescribed 
intervals or the result of poor inhaler technique. Indeed, in an 
observational study trialling their INCA device, Sulaiman et al. 
found that only 21 of 103 participants used their inhaler both 
correctly and in a timely manner. They further reported that, of 
60 possible doses per month, although 82% were attempted, 
only 57% were actually taken correctly (99). This may well be 
even lower in a real-world population. 
Only two studies (157, 158) reported the use of an app. Other 
studies generally involved the study team downloading 
information directly. In introducing these devices for real world 
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use, an alternative means to hard data download should be 
considered to limit resource impact on an already stretched 
clinical service. Alternative means of data download could also 
permit time for data to be converted into a format that is 
clinically meaningful.  
3.5.3. Study intervention 
Unlike drug trials that test a single chemical substance, 
behavioural studies can be difficult to evaluate as a group 
because of varying interventions and methodology. Particularly 
challenging is identifying how to control these studies.  
Methods of participant blinding in this review included blinding 
control participants to their own adherence data, blinding all 
participants to the full study hypothesis (100, 118) and even 
covert monitoring (67, 68, 71). Covert monitoring or blinding 
participants to the EMD’s full function may particularly help to 
reduce the impact of the knowledge of being watched i.e. the 
Hawthorne effect (143, 155). This may allow for the observation 
of behaviours that may not otherwise be reported. Patel et al., 
for example, in their covertly monitored study, found surprising 
levels of SABA overuse (95, 107). However, covert monitoring 
is accompanied by ethical issues requiring careful consideration. 
These include the process of obtaining informed consent and 
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management of patients who go on to use their inhalers in a 
mode indicative of a real-time medical emergency.  
In the studies examined, there were varying applications of 
what was termed ‘standard’ or ‘usual’ care. These differences in 
control groups make comparison between studies challenging 
and may lead to an underestimation of the true effect of EMD-
based adherence interventions. Innovative intervention design, 
on the other hand, is needed. It should be noted that, on the 
whole, adherence benefit has been seen in this review across a 
range of interventions from simple to complex, suggesting that 
at least for adherence, the benefits of EMD-based interventions 
exists regardless of the nature of the intervention.  
Not all studies incorporated real-time automated reminders, 
which primarily target unintentional non-adherence. This may 
not be an essential component of such a function. Those that 
did and reported adherence over time all reported decay in 
adherence gains (67, 68, 71, 157). Speculatively, this may 
relate to a tolerance - or perhaps rather growing intolerance - 
of the reminder function, such that the positive effect initially 
seen is lost. Furthermore, with the exception of only two studies 
(68, 118), studies showing a decline in adherence in the 
intervention group did not incorporate any feedback on EMD 
use (67, 70, 71) whereas all of the studies reporting 
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maintenance of adherence gains did (69, 99, 100, 156, 157). 
This may indicate that clinician interaction in addition to 
technology is important, perhaps reinforcing the idea that the 
participant is being monitored. This sense of being observed 
may have otherwise worn off over time. The clinician interaction 
may separately be important due to the ability to personalise 
advice to users.  
It is worth noting that neither study using a primarily 
behavioural strategy found improved adherence or outcomes as 
a result (68, 118). Other review findings suggest that tailored 
behavioural management interventions can be effective in 
improving objectively measured adherence (46), but warn that 
there is little evidence to suggest such strategies are more 
effective than ‘simple’ interventions (46). In both research and 
the real world, more complex interventions will be associated 
with increased training needs and time to deliver, consequently 
reducing external validity. Foster et al., for example, discussed 
difficulties providing training and standardising delivery with 
their study design. 
It is possible that the interventions included in this review did 
not have long enough to translate into significant clinical 
outcomes. Indeed, the exacerbation benefits in the study by 
Morton et al. became marked in the second six month period of 
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their twelve-month study (69). Whilst running studies for a year 
or more would undoubtedly be costly, a positive result may be 
more generalizable. A negative result in this setting could cast 
serious doubt on the value of EMDs for improving real world 
outcomes in asthma and on their future in the areas of 
behaviour change and self-management in asthma. 
Finally, free inhaler provision may have artificially inflated 
baseline adherence compared to a real-world situation. In 
several studies, this unintentional adherence barrier was 
removed in addition to the use of EMDs (67, 68, 100, 118).  
3.5.4. Study quality 
Quality measurement in this field has often relied on a standard 
set of expectations (114), however these do not recognise 
features unique to EMD-based interventions. Increasingly, truly 
covert measurement is becoming logistically challenging, with 
participants having easier access to external information than 
thirty years ago. Additionally, device reliability forms an 
essential part of critical evaluation, but is an aspect not 
normally considered. Chapter 2 presents a concerted effort to 
adapt a widely recognised meter, the Cochrane quality score, 
for use in electronic adherence. This chapter presents only 
essential considerations, separating study blinding and covert 
monitoring as well as considering device reliability. 
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That no study in this review is completely free of concern in this 
review demonstrates how challenging study design is in this 
field, particularly when judged without consideration of the 
unique aspects of technology-based interventions. If a useful 
evidence base in this area is to be built, a more considered 
approach to study quality considerations will be needed. 
However, this must not preclude rigorous design, conduct and 
evaluation. 
3.5.5. Future applications 
This review’s findings, although specific to the role of EMDs in 
improving adherence and clinical outcomes in asthma, are in 
line with existing literature that questions whether adherence 
interventions in asthma do actually improve clinical outcomes. 
That study design is likely to play a significant role in this lack 
of impact is borne out by the fact a 2003 review found less 
accurate measures may have led to an underestimation of the 
impact of interventions on adherence (162). The increased 
accuracy of electronic monitoring over other measures of 
adherence has moved the field forward such that it can be 
accepted that EMD-based interventions do impact adherence. It 
may be that similar attention to other aspects of study design 
in the context of such rapidly evolving technology may narrow 
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the gap between adherence and clinical outcomes seen in the 
current evidence.  
Findings from this review suggest some basic considerations for 
future research in this field. These are summarised in Table 3-
9 (below). Finally, where participants have evidence of 
disengagement (e.g. device loss, difficulty organising follow-up 
appointments), researchers should attempt to assess the 
reasons why as this may be important for future clinical 
application.   





1. Longer term studies (i.e. ≥ 12 months).  
2. Studies should be adequately powered to detect changes in both adherence 
and outcomes. 
3. Consider pragmatic, real-world study design that is primarily delivered by 
the usual care team with study requirements delivered as remotely as 
possible to minimise risk of bias and maximise generalisability. 
4. Baseline objective adherence should be measured, either using prescription 
data or a run-in period using the EMDs, possibly both as run-in 




1. Studies should enrich for participants who have had a recent exacerbation. 
This is the group with the most evidence at present for clinical outcomes. 
2. Study designs should find innovative ways to engage potential participants 
with baseline poor adherence, bearing in mind the consideration that 
studies by their nature select participants who are likely to have a higher 
adherence than seen in the general population. Consider that individuals 
who have traditionally been difficult to engaged may also have more 
specific attitudes and behavioural needs that will need to be elicited and 
may require more complex interventions to address. 
3. Consider subgroup analysis of individuals more likely to be corticosteroid-
responsive (e.g. known eosinophilia) as a subgroup for clinical outcomes. 
The 
intervention 
1. EMD devices should be selected, not only based on their own capabilities, 
but on the basis of the inhaler device they fit to, considering (where 
possible) factors such as a participant’s inhaler preferences. 
2. Reliability, not just of a device brand, but also of specific models, must be 
an essential consideration in EMD selection.  
3. Inhalation quality/technique detection/assessment should be measured in 
future studies to assess whether this is the cause of the gap between 
improved adherence and improved outcomes. 
4. Studies should separate different behavioural components of the 
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intervention: 
a. EMD + reminder 
b. EMD + feedback 
c. EMD + reminder + feedback. 
5. More evidence is needed on evidence-based but easily deliverable 
behavioural interventions. 
Outcomes 1. Any study assessing the effect of EMDs on adherence should measure at a 
minimum standardised markers of severe exacerbation and ideally also 
FEV1. If possible to measure eosinophilia, or a surrogate marker for this, 
with minimal discomfort and inconvenience to the patient, this should be 
done as well. 
2. A standardised measure of symptom control such as the ACT™ or ACQ 
should be used. Also consider objective SABA monitoring to support this. 
3. Patient-related outcome measures which impact on adherence such as 
inhaler satisfaction should also be assessed. 
 
Improving asthma treatment using inhaler technology 
This thesis later presents a pilot study using and EMD-based 
intervention (see Chapter 5). The following considerations were 
incorporated into its design: 
1. Pragmatic, real-world study design: Participants’ 
usual care was conducted by their own clinicians rather than 
the study team. Adherence reports, where appropriate, were 
sent to participant’s own clinicians to decide on appropriate 
interventions. There was no official study drug – participants 
were enrolled if their inhaler was compatible and formulation 
switches to enable this were avoided as much as possible. 
Study contact was remote during the middle months of the 
study to minimise study team contact. 
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2. Enriched for exacerbation: self-reported exacerbation 
within the preceding 12 months was a study eligibility 
criterion. 
3. Recording of phenotyping data: whilst this pilot study 
was small and not designed for subgroup analysis, data on 
the presence or absence of historical eosinophilia, raised 
fractional exhaled nitric oxide (FENO) and airflow obstruction 
were recorded. 
4. EMD selection: the study selected the Smartinhaler™ 
platform as a brand which had been tested in multiple 
studies and had good validation data, including for the 
generation of models used. 
5. Intervention selection: the study was designed to 
separate the effect of feedback from other measures as its 
primary intervention. 
6. Outcome measures: the study measured severe 
exacerbations, FEV1, ACT™ and AQLQ as well as 
electronically-monitored SABA use as clinically relevant, 
standardised and comparable outcome measures. 
Due to its nature as a pilot study, it was not designed to be fully 
powered. Furthermore, due to limitations regarding available 
devices available at the time, technique assessment was not a 
feature of the EMDs chosen. Finally, the study incorporated a 
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qualitative aspect which aimed to explore user perspectives in 
more detail given the relative novelty of this field.  
3.6. Conclusion 
EMDs may be an important tool in combatting the results of 
poor adherence to inhaled medications in asthma; however, 
studies to date have shown limited benefit in both subjective 
and objective clinical outcomes. This should serve as an alert to 
both the research community and relevant stakeholders, 
stimulating more considered research in this field.  
Studies should be designed to be rapidly deliverable, adapting 
to changes in technology, widely generalizable and with 
relevant outcome measures. Designs should give careful 
thought as to who will benefit from these interventions and 
precisely which interventions they are likely to benefit from. 
This will create an opportunity for risk reduction and allow the 
identification of the subgroup of patients with truly treatment-
resistant asthma. 
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Chapter 4: Accuracy and reliability of 
Smartinhaler™ technology – experience 
from a feasibility study 
4.1. Introduction 
This thesis examines the rationale for the use of EMDs in clinical 
practice, prior study evidence, the gaps in that evidence and 
the ways in which those gaps might be filled. In 2017, the UK’s 
National Institute for Health and Care Excellence (NICE) 
appraised the Smartinhaler™ system with a view to use in 
clinical practice (154). However, for these devices to translate 
readily into clinical practice, they must also be reliable and easy 
to use. For the pilot interventional study later presented in this 
thesis, the Smartinhaler™ system from Adherium (New 
Zealand) was used for both interventional and control groups. 
This was both due to investigator experience with the system 
(95, 96, 163, 164) and supportive validation data (163, 165, 
166). A gap is noted in several studies reviewed in both Chapter 
2 and in Chapter 3 of this thesis in reporting on device validity 
and failure. This is noted to be important in the interpretation 
of study results. Investigator experience of device reliability 
from the study is therefore presented in this chapter.  
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4.2. Aims and objectives 
This chapter aimed to: 
1. Review investigator-led validation data for the 
Smartinhaler™ system.  
2. Present methodology adapted from validation studies.  
3. Present device testing results from a pilot study of 
adherence.  
 
4.3. Literature review 
Six investigator-led papers published between 2006 and 2016 
were found to describe the use of the Smartinhaler™ system 
(163, 165-169). They are presented in Table 4-1. When judged 
on actuations, the Smartinhaler™ system consistently provided 
a greater than 90% accuracy in recording inhaler actuation 
events, where accuracy was defined as number of actuations 
correctly recorded (see Table 4-1). However three of the six 
papers suggest a spread of erroneous recording across devices 
rather than concentrated in a small number of faulty devices 
(166-168). Thus, whilst it appears that a high level of data 
accuracy can be expected from the system, it is possible 
multiple individual devices may mis-record events on occasion.  
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Table 4-1: Literature review of device testing 
Paper (First 
author, year) 





Study 1: 30 days, two puffs twice daily 
Ten Smartinhaler™ devices. Canister weight before 
and after each pair of actuations 
Date and time manually recorded, recorded by the 
Smartinhaler™ and recorded by the Doser CT 
manually entered onto spreadsheet for 
comparison. 
Study 2: Single day  
Six Smartinhaler™ devices had 30 actuations in 
rapid succession. Data downloaded was compared 
to known number of actuations. 
By device: 
5/10 devices 100% accurate 
By total actuations:  
111/120 (92.5%) 
Rapid actuations:  
All devices record 30 
actuations but time stamp 
all with first actuation time. 
Five devices missed first or second dose only. This 
appears related to how firmly the canister has been 
inserted into the device. Recommendation: the canister 
should be actuated on insertion. 
Note: The time stamp is repeated when actuations are in 
rapid succession.  
Foster, 2012 
(168) 
SmartTrack™  Study 1: Single day, 10 devices. Test markers of 
device functionality including clock accuracy, 
accuracy of x3 actuation logs and 
insertion/removal logs, and reminder functions. 
Study 2: Devices passing Study 1 testing. Two days 
of two puffs twice daily, followed by 30 actuations 
in rapid succession. Date/time recorded in a log as 
was dose counter reading before and after each 
pair of actuations and before and after the rapid 
succession routine. Data downloaded compared. 
Study 3: Devices passing Studies 1 & 2 testing. 
Seven days patient field testing. 
By device:  
6/10 devices 100% 
2/10 devices minor issues 
only 
 
By total actuations:  
Study 2: 98.8% 
Study 3: 97% dose counter 
agreement, 95.6% paper 
diary agreement 
One device failed Study 1, not logging any events. 
Three devices showed minor issues in Study 2. One 
device had 2/38 actuations differing from diary times by 
up to 35s, although it was noted this was likely due to 
human error. Two devices recorded spurious events – 
one on device inhaler insertion, the other duplicating a 
single event. One device failed Study 2 with electrical 
circuit failure.  
There was no evidence of missed actuations. Two devices 
recorded extra actuations on insertion of the MDI. 
At seven days, median battery life was ¾ bars. 
 




Device Study Design Device accuracy Author comments and recommendations 
Foster, 2012 
(168) 
   Recommendations: “Routine QC testing prior to 
dispensing and after return remains essential for any 
electronic monitoring device, in both research and clinical 
practice.”  
The authors also suggest expectation of a 20% 
malfunction rate and provision to therefor be mad for 
purchase of 10-20% extra devices to replace device 
failures. 
Remove from analysis any actuations with same stamp as 
inhaler insertion. 
Advise three attempts at upload as routine. 






Testing at 0, 8, 16 and 24 weeks.  
Study 1: 2 days: 2 actuations 10-20s apart repeated 
at least 2 hours later. 
Study 2: Single day: 2 actuations 10-20s apart 
repeated at least 2 hours later. 
Study 3: Single day: 8 actuations 10-20s apart 
repeated on 2 other occasions on the same day 
General function: battery charge, data retention, 
spurious log, clock accuracy etc. 
By device: 20/22 (90.9%) 
 
By total actuations:  
2170/2176 (99.7%) number 
of actuations 
2160/2176 (99.3%) 
accurate date/time stamp 
All missed actuations were during low-use testing. Some 
extra actuations were related to computer connection. A 
mean time drift of five weeks was noted over the testing 
period. Battery charge at 24 weeks was full charge.  
Recommendation: Pre-study screening checks to screen 
for faulty devices are require prior to patient use. 
Data recorded on study visit days could be removed from 
analysis to prevent inclusion of spurious connection 
events and dose dumping. 









24 week RCT – visits at 3, 10, 17 and 24 weeks 
Pre-study protocol: 
1. Monitor clock synchronised 
2. Two actuations, simultaneous paper diary 
log 
3. A further two actuations two hours later, 
simultaneous paper diary log 
4. Accuracy check and all failed devices 
returned 
Within-study protocol: 
1. Check 48h before next study visit. 
2. TEST function selected (monitor reset by 
software) 
3. Investigators prompted to actuate device 
twice 
4. Software checked monitor and computer 
clock, date/time stamp, battery charge. If 
device failed any element, software 
prompts for return to manufacturer.  
Within-study data protocol: 
1. Investigator preview of data 
2. Investigator upload of data 
3. Time discrepancy>=15 minutes between 
monitor and computer clock prompts 
identification of device for reference RE 
data and return to manufacturer 
By device: 2678/2728 
(98.2%) monitors pass pre-
study checks 
2498/2642 dispensed 
monitors (94.5%) and /2549 
returned monitors (98.0%) 
had complete data. 
 
 
Of 50 devices failing pre-study checks, 26 missed 
actuations, 20 recorded extra actuations, four had 
structural faults. 15 were repaired and used 
subsequently. 
Of 76 devices failing within-study checks, 33 failed due to 
battery, 25 due to MDI nozzle blockage, 12 had 
erroneous actuation records and four duplicated 
actuation records. 
Of 51 monitors failing data upload checks, the majority 
showed evidence of moisture damage. 
Recommendation: Smartinhaler™ Tracker is highly 
reliable.  
Extensive pre- and within-trial processes should be 
implemented. Incorporated systems may assist with this. 
Bench testing and canister weighing should also be 
considered to establish validity. 




Device Study Design Device accuracy Author comments and recommendations 
Pilcher, 2015 
(166) 
SmartTurbo™ 12 week bench testing (testing days 0, 5, 6, 7, 8, 9, 
14, 21, 28, 56, 84 
Low use pattern:  
Two actuations up to two minutes apart, no use for 
>=1.5 hrs, 2 actuations up to 15 minutes apart 
High use pattern:  
8 actuations within 5 minutes, no use for >=1.5hrs, 
8 actuations within 5 minutes 
By devices: 
15/20 (75%) record 
actuation events with 100% 
accuracy (i.e. no missed or 
spurious events). 18/20 
record all insertion/removal 
events accurately. 
By actuations: 2796/2800 
(99.9%) accurately 
recorded actuations 
Issues with spurious actuations and clock found to be 
central programme algorithmic issues rather than device 
issues. 
Recommendation: The SmartTurbo is an accurate device. 
Close cooperation with the manufacturer is 
recommended.  
Studies should allow for time drift. 
Clear education regarding Turbohaler use essential. 
Note: Algorithms still in development 
Pilcher, 2016 
(165) 
SmartTouch™ 10 weeks 
Ventolin 
Pre-study simulation: 
Two actuations separated by 10-20s, at least 15 
minute break, two  further actuations separated by 
10-20s 
Within-study simulation: 
MDI replaced, two actuations 10-20s apart. 
Failure = missed actuation, spurious actuation, 
battery light not green 
By device:  
18/20 (90%) record 
actuation events with 100% 
accuracy (i.e. no missed or 
spurious events).  
One device missed one 
insertion and one removal 
event. 
By actuations: 2558/2560 
(99.9%) 
All devices passed initial study, within-study and battery 
checks. 
Recommendation: The SmartTouch™ is an accurate 
device for measuring actuations over a 10 week period. 
Initial study and within-study checks should be 
performed 
Participants and investigators should be trained as to 
correct use 
Allow for time drift  
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This was also demonstrated in Pilcher’s most recent evaluation 
of the SmartTouch™ device where all devices passed basic pre-
study and within-study simulated checks, but two actuation 
events went unrecorded (165). However, whilst occasional mis-
recorded events occurred, this did not appear to demonstrate 
systemic issues. As Burgess et al. (167) showed, early missed 
doses did not necessarily go on to signal general device failure 
and could be explained.  
The studies highlighted particular device idiosyncrasies for 
consideration. One, for example, suggested that canisters be 
inserted with enough pressure to generate an actuation to 
confirm good fit (167) and another highlighted the importance 
of the inhaler technique with regards to turns in the Turbohaler 
(166). A third highlighted the importance of thumb placement 
(at the base of the device) for the SmartTouch™ (165). Several 
authors caution to expect a clock drift over several weeks of 
usage. For earlier devices, the manufacturer gave an estimate 
of 15 minutes of clock drift over 12 months (163). For newer 
devices, this is reported as 60 minutes over 12 months (165).  
In summary the Smartinhaler™ system has consistently been 
validated as accurate with a caution around the unpredictability 
of mis-recorded events. These occasional mis-recorded events 
do not appear to represent systemic malfunction. Study authors 
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consistently advised pre-study and within-study checks and 
earlier authors advocated post-study testing as well. Pilcher et 
al., (166) further advocated for close involvement of the 
manufacturers as part of the quality assurance process. 
Exclusion of data around inhaler insertion and visit days is also 
suggested to improve the quality of data analysed. 
4.4. Methods 
Methodology was derived from three of the studies already 
discussed (163, 165, 169). The initial decision was taken to 
perform pre-study checks and within-study checks as 
described; however, due to ongoing issues as the study 
unfolded, post-study testing was introduced on a batch-by-
batch basis on all devices which had been provided to 
participants. Furthermore, a rapid device check for devices that 
had their initial testing more than six weeks in advance was 
instituted. Thus, whilst pre-study and within-study protocols 
were determined a-priori, pre-dispensing and post-study 
checks were implemented and adapted during the course of the 
study. 
4.4.1. Devices 
The Smartinhaler™ system (Adherium, New Zealand), 
rebranded Hailie™ during the study, was used. As the EMDs 
were designed to be inhaler-specific, SmartTouch™ devices to 
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fit Seretide (fluticasone/salmeterol), Fostair 
(beclomethasone/formoterol), Ventolin (salbutamol) and 
Salamol (salbutamol) were obtained. During the study, the 
decision to include the Symbicort (budesonide/formoterol) and 
Bricanyl (terbutaline) Turbohalers was taken and the 
SmartTurbo™ devices to fit these were included in the study 
protocol. The devices attached to their respective inhaler 
devices as illustrated below in Figure 4-1 and Figure 4-2.  
Figure 4-1: SmartTouch™ device 
 
 
Figure 4-2: SmartTurbo™ device 
used in the study, an earlier version 
of the Hailie® sensor for use with 
SYMBICORT® Turbuhaler® inhaler 
 
Actuations were detected by the devices using a small 
electromechanical sensor. In the SmartTouch™, this was 
situated at the base of the device and so detected depression 
of the inhaler (165). The SmartTurbo™ used a torque 
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mechanism to detect completed Turbohaler turns (166). These 
detected actuations were transmitted via Bluetooth® to an 
associated mobile phone application (app) which in turn 
transmitted this via Wi-Fi to a cloud-based server. The events 
could therefore theoretically be seen in real-time, so long as the 
device and Bluetooth® device were in close enough proximity 
and Bluetooth® and Wi-Fi were activated (Figure 4-3).  
Figure 4-3: Example of the Hailie platform 
 
© Adherium 
Two versions of the Smartinhaler™ app were available. In the 
full version, users were able to see their prescribed doses and 
their data. This app version was provided to the intervention 
group as part of their feedback. In the control version of the 
app (“Smartinhaler™ Lite”), users could see only their device 
battery and synchronisation status. This was the app version 
provided to the study control group. There was also potential 
to download event logs via universal serial bus (USB) using 
dedicated software (“Connection Centre”). 
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4.4.2. Pre-study testing 
All devices were checked by a trained investigator prior to being 
dispensed as follows: 
1. A unique test ID was created for each device. 
2. A battery check was conducted by pressing the button 
located on the side of the SmartTouch™ or 
SmartTurbo™ device. Devices passed this if the LED 
flashed green. 
3. The device was then connected to the mobile app via 
Bluetooth.  
4. Devices were then fitted to the appropriate inhaler 
(dummy or test). The time of fitting (as per the 
computer clock) was recorded to the second on a 
purpose-designed electronic spreadsheet log. 
5. Two actuations about 20 seconds apart were 
discharged. The time of each actuation was recorded 
onto the spreadsheet. 
6. After a gap of around 15 minutes, two further 
actuations about 20 seconds apart were discharged. 
The time of each actuation was recorded on the 
spreadsheet. 
7. The inhaler was removed from the device and time of 
removal recorded on the spreadsheet. 
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8. The application was then changed over to the control 
group (Smartinhaler™ Lite) mode via the web-link.  
9. The whole test process (steps 4-7) were repeated in 
the Lite mode with a check that no actuation data 
would be visible. 
10. Electronic log records were checked to see whether 
there was a match in: 
a. Insertion times 
b. Actuation times 
c. Removal times 
There was a column for recording of missed or spurious 
events and comments to include suspicion of human 
error. To accommodate for clock drift, lack of 
synchrony between computer and mobile phone clocks 
and human error, delays of up to 60 seconds between 
investigator-recorded times and the device log were 
accepted. 
11. A final battery check from both the web link (≥3 bars) 
and the device (green LED) was performed. 
12. Finally, the device was checked for ability to connect 
to the USB download PC software (Connection Centre). 
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Devices were declared for participant issue if the following 
conditions were met: 
1. Battery checks were passed (≥3 bars and green LED) 
2. All insertion and removal logs were recorded within 60 
seconds of the manual times entered on the electronic 
log 
3. No actuation events were missed and all actuation 
events recorded were within 60 seconds of the 
manually recorded times on the electronic log 
4. No spurious actuation events were recorded 
5. There were no visible data in the Lite half of the testing 
protocol 
6. The device connected to the download software 
Devices which did not meet these criteria were re-tested, in 
case of there being clear, remediable explanations for the 
original test failure. Re-test devices were generally given new 
unique test IDs. Where devices failed the re-test or passed the 
re-test with no potential reasons for having failed in the first 
place, liaison with the manufacturer took place and they were 
removed from circulation. 
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4.4.3. Immediate pre-dispensing checks 
During the course of the study, where the duration between the 
original pre-trial testing and dispensing of the devices was 
prolonged (generally more than six weeks), a rapid pre-
dispensing check was conducted as follows: 
1. The same test ID as on the last successful pre-trial test 
(or a new test ID accounting for testing on the day of 
issue) was used in full mobile app mode.  
2. A dummy or pre-specified test inhaler was inserted 
into the device and the date and time entered 
manually on the electronic log. 
3. Two actuations about 20 seconds apart were 
discharged and the time for each manually entered on 
the electronic log. 
4. The inhaler was removed and the time of removal 
manually entered on the electronic log. 
5. The battery on the device was checked as was the 
battery status on the online web-link. 
Devices were marked for issue if: 
1. Battery checks were passed (≥3 bars and green LED) 
2. No actuation events were missed.  
Page | 155  
 
3. All actuation events recorded were within 60 seconds 
of the manually recorded times on the electronic log if 
the device had been synchronised with the mobile app 
prior to testing (clock drift was permitted if this had 
not occurred). 
4. No spurious actuation events were recorded 
4.4.4. Within-study testing 
At approximately monthly intervals, simultaneous with 
participant data checks, the online web-link was accessed. 
Information was stored on the electronic spreadsheet log. The 
following information was logged: 
1. Battery life 
2. Insertion of an inhaler detected 
3. Actuation detected 
4. Date since last upload 
5. Concerns/comments 
Concerns and comments could include where there had been 
more the seven days since the last recorded upload, where on 
review of the data there were recurrent episodes of sporadic 
missed doses or sections where no actuations had been 
recorded, or where participants themselves had raised concerns 
in the intervening period. 
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4.4.5. Post-study testing 
1. Devices were generally matched to their prior unique 
test ID or had a new ID created where the test and 
study ID were the same.  
2. A battery check was conducted as in the pre-study 
tests. 
3. The device was then synchronised with the mobile app 
via Bluetooth.  
4. Devices were then fitted to the appropriate inhaler 
(dummy or test). The time of fitting (as per the 
computer clock) was recorded to the second on a 
purpose-designed electronic spreadsheet log. 
5. Two actuations about 20 seconds apart were 
discharged. The time of each actuation was recorded 
onto the spreadsheet. 
6. After a minimum gap of around 15 minutes, six further 
actuations about 20 seconds apart were discharged. 
The time of each actuation was recorded on the 
spreadsheet. 
7. The inhaler was removed from the device and time of 
removal recorded on the spreadsheet. 
8. Electronic log records were checked to see whether 
there was a match in: 
a. Insertion times 
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b. Actuation times 
c. Removal times 
As with pre-study testing, there was a column for recording of 
missed or spurious events and comments to include suspicion 
of human error. Delays of up to 60 seconds between 
investigator-recorded times and the device log were accepted. 
Longer delays were recorded and did not constitute a major 
fail, particularly if synchronisation with the mobile app 
occurred later in the testing process. Devices were then linked 
to the Connection Centre software and, where there was a 
discrepancy between previously uploaded logs and the USB 
download logs, additional logs were downloaded.  
4.4.6. Further considerations 
During post-study testing, it became clear that certain devices 
were particularly liable to miss logs where there was a short 
period of time between insertion/removal events and actuation 
events. In subsequent tests, a gap of 60 seconds was left 
between insertion or removal and actuations to reduce the risk 
of missed actuations.  
4.4.7. Analysis 
Data were entered directly onto an electronic spreadsheet log 
(Microsoft Excel, 2016). This was uploaded into Stata (Stata 
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version 15, Statacorp) for further analysis. Numbers of devices 
which underwent pre-study testing as a proportion of total 
devices obtained and which passed pre-study testing as a 
proportion of total devices tested were calculated. Proportions 
of devices which failed pre-study testing were also calculated 
for the batches received, different device types and for each 
study group. Non-parametric tests (Wilcoxon’s Rank Sum) were 
used to assess whether the batch, device type or study group 
were associated with an increased likelihood of device failure 
pre- and/or post-study use.  
Numbers of devices which were returned as a proportion of 
those issued and of those which passed post-study testing as a 
proportion of those returned were also calculated. Non-
parametric tests were again used to assess whether devices 
which required re-testing prior to their study use were more 
likely to fail post-study testing than those which passed pre-
study testing first time. Similarly, non-parametric tests were 
also used to assess whether devices passing pre-study testing 
with minor issues (such as clock discrepancies) were more likely 
to fail post-study testing than those which did not pass with 
minor issues.  
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4.5. Results 
4.5.1. Pre-study testing 
Over the study period, 145 SmartTouch and SmartTurbo 
devices were obtained from the manufacturer (see Figure 4-4). 
Of these, 130 devices underwent pre-study testing. Table 4-2 
details the results of this. Of 130 devices which were tested 
prior to issue, 82 (63%) passed first time with no issues, 23 
(18%) passed on re-testing (the reasons for these are detailed 
in Table 4-3) and nine (7%) passed with minor issues (Table 4-
4) giving a total of 114 (88%) devices which passed pre-study 
testing. Of 2726 events carried out in pre-study testing, only 
169 were missed, giving a proportion of 94% events correctly 
detected by tested devices.   
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Figure 4-4: Testing procedures and device flow 
 
*single device issued twice to separate participants 
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Devices requiring re-testing prior to pre-study testing pass 
With regards to devices which passed on re-testing (Table 4-3), 
devices were re-tested following initial test failure if there did 
not appear to be an intrinsic device reason for failure (i.e. 
human error may have been implicated in the testing failure). 
In three devices which were returned for a second round of 
testing after having been reviewed by the manufacturer, the 
battery had not been fully charged prior to re-testing. In five 
devices, a clock discrepancy (i.e. the electronic time stamp was 
more than 60 seconds out compared with the investigator-
recorded time stamp) was probably due to the device not 
having been synchronised to the mobile phone app prior to 
testing. Where this was the case, synching would automatically 
occur later in the test such that later timestamps did match up. 
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Table 4-2: Device flow with pre-study and post-study testing results 
Device (by compatible 
inhaler) 
Total tested, n=130 (% 
total obtained, n=145) 
Passed pre-testing, n=114 
(% total tested, n=130) 
Issued to participant, 
n=100  
Returned to site, n=81 (% 
issued, n=100) 
Unable to post-test, due 
to battery n=5 
Passed post-testing, n=67 
(% returned, n=81) 
Bricanyl 4 (100) 4 (100) 2 2 (100) 1 0 (0) 
Fostair 39 (85) 33 (85) 32 25 (78)  17 (68) 
Salamol 14 (100) 13 (93) 10 8 (80)  8 (100) 
Seretide 13 (76) 9  (69) 5* 5* (100) 1** 4** (80) 
Symbicort 13 (81) 13 (100) 13 10  (77)  10 (100) 
Ventolin 47 (98) 42  (89) 38 31 (82) 3 28 (90) 
Total 130 (90) 114 (88) 100 81 (81) 5 67 (83) 
*701210 was issued twice **701210 passed the first post-study test and was unable to be tested for the second post-study test due to battery failure 
 
 
Table 4-3: Causes of failure for devices which passed on re-testing 
Fail category Number of devices, 
n=23* 
Issued to participant, 
n=20 
Returned to site, n=14  (% 
issued, n=20) 
Passed post-testing, n=12  
(% returned, n=14) 
Battery not fully charged 
prior to testing 
3 3 2 (67) 1 (50) 
Clock fail (>60 second 
time discrepancy) 
5 5 3 (60) 3 (100) 
Unable to connect with 
app 
1 0 - - 
Missed initial installation 4 3 1 (33) 1 (100) 
Missed single actuation 11 10 8 (80) 7 (88) 
Missed multiple 
actuations 
3 3 3 (100) 2 (67) 
*Some devices met more than one failure category 




Table 4-4: Devices which passed with minor issues 
Fail category Number of devices, n=9 
(% total passed, n=114) 
Issued to participant, n=9 Returned to site, n=8 (% 
issued, n=9) 
Passed post-testing, n=6 
(% returned, n=8) 
Battery at half-life  6 (5) 6 5 (83) 4 (80) 
Clock fail (>60 second 
time discrepancy) 
3 (3) 3 3 (100) 2 (67) 
Total 9 (8) 9 8 (89) 6 (75) 




Further into the study, it was noted that several devices had 
missed initial device fit events, removal events or actuation 
events immediately prior to or after these events on pre-study 
testing. It emerged that, because the electronic timestamp was 
often slightly delayed for device fit and removal events, there 
was overlap between these and actuation events. In 
subsequent testing, a 60 second gap was left before and after 
monitor fit and removal events; however prior to this, four 
devices failed initial testing due to missed device fit events and 
eleven devices failed due to single missed events.  
Human error was another possible cause of isolated missed 
events (i.e. time of intended actuation was recorded without 
actuation taking place). Finally, three devices appeared to miss 
multiple actuation events, although this appeared to resolve on 
repeat testing.  
In total, of 76 devices which were returned by participants and 
could be tested on their return after the study, 15 (20%) had 
experienced at least one test failure prior to issue. Initial failure 
did not appear to predict post-study failure however as 13% of 
devices which had experienced a test failure were found to fail 
following their return, compared with 11% of devices which had 
not had any test failures prior to issue (p=0.84). 
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Devices issued following a minor fail 
Nine devices were issued following a minor test fail. In one 
batch of Ventolin devices, the battery on initial testing was 
noted to be at half-life. This was discussed with the 
manufacturer who reassured that they would last the duration 
of the study. Three devices had minor clock issues as discussed 
above. This was not detected prior to issue in one device, 
however the two devices where it was noted also underwent 
pre-visit checks and where the time stamp discrepancy was 
shown to be due to be human error in the test process. 
In total, of the 76 devices tested following study use, seven had 
experienced minor fail in the test prior to issue. Of the seven, 
one device (14%) went on to fail post-testing compared with 
eight devices (12%) of devices which did not experience a 
minor fail. This difference was not statistically significant 
(p=0.83). 
Failed devices by batch 
Devices were ordered at various points in the study with the 
result that they were received in 11 separate batches. As most 
device failures appeared to occur in the earlier part of the study, 
failed devices were analysed by batch provided (Table 4-5). 
There were no failures in the last five batches obtained. There 
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was an association between batch and the proportion of device 
failures (p=0.002). 
Table 4-5: Device failures by batch obtained 


















0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 
4.5.2. Immediate pre-dispensing checks 
Immediate pre-dispensing checks were carried out where either 
a significant period of time (four to six weeks) had elapsed 
between pre-study testing and the date they were due to be 
issued or because there was a minor issue (see Table 4-4) found 
in pre-study testing. The aim of pre-dispensing checks was to 
ensure that battery life was maintained and that devices were 
still able to record every actuation.   
Seventy-four devices underwent pre-dispensing checks 
(including one which underwent pre-visit testing twice for issue 
to two separate participants). Of these, six (8%) failed testing 
and were not issued to participants. Five of these test fails were 
returned to the manufacturer for review. 
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4.5.3. Within-study replacements 
Ninety-nine devices were issued to participants (one device was 
issued twice giving 100 device issues). Most participants were 
issued a single preventer device and a single reliever device; 
four participants who indicated at enrolment their use of 
multiple reliever devices were also provided with a second 
reliever device. Of devices issued, 22 devices were replaced 
before the end of the study period, 16 for possible malfunction 
(see Table 4-6). Three of these possibly malfunctioning devices 
were from control group participants (7% of control group 
devices) and 13 were from intervention participants (24% of 
intervention group devices).  
Table 4-6: Reasons for replacing devices during the study 
Event Number of devices, n=22  
Suspected malfunction 16 
Device loss 2 
Change of inhaler regime 2 
Incorrect device for inhaler 2 
 
Of the 16 devices with a suspected malfunction, only three 
devices failed post-study testing – one fail due to battery failure 
and two fails due to failure to record actuations.  
4.5.4. Post-study testing 
Overall, of the 100 device issues, 19 devices were never 
returned (12 because of participant loss to follow-up and seven 
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because participants lost them). Five issues were unable to be 
tested due to confirmed or probable battery failure (one of these 
occurring during the study as described). Nine devices failed 
post-study testing outright and 67 issues passed testing (Table 
4-2). Thus of 76 returned devices that were suitable for testing, 
the device failure rate was 12%. 
With regards to battery failure, devices were tested in batches 
and a few non-rechargeable devices drained before there was 
an opportunity to test them. In two Bricanyl-compatible 
devices, no actuations were recorded although the battery light 
showed green. One of these was tested at 356 days following 
original testing, the other at 501 days. Battery life expected was 
to be around 365 days for these devices. The latter device was 
therefore classified as a probable battery failure. The former 
device is likely to also be a battery failure but did not meet the 
365-day cut-off. 
When analysed by batch (eleven in total), participants received 
devices from all but the second batch (a single device which 
failed). There was no association between batch and likelihood 
of a device to fail post-study testing (p=0.402). This suggests 
that despite all pre-study device failures coming from devices 
supplied earlier in the study, earlier batches of devices which 
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passed testing and were issued to participants were no more 
likely to fail than later devices.  
4.5.5. Manufacturer feedback 
In total, 28 devices (19%) were returned to the manufacturer 
due to queries around their function. Sixteen of these devices 
had failed pre-study testing and never been issued, four had 
passed pre-study testing but were recalled by the manufacturer 
prior to being issued and eight had been issued to participants. 
Of the eight which had been issued to participants, five had 
passed post-study checks but had within-study concerns or had 
been recalled by the manufacturer. Formal feedback was 
obtained for 19 devices with informal feedback via email 
communication for the first batch of five Seretide-compatible 
devices (i.e. feedback for 86% of devices returned). This is 
detailed in Table 4-7.  
Table 4-7: Outcome of manufacturer investigation for devices returned to them 
(includes issued devices) 
Manufacturer investigation outcome Number of devices (% devices investigated), n=24 
Device fault confirmed 16 (67) 
Design fault 6 (25) 
Liquid damage 1 (4) 
Test process issue, no device fault 1 (4) 
Total 24 (100) 
 
Device faults primarily related to the first batch of Fostair-
compatible and Seretide-compatible devices received. The 
Fostair-compatible devices were found to be too tight for the 
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inhaler leading to missed actuation logs. Similarly, email 
feedback with regards to the Seretide-compatible batch also 
suggested a problem with the device’s plastic casing. Other 
device faults included problems with one device’s optical reader 
leading to spurious installation/removal events device, a logged 
data duplication in another device and a fault found within a 
device component which was causing excessive battery drain.  
Design faults on the other hand related to issues with the 
battery measure supplying an incorrect reading rather than any 
fault intrinsic to the hardware of the device in question. In 
another device, liquid damage was logged as occurring between 
the date of the last device test and issue to the participant, 
causing excessive battery drain. The device where a test 
process issue was identified highlighted an inadequate duration 
of time between installation/removal events and actuations. 
This had already been noted by the time the manufacturer 
feedback was received. Manufacturer feedback for devices used 
by participants is shown in Table 4-8.  
Table 4-8: Outcome of manufacturer investigation for devices which had been issued, 
by Study ID  
Study ID Outcome of manufacturer investigations, n=8 
SIT001 Device fault (x2 devices) 
SIT002 Device fault 
SIT006 Device fault 
SIT008 Device fault 
SIT011 Battery measure fault 
SIT016 Liquid damage 
SIT017 Battery measure fault 
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4.5.6. Devices by group 
The pilot study for which these devices were used divided 
participants into intervention (electronic monitoring device 
[EMD] + feedback including visible app data) and control (EMD, 
no feedback, no app data) groups. Eighteen control group 
participants were provided with 45 issues of 44 devices (a mean 
of 2.50 devices per participant). Eighteen intervention group 
had 55 devices issued (a mean of 3.06 devices per participant). 
Intervention group participants were more likely to be provided 
with devices that had suffered a minor fail in pre-study testing 
(i.e. one device was provided to a control group participant as 
opposed to eight devices which were provided to intervention 
group participants, p=0.032).  
Devices by inhaler compatibility were distributed relatively 
evenly between the groups. Overall there were no differences 
in the inhalers used by the groups (p=0.972) and, when taken 
by the first device issue, exactly the same number of 
participants in each group had Fostair-compatible, Seretide-
compatible and Symbicort-compatible devices (Table 4-9). 
Table 4-9: Inhaler compatible device by study group 
Inhaler type Intervention group (N=55), n  Control group (N=45), n 
Fostair 12  12 
Seretide 2 2 
Symbicort 4 4 
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Most importantly, of the 76 devices which underwent post-
study testing, 3 of 30 Group A (10%) and 6 of 46 Group B 
(13%) issues were found to fail and this difference was not 
statistically significant (p=0.688). The discrepancy between 
returned Group A and Group B devices is explained by the lower 
number issued to Group A participants (possibly due to 
replacements as discussed) but also by the lower number of 
Group A devices returned. Thirteen (29%) of Group A devices 
were not returned as opposed to six devices (10%) of Group B 
devices. This may in part be explained by the fact that five of 
the six participants lost to follow-up (accounting for 10 of the 
19 devices not returned) were control group participants.  
4.5.7. Fostair inhaler structure 
During the period when the study was running, Chiesi, the 
manufacturer of the Fostair inhaler, amended the design of the 
inhaler to incorporate a dose-counter and stopped distributing 
older models of the non-dose-counter inhaler in the UK. This 
created a potential impact on reliability of the Fostair-
compatible devices. Furthermore, almost all of the post-study 
device failures (89%) were from the Fostair-compatible 
devices. It was unknown whether participants used integrated 
dose-counter or non-dose-counter inhalers and this, in addition 
to the variability of Fostair device reliability across the batches, 
Page | 173  
 
makes it impossible to rule out that the change in inhaler design 
may have played a role in device reliability. Excluding the 
Fostair devices from the pre-study testing figures only slightly 
reduced the failure rate from 12% to 11%. Excluding them from 
the within-study testing figure more markedly reduced the 
device failure rate from 12% to 2%.  
4.5.8. Testing procedure exceptions 
During the study, there were some exceptions to the 
procedures detailed above. These are listed below. 
1. A subgroup of devices appeared to have low battery (half-
life) on initial wakening. This was discussed with the 
manufacturers and the study team was reassured that 
battery failure was not expected and so was adjusted on 
the testing protocol.  
2. Due to factors in obtaining devices and rapidly booking 
appointments, device testing occasionally took place the 
day before or on the day of the baseline visit rather than 
48 hours prior. This has been accounted for in data 
analysis by removing Day 0 from the data.  
3. Devices were used in the study where they had failed 
testing more than once so long as they had subsequently 
passed testing. This was particularly the case where 
devices appeared to have a clear reason for failure e.g. 
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investigator error in synchronisation pre-test leading to 
apparent clock failure or low battery in rechargeable 
devices where testing had already taken place previously. 
4. Testing took place more than six weeks prior to issue in 
two devices: 806033 issued to SIT034 43 days after 




4.6.1. Study findings 
This study obtained 145 devices compatible with six different 
inhalers from the device manufacturer. One hundred and thirty 
were tested in accordance with adapted published testing 
protocols. Although 94% of device events were accurately 
captured, there was a pre-study failure rate of 12% (n=15) and 
a post-study failure rate of 12% (n=9). Minor problems with 
clock and battery did not seem to impact on within-study need 
for replacement or, more importantly, with device reliability as 
predicted by passing post-study testing. Most importantly, 
devices were no more or less likely to fail in either the control 
or intervention group, although the intervention group did 
receive more devices and were more likely to return their 
devices to the investigators. A possible explanation for the 
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higher intervention group device turnover is that they had 
access to their inhaler data and were therefore more likely to 
suspect malfunction, whether or not it was later shown. They 
were also less likely to be lost to follow-up with 83% of 
participants who were lost to follow-up coming from the control 
group.  
Device failure rates in this study were higher than expected at 
12% given our group’s previous experience (163) but in line 
with the 12.5% median failure rate noted in the systematic 
review also presented in this thesis (see Chapter 2). In post-
study testing, this figure was irrespective of batch, indicating 
systemic issues rather than batch-dependent problems. 
However, this still suggests 88% of devices returned by 
participants provided reliable data.  
EMDs are a relatively new technology which are currently 
transitioning to use in the general healthcare market. Evidence 
supporting their value in improving adherence and asthma 
outcomes is mixed. Consequently, large scale, real world 
studies are still required to assess their value and place in 
routine clinical practice. This real-world study use of electronic 
monitoring devices highlights several issues. First, the pre-
study and within-study failure rates, whilst not the highest seen 
in the literature (see Table 4-1), have been disappointingly high 
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for newer generation EMDs. This suggests that there is still 
great value in conducting pre- and post-use quality control.  
In this study, all 15 pre-study device failures were confirmed by 
the manufacturer and reported as being due to problems with 
the plastic casing. It is significant that these failures were not 
picked up by the manufacturer’s own quality control system. 
Post-study failures appear to have been driven by the Fostair-
compatible devices and it was noted over the same period that 
the manufacturer of the Fostair inhaler changed the structure 
of the Fostair inhaler itself. This is likely to have exacerbated 
any underlying device flaw. This also highlights a weakness in 
the current model where inhaler and EMD manufacturers are 
separate entities. Whilst this model allows for a unified platform 
across multiple inhalers, it reduces manufacturer agility in being 
able to adapt devices to changes in inhaler structure or develop 
devices to match new inhalers. The devices’ reliability then 
depends on the relationships between the EMD manufacturers 
and their pharmaceutical colleagues.  
On the EMD manufacturers’ side, whilst the Smartinhaler™ 
system had been used widely in EMD studies previously, the 
newer generation models used in this particular study had only 
been validated in Pilcher et al.’s validation studies (165, 166) 
which demonstrated 75% rate of 100%-accurate SmartTurbo 
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devices and a 99.9% actuation detection rate for both the 
SmartTouch™ and SmartTurbo™ (see Table 4-1).  To this 
author’s knowledge, there are no published clinical trials using 
the SmartTouch™ and only two have used the SmartTurbo™, 
one of which did not report on device accuracy (157) and the 
other which reported no accuracy issues in devices which were 
not reported as broken, lost or forgotten or where there was no 
objective damage (69). This highlights an issue in terms of the 
validity of validation testing for previous models of a technology 
and the speed at which medical technologies can be evaluated. 
Newer models use Bluetooth upload capability for which bench 
testing data are only newly available. Our experience would 
suggest that more data are required. Validation testing is clearly 
required for every new model/generation brought to market at 
present; however, this will prove challenging if current 
processes for publishing validation data continue to be used. 
The technology appears to be developing more rapidly than 
studies are being published. 
As recommended by Pilcher et al. (166), close communication 
with the manufacturer was essential in proceeding in this study. 
In this case, the manufacturer was extremely helpful in 
investigating and replacing potentially devices. It was noted 
that the manufacturer for EMDs used in this study was based in 
Page | 178  
 
New Zealand with demand for their product in the North 
American market. From discussions with the manufacturer, 
neither of these were large markets for Fostair, which was used 
extensively in our local clinics. It is therefore possible this lack 
of emergent need reduced the manufacturer’s motivation to 
produce fixes for problems with the Fostair-compatible devices. 
4.6.2. Study limitations 
Whilst an a priori testing protocol was in place for pre-study 
testing, other testing procedures were developed as the study 
proceeded. In an ideal world, these would also have been 
developed a priori and their use in this pilot study would 
certainly inform protocol design were a larger study to be 
conducted. 
The devices were checked by a single investigator who also 
conducted the study and issued devices, introducing a potential 
for unconscious bias and the risk of human error.  
4.6.3. Implications for future use 
Clinical studies 
Our experiences underline the continued importance of quality 
control (‘monitoring the monitors’) in ensuring device validity. 
Other than the issues raised with Fostair-compatible plastic 
casings, device hardware was found to be consistently reliable. 
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However, without pre-study testing to exclude most unreliable 
devices, this may not have been the case.  
Investigators should be aware of commercial considerations 
when planning real world studies. Manufacturer relationships 
with pharmaceutical companies, ability to respond to changes 
in the market and motivation to supply in a way that meets local 
practices will need to be discussed. Adherence studies are 
challenging to control for. This process is made more 
challenging when participants are asked to change their usual 
inhaler device as part of the clinical study. Manufacturers should 
be made aware of this prior to a clinical study being conducted. 
Both issues highlight the importance of maintaining a good 
relationship with device manufacturers and raising issues 
arising in the study with them in real-time. Such relationships 
allow manufacturers to update designs and manufacturing 
procedures in a timely fashion, improving Research and 
Development in the EMD arena for future use.  
The use of previously published protocols also allows for greater 
comparison and should be encouraged. Resources will need to 
be allocated to planning, designing and carrying out quality 
control procedures as well as liaising with manufacturers where 
issues do arise.  
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Generally, the number of devices which fail (i.e. miss actuation 
events) are cumulatively more than the number of events 
missed as the literature suggests. Missed events should be 
expected to be spread across a number of devices. 
Investigators should therefore report the proportion of failing 
devices with the same weight as the accuracy of recorded 
actuations when considering EMD reliability.  
Clinical use 
Unfortunately, whilst bench validation studies are encouraging, 
our experience highlights the fact that EMD testing using 
validated methodology remains essential. This has implications 
in the clinical setting, where data collected may be used to 
inform treatment decisions and where missed actuations may 
be mistaken for non-compliance. Burdening clinicians with 
quality control processes in a field of ever-changing technology 
is not sustainable. Furthermore, as will be seen in the reporting 
of the pilot study, the main selling-point of devices, and indeed 
part of their mechanism of action in increasing adherence, is 
reliant on the trust of the user that it accurately and objectively 
assesses their device use. This leaves little margin for error.  
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4.7. Conclusion 
As part of a real-world study, 130 devices were tested prior to 
issue and 76 devices were tested after being returned. In both 
pre- and post-study testing, 12% of devices failed. This 
suggests that there remains a need for investigator quality 
control and close collaboration between investigators and 
manufacturers. Investigators should be aware that commercial 
factors and technological advancement may impact on 
individual model reliability. Stakeholders and manufacturers 
working in partnership should identify and address these 
problems such that, should definitive evidence of clinical benefit 
for EMDs in asthma become available, their real-world uptake 
is not delayed by a requirement for extensive quality control at 
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Chapter 5: Improving asthma treatment 
using inhaler technology 
5.1. Introduction 
This thesis has previously discussed the fact that inhaled 
corticosteroid (ICS) underuse has been linked with poor 
outcomes in asthma, including exacerbation, hospitalisation 
and death (30-32, 150, 151). The UK based National Review of 
Asthma Deaths in 2014 highlighted the importance of poor 
adherence as a contributor to asthma mortality (12). Guidelines 
for asthma highlight the importance of adherence assessment 
in clinical practice (1, 6, 21), and stakeholders and researchers 
alike highlight adherence interventions as a research priority (5, 
15, 152). In this chapter, a pilot study is presented which 
assesses the effect of an EMD-based adherence intervention on 
adherence and asthma control. This study hypothesised that 
access to feedback would improve both adherence and clinical 
decision-making and thus improve clinical outcomes, 
particularly severe exacerbations. 
In Chapter 3, this thesis presented data suggesting that 
electronic monitoring device (EMD) based interventions 
improve adherence in asthma but have a less clear effect on 
clinical outcomes, particularly in adults (170). In that 
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discussion, the importance elucidating which components of 
EMD interventions mediated response and of considering 
pragmatic, real-world study design was highlighted. This pilot 
study isolated feedback from an investigator and mobile 
application (app) as its intervention to be clear on the 
intervention being tested so that intervention effectiveness 
could be properly evaluated. It was designed to minimise 
investigator input in order to be as close as possible to how 
EMDs could be integrated into future clinical care, with 
participants using, for the most part, their usual prescribed 
inhalers and treatment decisions being left in the hands of 
participants’ usual clinical teams rather than investigator-
driven.  
The review noted a range of study populations, including those 
with over half of participants who had not required systemic 
steroids or admission for exacerbation in the preceding year. 
This is despite the evidence that previous exacerbation is a 
powerful risk factor for future exacerbation and the evidence 
that good ICS adherence is important in reducing exacerbation 
rate. This pilot study was therefore designed to enrich for 
exacerbation.  
Also highlighted by the review of interventional studies was the 
importance of using outcome measures which were comparable 
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to other studies and clinically useful such as severe 
exacerbations, forced expiratory volume in one second (FEV1) 
and standardised measures of symptom control such as the 
Asthma Control Test™ (ACT™) (170).  
5.2. Methods 
5.2.1. Study protocol 
The study protocol with a list of trial amendments is included in 
Appendix C. 
5.2.2. Study design 
This was a randomised controlled trial with a 1:1 allocation to 
intervention and control groups. Participants were recruited for 
six months and followed up on an approximately monthly basis.  
5.2.3. Recruitment, research site and ethics 
Recruitment opened December 2016 and extended to 
December 2018. Participants were recruited from primary and 
secondary care, the Nottingham Respiratory Research Database 
(NRRD) and by public advertisement. Primary care sites 
included General Practices in Nottinghamshire, Derbyshire and 
Lincolnshire. Secondary care recruitment was carried out at 
respiratory clinics at Nottingham University Hospitals (NUH) 
NHS Trust, respiratory wards at NUH as well as the Emergency 
Department (ED) at NUH. The NRRD was a list of individuals 
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who were interested in being contacted for the purpose of 
research participation and who had consented to basic 
demographic, treatment and phenotyping information being 
held for this purpose. Public advertisement was conducted 
through display of posters at NUH, the University of Nottingham 
and General Practices in the catchment area as well as through 
advertisement on the Nottingham Respiratory Research Unit 
(NRRU) Facebook page.  
Prior to being approached, patient records were screened for 
eligibility by the research team (NRRD and secondary care) or 
by the patient’s General Practitioner (primary care). Contact 
details for the research team were provided directly to those 
approached in person, by telephone or by letter and also 
displayed on posters and online advertisements. Individuals 
who were interested then went through more detailed eligibility 
screening and, if likely to be eligible, were invited for a formal 
visit. 
The study was conducted at the NRRU, Nottingham, UK. 
Occasional visits were also conducted in patients’ local primary 
care practices (part of the East Midlands Primary Care Research 
Network) by prior arrangement. Ethics approval was gained 
from the London Central Research Ethics Committee. The NRRD 
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existed under a separate ethics agreement from the East 
Midlands Research Ethics Committee.  
5.2.4. Eligibility criteria  
Participants were included if the following were demonstrated 
at enrolment: 
- Age 18-65 inclusive 
- Systemic corticosteroid use for worsening asthma (or an 
increase from baseline dose in patients on long-term oral 
corticosteroids) in the prior 12 months (patient reported) 
- Doctor’s diagnosis of asthma for at least 12 months 
- On British Thoracic Society (BTS) step 2-5 treatment via 
an inhaler compatible with a study monitoring device 
- Use of own internet-enabled, compatible mobile phone 
- Willingness and ability to give informed consent for 
participation in the clinical investigation 
- Willingness and ability to comply with all clinical 
investigation requirements 
- Willingness to allow their General Practitioner (GP) and 
consultant, if appropriate, to be notified of participation 
in the clinical investigation. 
Participants were excluded if the following were demonstrated 
at enrolment: 
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- Diagnosis of chronic obstructive pulmonary disease 
(COPD) or onset of symptoms after the age of 40 in 
patients with ≥ 10 pack year history of smoking 
- Other clinically significant coexisting respiratory disease 
e.g. fibrosis, bronchiectasis 
- No personal mobile smartphone 
- Use of maintenance and reliever therapy (MART) 
- Any other significant disease or disorder which, in the 
opinion of the investigator, may have put the participant 
at risk, influenced the result of the clinical investigation 
or influenced the participant’s ability to participate in the 
clinical investigation. 
Use of a MART regime was excluded due to the complexity of 
analysing adherence and comparing it to standard regimens, 
particularly in the presence of potential ICS overuse patterns 
unique to MART and the exclusion/reduced reliance on SABA. 
5.2.5. Randomisation 
If screening was successful, participants were randomised to 
the intervention (EMD with app and investigator feedback) or 
control group (EMD, no feedback) using a 1:1 group allocation 
without stratification. To do this, the investigator conducting the 
baseline visit fed the participant’s study identification number 
and date of birth into a database front-end. Permuted block 
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randomisation with a block size of six was then performed by a 
computer-generated algorithm, using the online tool from 
www.sealedenvelope.com (London, UK Copyright © 2001–
2021 Sealed Envelope Ltd). The resulting allocation was 
displayed on the database front-end. The investigator then 
noted both the randomisation code and the group allocation and 
proceeded with the remainder of the baseline visit.  
Given the nature of the study design, investigators were aware 
of group allocations. All participants were aware in vague terms 
that the EMD provided would look at patterns of inhaler use 
which would be reviewed by the end of the study and consented 
to participate in the study based on this. Once randomised, the 
study hypothesis and intervention procedures were discussed 
with participants in the intervention group, at which point they 
were asked to complete a second consent form. The existence 
of an intervention arm and the real-time capabilities of the 
EMDs were not discussed with control group participants until 
their final visit unless they requested this information directly.  
5.2.6. Study procedures 
General study procedures 
These summarise the Clinical Investigation Assessments, the 
schedule of activities which can be found in Appendix C on page 
432. At a baseline face-to-face visit conducted either at the 
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NRRU or at the patient’s primary care practice, participants 
were screened and randomised (if they were found to be eligible 
on screening). They were then questioned on their asthma 
status and history (including exacerbations in the year 
preceding study entry). Spirometry, reversibility, asthma 
control (using the ACT™) and asthma-related quality of life 
(using the mini-Asthma Quality of Life Questionnaire [mini-
AQLQ]) were measured. Participants were provided with a 
written asthma action plan and a Smartinhaler™ compatible 
with their inhaler. They also had their inhaler technique 
checked.   
Participants were followed up for six months at approximately 
monthly intervals (giving a total of seven study visits). Follow-
up visits were primarily over the telephone but were face to face 
if this coincided with routine hospital visits. All participants had 
their ACT™ and mini-AQLQ repeated monthly by an 
investigator. Participants were also asked to report any events, 
scheduled or unscheduled, that had taken place since their last 
study visit at this time. Usual care was provided by participants’ 
own primary or secondary care team.  
At a final visit conducted either at the NRRU or at the patient’s 
primary care practice, participants again repeated the ACT™ 
and mini-AQLQ questionnaires, spirometry and reversibility and 
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reported any intervening events. All participants received 
feedback on their inhaler use data at this time. Finally, 
participants were invited to take part in a qualitative interview 
to discuss their experiences of being in the study and of using 
the EMDs provided. Findings from the interview are presented 
in Chapter 6.  
Electronic monitoring device 
The Adherium Smartinhaler™ platform was used to remotely 
record actuations, using Bluetooth® technology to periodically 
upload contemporaneous date and time stamps for actuations 
to the associated mobile app and from there to a cloud-based 
server (see also Chapter 4). Initially, devices were limited to 
SmartTouch™ devices which attached to compatible with 
Fostair, Salamol, Seretide and Ventolin MDIs as an external 
clip-on sleeve. SmartTurbo™ devices compatible with Bricanyl 
and Symbicort inhalers were also included later in the study. 
These clipped onto the base of the Turbohaler inhalers. Both the 
SmartTouch™ and SmartTurbo™ devices have been validated 
(165, 166) and were commercially available.  
Depending on their study group allocation, participants were 
provided with either the Smartinhaler App™ (intervention group 
participants) or the Smartinhaler Lite App™ (control group 
participants). These are described in further detail below. 
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Intervention group additional procedures 
In addition to the above procedures, intervention participants 
were also given feedback on their inhaler use data. This came 
from two sources. First, they were able to see their own data 
on a day-to-day basis in the app, which had a dashboard 
showing the proportion of expected inhaler actuations which 
had occurred that day.  A further screen also showed a graph 
of actuations over a longer time period, with a line demarcating 
how many actuations were expected. In addition, the preceding 
month’s data was reviewed by the investigator (IA). This was 
discussed with participants at Visits 2-6, with the emphasis of 
discussion on uncharacteristic SABA overuse or ICS underuse 
averaging <70%. Where there was evidence of SABA overuse 
or ICS underuse but not of device malfunction, these data were 
fed back to the participant’s own clinical team and it was 
suggested to the participant that they discuss with their usual 
care team whether alterations to their management were 
required.  
Control group 
In order to maintain a level of partial blinding, control group 
participants saw a limited version of the mobile phone app 
which showed a cartoon of their device, the name of the inhaler 
it was linked to and the device’s battery status as well as 
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whether or not it had been successfully paired. Data were not 
fed back to the usual care teams of control participants. At the 
final visit, the option to have a summary of their inhaler use 
data over the course of the study was provided with the option 
to relay this to their usual care teams themselves if they so 
desired.  
Investigator roles 
Three investigators (IA, NT, CP) conducted screening, 
randomisation and baseline study visits. Although not 
designated in the study protocol, NT conducted study visits 2-5 
for control participants (with the exception of one visit – 
SIT006, Visit 3 conducted by IA) and IA conducted study visits 
2-5 for intervention participants. NT did not access inhaler use 
data during the course of the study. All participants were seen 
at final visit by IA. 
5.2.7. Clinical outcomes 
Exacerbation events were defined as three or more days of 
systemic steroid use (or an increase in usual systemic steroid 
dose by at least double) in the context of acutely deteriorating 
symptoms of asthma. Events 14 or fewer days apart were 
counted as a single event.  
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The ACT™ is a questionnaire with response measured on a five-
point scale. Good asthma control was considered to correspond 
to a score of 20 or more (171). The mini-AQLQ is a 15-item 
questionnaire split into four domains (symptoms, activities, 
emotions and environmental stimuli). To score, the mean of 
each domain was calculated in addition to the mean of all 15 
questions. Each question was measured on a seven-point scale 
giving a maximum score of 7.0 for each of the domains as well 
as the overall test. Clinically meaningful improvement was 
considered to be 3 for the ACT™ (172) and 0.5 for the mini-
AQLQ (173). 
5.2.8. Study endpoints 
Co-Primary endpoints 
1. Preventer use: The mean percentage of prescribed ICS 
dose taken daily over the study period.  
2. Reliever Use: The number of days with >16 
actuations/day of short-acting beta agonist (SABA) 
taken in a 24-hour period. 
For both primary and secondary adherence endpoints, each 
“day” has been defined as midnight to midnight. 
Secondary endpoints: ICS use 
1. Number of days of ICS non-use 
2. Number of days of 100% preventer adherence  
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3. Mean percentage of prescribed preventer dose taken 
daily by month  
4. Number of days of overuse of preventer treatment  
5. Mean daily ICS (preventer) dose (total number of 
actuations over study period multiplied by dose per 
actuation) divided by number of days of treatment 
exposure 
Secondary endpoints: SABA use 
1. Overuse of reliever: Number of days of >24 and >32 
actuations of SABA in a 24 hour period 
2. Number of days of zero SABA use  
Secondary endpoints: power calculation 
Derivation of a power calculation for a real-world study, based 
on adherence 
Secondary outcomes: clinical control 
1. Number of exacerbations (treatment with systemic 
corticosteroids for asthma or antibiotics) 
2. FEV1 
3. Asthma control (ACT™ score) 
4. Asthma-related quality of life (Mini-AQLQ score) 
Secondary outcomes: treatment decisions 
1. Studying the utility of differing thresholds for feedback 
(e.g. ICS adherence of <75% or <80%; SABA thresholds 
based on number of days of at least one SABA actuation 
or maximal daily number of actuations) 
2. Study practicality of data feedback processes 
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3. Episodes where advice provided to seek GP/clinical review 
based on monitoring data; and, episodes when 
participants actually sought review subsequently 
* assessed via interview at final visit 
5.2.9. Statistical plan 
The study sample size was chosen in keeping with the study’s 
nature as a pilot study. Quantitative data were analysed using 
STATA v15, StataCorp LLC (Texas). For the Intention to Treat 
(ITT) analysis, all participants who provided any data were 
included. Participants who provided no data were excluded as it 
could not be determined whether this non-provision of data was 
due to non-use or device fault. Participant data were included 
up to the last day of data provision.  
Parametric continuous data were summarised using means and 
standard deviations (SD) and non-parametric data were 
summarised using medians and inter-quartile ranges (IQR). 
Daily ICS adherence has also been reported using means and 
SDs in line with the literature. A student’s t-test was used to 
test for differences in adherence and parametric outcomes. 
Wilcoxon’s Rank Sum statistic was used to test for differences 
in non-parametric continuous clinical outcomes. Chi-squared 
tests were used for categorical outcomes and a mixed-effects 
linear regression model was used to assess the effect of study 
group on ICS adherence over the course of the study. The 
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mixed effects model was chosen in order to account for the fact 
that this outcome involved monthly repeated measures from 
participants.   
Secondary outcome SABA data was calculated as the number 
of participants with any recorded overuse at each threshold. 
SABA non-use was as the number of days of non-use per 
person-days, accounting for varying durations of study 
participation. 
Exacerbation rate was analysed per 1000 person-days to 
account for differing durations of study participation. 
Exacerbations were also expressed categorically as participants 
who had experienced exacerbation vs. participants who had not 
using the chi-squared statistic.  
To assess utility of differing thresholds of adherence, cut-offs 
were defined as follows: 
 Preventer use recorded at 50%, 60%, 70%, 75%, 80% 
and 90% prescribed 
 SABA use of ≥3 days per week (equivalent to poor 
control and suggestive of need for escalation of therapy) 
(1)  
 SABA use equivalent to use more than one canister per 
month (i.e. >120 actuations of terbutaline and >200 
actuations of salbutamol (6, 174, 175)). 
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These cut-offs were assessed by study group using the chi-
squared statistic to ascertain whether there was a significant 
difference between groups. Selected cut-offs were then 
assessed against clinical outcomes using student’s t-test for 
parametric data and Wilcoxon’s Rank Sum for non-parametric 
data.  
A major concern during the study was the role faulty devices 
may have played in study outcomes. To combat this, a 
sensitivity analysis was carried out using only trusted devices 
to assess whether elimination of faulty or potentially faulty 
devices would have any effect on outcomes. These were devices 
which were either returned for testing and passed post-study 
testing or were not returned by participants but had no major 
concerns during their study usage. 
5.3. Results and analysis 
5.3.1. Recruitment 
In total, 36 participants were randomised, 18 to the 
intervention group and 18 to the control group (see Figure 5-
1). Recruitment took place over a period of 24 months (Figure 
5-2). Overall, 30 participants attended the final visit for the 
study. Four participants did so having missed intervening visits 
either due to difficulty contacting them to arrange these visits 
or, for one participant, due to a request to withdraw from the 
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study. Six participants were lost to follow-up. Five of these were 
control participants. Thus, 14 intervention and 12 control 
participants completed all study visits and 17 intervention and 
13 control participants attended the final visit.  
Data were obtained from 33 participants (18 intervention and 
15 control participants). All 33 were included in the analysis. 
For one intervention participant, technical issues meant that 
their real-time data were not available to either them or to the 
investigators for monthly feedback. Their data were analysed 
according to group allocation regardless. Duration of ICS data 
analysed ranged from 35 days of data to the full 168 days. 
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Figure 5-1: CONSORT diagram of study recruitment 
  
CONSORT 2010 Flow Diagram 
Assessed for eligibility (n=1190) 
Excluded (n=1154) 
   Not meeting inclusion criteria (n=940) 
   Unable to contact (n=89) 
   Declined to participate (n=81) 
   Missed or cancelled baseline visit (n=15) 
   Other reasons (n=29) 
Analysed  (n=18) 
 Excluded from analysis (give reasons) (n=0) 
Lost to follow-up (n=1) 
Discontinued intervention (unable to attend 
middle visits but attended final visit) (n=3) 
Allocated to intervention (n=18) 
 Received allocated intervention (n=17) 
 Did not receive allocated intervention (n=1) 
Lost to follow-up (n= 5) 
Discontinued intervention (participant 
requested to withdraw but attended final visit) 
(n= 1) 
Allocated to control (n=18) 
 Received allocated intervention (n=18) 
 Did not receive allocated intervention (n=0) 
Analysed  (n=15) 
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Figure 5-2: Recruitment over study period 
 
5.3.2. Baseline characteristics 
Baseline demographics are shown in Table 5-1. Participants’ 
ages ranged from 18 to 64. Sixty-seven percent of participants 
were female and the majority of participants (83%) identified 
as Caucasian. Other than a slightly higher age at both 
enrolment and diagnosis in the intervention group, the 
intervention and control groups were relatively well-matched 
demographically. Participants who attended Visit 7 and the six 
participants who were lost to follow-up (and consequently had 
few or no days of data) were also well-matched (Table 5-2). In 
terms of baseline asthma severity and phenotype, half of the 
participants had evidence of inflammation (either an eosinophil 
count of >0.4 x10-9/L or FENO of ≥40 ppb), just under half had 
evidence of atopy (total IgE of >100 kU/L or allergen-specific 
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IgE positive >0.35 kU/L) and two thirds were never smokers. 
These were evenly split between the groups. 








Age, median (IQR) 48.3 (33.5, 55.4) 50.0 (34.9, 58.6) 43.5 (32.2, 50.9) 
Female, n (%)  24 (67) 11 (61) 13 (72) 
Caucasian race, n 
(%) 








15.12 (4.9, 30.6) 17.0 (4.8, 45.0) 13.5 (4.9, 27.6) 
BTS stage, n (%) 
 
 3 8 (22) 4 (22) 4 (22) 
 4 22 (61) 10 (56) 12 (67) 
 5 6 (17) 4 (22) 2 (11) 
ICS dose*, median 
(IQR) 
1600 (800, 1600) 1600 (800, 
1600) 




18 (50) 9 (50) 9 (50) 
Evidence of atopy, 
n (%) 
17 (47) 9 (53) 8 (47) 
History of 
reversibility, n (%) 
6 (16.67) 2 (11) 4 (22) 
Smoking status, n 
(%) 
 
 Smoker 3 (8) 2 (11) 1 (6) 
 Ex-smoker 9 (25) 4 (22) 5 (28) 
 Never smoker 24 (67) 11 (61) 13 (67) 
Pack years, 
median (IQR) 
8.25 (4.18, 13.50) 8.25 (6.00, 9.50) 8.84 (2.59, 
22.50) 
BMI, mean (SD) 30.75 (7.23) 32.04 (8.66) 29.37 (5.24) 
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* Beclometasone diproprionate equivalent (BDPe), micrograms  
 
 
Table 5-2: Demographics by loss to follow-up 
 







46.7 (34.9, 54.3) 50.4 (26.1, 56.4) 0.932 
Female, n (%)  19 (63) 5 (83) 0.900 
Caucasian race, 
n (%) 
25 (83) 5 (83) 1.000 
 
There was a difference between the groups in baseline mini-
AQLQ (Table 5-3). The intervention group also had a slightly 
higher proportion of participants with uncontrolled asthma as 
measured by the ACT™ and a slightly lower median percentage 
predicted FEV1. The groups had a similar exacerbation profile. 
Self-reported exacerbations were confirmed for all but one 
participant (Figure 5-3). 
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FEV1 (L),  median 
(IQR) 
2.47 (1.50, 3.06)  
 
 
2.39 (1.55, 2.86) 
 
 






75.5 (48.6, 90.4) 73.8 (54.5, 86.5) 82.2 (48.6, 95.9) 
FEV1 reversibility 





3.47 (1.21, 7.09) 
Proportion 
reversible at 
baseline, n (%) 
12 (33.33) 6 (33) 6 (33) 






ACT™ score, mean 
(SD) 
14.9 (4.9) 13.6 (4.5) 16.3 (4.9) 
Uncontrolled by 
ACT™, n (%) 
30 (83) 17 (94) 13 (72) 
AQLQ score, 
median (IQR) 





2 (1, 5) 2 (1, 6) 2 (1, 4) 
Participants with 
≥3 exacerbations in 
preceding 12 
months, n (%) 
15 (42) 8 (45) 7 (39) 
Hospitalisation 
ever, n (%) 
26 (72) 14 (78) 12 (67) 
Critical care ever, n 
(%) 
10 (28) 5 (28) 5 (28) 
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Figure 5-3: Number of confirmed exacerbations in year preceding enrolment 
 
 
5.3.3. Co-primary endpoints 
Table 5-4 presents the data for the co-primary endpoints. Three 
participants were excluded from the intention to treat analysis 
as they were lost to follow-up after their first visits and had no 
data upload from their devices. Three further participants were 
lost to follow-up and four did not complete all study visits. Data 
for these seven were analysed for the duration over which they 
provided data. There was no significant difference between 
intervention and control group adherence or SABA overuse 
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(>16 puffs per day) over the study period. This did not change 
on sensitivity analysis (Table 5-5).  











mean daily ICS 
adherence, 












65.6 (32.0) 70.7 (32.1) 59.4 (31.9) 0.319 
Median days > 16 
SABA puffs 
(IQR) 
0 (0, 0) 0 (0, 2) 0 (0, 0) 0.648 
 
Table 5-5: Mean daily preventer adherence and bronchodilator overuse by study 










mean daily ICS 
adherence, 
median (IQR)  
85.8 (43.6, 
92.4) 







mean (SD)  








Median days > 
16 SABA puffs 
(IQR) 
0 (0, 0) 0 (0, 0) 0 (0, 1) 0.754 
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5.3.4. Secondary endpoints 
ICS use 
There were no significant differences between intervention and 
control groups for the rate days of ICS non-use, 100% ICS 
adherence, ICS overuse, mean daily ICS dose by month and 
mean daily ICS dose overall (Table 5-6).  







































Mean daily ICS 
dose per day 
exposed†, 
median (IQR) 
772 (390, 1450) 731 (390, 1550) 949 (353, 1398) 0.691 
 
* Per person-days  
† BDPe, micrograms 
 
A repeated measures mixed effects model to assess difference 
in adherence between groups on a month by month basis was 
not significant for time (coefficient -0.1%, 95% CI -1.5 to 1.3, 
p=0.849) or study group (coefficient 11.5%, 95% CI -9.7 to 
32.7, p=0.287). However, whilst there was no overall 
difference, a linear plot of adherence by month suggested a 
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separation between the groups in the middle part of the study 
which resolved in the final month when control participant 
adherence drastically increased (Figure 5-4).   
Figure 5-4: Mean preventer adherence by month 
 
Reliever use 
The rate per person-days where SABA was not required is 
presented in Table 5-7. Three thresholds for reliever overuse 
were considered: >16 SABA actuations in one day, >24 SABA 
actuations in one day and >32 SABA actuations in one day. For 
each of these thresholds, the number of participants who did 
not demonstrate SABA overuse at any point in the study are 
presented. There were no statistical differences in reliever use 
between intervention and control groups for either the rate days 
of non-use or the rate of overuse days of SABA.  
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2 (6) 0 (0) 2 (13) 0.110 
 
* Per person-day 
† Number of participants with one or more episodes of overuse as described 
 
Power calculation 
A power calculation to predict sample size needed to detect a 
difference in ICS adherence between groups based on this study 
design of feedback vs. no feedback was derived using levels of 
ICS adherence from this study.  Power was set at 90% to 
account for loss to follow-up. For a difference in daily ICS 
adherence of 11% between the intervention and control groups 
and significance level of 0.05, a sample of 340 (170 per group) 
would be required. 
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Clinical control 
Exacerbations, defined as usually seen in the literature (176, 
177) as acute deterioration of symptoms and three or more 
days of systemic steroids or doubling of usual steroids, are 
presented below (Table 5-8). Also presented are exacerbations 
where this definition is expanded to include antibiotics. When 
defined as symptoms and steroid or antibiotic use, there was a 
borderline significant higher exacerbation rate in the 
intervention group. There was no correlation between 
exacerbation rate and adherence. Pearson’s r statistic was -
0.06 (p=0.731) for exacerbations measured by steroid use only 
and -0.15 (p=0.402) for exacerbations measured by steroid 
and antibiotic use. A box-plot below shows median adherence 
grouped by number of exacerbations over the study period 
(Figure 5-5). 
Whilst there were no other significant findings in clinical 
outcomes, it should be noted that the significant difference in 
asthma-related quality of life and the trend towards a difference 
between groups in asthma control seen at baseline was no 
longer present at the end of the study, suggesting a possible 
trend towards a greater change in asthma-related quality of life 
and asthma control in the intervention group.  
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5.3 (5.1, 6.7) 
n=30 
5.3 (3.9, 6.3) 
n=17 




* Asthma symptoms and systemic steroids 
† Asthma symptoms and systemic steroids or antibiotics 
‡ Per person-year 
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The table below demonstrates that the intervention group had 
more adherent participants than the control group. This was 
borderline significant at an adherence threshold set at 75-80% 
(Table 5-9). Clinically, however, this does not appear to 
translate into a difference in outcomes (Table 5-10). 
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(n=18) – proportion 
good adherence, n (%) 
Control group (n=15) 
– proportion good 
adherence, n (%) 
p  
50% 13 (72) 9 (60) 0.458 
60% 12 (67) 6 (40) 0.126 
70% 12 (67) 6 (40) 0.126 
75% 12 (67) 5 (33) 0.056 
80% 12 (67) 5 (33) 0.056 
90% 7 (39) 3 (20) 0.240 
 
Table 5-10: Clinical outcomes at final visit compared between participants with good 
adherence and poor adherence (defined at a 75% threshold) 








FEV1, median (IQR) 
67.6 (45.2, 84.6) 
n=15 
87.9 (62.8, 91.4) 
 
0.206 







5.43 (4.13, 6.50) 
 




≥1 exacerbation*, n (%) 






*Asthma symptoms and systemic steroids 
 
In total, 753 weeks of reliever data were examined for use on 
three or more days of the week. Overuse by this threshold was 
observed on 294 weeks (39% weeks). Overall, 188 months 
were examined for reliever use equivalent to a whole canister 
in a single month. Overuse by this threshold was observed on 
15 months (8% months). There were no differences between 
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the groups in the number of participants who did not overuse 
their reliever inhaler (Table 5-11). 
Table 5-11: Proportion of participants with no inappropriate SABA use by study group 
Adherence threshold Intervention 
group (n=18) – no 
inappropriate  
use, n (%) 
Control group 
(n=15) – no 
inappropriate  
use, n (%) 
p  
Poor control (≥3 days 
per week) 
3 (17) 4 (27) 0.484 
Overuse (≥1 canister 
per month) 
15 (83) 14 (93) 0.381 
 
In terms of clinical outcomes, participants with an overuse 
pattern suggestive of poor control demonstrated clinically and 
statistically significant lower asthma control and asthma-related 
quality of life than participants not demonstrating this pattern 
of reliever overuse (Table 5-12). Similarly, participants who had 
used the equivalent of a full canister of reliever inhaler in any 
one month demonstrated a lower percentage predicted FEV1, 
lower asthma control score and were more likely to have 
experienced at least one exacerbation (defined as symptoms 
and systemic steroid use) at the study end (Table 5-13).  
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Table 5-12: Clinical outcomes at final visit compared between participants with 
appropriate SABA use and SABA use on ≥3 days per week 
Outcome Appropriate use 
(n=6) 
Use on ≥3 days 
per week (n=24) 
p 
Percentage predicted 
FEV1 median (IQR) 
83.5 (67.6, 89.6) 77.2 (45.2, 91.4) 
n=23 
0.554 
ACT™, mean (SD) 22.7 (2.9) 15.1 (5.3) 0.003* 
mini-AQLQ, median 
(IQR) 
6.77 (6.60, 6.87) 5.20 (4.03, 5.93) 0.001* 
Participants 
experiencing ≥1 







Table 5-13: Clinical outcomes at final visit compared between participants with 
appropriate SABA use and SABA overuse equivalent to a whole canister in any month 
Outcome Appropriate use 
(n=26) 
Overuse (n=4) p 
Percentage predicted 
FEV1, median (IQR) 
83.7 (62.8, 91.4) 
n=25 
42.1 (35.7, 56.7) 0.019* 
ACT™, mean (SD) 17.5 (5.6) 11.0 (5.0) 0.037* 
mini-AQLQ, median 
(IQR) 
5.60 (4.60, 6.60) 4.40 (2.83, 5.43) 0.127 
Participants 
experiencing ≥1 








Five intervention participants were referred to their GP for six 
occasions of ICS underuse (<70%) and 10 intervention 
participants for 22 occasions of SABA overuse (more than usual 
for them). There are 10 occasions where asthma reviews in 
primary care appear to coincide with these referrals suggesting 
an uptake rate of 37-45%. 
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In practice, feedback was complicated by concerns about device 
reliability, individual need (some participants, for example, 
reported that because they were already on maximal treatment, 
feedback of SABA use to GPs did not result in treatment changes 
as there was no further escalation possible in primary care) and 
place of care. Where care for a patient was coordinated by 
tertiary care, the provision of data to severe asthma teams 
served more as information – participants did not report specific 
actions resulting. Finally, where participant visits were delayed, 
this resulted in a delay in feedback as verbal consent was taken 
at these visits to share information. 
5.4. Discussion 
Study findings 
A real-world randomised controlled pilot study was designed to 
investigate the effect of providing in-app and investigator 
feedback on EMD-measured inhaler adherence. Whilst an 11% 
difference between intervention and control arm ICS adherence 
was observed, this was not statistically significant and a power 
calculation suggests that the study is significantly 
underpowered to find a difference in adherence using this 
design. This study also found a non-significant difference in 
exacerbation rates in favour of the control arm. With a broader 
definition for exacerbations, this difference in exacerbation rate 
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approached statistical significance. There were no statistically 
significant differences in clinical outcomes between the groups.  
When assessing treatment decisions, a greater proportion of the 
intervention group had an adherence level of ≥75% compared 
with the control group, although this had only borderline 
significance (p=0.056) and was not associated with a difference 
in clinical outcomes. There was no difference in SABA overuse 
between the groups; however participants who overused their 
SABA demonstrated a lower percentage predicted FEV1, asthma 
control and asthma-related quality of life score as well as a 
higher exacerbation rate at their final visit.  
Also of interest was the increase in adherence in the control 
group ahead of their final study visit, suggesting that, although 
many control participants expressed awareness that they were 
being monitored (see Chapter 6), this did not lead to maintained 
adherence throughout the study period. In keeping with this 
finding, more participants in the control group were also lost to 
follow-up.  
Current evidence and context: study design 
EMD-measured inhaler adherence has become increasingly 
accurate, with newer devices including capabilities such as 
detection of inhalation and inhaler technique (5, 178, 179). In 
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Chapter 3, this thesis presents evidence that EMD research 
strongly supports the role of EMD-based interventions in 
improving ICS adherence; however, previous studies have not 
always been clear on which component of an intervention has 
led to its effect. Surprisingly, it also suggests that, despite the 
strong link between poor adherence and outcomes in asthma, 
there remains little evidence, particularly in adults, that EMD 
based interventions lead to improved outcomes in asthma. 
Potential reasons for this include recruitment of participants 
with high baseline adherence or at lower risk of adverse 
outcomes, such that a change would not be observed in the 
three to twelve month study periods commonly employed in 
adherence studies. Importantly, no study has thus far been able 
to define the magnitude of change in adherence needed to lead 
to a change in clinical outcomes.  
We designed a pilot study that would be as close to real world 
in nature as possible. Our protocol enriched for individuals with 
asthma who were at risk of exacerbation and narrowed the 
observed EMD-based intervention to clinician and app feedback. 
Despite this, our study did not observe a statistically significant 
change in mean daily ICS adherence, nor did it observe a 
statistically significant difference in SABA overuse. The study 
did demonstrate a non-significant difference in adherence 
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(compared with most studies which have found significant 
between-group difference). This lack of significance in the 
context of previous evidence suggests that clinician/app 
feedback may act synergistically with other elements of EMD-
based intervention (such as reminder alarms), but may be less 
effective when used alone. This is supported by the power 
calculation which indicates that, as a solitary intervention, a 
sample of 340 participants would be needed to see a significant 
difference in adherence between the intervention and control 
groups.  
The non-significant adherence rate difference between the 
groups of 11% is in keeping with the estimate from the meta-
analysis in Chapter 2, which suggests that interventions may 
expect to see a roughly 13% improvement in adherence. In 
Chapter 3, however, this thesis discussed that, given the high 
baseline adherence of interventional study participants, such 
increments in adherence may be too small to translate into 
improved clinical outcomes. Furthermore, the studies in 
Chapter 3 which did show a translation of adherence 
improvements into clinical outcomes had effect sizes of around 
20% and 50% (69, 71). Whilst, as per the original investigation 
plan, the effect size for the power calculation was drawn from 
the results of this study, the possibility that a much larger effect 
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size may be required to see a translation from improved 
adherence to improved clinical outcomes should be considered. 
More complex adherence outcome measures (inhaler technique 
outputs for example, or accounting for the effect of seasonal 
changes) may be informative but there is currently little in the 
literature to support their use as primary outcomes. Future 
studies should certainly consider these important factors and 
incorporate such outputs into the analysis plan where 
appropriate. 
Current evidence and context: clinical outcomes 
Evidence suggests that increased adherence leads to reduction 
in exacerbation rates (31, 32, 180); however, in this study, the 
opposite was noted. Whilst this study was pilot in nature and 
not powered for exacerbations, it does suggest that in a real-
world setting where changes in care are provided by an 
individual’s usual care team, factors other than adherence may 
influence clinical outcomes. This may shed some light on why, 
despite positive effects on adherence, EMD-based interventions 
have not led to the improvements in clinical outcomes expected.  
Potential candidate factors have emerged from interviews with 
participants (see Chapter 6 – Results: Participants’ experiences 
of the Inhaler Technology Study) who consistently reported that 
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the main impact of study participation was on their awareness 
of their condition and medication use. It may be that, for 
intervention participants, the combination of this awareness 
with app and/or investigator feedback led to the increased 
frequency of exacerbation observed. Another possibility is that 
the process of GP referral as an intervention may have led to 
an increase in help-seeking behaviours not seen in the control 
group. Lastly the real-time in-app access may have played into 
health anxieties which emphasised symptoms that would 
previously have been ignored.  
Whilst these factors may modify the risk of exacerbation in 
EMD-based interventions, they may also maintain engagement. 
More participants from the control group (who did not receive 
regular feedback) were lost to follow-up. It may be that the 
regular feedback led to increased engagement with a proportion 
of device users who may not otherwise have remained engaged. 
These findings have implications for future real-world studies in 
asthma where responsibility for clinical management is placed 
with the usual care team and exacerbations are defined based 
on symptoms. Increased symptom awareness or even 
engagement should not be presumed to be beneficial and the 
potential effects of increased help-seeking and/or anxiety 
should be mitigated for.  
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SABA overuse did not differ between the groups, however it did 
appear to be associated with clinical outcomes. This was 
demonstrated with thresholds from both the Global Initiative for 
Asthma (≥3 days of use in a given week)  and the BTS (more 
than one canister in a given month) (1, 6). Patel et al. have 
previously demonstrated that electronically-monitored SABA 
overuse may identify individuals at risk of poor asthma control 
(96) and hospitalisation (95). Whilst use of more than one 
canister a month would be flagged on electronic records, the 
softer overuse definition of ≥3 days of use a week would not 
necessarily, suggesting a possible role for EMDs in identifying 
moderate SABA overuse. 
Even where such a role is found, however, there remains a 
question of standardising an appropriate response. No 
participants whose care was primarily under tertiary services 
reported any change as a result of data being sent to their 
healthcare team. This is likely to be because there was no clear 
pathway for action and participants under tertiary care were 
generally on maximal treatment already. Thus, future 
interventions would need to be tailored to individual users’ 
needs and have a clear process of response. 
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Study limitations 
This study was limited by lower levels of recruitment than 
planned and a high attrition rate (17%), particularly in control 
participants. Note is made of the significant shift towards MART 
regimes, which are now enshrined in guidelines (6, 24). This 
study excluded individuals using a MART regime and findings 
cannot be generalised to this group. Given the marked rise in 
the usage of MART regimes and their inherent potential for 
increased ICS exposure, a future study must consider how to 
incorporate them into its analysis. The study was also hampered 
at various points by poor device performance, and post-study 
testing revealed a small subset of devices with potentially 
unreliable results, although this has been accounted for in the 
sensitivity analysis. Due to its nature as a pilot study, one 
investigator performed both interim analysis of adherence data 
and outcome monitoring, which could have been a source of 
observer bias.  
As a pilot study, a study goal was to calculate the sample size 
that would be needed to adequately power this study design. 
Due to the fact that the study has been found to be significantly 
underpowered, caution is exercised in generalising its findings. 
Strengths of the study include its nature as a randomised 
controlled study and its real-world nature which increases its 
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applicability to clinical practice. Participants were not excluded 
on the basis of multi-morbidity or smoking unless the smoking 
history increased the likelihood of chronic obstructive 
pulmonary disease, again increasing its applicability. The 
mixture of participants from primary and tertiary care allows for 
implications to be drawn for both populations. Finally, clinically 
useful and validated outcome measures were collected, 
allowing for a level of comparability to both existing evidence 
and clinical practice.  
Learning from this study 
Future studies of EMD-based interventions should aim to use 
feedback to maintain adherence in combination with one or 
more other elements of EMD-based intervention (such as 
reminder alarms). From a clinical control perspective, further 
research into both the threshold of adherence and the 
magnitude of change in adherence required to bring about 
improvement in clinical outcomes is still required. There may be 
a role for electronic SABA monitoring to identify individuals with 
moderate overuse at risk of poor asthma control. Having said 
this, despite their popularity with study participants, EMD-
based interventions may not have as direct a relationship with 
clinical outcomes as previously thought. Further research is 
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A pilot study of an EMD-based adherence intervention suggests 
that feedback alone does not lead to a significant improvement 
in adherence. Further work on the threshold and magnitude of 
adherence required to see an improvement in clinical outcomes 
is needed. Elucidation of the mechanisms by which adherence 
interventions influence clinical outcomes is required, 
particularly as they may not be as direct as previously thought. 
This should happen before EMD-based interventions are 
introduced into routine clinical practice.  
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Chapter 6: Experience of 
Smartinhaler™ technology – patient 
perspectives 
6.1. Introduction 
A qualitative study was conducted as part of a pilot study of 
adherence (see Chapter 5). This was done to gain a deeper 
understanding of how study participants viewed their asthma, 
its treatment, their participation in the study (with particular 
focus on their experience of using electronic monitoring devices 
[EMDs]) and the acceptability of potential future avenues of 
EMD use. By considering aspects which fall outside the focus of 
quantitative inquiry, a qualitative approach opens up the 
opportunity to engage individuals with asthma in their own 
care.  
This chapter examines the theoretical underpinnings for 
qualitative inquiry and discusses the reasons behind the 
methodology chosen for the study. Study findings will then be 
presented and, by situating findings from this specific cohort in 
the context of current evidence, potential implications for future 
EMD use will be suggested.  
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6.1.1. Current evidence in the use of EMD interventions for 
behaviour change 
Whilst there has been extensive quantitative research into the 
measurement of adherence and interventions for poor 
adherence in asthma (35, 45, 46, 103) and a growing and 
significant body of work into barriers to adherence in asthma 
(43, 54, 56, 59, 62, 83, 181-183), as well as enquiries into user 
acceptability (71, 168), there has been little work done directly 
aimed at understanding individual experiences of EMDs with 
relation to inhaled corticosteroid (ICS) adherence (152).  
Two adolescent and one adult study have been identified which 
used in-depth semi-structured interviews to achieve a similar 
aim to that described above (184-186). Howard et al. (185) 
looked at attitudes of adolescents with asthma towards an 
earlier iteration of the Smartinhaler™ through the medium of 
structured interviews. Seven adolescents used the devices for 
a one month period. In this observational study, investigators 
found that adolescents felt more positively towards it than 
towards other forms of adherence monitoring. Adolescents 
reported feeling that it gave them an increased sense of control 
over their condition as well as increasing their sense of 
responsibility and making it clear to others that they were 
responsible. They felt that the awareness that their parents and 
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clinicians were potentially monitoring their inhaler use may 
have affected their inhaler use behaviours and discussed how it 
helped them talk about their asthma status with their 
healthcare team. They were aware that they did not want such 
data widely shared. They had mixed feelings on the reminder 
alarm function and generally felt that the appearance of the 
devices led to concerns about unwanted attention/questioning 
and even whether they would use it.  
A more recent study carried out semi-structured interviews with 
eight adolescents and their caregivers. The patients were drawn 
from a difficult asthma service and had been issued with an EMD 
for 6-8 weeks (186). Investigators found that experience of 
requiring urgent, unplanned care and medical treatments had 
been frightening for both participants and their caregivers. 
Some participants expressed a perceived role for both 
preventative medication and healthcare professionals in 
reducing the risk of this recurring. While some perceived EMDs 
as playing a role in this, other participants and the caregivers 
described feeling that the provision of and EMD was a sign that 
they were not trusted by their healthcare professionals, that 
they required surveillance and that their healthcare professional 
was attempting to “catch them out”. There was an associated 
risk perceived of their clinical team seeing the data rather than 
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seeing them. Participants described how the introduction of 
EMDs may have complicated the process of adolescent users 
taking responsibility for their asthma, including caregiver 
concerns around device fragility leading to increased 
surveillance of their adolescents and the risk of relapse of 
behaviours following EMD withdrawal. 
Finally, in the only qualitative studies carried out for participants 
who had used EMDs as part of a behavioural intervention study 
and to date, Foster et al. carried out in-depth, semi-structured 
interviews with eighteen adult intervention participants focused 
around their study experience and the acceptability of the EMDs 
used (184). Study participants found the devices and reminder 
alarms easy to use (although there were mixed responses as to 
the role of the reminder alarms). There was a mixed response 
to their appearance with some participants finding them to be 
“bulky”. As in the previous studies, there were concerns around 
device fragility and unwanted attention. However, importantly, 
Foster et al. found that participants perceived the EMDs to be 
effective reminders for preventer use leading to “behaviour 
change and habit formation”. Some participants further 
identified the of EMDs role in leading to improving their asthma 
symptoms and general asthma status. They described a change 
in their attitudes towards self-management and how it opened 
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conversations with their healthcare practitioners which they had 
previously been unable to have. These experiences were not 
universal. They rather appeared to be linked to baseline 
attitudes e.g. necessity beliefs and concerns and pre-existing 
adherence to or dislike of routines. Participants were mixed in 
how sustained they felt its effect was in the months after 
withdrawal of the EMD with some speaking about how they 
would have appreciated using it for longer and others discussing 
either “sustained behaviour change” or being motivated to find 
new strategies to sustain behaviour change. 
6.1.2. Behavioural models of adherence and intervention design 
Theories of behavioural change and their resultant models may 
assist in identifying the behavioural targets for change and 
pinpointing the mechanisms for behaviour change. This could 
mean that when interventions succeed or fail, they could aid in 
identifying how and why, allowing future research to build on 
that knowledge (187, 188).  
In their systematic review, Holmes et al. found that elements 
associated with the self-regulatory perspective (self-efficacy, 
necessity beliefs and concerns about medication) were 
consistently significantly associated with adherence (189). This 
framework has been used in examining adherence behaviours 
in asthma. Horne et al. found poor self-reported adherence was 
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independently associated with doubts about preventer inhaler 
necessity and concerns about using preventer inhalers (a 
necessity-concerns framework) (59). Foster et al. in the first 
study to use electronic adherence monitoring to investigate 
modifiable beliefs built on this framework, found that adherence 
was related to treatment beliefs (benefits outweigh harm, 
concerns about side effects, concerns about safety, necessity of 
preventer to maintain good control), motivation (the desire to 
adhere), illness perceptions (asthma as a long-term disease), 
community support (advice from important others) and 
routines, again showing strong statistical associations between 
beliefs and behaviours (54). 
Whilst it is generally accepted that behavioural change models 
are useful for intervention design (35, 187, 189), it is also 
acknowledged that this approach does not guarantee 
effectiveness (188, 190). This study sought to use current 
evidence in this area to aid interpretation of observed findings 
such that suggestions for implementing behaviour change could 
be made.  
6.1.3. Quantitative worldviews and qualitative research 
Approaches towards the conduct of research are intrinsically 
tied to a researcher’s underlying way of seeing the world (also 
described as a paradigm or worldview). In qualitative research, 
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engagement with this underlying worldview is seen as a central 
part of the research process. This thesis, for example, asks 
whether EMD technology could be used to effectively measure 
and change adherence behaviours, leading to improved 
outcomes in asthma. Randomised controlled trial (RCT) 
methodology comes from a paradigm that expects the answer 
to such a question can be found (or approximated) through 
study. This answer can then be generalised beyond the local 
sample to the population. Whilst hypotheses are neither truly 
proven nor disproven, they are accepted or rejected on the 
strength of the evidence. This would be described as a realist 
paradigm (191).  
That poor adherence exists is in itself evidence of a worldview 
difference between researchers and clinicians on the one hand, 
and their patients on the other. To the former, ICS reduces risk 
of poor outcomes in asthma and therefore should be used 
regularly as prescribed. Clearly many individuals with asthma 
either do not share this understanding, or do not find this 
understanding enough to lead to a change in their behaviours.  
Denzin and Lincoln define qualitative research as follows: 
 “Qualitative research is a situated activity that 
locates the observer in the world. Qualitative 
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research consists of a set of interpretive, 
material practices that make the world visible… 
attempting to make sense of or interpret 
phenomena in terms of the meanings people 
bring to them.”  
DENZIN AND LINCOLN, 2018, P. 10 (192) 
One prominent ethnographer further expressed the aim of the 
qualitative researcher as follows: 
“I want to understand the world from your point 
of view. I want to know what you know in the 
way you know it. I want to understand the 
meaning of your experience, to walk in your 
shoes, to feel things as you feel them, to 
explain things as you explain them. Will you 
become my teacher and help me understand?”  
JAMES P. SPRADLEY, 1979, P. 34 (193) 
This centrality of the individual’s experience has the potential 
to give critical context, depth and colour to both quantitative 
findings and their application. As a result, although it has 
previously had a difficult time being accepted as part of rigorous 
scientific research (192), including in the medical field (194, 
195), the employment of qualitative research in answering 
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questions not suited to quantitative inquiry is increasingly 
recognised (196). 
6.1.4. Constructivism  
Constructivism (or constructionism) is a philosophy originating 
in Piaget’s developmental work (197). In their synthesis of 
paradigms of qualitative inquiry, Lincoln, et al. describe the 
translation of constructivism into the field as leading to “co-
constructed realities” and “co-created findings” (191, 192, 
197). For this study, in recognising the importance of user 
perspectives to contextualise quantitative study findings and 
guide future directions, this paradigm was ideal for the following 
reasons: 
1. It recognises participants are not passive objects 
providing data for analysis but significant actors in the 
process of creating new knowledge.  
2. It recognises that the researcher is less a disinterested 
external observer, more an individual whose perspective 
is shaped by their own constructs of reality, allowing this 
to be taken into consideration in the interpretation of 
study findings. 
3. The use of the interview as a method of inquiry (as 
employed by this study) is approached particularly 
effectively from this paradigm.  
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Where both participant and researcher are recognised as being 
active in the knowledge-creating process, it is important to 
acknowledge the issues of generalisability and of rigour. In this 
study, the approach has been taken to find meaning from what 
has been expressed in the participant-researcher interaction 
rather than to summarise participants’ perspectives and 
attempt to generalise to a wider population. In the context of 
medical research in particular, this could prove invaluable in 
helping to “fill in the gaps between theory and practice” (191, 
198). Furthermore, this chapter acknowledges the requirement 
from a constructivist paradigm for the researcher to be clear on 
their own role in the knowledge-creation process through 
reflection. 
6.1.5. Choice of the semi-structured interview 
To better understand both adherence behaviours and 
participant experience with EMDs, this project chose to use a 
one-to-one interview technique. These are generally subdivided 
into structured interviews which have a fixed schedule of 
questions, semi-structured which have some fixed questions 
and ideas to explore but flexibility within the interview to add 
to these, and unstructured where a few open questions allow 
the interviewee to determine the direction of the interview 
(199).  
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The choice of the semi-structured interview in this study 
allowed for the best of both worlds, permitting freedom to 
explore unanticipated ideas and to add clarification where 
needed (199). In theory, the process of social interaction had 
the potential to bring down barriers, allowing for greater 
openness on the part of participants and maximising the 
knowledge obtained. However, there was also freedom to guide 
the interview such that the main questions which had been 
identified as central to the investigation could be explored 
(199).  
6.1.6. Aims and objectives 
1. To investigate EMD user experiences of their asthma and 
its treatment. 
2. To investigate EMD user experiences of an EMD system 
deployed as part of a pilot study of an adherence 
intervention. 
3. To explore EMD user perceptions of EMDs based on their 
experiences and to understand how this may influence 
ideas about their future implementation. 
4. By drawing on behaviour change theory, to present a 
working model for behaviour change based on the 
findings of this study. 
 




The initial aim was for purposive sampling of 20-30 participants 
based on self-reported adherence. These participants would be 
selected from a clinical trial assessing the effect of EMD 
monitoring with feedback on adherence and asthma control. 
Recruitment for interview would end when data reached 
saturation (anticipated at around 30 participants). In the end, 
due to lower than anticipated study numbers, all participants 
who attended for a final visit were invited to participate, 
culminating in a convenience sampling approach. 
6.2.2. Interview process 
Pilot study enrolment was for six months commencing between 
December 2016 and December 2018. This permitted 
participants the opportunity to experience the device and any 
effects it may have had. Interviews were conducted at the final 
study visit for each participant by a single interviewer (IA), 
primarily to allow for the capture of those experiences but also 
to maximise participation by limiting participant inconvenience, 
and to combat recall bias resulting from holding the interviews 
a significant period of time after the study had ended. 
The guide was informed by previous work in the area with input 
from various members of the study team. Questions were 
Page | 237  
 
designed to assess participants’ experience of their asthma, 
their medication, their experience of being in the study and their 
experience of Smartinhalers™. They were also designed to elicit 
participant responses to potential future uses of EMDs. As 
implied by its nature as semi-structured, participants were able 
to direct the flow of conversation, with the questions providing 
a guiding frame of reference for the subject matter to be 
covered (200). Follow-up (probing) questions to responses not 
anticipated in the design of the guide are therefore not included.  
The following general topics were covered: 
- Discussion of baseline asthma control 
- Exploration of baseline medication beliefs 
- Exploration of experience with Smartinhalers™ 
- Exploration of perception of the impact of having inhaler 
use monitored 
- Exploration of experience of feedback 
- Discussion of impact on self-management of asthma 
- Response to potential future avenues for data capture 
- Response to future application/delivery of 
Smartinhalers™ in the context of clinical provision 
- Desirability of Smartinhalers™.  
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The full text of the interview guide as used in its final version is 
included in Appendix E. 
6.2.3. Analysis 
In this study, interviews were audio-recorded. This allowed the 
interview to proceed without distraction and for more accurate 
analysis (with more avenues for analysis) afterwards (201). 
Whilst recognising the inherent value of researcher 
transcription, as discussed in the project protocol, for the 
purpose of time, this project used an external transcription 
service. Transcripts were linked with original audio files using 
the study ID and any identifiable information was removed or 
anonymised. 
A thematic approach was used for analysis. This is a structured 
approach based on grounded theory that takes data from the 
collecting stage through to abstraction (202). Its five phases 
are: 
1. Familiarisation 
2. Construction of the initial thematic framework 
3. Indexing and sorting 
4. Reviewing data extracts 
5. Data summary and display 
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Familiarisation (or immersion in the data to enable construction 
of the initial framework) was conducted in this study by 
listening to the first three interviews during the initial coding 
process, conducted by hand. Codes were applied to transcripts 
and these were then mapped onto A3 sheets. The process was 
repeated for the next three interviews, using themes emerging 
from the initial mapping process, allowing for both expansion 
and refinement as needed. Investigator triangulation (where 
data were independently examined by two researchers and 
resultant codes checked for similarity and applicability) ensured 
that the interpreted themes were grounded in the data. 
At the end of this process, an initial framework was constructed. 
Themes were then indexed separately to facilitate analysis of 
the remainder of the data. NVIVO versions 11 and 12 (QSR 
International, also known as computer-assisted qualitative data 
analysis software) was used to assist the  process of indexing 
and sorting the results of the mapping process (202).  
In accordance with Glaser and Strauss’s inductive method 
(202), the next selection of interview transcripts were coded 
based on the framework. Themes were developed and refined 
as the analysis process progressed, adjusting the emerging 
framework to ensure it reflected the accumulating data. Codes 
were then re-indexed as required.  
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At the end of this process, further validity checks took place 
with a repeat process of triangulation. The six initial transcripts 
were reviewed to ensure that the framework was still relevant. 
During this process, major codes were extracted from NVIVO 
into a more visual format and circulated to the wider 
supervisory team for input. Finally, the last set of transcripts 
were analysed according to the thematic framework with further 
theme refinement taking place. Themes were reviewed by two 
investigators and finalised by consensus.  
Even with inductive methodology, there remained the risk of 
misinterpreting data based on the researcher’s own social 
constructs of reality. There was also a risk of trying to force 
data into categories that it did not fit. Finally, there was a risk 
that, in the process of coding and achieving ‘higher order’ data, 
these abstractions could become removed from the original, 
authentic data (203). In order to maximise data validity, 
investigator triangulation was conducted as described. A 
rigorous inductive method was undertaken, with data reviewed 
and re-reviewed, verifying that the thematic framework had 
been generated from the data. A reflexive statement provided 
below clarifies the primary investigator’s role and voice. Most 
importantly, this report has included quotes from study 
participants, permitting them to speak “in their own voice” and 
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allowing the reader to judge for themselves how well they are 
represented by the frameworks formed.  
 
6.3. Reflexive statement 
As discussed, reflection is an essential aspect to both the 
qualitative research process and its validity (204-206). 
Interpersonal interactions varied, influencing the nature of the 
interview. In all cases, preconceptions about the participant-
researcher relationship were present. As the interviews 
progressed, these preconceptions were challenged, particularly 
where relating to how natural and authentic the interview 
process would feel. It also became apparent that some 
participants had self-stratified into “non-adherent” and 
“adherent” persons, likely colouring how they projected 
themselves.  
In this study, the initial aim was to minimise the ‘researcher’s 
footprint’ by limiting the presence of the researcher voice on 
tape between questions (200). It became rapidly apparent non-
verbal encouragement would be an essential substitute and it 
was explained to participants that these would not denote 
approval or disapproval (200). 
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Where misconceptions emerged, awareness of a felt need to be 
an educator were present (200, 201). There were moments of 
language barrier – later interviews, for example, demonstrate 
attempts to steer away from using the expressions “preventer” 
and “reliever” to describe ICS/LABA and SABA inhalers (201). 
More subtle were the power dynamics issuing from being a 
healthcare professional. Attempts were made to mitigate this 
over the course of the study, e.g. encouraging the use of first 
names (201).  
The initial approach to theme construction was to attempt to 
summarise what participants were saying. It was soon apparent 
that there were moments where the recording, the memory of 
the individual and their progress in the study, the previous 
conversations that were had were all needed to provide 
context; and yet faithfulness to the text of what had been said 
was also required. Over the course of the study, increased 
confidence was found in using identified themes to avoid the 
loss of the participants’ projected ‘selves’.  
6.4. Results  
Thirty-six participants were recruited to the pilot study. Of 
these, 30 attended the end of study visit. Two participants were 
unable to undergo interview (one declined and one was unable 
to because of time pressures). Sixteen of the 28 participant 
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interviews were with individuals from the intervention group 
(Table 6-1). 
Table 6-1: Qualitative study – Participant demographics 
 Overall Intervention Control 
Number 28 16 12 
Mean age (SD) 43.8 (13.1) 46.0 (13.6) 40.9 (12.5) 
Female n (%) 19 (68) 8 (67) 11 (69) 
Caucasian n (%) 24 (86) 15 (94) 9 (75) 
 
6.4.1. Summary of themes 
Over the course of the interviews, five themes were interpreted 
(Table 6-2). These related to participants’ experiences of having 
asthma, their experiences of asthma treatment, their 
experiences of being in the study and their thoughts on 
potential future applications of Smartinhaler™ Technology. 
They are explored below, with supportive excerpts throughout.  
In the text, participants are identified by their study 
identification number, the letter C or I signifying their status as 
either a control or an intervention participant and the letter F 
or M signifying their sex. This is followed by their age. For 
example, “SIT001IF, 54 yrs.”, identifies participant SIT001 
who was an intervention group participant, female and aged 54 
years. 
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Table 6-2: Themes and subthemes 
Themes Subthemes 
Theme 1: Participants’ experiences of 
asthma 
Beliefs and attitudes 
Participants’ experiences of their asthma symptoms 
Participants’ experiences of healthcare services 
Theme 2: Participants’ experiences of 
asthma treatment 
Participants’ beliefs about asthma treatment 
Experiences of changes to asthma treatment  
Patterns of inhaler use 
Participants’ experiences of using their inhalers in public 
Theme 3: Participants’ experiences of 
the Inhaler Technology Study 
General comments about participating in research 
Participant experiences of using the Smartinhaler™ system 
Participants’ comments on study feedback 
Participants’ awareness of being monitored 
Acceptability of monitoring to participants 
Impact of the study on awareness and control 
Impact of the study on behaviour 
Participants do not perceive an impact from participating in the study 
Theme 4: Future applications of digital 
inhaler technology – potential 
improvements and uses 
Future characteristics of a digital inhaler system 
Views on the nature of feedback 
Views on potential future uses of digital inhalers 
Theme 5: Future applications of digital 
inhaler technology – desirability, ethics 
and wider impact 
Desirability of the Smartinhaler™ system 
The subject of data ethics 
Participants’ views on the potential wider impact of digital inhaler technology 
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6.4.2. Participants’ experiences of asthma 
Participants’ perceptions of their condition, of its aetiology, 
importance and of their sense of control over it formed the 
backdrop to their experience of asthma treatment and, 
consequently, of the study. In this theme, participants explored 
their experiences of asthma from the beginning of their asthma 
journey. They also explored how these experiences shaped the 
ways in which they related to their asthma. 
Beliefs and attitudes 
Many participants shared stories and beliefs around the 
commencement of their asthma. Overall participants described 
three distinct periods of diagnosis. There was an early childhood 
diagnosis group who generally described their experience of 
asthma as a “background” reality or described prominent early 
memories of being obliged to take treatment. This was 
succeeded by a group who were diagnosed in adolescence/early 
adulthood. A third group described recent diagnoses one or two 
years prior to entering the study.  
For some, their asthma onset seemed to have a precipitating 
factor. For one participant it was childhood measles. For another 
it was pneumonia, which he interpreted as being occupation-
related. Finally, a couple of participants described their asthma 
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being complicated by other lung problems, making it 
challenging to distinguish the cause of their symptoms. 
The study sought to recruit individuals with asthma who had 
suffered a recent exacerbation. Participants therefore tended to 
contextualise their experience of asthma from this perspective. 
For some participants, exacerbation was an “eye opener” to 
how serious asthma could be.   
 “I think there isn’t enough information on how 
quickly that can deteriorate… and I guess I also 
didn’t realise how quickly that would affect me 
as well. So I suppose that scare has changed 
my perspective on it slightly …” SIT030IM, 49 yrs.  
For others the memory of exacerbation provided an important 
motivation to maintain control. As well as severity, another 
participant discussed how her perception of asthma as a chronic 
disease had been challenged through changes in management. 
 “I suppose I probably hadn’t really appreciated 
what a long-term condition was, but now I know 
… it’s not going to go away.” SIT003IF, 47 yrs. 
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Participants generally felt they were in control of their asthma; 
however, for most this was conditional on how susceptible they 
were to triggers and how identifiable/avoidable those triggers 
were. Control was generally expressed as an abstract concept, 
but occasionally described more practically in terms of the 
degree to which participants were restricted by their condition.  
“I would say 80% of the time I feel like I’m in 
control of it.  Because as I say, it doesn’t largely 
stop me doing most things but it can be quite 
debilitating …” SIT030IM, 49 yrs. 
Also described in practical terms were the ways participants 
actively exerted control over their asthma through self-care 
behaviours. These included being attentive to medication 
regimes, practising trigger-avoidance or finding ways to 
improve lung capacity through weight-loss or exercise. 
Healthcare teams were also seen as contributors, at times key 
contributors, to good control. For some participants, this came 
with a sense of surrendering control to their medical team, 
whilst others described help-seeking as a means of them 
actively exerting control.  
In contrast, some participants expressed perceiving a persistent 
lack of control. This appeared to be linked to a sense of doing 
all the right things with no tangible results. For one participant, 
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this lack of agency appeared to sit side by side with a sense 
that responsibility for her condition lay outside of herself.  
“I feel like the doctors should have responsibility 
over my asthma… I don't feel like they’re 
actually looking into it as much as they should 
be doing.” SIT012IF, 18 yrs. 
Whilst she was not alone in placing responsibility for her 
condition with her healthcare team, overwhelmingly, 
participants seemed to express a sense that they were primarily 
responsible for their own asthma. They described healthcare 
teams as being there to give individuals the tools to enable self-
care and to support when individuals came to the end of their 
capacity to control their condition. 
“Because they’re my lungs and I know how I’m 
feeling, I know my body.  And it’s my 
responsibility to make sure that if they’re 
deteriorating or I feel unwell it’s my 
responsibility to contact my GP* and let them 
know.” SIT014CF, 57 yrs. 
*General Practitioner (GP) 
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Participants’ experiences of their asthma symptoms 
Enrolled participants experienced varying levels of symptoms 
which changed over time. Some were battling a decline in their 
condition; others had previously experienced a high symptom 
burden but were seeing improvement. Some described 
persistently good or persistently poor symptom control; others 
described labile symptoms, sometimes limiting, sometimes 
unpredictable.  
Participants defined good symptom control as a lack of reliance 
on their reliever inhaler (occasionally on their preventer inhaler 
as well) and the ability to go about their day-to-day activities 
unlimited.  
“I’ve done really well and not seen very many 
interval symptoms and things like that, so still 
managing to exercise well and not really having 
to take my blue inhaler.” SIT005IF, 27 yrs. 
Poorer symptom control manifested as a sense of limitation and 
escalating healthcare needs whether it be medication or 
hospital admission. For some, periods of high symptom burden 
were clearly linked to triggers, such as respiratory tract 
infections, and were therefore more episodic. For others, poor 
symptom control appeared unprecipitated and consistent.  
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“I used to be very active, I’d do a lot of 
exercise, I do boot camp, running, swimming, 
and as long as I took my inhalers prior to 
exercise… I was okay. But it’s not been working. 
When I’ve tried, I’ve been wheezing before, I’ve 
been wheezing throughout, I’ve been extra 
short of breath afterwards, so I’ve thought, I 
didn’t really feel like doing it…”  SIT035CM, 38 yrs.    
 
Some participants expressed the feeling that, because they had 
acclimatised to their symptoms, their actual disease control 
may have been poorer than they perceived. One participant was 
aware of a disconnect between her actual disease status and 
her symptom experience and described the role of anxiety in 
that. 
“The respiratory team have learned me to 
remember people do get out of breath and it’s 
not always my asthma and not to panic because 
that will make me short of breath.” SIT014CF, 57 
yrs. 
 
A sense of frustration emerged from some participants, 
particularly where symptoms had become limiting, intrusive or 
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appeared to disqualify them from engaging in certain activities. 
Some participants also expressed an anxiety with regards to 
what the future held. 
“If I'm truthful, I find it, it scares me a little bit 
because I feel I'm 47 but I'm coughing like a 70 
year old and that worries me because I can’t 
actually see an end to it because it feels like it’s 
been a – you know – a slow but sure decline in 
my health.” SIT003IF, 47 yrs. 
However, a few participants had found a way to utilise their 
symptoms, describing them as a bellwether for needing to pay 
attention to general self-care.  
 “Sometimes if I’m a bit overtired or a little bit 
stressed at work, that kind of thing, it’s what I 
might call a bit of a friend, it’s the one thing 
that tells me that I need to slow down a little 
bit.” SIT030IM, 49 yrs. 
 
Participants experiences of healthcare services 
Participants described experiences of interactions with 
healthcare services as either neutral, routine events or with 
more emotionally charged language. The latter group expressed 
Page | 252  
 
concern, disappointment, frustration but also empathy and 
gratitude. Participants who explored positive experiences in 
more depth tended to do so on a background of having 
experienced what they perceived to be good care and a sense 
of partnership with their healthcare teams on the journey 
towards better symptom control.  
“The hospital visit was… a big turn… They’ve 
really helped me see that I should keep a better 
eye on it, than just accept this is how my life is 
and I’m just going to be a wheezy person for 
the rest of it.” SIT036CF, 50 yrs. 
Negative experiences were attributed to a lack of knowledge on 
the side of the healthcare professional, a sense of not having 
received attentive or personalised care, service pressures and 
a lack of continuity of care. 
6.4.3. Participants’ experiences of asthma treatment 
A central hypothesis of the therapeutic use of electronic 
monitoring devices is that they can modify the individual’s 
relationship with their inhaled medication leading to improved 
disease control.  In this theme, participants explored their 
perceptions of and experiences with asthma treatment with 
particular focus on these prior to study enrolment. 
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Participants’ beliefs about asthma treatment 
Participants had differing experiences of drug efficacy for both 
asthma medication generally and specifically for preventer 
inhalers. Perception of efficacy appeared to be intrinsically tied 
to past experiences for almost all participants. Participants 
freely attributed a reduction of interval symptoms such as 
breathlessness and wheeze, reduced frequency of infective 
exacerbations of asthma, reduced requirement for reliever 
inhalers, increased ability to exercise, and increased peak flow 
to the use of preventer medication.  
“…using the Fostair twice a day has made a 
huge difference in… I can’t remember the last 
time I used my blue inhaler, I think it was 
sometime in April, to be honest. That was ages 
ago which is a big thing for me.” 
SIT005IF, 27 yrs. 
 
For some participants, efficacy was dependent on the choice of 
preventer drug, its formulation (metered dose inhaler versus 
dry powder inhaler for example), inhaled corticosteroid dose, 
addition of adjunct treatment (such as biological therapy) or 
presence or absence of triggers. The idea of inhalers being only 
partially efficacious was a recurring refrain. Several participants 
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described that on a day to day basis, their treatment kept them 
only just well enough to just function without eradicating their 
symptoms. For some, such partial efficacy led to a questioning 
of whether any symptom relief experienced was indeed due to 
the inhalers. 
“I don’t really know if I notice it working 
because I take it as a preventer in the morning 
and at night, I still get symptoms throughout 
the day so I don't know if I’d get more 
symptoms throughout the day if I didn’t take it.” 
SIT033CM, 32 yrs. 
 
Alongside this idea of partial efficacy, one participant also 
described a worsening of symptoms despite remaining on 
treatment i.e. a reduction in efficacy over time. Another 
described an improvement of symptoms such that he had 
stopped taking his inhaler with little effect, also leading to 
questioning of its original efficacy. 
 “Well, I stopped taking them and I’ve not 
changed.  Now is that because I’ve got better or 
because they helped me get better?  I don’t 
know, there’s going to be no proof…” SIT015CM, 
41 yrs. 
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Finally, for a few participants, there was no 
perception/experience of preventer inhaler efficacy. 
 “I still don’t feel like they do anything.  Apart 
from obviously my blue Ventolin which does 
calm it down, but I don't feel like the preventers 
that they give me do anything.” SIT012IF, 18 yrs. 
 
Related to the question of efficacy was the question of whether 
participants perceived their asthma treatment as necessary. 
Participants, on the whole, defined necessity based on 
experienced effects of the absence of medication. They feared 
the symptoms of breathlessness, wheeze, tight chest and 
fatigue as expected results of missed doses. They anticipated 
that persistent missed doses would lead to increased reliance 
on their reliever inhalers. They also feared exacerbation with its 
resultant loss of function and hospital admission. 
“I notice if I don’t take it, I would definitely be 
wheezy, my chest would be tighter and then I’ll 
end up having to take it more as a reliever than 
as a preventer, so it’s better to just take it as a 
preventer.” SIT025CF, 22 yrs. 
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A few participants defined necessity in a more positive light, 
linking it to their experiences of preventer efficacy rather than 
relying on experiences of missed doses. 
“Well, because the preventer has obviously 
largely maintained my breathing and given me a 
consistent lack of wheeze and all that kind of 
thing, so generally I find it’s essential.” 
SIT030IM, 49 yrs.  
A few participants also made a direct link between necessity 
and being instructed to use medication by their medical team 
and found this to be adequate justification.  
Some participants were more dubious of treatment necessity 
but were also averse to risking missing doses to prove or 
disprove this. A significant minority were, however, clear that 
their treatment – either their preventer or an adjunct – was not 
necessary, either due to a described lack of efficacy with 
regards to experience of interval symptoms or on a more 
theoretical note for one participant who believed his asthma 
was seasonal and so did not feel there was any need for 
perennial treatment.  
“For instance, for six months of the year, they 
could be completely useless in terms of I might 
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not need them at all during the periods where 
it’s good, so summer and winter, I might not 
need them but it’s not a theory I'm willing to 
test out, if I'm honest!” SIT026CM, 42 yrs. 
 
Some participants also described a perception of necessity with 
regards to their reliever inhaler. These participants explained 
their sense of panic when they had forgotten to carry it and/or 
a sense of reassurance at its presence, whether or not they 
were presently experiencing symptoms.  
“…because I play a lot of sport, I go to the gym 
a lot, I play roller-derby, I always have my 
inhaler with me so that I can do that, so they’re 
my lifeline, I can’t be without them. And if 
anything, if I don’t carry my blue inhaler I am 
actually liable to have an asthma attack because 
it starts as a panic attack that I’ve not got it …” 
SIT008CF, 44 yrs. 
 
Several participants expressed a sense of reluctance to use 
asthma treatment and a significant discomfort with their 
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reliance on treatment or requirement for increased doses of 
treatment.  
“…the more you're told that you have to take 
these drugs and I accept that, I hate it. I hate 
the fact that I have to, you know, some things 
are long term but I understand again why I 
would have to do that…” SIT003IF, 47 yrs. 
A few participants also described experiences of perceived side 
effects. For some, dry powder excipient was considered to be 
the culprit, thought to cause excessive mucus or increase in 
symptoms. For another, a specific formulation was described as 
causing tremor. Only one participant linked inhaler use to 
muscle growth (this participant also described a mistrust of 
steroids/conventional medicine).  
Experiences of changes to asthma treatment 
Many participants described changes to their treatment which 
had taken place over time. For a few, this had been a neutral 
experience; for others it had not been. Several participants felt 
that their healthcare teams had changed their treatment regime 
in order to achieve improved symptom control or to reduce side 
effects. One participant describes a collaborative decision-
making process to her regime change. Whilst she admitted an 
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element of trial and error involved in achieving stability, other 
participants described a greater sense of arbitrariness. 
“I think it varies from doctor or nurse to 
whoever because sometimes it’s a case that 
they’ll just leave you on whatever medications 
you’re on, some are a bit more experimental… 
I’d been through lots of varying colours of the 
rainbow….” SIT008CF, 44 yrs. 
 
Some participants cited these changes as having had a positive 
effect; however, for other participants, the changes did not lead 
to an improvement in symptoms. Another participant described 
a sense of frustration at the changes. Finally, one participant 
described experiencing a change in inhaler after having reached 
a steady state. His response to what felt an arbitrary change in 
medication was to stop using his preventer altogether. 
Patterns of inhaler use 
Participants generally described regular inhaler use, often in 
quite definite terms. 
“I always used it as prescribed, two puffs in the 
morning, two puffs at night…” SIT001IF, 54 yrs.  
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A few described a pattern that was more dependent on and 
responsive to their asthma status. Some participants qualified 
a description of regular usage as prescribed with admissions of 
occasional over- and/or under-use. Yet other participants freely 
admitted to poor adherence, whether regular overuse, irregular 
use as described below or even absolute preventer non-use. 
“Probably used it … a few times a week, it 
depended…” SIT025CF, 22 yrs. 
 
Participants also described factors which made them more or 
less likely to use their inhalers. Participants emphasised the 
importance of habit formation and cited the role of visual or 
action reminders such as inhalers being left on the bedside table 
or in the bathroom so that they would be in view when getting 
out of bed, when going to bed, when brushing teeth or when 
taking tablets. Other reminders included important others (e.g. 
partner), written reminders and mobile phone applications 
(apps) or alarms, sometimes a combination. For example, one 
participant described taking her inhalers at the same time as 
her tablets and having an alarm as a back-up reminder.  It 
should be noted that not all participants felt positively about 
alarms. One young participant described them as “annoying”. 
She explained that this was due to their intrusiveness: 
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“…when you’ve got a weekend off and then it’s 
dinging at eight o’clock telling you to take your 
tablets.” SIT012IF, 18 yrs. 
 
Some participants cited the importance of factors such as 
emphasis on treatment importance from the treating team and 
increasing age and maturity. For others, increased awareness 
of their asthma as a result of disease progression or of recent 
experiences of asthma exacerbations was a motivating factor. 
Several participants cited more than one of these factors, 
sometimes a mixture between reminders and experiences, in 
promoting regular medication use. 
Less discussed were factors that reduced regularity of inhaler 
use. Supporting the identification of habit formation as an 
important part of regular use, participants identified factors 
which affected routine such as being busy and shift work. One 
young participant felt that having been an adolescent reliant on 
her parents to take responsibility for her asthma had been a 
factor in poor preventer use. For other participants, a perceived 
lack of efficacy affected motivation for inhaler use. 
“…with me I just find if I know it doesn’t work, 
like my Foster when I was on that, I took it 
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regularly for months and then once they wasn’t 
listening to me that it didn't work, I just got out 
of the routine of taking it because I knew it 
wasn’t helping me or benefiting me.” SIT012IF, 
18 yrs. 
Participants also admitted to overuse of inhalers related to 
triggers (cold weather, viral illness) or the experience of higher 
levels of symptoms. 
Participants’ experiences of using their inhalers in public 
Generally, participants described taking their preventers at 
home due to the time of day they were taken. However, whilst 
not directly impacting on preventer inhaler use regularity, a 
proportion of participants did express difficulty with using 
inhalers in public. This uncovered their perception of how others 
viewed them in light of their condition. It also provided a 
window into how these perceptions shaped participants’ own 
attitudes towards their inhalers and, ultimately, towards 
themselves in the context of their asthma.  
Primarily, participants complained of unwanted attention. They 
reported a sense of having to shoulder the burden of how people 
who had noticed them processed their inhaler use or the fact 
that they had asthma. A few participants were aware that they 
were projecting their own views onto others. One described 
Page | 263  
 
how, growing up, inhaler use was a sign of “weakness” as were 
other physical attributes such as needing glasses. She went on 
to admit that whilst she felt taking her inhaler was a sign of 
weakness, she had noted that others appeared not to have 
similar qualms.  
“I see people in the gym, they take their 
inhalers with them in the spin class. I wouldn't 
do that.” SIT003IF, 47 yrs. 
Another participant described verbal name-calling he 
participated in as a child, calling a fellow asthmatic schoolboy 
“Darth Vader”. To him, this appeared to be exemplar of the 
stigma he now felt, describing asthma as “taboo”. Other 
participants described childhood experiences of being bullied or 
of asthma not being “cool”. They associated it with other causes 
of shame, such as being overweight. Some participants 
described their embarrassment as stemming more from a sense 
of self-consciousness or an anxiety that was not necessarily 
borne out by experience. One gentleman described his concerns 
that managers would object to his inhaler use as leading to 
embarrassment. However when he clarified this with 
management, they had no problem with him using his inhaler 
on the shop floor if needed.  
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For all of these participants, there was a clear sense of wanting 
to keep their condition hidden. In practice, they described their 
methods of avoiding attention. Participants would leave 
meetings and public spaces or delay taking their inhalers 
(usually reliever inhalers) until there was an opportunity for 
greater privacy. 
“I hate it.  I always hide behind my mum or 
someone, or behind a wall and take it.  I never 
do it in front of people, even at work I’ll go to 
the toilets to take my inhaler.” SIT012IF, 18 yrs. 
This sense of embarrassment, whether as a result of perceived 
stigma or unwanted attention, was not necessarily fixed. For 
one participant, there was what appeared to be a continuous 
and co-existent conflict between wearing his inhaler “almost like 
medals” and other times a keen sense of “taboo”. Others 
described overcoming stigma, sometimes as a result of age and 
habit but also as much by a sense of necessity. These latter 
participants described having no choice but to become 
comfortable with their inhaler use and choose to ignore or 
reframe other feelings and perceptions. 
“I think just me getting older, honestly and just 
not really caring!  Realising that my health is 
important and many people have asthma and 
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actually, no-one really cares if you have an 
inhaler or carry it around or take it out in 
public.” SIT025CF, 22 yrs. 
Finally, this sense of stigma was not by any means universally 
shared. Several participants stated that public inhaler use had 
never been an issue. Encapsulating the feeling from this group 
of participants, one simply stated,  
“I’ve never had a problem with using inhalers in 
public. If you need to breathe, you need to 
breathe.” SIT008CF, 44 yrs 
 
6.4.4. Participants’ experiences of the Inhaler Technology Study 
Participants’ experiences of the study were influenced by their 
beliefs and experiences before the study, their understanding 
of research, motivations for participating in research and their 
experiences in the study itself. The first two themes explored 
pre-study perceptions. This theme elucidates some of the 
within-study experiences, which had potential to shape 
participants’ views of the technology and even modify their prior 
held beliefs. 
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General comments about participating in research 
Participants described being motivated to take part in the study 
out of a general desire to contribute to knowledge about 
asthma, to raise awareness about environmental pollutants as 
triggers and to help other people with asthma understand the 
benefits of using their medication as prescribed. For one 
participant, her motivation for raising awareness about how 
serious asthma could be came from an even more personal 
experience of bereavement.  
“…my sister died when she was 34. She had an 
asthma attack and died and it was really 
important for me to understand and to 
contribute to this because I think other long-
term conditions or horrible diseases get a lot of 
air space, asthma doesn't.” SIT003IF, 47 yrs. 
On a different note, one participant explained that her 
motivation for taking part in the study stemmed from having 
previously noted that the accountability of participating in 
research had reduced her likelihood of smoking. 
Participant experiences of using the Smartinhaler™ system 
Where described in general terms, participants generally 
described the Smartinhaler™ devices as “good” and, less 
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commonly, “helpful”. A couple of participants spoke of the 
appeal of trying out a new technology for its own sake. 
“I think it’s quite cool. It’s quite fun having 
something on your inhaler that lights up…” 
SIT008CF, 44 yrs. 
 
The devices’ physical characteristics drew a variety of 
responses. Some participants saw them as bulky. This was at 
times positive (better inhaler grip, increased inhaler use 
awareness), others described acclimatising to it. Some stated 
that they did not find the devices bulky or intrusive or find that 
they affected use of their inhaler or spacer. For several, 
however, the perceived bulkiness was a significant negative. It 
affected how effectively they felt able to use their underlying 
inhalers, creating a perception that they were harder to carry 
around, harder to use or more embarrassing to use in public.  
Other physical characteristics which were highlighted by 
participants included the presence of the light-emitting diode 
(LED). Some participants found this to be a factor which helped 
them to engage with the Smartinhaler™ system. For some 
participants, the nature of the device as attached to the inhaler 
meant that they had to be particularly conscious to prioritise 
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only using inhalers with the device attached. They admitted that 
this was not always possible.  
“Making sure I always had the inhaler with the 
device on, that was a little bit awkward, because 
I have inhalers dotted around in every handbag, 
everywhere, and it’s thinking, “No, I need that 
one”, but that was all.” SIT031IF, 50 yrs.   
 
Participants variably noted that the devices were easy or 
difficult to attach and detach. The devices were reported to be 
easy to recharge and, on the whole, did not need recharging as 
frequently as expected (they had been instructed to recharge 
weekly). Some participants used the app as a guide to when 
the devices needed recharging rather than regularly charging 
at a set frequency. Not all participants, however, recalled that 
the devices required recharging.  
With regards to the app, some participants complained that the 
original process of downloading was complicated. Participants 
described problems with connectivity, generally between 
devices and the app. They described needing to re-synchronise 
the device and the app on multiple occasions.  
Page | 269  
 
“Temperamental would be one.  Other than 
that, when they work they’re good but when 
they don’t it is a bit of a nightmare having to 
keep syncing them up all the time.” SIT009IF, 34 
yrs.   
Participants were split over how easy the app was to use, with 
some finding it straightforward and some even finding that 
synchronisation was occurring automatically. One participant 
found the device’s general acceptability was balanced against 
the battery drain he attributed to using the Smartinhaler™ 
system. Another, however, described the app as not taking up 
excessive amounts of room on her phone such that it could 
interfere with her phone’s usual functions. One participant 
noted that the battery LED proved an inaccurate guide to 
remaining battery life. 
In some cases, participants further volunteered a frustration 
with the reliability of the system, generally relating to delay in 
recording inhaler actuations. For a few participants, there were 
issues with the app picking up inhaler actuations unrelated to 
whether or not it was synchronised. Some participants noted 
that there were actuations which did not register at all. One 
participant noted that there were spurious actuations and 
another that there was cross-talk between the two devices 
Page | 270  
 
resulting in actuations taken on the preventer device registering 
as also taken on his reliever device. Of the participants who 
noted such issues with reliability – whether due to a delay in 
registering actuations or not registering actuations at all, some 
described a sense of frustration and annoyance – particularly 
when it was felt that there was a sense that the system was 
misrepresenting their inhaler use.  
“…there were connectivity issues so I wasn’t 
really sure that all the registered puffs were 
going through and things like that.  Sometimes I 
would’ve taken eight puffs and it might show 
five, and I don't know if that was because it 
wasn’t picking up or because it wasn’t synching 
correctly.  I stopped trusting what I was seeing 
there.” SIT013IM, 28 yrs. 
This particular participant went on to describe a gradual 
disengagement with the study.  
Other participants also discussed how engaged they felt with 
the Smartinhaler™ system. This was generally split along the 
group allocation (i.e. control versus intervention).  
“…it just said ‘Smartinhaler’, it didn’t really tell 
me much…” SIT014CF, 57 yrs.   
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“…when it was working and I could see how it 
was supposed to work, I thought it was very 
clever and plenty of information there.” 
SIT017IM, 58 yrs.  
Participants’ views on study feedback 
Participants identified three aspects as to what they felt was 
study feedback: the questionnaires, the feedback conversation, 
and data from the app. For control participants, only the 
questionnaires and a one-way update from participant to 
investigator were available. Consequently, in their evaluation of 
study feedback, control participants in general spoke about a 
lack of intrusiveness in arranging and participating in the 
interim appointments and varying degrees of helpfulness (or 
lack of) of the questionnaires.  
 “Some of the questions I think were stinkers, 
for me ambiguous, which could have been 
worded better so I don't know how it’s going to 
reflect…” SIT015CM, 41 yrs. 
Although not universal amongst control participants, those who 
did find the appointments helpful shared with intervention 
participants a sense of increased awareness of their condition.  
“I suppose, I found it useful in trying to… just 
sort of gather my thoughts myself of how… my 
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asthma’s been controlled for the last two weeks 
or the last month; because I suppose because 
I’ve had this condition since I was a young child, 
you take it for granted and I just accept it, it is 
what it is, without necessarily thinking about 
keeping it under control or triggers or things 
that maybe happened with it, or how I feel 
about it, so yeah.” SIT035CM, 38 yrs.  
 
Generally, for intervention participants, and for an occasional 
control participant, there was an appreciation for having 
clinician contact over and above their usual asthma follow-up. 
For intervention participants, this allowed for further 
conversation and so these participants tended to talk less of the 
frustration of the questionnaires’ rigid wording. Intervention 
participants also used the appointments as an opportunity to 
discuss issues around the Smartinhaler™ system’s functioning 
and reliability. 
“I liked having the regular phone calls because 
it gave me someone to speak to about my 
asthma in a way…  like I say, I can’t really 
speak to anyone else about my asthma so 
having someone there to tell me how it’s going 
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and how my asthma should be, about my 
inhalers, it helped a lot.” SIT012IF, 18 yrs. 
Participants’ awareness of being monitored 
Participants were generally aware that their inhaler use was 
being monitored, irrespective of whether or not they were 
intervention or control participants. During the process of 
consent, all participants were informed in vague terms of the 
function of the Smartinhaler™ devices, that the devices would 
collect ‘patterns of inhaler use’. Some participants recalled 
these terms, discussing collection of “patterns”, “readings” and 
the provision of “data”. Others were clearer in understanding 
that the device “picks up exactly how many dosages I take”. Of 
particular interest was just how clear some control participants 
were on the purpose of the devices despite only having had 
minimal information to start with and not having the 
reinforcement of regular device or investigator feedback during 
the course of the study. One described the Smartinhaler™ 
system as being “like Big Brother watching me”. 
“Basically, every time I use my inhaler, it stores 
my information and then at the end of the 
research programme, you guys will check my 
results out and see how often I’ve needed my 
inhaler and how bad my asthma is and then 
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from there, you guys will see what other 
methods you can do to help me with my 
asthma.” SIT006CF, 27 yrs. 
Control participants also described the light flashing as a marker 
that their adherence was recorded.  
Some participants did find that their awareness of being 
monitored reduced with time. Others found that, having 
previously reduced with time, their awareness was re-triggered 
by illness. Still others described trying to deliberately ignore the 
fact that their inhaler use was being monitored.  
“…If I’m brutally honest, I just kind of almost 
preferred to keep taking it as normal… I didn’t 
want to know if you follow me, pick up on my 
right wrong and any indifferent practices that I 
had.” SIT024CF, 39 yrs. 
Finally, some participants perceived additional information as 
having been recorded that was not actually collected such as 
symptoms and location. 
Acceptability of monitoring to participants 
Participants expressed that the acceptability of monitoring was 
intrinsically linked to its purpose in improving asthma within the 
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context of the study. Some described being suspicious of data 
collection as a principle but accepting it for the sake of research.   
“If it was anything else that was being 
monitored, I would be bothered but because it’s 
of a benefit to me and other people, I don't 
think it bothers me at all.” SIT002CM, 57 yrs. 
A couple of participants described being wary of the research 
team being able to see when they were not adherent but that 
they acclimatised to this with time.  
“At first, I wasn’t too keen because I was first 
thinking what if I mess it up, am I going to stick 
to it properly because I use my inhalers in the 
morning and the night but then I got a new 
asthma technique where I’ve had to use it in the 
afternoon, I thought to myself am I going to 
keep up with it?  But  then since I’ve started 
becoming more ill, I’ve had to stick to it and to 
be honest I've  got used to it, at the beginning, 
everyone goes through that phase where “no”, 
but once you're into it, you're into it.” SIT006CF, 
27 yrs. 
Others, however, specifically stated that they did not feel their 
privacy was affected. Some were further able to describe the 
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idea of being monitored as an actively positive thing. For these 
participants, it was “reassuring”, it increased their sense of self-
esteem and it helped provide them with a record of their own 
inhaler use, both for self-monitoring and for having objective 
data to aid communication with their clinicians. 
During the interview, some participants were asked 
hypothetically whether their acceptance of monitoring would 
have been different had it been covert. In general, their 
response did not become more negative. An exception to this 
was one participant who suggested that covert monitoring 
would cross a line, although also stated that he understood that 
in the context of research a control group is necessary. 
Interestingly, one participant expressed discomfort less 
directly.  
“I don’t suppose you’d be very impressed if you 
were monitored and you didn’t know. I don’t 
know that I would mind, personally, because, 
why? I haven’t got anything to hide. But I 
suppose some people would get quite cross 
about that.” SIT029CF, 49 yrs.  
Impact of the study on awareness and control 
Participants did not express any particularly large shifts in how 
they perceived their inhalers from participating in the study but 
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a few did identify the study as reinforcing their importance. 
Similarly, participants – both control and intervention – noted 
that participation in the study, awareness of being monitored or 
the device or app increased their awareness of how they used 
their inhaler in terms of timing, frequency and adherence. 
“I think sort of being in the study has made me 
think more proactively about taking my inhalers 
and about my Fostair and when I'm using it and 
making sure I am using it at those regular times 
and not forgetting to do it, not like going to bed 
at night and falling asleep before taking my 
inhaler and things like that, so I think it’s been 
really helpful in that respect.”  SIT005IF, 27 yrs.  
A more specific awareness benefit of the Smartinhaler™ system 
for intervention participants who could not remember whether 
or not they had taken a dose was being able to check the app 
for confirmation. Whilst unanticipated, a few intervention 
participants also reported finding the alarm function on the app 
and activating it, further increasing awareness of when they 
needed their doses. 
In addition to increased awareness of treatment use, 
participants widely reported increased awareness of their own 
asthma status, including their symptoms and its general 
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importance as a condition. Whether well or poorly controlled, 
participants had learned to live with their symptom level. They 
took good control for granted or acclimatised to poor control, 
no longer recognising it as such. Increased awareness was 
particularly attributed to the questionnaires (as already 
discussed) and also to the reliever Smartinhaler™ (particularly, 
as noted by the control participant below, its LED light).  
“It was a bit of a shock when I first started 
using them and I’d sync them and I’d go on to 
the app and it's like I’d used 170 in seven days 
and that’s just on my blue one.” SIT012IF, 18 yrs.  
 
For a few participants, this ability to self-monitor and the 
resulting monitoring feedback provided an increased sense of 
control over their condition, or at least the hope that their 
symptoms could improve. In this context, the study not only 
increased their awareness of their asthma status but also 
caused them to consider its emotional effects. This level of 
mindfulness sometimes led to an appreciation of how well 
controlled they were. It sometimes also heralded potential for 
changing behaviour as expressed below. 
Page | 279  
 
“…the device, because it’s flashing, I'm seeing 
how many times I'm using the inhaler because 
obviously it flashes, you don’t forget it because 
it’s such a bright colour so I know when to go to 
the doctor’s and when I need medical help.” 
SIT006CF, 27 yrs. 
 
For some participants, conversations with investigators helped 
them have a better understanding of asthma at a more general 
level. One participant described appreciating the opportunity to 
discuss the links between upper airway and lower airway atopy. 
Another simply felt impacted by the knowledge she was not 
alone in her condition. 
For a group of participants, there was a sense that the study 
impacted how they felt about using their inhalers in public. One 
47 year old participant began by describing how her underlying 
dislike and avoidance of public inhaler use had not essentially 
changed. However, she then went on to explain how she had 
found herself showing her colleagues her inhalers with the 
devices attached – behaviour which she described as “bizarre”. 
Thus, for some, the increased public attention was a positive, 
raising awareness of a condition that was important to them to 
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speak about. For others, it was a significant negative however, 
increasing their already-existing sense of embarrassment.  
“That puts you back a bit because people are 
looking at you… I find it embarrassing getting 
the inhaler out… but on top, because there’s a 
device on top of it, it’s even more 
embarrassing…” SIT006CF, 27 yrs. 
 
Impact of the study on behaviour 
Several participants described changes in behaviour resulting 
from participation in the study. These included increased 
confidence asking for help and subsequent increased help-
seeking behaviour. Some described increased preventer use, 
increased use of inhalers in public and more intelligent 
preventer use e.g. spreading out doses to increase proportion 
of time covered. With regards to relievers, participants 
described increased reliever carriage (although this was not 
universal) and decreased reliever overuse. Finally, some 
participants felt more informed about their triggers and more 
consciously practised trigger-avoidance.  
In addition to directly impacting participant behaviours, a key 
study aim was to assess whether the use of the Smartinhaler™ 
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System had any impact on intervention participants’ treating 
teams. Only a few participants described this having happened. 
Where they did, the effects they noted included responses of 
both cynicism and interest. One participant described how her 
Practice Nurse felt a sense of having reached the limit of 
treatment options irrespective of the data. However, some 
described improved communication due to the presence of 
objective data and even changes in medication regimes. Whilst 
it is impossible to surmise whether or not the changes in 
medication regime would have taken place without the study, 
participants appeared to attribute the data to having played a 
role in decision making.  
“She [the Practice Nurse] saw that because I 
was using the Bricanyl more than they would 
like, it suggested a change to my routine so I 
went onto the MART routine instead of using the 
Bricanyl.” SIT021IF, 50 yrs. 
“Like I say, I’ve been on the Fostair for ages 
and it wasn’t until I had the app and I went in 
and showed them, until they started trying me 
on new things so it did help me in that way.”  
SIT012IF, 18 yrs.  
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Finally, some participants described changes in behaviour which 
were not intended by the study. The most common of these was 
that participants described having to be conscious of which of 
their inhalers had the study devices attached and took extra 
steps to ensure that they used that particular inhaler. Others 
described occasions when they were unable to take those steps, 
in which case their data was not recorded for those particular 
actuations. Other participants described it changing how they 
interacted with their inhaler, for example, using their inhaler 
with two hands to make sure every actuation registered or 
compressing device clips (which detach the device) every time 
their inhaler was used. One participant described not 
performing the priming dose on the commencement of a new 
inhaler to avoid actuation data inaccuracy. Of more concern, a 
60 year-old male participant described how had elected to leave 
his inhaler in his locker when he was at work as he felt it was 
too bulky to keep in his pocket. 
Some of these changes were, however, positive. One 
participant described how the pre-study change in formulation 
from dry powder to aerosol improved his control. Finally, a small 
number of intervention participants identified how to use extra 
features on the app such as peak flow recording and reminder 
alarms.  
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Participants do not perceive an impact from participating in the study 
Not all participants perceived an impact from being in the study. 
Some participants felt that it impacted their awareness but not 
their behaviour. With regards to inhaler use behaviour, some 
participants who perceived this lack of impact explained that 
they had been taking their inhalers regularly prior to the study. 
The implication from them was that there was no requirement 
for behaviour change. 
Similarly, when asked whether there was an impact on their 
asthma control, some participants responded that there was 
either a perception of no impact at all or an impact on 
awareness of asthma status but not on the condition itself. This 
sense of lack of impact was also attributed to baseline status or 
factors outside of the study’s control, a sense that their 
particular condition was, as it were, outside of the study’s 
jurisdiction, either because their control was too poor or, 
indeed, stable prior to the study. 
“I probably wouldn't say it has in that respect 
because like I say, I'm still on trial and error at 
the minute with the doctor’s, so my symptoms 
are always going to be bad until they can find 
something that suits me well.”  SIT012IF, 18 yrs.  
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For other participants, the study’s lack of impact was due to 
intrinsic study factors such as how well the Smartinhaler™ 
system functioned, the study’s duration and the fact that the 
study was not a drug study.  
 “…but I'm not going to say it cured me, there 
was no special medicine you gave me. It was 
totally un-invasive…” SIT015CM, 41 yrs.  
Finally, some control participants identified the lack of feedback 
as a factor for lack of impact. 
“If I saw the results from it, because I’m quite 
mathematically minded and I do like a 
spreadsheet and a chart, if you were seeing 
your own results out of it, so you had access to 
that information, then I think you probably 
would feel more in control because you could 
see exactly what time of day you take your 
inhalers.” SIT008CF, 44 yrs.  
 
It should be noted that a number of participants expressed a 
perception of lack of impact but then went on to describe cases 
of impact. One participant explained the complexity of trying to 
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attribute behaviour change to a research intervention at an 
individual level.  
“I don't think the study has been, I can’t think 
of the word but I don't think it’s been part of my 
self-control.  Yes, it prolonged the usage of the 
inhalers which then allowed me to gain control 
but without research, would I have still been 
taking the inhalers?  Quite possibly.” SIT015CM, 
41 yrs. 
 
6.4.5. Future applications of EMD technology – potential 
improvements and uses 
The final part of the interview asked participants to give their 
responses to potential future iterations of and uses for this kind 
of technology based on their experiences of asthma and of 
being in the study. 
Future characteristics of a digital inhaler system 
Physical characteristics 
Physically, some participants felt that the devices needed to be 
easier to attach and detach. Several also felt that they needed 
to be less bulky, for example having smoother edges. Others 
suggested designs that could appeal to younger and male users.  
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“I know, not from me but from a male side, a 
young male side, they don’t want pink inhalers, 
it’s not right, it’s not cool, so maybe jazz them 
up a bit …” SIT011IF, 46 yrs.   
One participant suggested that rather than having the chip 
embedded into existing inhalers, digital inhaler devices could 
operate more like a canister sleeve, similar to the earlier models 
of the Smartinhaler™ system. There was a general consensus, 
however, that integrating a digital inhaler system such that it 
was incorporated into existing inhalers rather than attached to 
them was a good idea. Some concerns about such technology 
were also expressed. These were related to the financial and 
environmental costs of having extra disposable chips embedded 
into every inhaler.  
“You just need to think about how 
environmentally friendly it is because obviously 
at least with it just being something you clip 
into, you’re going to use that for as long as it is 
still working rather than throwing away 
mechanics every couple of months when you 
finish an inhaler. I’d rather not be wasteful.” 
SIT008IF, 44 yrs. 
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App and general platform 
With regards to the platform, an expectation that future devices 
would prove more reliable recurred. This was expressed 
strongly where participants felt the data produced during the 
study had poorly reflected their actual inhaler use behaviours, 
delayed data synchronisation, or simply did not function with 
their phone’s operating system.  
“I think the main problem was the data link 
didn’t work!  That’s the very obvious thing, if it 
doesn't synch with the phone, then it’s useless, 
both from the patient’s point of view and for 
anyone gathering data, that’s the one thing that 
has to be most clearly sorted out before it’s 
implemented on a wider scale.” SIT001IF, 54 yrs.   
 
More generally, the same participant also suggested softer in-
app wording.   
“’Adherence’ sounds a little bit… It didn’t bother 
me but I guess some people might, if it was sort 
of termed in a more friendly way, that might 
help some people…” SIT001IF, 54 yrs. 
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Other participants suggested that, when the app detects non-
use of inhalers, a reminder notification with or without alarm 
could be activated. A diary function for if the app failed to record 
data or means of notifying the user that there had been a device 
malfunction were also suggested. One participant suggested an 
in-app guide to pairing the app and device.  
For some control participants, the ability to see their own 
inhaler use data was felt to be useful. Similarly, for some 
intervention participants, more granular data such as the ability 
to see actual time stamps (rather than just an am/pm division) 
was felt to be useful. Practically, several participants suggested 
a notification to warn when the canister in use was close to 
needing replacement.  
Collection of trigger data 
Participants anticipated the usefulness of a platform that would 
integrate inhaler use data with trigger data such as pollen 
counts or with additional information from the user such as their 
asthma plan or a symptom diary, with the potential to deliver 
notifications on impending appointments. 
“…there is potential to have far more stuff on 
there in terms of self-care and flagging and 
things like that and maybe a bit of narrative, so 
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you've got feeding back to you, “this has come 
up, have you thought about ..?”, so just having 
those red flags or that advice…” SIT003IF, 47 yrs. 
Similarly, a control participant noted that a time stamp would 
allow for cross-referencing with other wearable health apps to 
relate activity and inhaler use.  
When asked about other avenues of data collection to increase 
the impact of the Smartinhaler™ platform, there were a range 
of responses. A few participants expressed concerns around 
potential impact on privacy or expressed a lack of interest based 
on a perceived lack of potential impact on their own asthma. 
“What would be the benefit of that though?  
That would be my question. I know my triggers 
so I wouldn't feel like I needed it to be linked to 
them…”  SIT025CF, 22 yrs. 
Most participants, however, felt some level of trigger data 
collection and/or mobile health (mHealth) data linkage would 
be useful. Environmental suggestions were pollen, weather 
(including humidity and temperature), pollution and notification 
of local respiratory infection outbreaks with some volunteering 
location tracking as a means of personalising this information. 
Physiological markers included heart rate, lung function (FEV1 
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as well as peak flow), oxygen saturation and other stress 
markers. Other automated inputs suggested included step 
counters and night-time wakening. Finally, user-determined 
inputs included symptom diaries, asthma control 
questionnaires, non-inhaler medication use e.g. 
nebulisers/OCS, allergy profile, dietary profile, smoking status 
and presence of other chronic diseases.  
Uses for such data collection included being able to track 
whether increased reliever use was linked to particular 
environments (e.g. high pollen), activities (e.g. exercise) or 
circumstances (e.g. stress).  
“… if you could track somebody’s movements all 
round, you could see where they’ve been, what 
the weather was like and you'd probably 
understand the symptoms of asthma better and 
why they get asthma and why they don’t get 
asthma…” SIT002CM, 57 yrs 
Other suggestions involved using lung function, night-time 
wakening data, symptoms or medication diary to record and 
monitor asthma status. One participant wondered whether such 
a platform would allow people with asthma to gauge where their 
levels of exercise were in relation to what would be expected 
for their level of severity.  
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Participants also posited that such data could be used to identify 
and evidence triggers where not previously known. This could 
empower users to take preventative measures including 
avoidance, ensuring their reliever inhaler was on their person, 
and prophylactically taking their antihistamines.  Participants 
suggested that a platform linked to other wearables could 
permit early recognition and rescue either using physiological 
markers like heart rate or lung function to advise reliever use 
or even seeking medical attention.  
“When you were saying about the Fitbit and 
things like that, I did wonder about heart rate 
target zones then and triggers for when you 
need to take your reliever…” SIT013IM, 28 yrs. 
Other participants suggest that such a platform could monitor 
the physiological response to treatment e.g. heart rate 
response to SABA use. Finally, one participant suggested linking 
in such a platform with National Health Service (NHS)-provided 
advice regarding asthma. 
 
Global positioning system (GPS) acceptance 
If environmental data collection is to be tailored to the user, the 
use of location data (GPS) needs to be considered. This question 
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was therefore posed to participants and elicited a range of 
responses. A sizeable number of participants were 
unconditionally accepting of its use. As several participants 
noted, their smartphones and many of their mobile applications 
already employed location data. A few participants expressed 
that acceptance of such data collection was conditional on 
guarantees of data security as well as the ability to opt-out and 
turn off location tracking when they did not feel it would be of 
relevance to their asthma. Some participants appeared more 
hesitant in their acceptance, generally expressing this by 
stating that others may find the idea more difficult.  
“Some people are paranoid!  [laughs]  You 
know, the Big Brother scenario.  Yeah, I'm 
never anywhere I shouldn't be!  It doesn't 
bother me who knows… well… yeah… it doesn't 
bother me but I could imagine it might bother 
some people!”  SIT001IF, 54 yrs. 
 
For a few participants the idea of GPS tracking was not 
acceptable and was even described as “invasive”. One 
participant articulated the ethical issues at play. 
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“Yes, it’s where you start to stray into why 
that’s important which I suppose if you're 
looking at weather or pollen or environmental 
factors, that it would be but obviously a lot of 
asthmatics carry their inhaler with them at all 
times… that gives you access to quite a lot of 
information about somebody that is irrelevant to 
their healthcare and, like a lot of things, you 
would want some assurance that it was being 
used properly…” SIT026CM, 42 yrs. 
 
Views on the nature of feedback 
As part of the study, participants had a monthly telephone call 
either just to collect asthma control/quality of life data for 
controls or also to feedback inhaler use data for intervention 
participants and discuss whether this suggested need for 
further medical input. This was taken as a base experience from 
which to ask participants what they felt such feedback should 
look like if a digital inhaler system was employed in routine 
care.  
Content-wise, one participant responded that she would like a 
record of her questionnaire responses to self-monitor her 
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asthma status. Some control participants mentioned that they 
would have liked access to their own inhaler use data.  
“Oh, I want to see charts. I would love my… if 
you could link into it. Like you’ve got the app on 
the phone at the moment, if that came up and 
almost like your health apps that you get on 
your phones now, if it just gave you a chart that 
explained what was happening when and you 
could see your own trends and information, that 
would be dead cool, I’d like that.” SIT008CF, 44 
yrs. 
Others suggested a record of lung physiology data (such as 
spirometry), again as part of self-monitoring. Participants 
suggested a platform that could offer support based on inhaler 
use, for example signposting to relevant self-management 
advice. For other participants, the capacity for unstructured 
conversation remained an important part of the feedback 
process. 
Participants’ feelings on how frequent such feedback should be 
tended to be related to their own underlying asthma status and 
how frequent their own healthcare service use was.  
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“Probably as and when you need it, I don't think 
if your asthma is on an even keel and you’re 
relatively okay, you probably don’t really need 
any feedback, it’s maybe if you're becoming 
poorly and it looks like … you're having a flare 
up, then that’s when they should probably be 
contacting you.” SIT021IF, 50 yrs. 
For participants with milder asthma (even if known to the 
hospital), incorporating such feedback into the annual or 
biannual asthma review with an option for expedited review if a 
problem was remotely detected, was adequate. Hospital 
patients tended to focus on more regular reviews (e.g. monthly, 
six-weekly, two-monthly, three-monthly or three-to-six-
monthly).  
“I see my doctor probably most months, about 
something, sometimes it’s a couple of months 
but yeah, it’s probably about every six weeks 
maybe, when you're someone that has got quite 
a few health problems, especially if you're not 
dealing with it very well … so probably every six 
to eight weeks you need to see somebody.” 
SIT027IF, 58 yrs.   
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One primary care patient discussed regular appointments 
similarly to the secondary care participants. Of interest, some 
participants saw the potential for technology to play a direct 
role in feedback, for example monthly prompts through the app 
or texted feedback with the option for an appointment only if 
required rather than a fixed regular appointment.  
“…if you were going to have prompts on the 
app, maybe as and when it happens, obviously 
that’s not always able to happen when it’s a 
person, maybe as it was being done on a 
monthly basis, just to check in “Is everything 
okay?”, and then if there’s any issues, 
discussing them through then or being able to 
discuss the issues as they arise, if they’re more 
pressing…” SIT005IF, 27 yrs. 
 
Participants variously suggested uses of technology which 
would mostly replace face-to-face interactions with clinicians or 
support existing interaction. Several were keen to keep, at a 
minimum, their annual or biannual asthma review. This would 
be an opportunity to discuss the data in greater depth and fit 
them into the context of an outside view of the user’s asthma 
status, making them more personally relevant to the user whilst 
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using them to modify management. The risk of not having a 
face-to-face conversation was felt to be that users may be 
unable or unwilling to communicate their full asthma status 
remotely, giving clinicians only a partial view with which to 
propose updates to management.  
“Personally, I’d be quite happy to do it digitally 
but then I think you still need to have a physical 
face-to-face meeting on a regular basis, six-
monthly or 12-monthly.  But then, as I say, that 
information would actually inform that review 
much better than just doing an on-the-spot 
peak flow and blood pressure and asking you 
how you’ve been and then they look to see if 
you’ve had anything different prescribed or 
whatever and then off you go for another six 
months.” SIT030IM, 49 yrs. 
Most participants expressing a preference for face-to-face 
reviews were open that this was a personal preference. 
“I’d prefer face to face because that’s how I like 
doing things, I don’t like sending emails, I’d 
rather phone someone up because it’s 
personable and you don’t get any 
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misinterpretations and if you do, they’re 
eradicated there and then.” SIT015CM, 41 yrs. 
 
Many participants were happy with at least an element of 
feedback being remote, generally via a telephone call supported 
by email or text. Video-call was suggested as a way of remotely 
facilitating face-to-face feedback conversations. Some 
participants suggested that the mode of feedback would depend 
on the patient. For elderly patients or non-adherent patients, 
face-to-face clinician appointments were suggested. Text 
messaging was a suggestion for users with milder, more stable 
asthma.  
The majority of participants felt that feedback should be 
coordinated by the primary care practice, whether GP or 
Practice Nurse. A few participants saw a role for the hospital if 
a patient was under hospital care and for two participants, 
hospital care in the form of an Asthma Nurse Specialist or 
consultant respectively, was preferable to primary care.  
“Consultant-wise, it depends though who’s the 
GP because if they are just new to the surgery 
or new to the job, I wouldn't feel very 
comfortable with it because they wouldn't know 
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the situation I’ve been in and where I am right 
now, whereas consultants, because obviously 
they see asthma patients constantly every day, 
so do that, I wouldn't mind, it’s just that GP 
wise I wouldn’t feel comfortable with.” SIT006CF, 
27 yrs. 
Where participants gave a clear reason for preferring their 
primary care clinicians, there were expressions of the fact that 
there was a pre-existing relationship, that their healthcare 
providers knew or had access to information on their 
background and that they would go on to initiate and continue 
management.  
“…when you go to the doctors you kind of talk 
about everything and they already know you. 
And because I’ve used this particular doctor’s 
surgery on and off since I was 11, they kind of 
know you and they’ve got your background … 
So, you’re more comfortable with them and 
you’re more happy, I think, to talk about how 
you’re feeling and perhaps how different things 
are going on with your health.” SIT008CF, 44 yrs. 
Most participants expressed a desire for joint responsibility to 
self-monitor with their chosen clinicians. The clinical team’s role 
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would be first to support the user in interpreting the data in a 
way that would have meaning to them, potentially within the 
context of the asthma review and then to support in placing this 
in the context of their asthma management where, for example, 
changes to lifestyle or medication regime were needed.  
“Well, I should be responsible for keeping my 
eye on it, it’s my body, it’s my asthma, so I 
need to know what’s going on first and then if 
something’s happening then I could probably 
say, ‘Right, well if it’s connected with any of 
them’ then I could just say, ‘This is what’s been 
happening’ and you can just have a look and, 
but I’m responsible for my asthma really. 
SIT011IF, 46 yrs. 
 
Participants were asked about the acceptability of a tailored lay 
service providing feedback. This was more divisive. Several 
participants cited concerns around lack of relationship and their 
own unwillingness to provide access for such a service to view 
their medical records to provide the necessary background 
information. Participants worried that, without clinical training, 
such a service would be able to do little more than signpost to 
clinical teams or provide technical support. Others worried 
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about the potential for provision of conflicting advice between 
such a service and a patient’s usual healthcare providers, 
leading to confusion for patients.   
“I'm not sure I’d want a call from a call centre, 
some private company giving me a call and 
saying, “You’ve not used your inhaler properly 
this week!”  I don't think I’d like that at all!” 
SIT026CF, 42 yrs. 
 
In terms of duration of device supply, there were three main 
camps. The first camp placed decision-making in the hands of 
the providing clinician and the potential user.  
“…that would sort of depend on the agreement 
between a doctor and the person with asthma, 
as to what’s best for that person at that time. 
Anything between a couple of months to a year, 
to cement it into somebody’s life.” SIT005IF, 27 
yrs.   
The second camp was clear that, because of the seasonal nature 
of asthma, the duration would need to capture all four seasons; 
therefore devices would ideally be supplied for a minimum of 
one year. A third group of participants advocated for long-term 
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or permanent use of the system to cover, not only 
environmental changes, but changes in asthma status that 
occurred with time. A few participants had no strong opinions 
“…so long as there’s a justification behind how 
long and … you have a choice…” SIT026CM, 42 
yrs.  
 
Views on potential future uses of digital inhalers 
Participants were directly asked about some potential data 
usage scenarios (see figure below). 
Figure 6-1: Excerpt from interview guide 
 
Participants were clear that they would want the opportunity to 
have their data discussed with them. They were at times more 
dubious of having to change their behaviour on the 
recommendation of their healthcare team in response to the 
How would you feel if your GP or consultant/another 
healthcare professional/a non-healthcare professional: 
a. Discussed the data they had obtained from it with you? 
b. Asked you to change something based on this data? 
c. Carried out an emergency intervention based on this data? 
d. Used it to monitor your response to treatment? 
How would you feel about this data being used to inform what 
treatment you are/are not prescribed? 
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data. Most participants were, however, open to this so long as 
there was a joint decision-making process. Similarly, all 
participants who responded to the question felt that monitoring 
response to treatment was a good use of the data.  
The question of emergency intervention was less 
straightforward. For some participants, there was a sense of 
losing control of decision-making to their clinicians. Others felt 
that emergency help should depend on the degree of 
intervention – a phone call or in-app alert were generally 
acceptable. Only a few participants were open to the possibility 
of the more extreme intervention of an ambulance being sent. 
Participants more accepting of this tended to have severe 
asthma, a history of multiple admissions or live alone. Some 
participants suggested that the intervention would need to be 
personalised to the user, for example, by taking into account 
their usual patterns of inhaler use.  
“I think the number’s really low but if you have 
like five or six puffs of your blue inhaler or 
something, that’s enough and you should be 
going to A&E.  I could have that for breakfast 
sometimes so it depends, if you're going by 
government guidelines, they’d probably 
intervene …” SIT033CM, 32 yrs.  
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Another suggested that there should be a way of cancelling a 
planned intervention. 
“I think you’d be embarrassed if an ambulance 
came though, you know what I mean, and you 
didn’t need it. There need to be some sort of, 
yeah, there needs to be something on the app 
that says, ‘It’s fine, it’s ok, I don’t need you’.” 
SIT029CF, 49 yrs. 
 
Most participants were accepting of the use of digital inhaler 
technology as a means of assessing suitability for treatment 
escalation (in the posed scenario, biological therapy). 
Participants who expressed concern about this generally did so 
from a personal standpoint. One young participant noted that 
she has benefited from her biological therapy and that, were it 
stopped because she had not met the adherence threshold, she 
feared she would be at high risk of deteriorating. Another 
severe asthma clinic patient had experienced issues with device 
reliability during the course of the study and questioned 
whether the devices were reliable enough to base such 
decisions on. Another participant questioned the fairness of 
such a proposed use and noted that being declined treatment 
on the basis of an arbitrary adherence cut-off might be 
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frustrating for the patient who had treatment escalation 
declined. Importantly, one participant noted that some people 
with asthma who are poorly adherent are also high risk.  
“… but if you’re the sort of person that has 
chronic* asthma and you’ve had it since you 
were a child and it’s stopped you doing anything 
then you’re going to be annoyed with it and 
you’re not always going to want to do what 
you’re supposed to do and you’re not always 
going to want to do what you’re told. So, I 
guess it would depend on the type of patient 
you were talking about…” SIT029CF, 49 yrs.  
* SIT029 used the word “chronic” as a marker of severity rather than time-course 
Participants felt that the data would provide their healthcare 
teams with more detailed, accurate and objective information 
on their asthma status that would enable better-informed 
decision-making and management. 
“Like I say, it shows that you're not lying then 
and that actually it’s there, it’s in black and 
white, you can see that I'm struggling.” 
SIT012IF, 18 yrs. 
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Participants were keen on data being used for research 
purposes on a wider scale as well as for personal asthma 
management. As well as more general desires “to develop 
people’s knowledge and education around asthma”, participants 
also discussed contribution to large datasets. One suggested 
that,  
“…for GPs it could be interesting to see if some 
of that data links into a spike in asthma and 
therefore they can readjust staffing to cope with 
extra footfall or for the hospitals…” SIT026CM, 42 
yrs. 
 
6.4.6. Future applications of digital inhaler technology – 
desirability, ethics and wider impact 
The responsible deployment of digital inhaler technology in 
routine practice requires wider considerations beyond efficacy. 
The collection of data as proposed potentially allows for a 
clearer, more accurate picture of an individuals’ asthma and, 
consequently, for more targeted treatment. However, there are 
also ethical implications. For some participants, these were 
obvious – even volunteered. For other participants, these were 
less thought-through or less uncomfortable. This theme 
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explores both reactions and the specific questions that 
provoked them. 
Desirability of the Smartinhaler™ system 
Overall, participants were generally open to having a 
Smartinhaler™ in the future. For some, this was a matter of 
personality. They were self-confessed technophiles who were 
engaged by the prospect of being able to digitise and data-
transform their asthma. Some participants felt that they would 
want to know that the devices would be more reliable first.  
For others, desirability was largely dependent on cost. 
Participants generally felt the current cost of £99 per unit was 
expensive. Only a few participants thought this was acceptable, 
or even expected. For many, the price was off-putting and 
appeared disproportionate to the technology available. For a 
few, the high cost was justified by the potential for impact.  
For most participants, the potential for impact (whether on their 
patterns of inhaler use or on their ability to take better control 
of their own asthma) was the main reason they would or would 
not want a device going forwards. This was the case whether 
they were looking at the potential for impact having 
experienced impact during the study or whether they were 
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anticipating this from the data that they expected would be 
generated.  
“I think it just comes back to data, the more 
data you've got, the better you can understand 
and manage things so I'm all for it really.” 
SIT024CF, 39 yrs. 
 
The subject of data ethics 
Participants had both varying opinions and varying strengths of 
opinion on issues such as what data it would be acceptable to 
collect, where such data should be stored, how it should be kept 
secure and who should have access to it. Generally, these views 
ranged from ambivalence or conditional acceptance of non-
healthcare interaction to more vehement distaste regarding the 
potential for non-healthcare entity interaction with their data. 
Each of collection, storage, security and access are explored in 
further detail below. 
Data capture 
The general feeling from participants was that we now live in 
an age of extensive data collection and so extra data collection 
was neither a new nor an unnerving concept. Furthermore, as 
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data collection would be aimed at directly benefitting their 
health, the purpose was largely seen to justify collection.  
“… I think generally, anything to do with your 
health and wellbeing, if a process is trying to 
help you with that, then you need to be as open 
and as candid as you can, obviously if it’s 
relevant.” SIT030IM, 49 yrs. 
Some participants, as already discussed, maintained concerns 
around location data. Another suggested that a line would be 
crossed if there were camera or microphone capabilities added 
to such a platform. Also as already discussed, the idea of covert 
monitoring generated a strong reaction. With all forms of data 
collection, there seemed to be two issues at stake: a question 
of necessity and, perhaps even more key, a question of trust. 
 
Data storage 
Several participants were happy for data to continue being 
stored on manufacturers’ servers on the condition that 
manufacturers only permitted access to relevant parties or that 
data remained anonymised. Several participants felt that a 
guarantee of data security, or NHS oversight, was required for 
this to be acceptable. Other participants were more hesitant, 
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primarily with concerns around data security but also in terms 
of data integrity. 
“New Zealand is a bit too far, anything could 
happen., anything could happen to the 
reading…” SIT006CF, 27 yrs. 
 
Most participants, however, were clear that, should this sort of 
technology be employed as part of routine clinical practice, the 
data would need to be stored within NHS information 
technology systems.  
“I think it needs to be moving into the NHS 
because if this is to have a positive direct 
impact on patients, what use is it sat with a 
manufacturer?  That’s okay for developing the 
products, the technology but that needs to be a 
two-way conversation, I think the data needs to 
sit with healthcare…” SIT003IF, 47 yrs. 
From a data security standpoint, there was a sense that there 
was greater accountability, where the NHS’s primary duty being 
for the benefit of the patient/user. Some participants began to 
look beyond data security to how this would allow for better 
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continuity of care by linking in with other existing health 
records. 
“I think it should be more on like individuals’ 
medical records really, somehow synced to each 
person, I know it would probably take a lot, but 
everybody’s different so it’s unique to them, so 
if there was a way of doing it that way I think 
that would be better.” SIT009IF, 34 yrs. 
 
Data security 
On the whole, participants who discussed data security as an 
issue felt it was important. For many, anonymisation was key 
(with few exceptions). Others noted (particularly in light of 
recent media items) the importance of reassurance that servers 
were secured against breaches and that personal information 
could not be leaked.  
“…that’s the only big worry for me, is making 
sure that my personal information isn't getting 
into the hands of the wrong people and people 
who are going to hassle me on a daily basis…” 
SIT005IF, 27 yrs. 
One participant, however, uniquely expressed a lack of concern.  
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“I can’t think of anyone  that  I’d be worried 
about because if they can get my data through 
one app, they can get it through another app so 
unless you block all permissions, people are 
going to find you if they look hard enough. I'm 
not worried about people hacking into my phone 
and taking my bank details, good luck to 
them...” SIT015CM, 41 yrs. 
 
Data access 
There were mixed opinions on who should or should not have 
access to data. Some participants felt that access for profit was 
unacceptable.  
“I think if they’re going to make them rich, 
somebody you can’t trust, I'm not against rich 
people but do you understand what I mean?! …  
I'm doing this study so that things can get 
better, not for companies to make millions of 
pounds, if you see what I mean.” SIT002CM, 57 
yrs. 
Others felt that access should only be provided to entities within 
the NHS, with some specifically naming pharmaceutical 
companies, health insurance companies and government as 
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bodies which should not have access to such data. However, for 
others, there was less discomfort about access being given to 
entities outside of the NHS. Indeed, for some participants, such 
access was important. One participant noted an advantage to 
manufacturers having potential access to data for ongoing 
product improvement. 
“The people who are developing it to share 
amongst the healthcare professionals, I think 
are the most important people.”  SIT014CF, 57 
yrs. 
Even here, however, several participants felt such access was 
dependent on their data being anonymised and access to 
patients and their healthcare teams being guaranteed. 
Participants not only felt that this should be available, but also 
that healthcare teams had a responsibility to empower users to 
understand their data. 
“So, the fact that we’re doing recordings and 
there’s lots of data, if that’s not user friendly … 
if there is medical data that, as a patient, I 
might not necessarily understand then just a bit 
more clarity around what, as a clinician, that 
suggests to you…” SIT030IM, 49 yrs. 
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Participants also discussed how integration with health records 
could also lead to integration across primary and secondary 
care services so that this data would also be accessible to 
hospital specialists when they were referred for escalation of 
care. 
What also clearly emerged from a group of participants was a 
sense that access, whoever it was given to (i.e. whether NHS 
or non-NHS bodies), should be on a need-to-know basis. The   
end-user’s benefit should be prioritised. This may be directly in 
terms of the individual patient, or more broadly in terms of 
developing the best possible product for people with asthma.  
Finally, some participants expressed their overall feelings in 
terms of trust, similar to views regarding data capture. In a 
similar vein also to discussions which took place around the 
acceptability of covert monitoring, there was a sense that 
participants would want to be given all the relevant information 
as to which parties had access to their data and what they would 
be using it for. They would also want the right to opt out if they 
wished and they would want to know that they could trust 
those. 
“I suppose it doesn't matter who has access, so 
long as you're clear to whoever you're capturing 
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that data from, that that’s where it’s going, I 
think that’s actually more important than who 
should or shouldn’t, I think so long as you're 
informed and you have that choice as to 
whether you want that particular company or 
person to have access to that data, that’s 
probably more important.”  SIT026CM, 42 yrs. 
 
Participants’ views on the potential wider impact of digital inhaler 
technology 
Impact was generally interpreted at a personal level. A few 
participants, however, did also consider the wider potential for 
impact in people who had asthma. 
“If that’s the way that the future is going, then 
it’s a way of monitoring more effectively, getting 
the information, reviewing it, to try and 
improve, the way we study asthma and the way 
that we treat asthma then I’m okay for that to 
be forever, if that’s the way that it is.” 
SIT035CM, 38 yrs. 
In terms of relationships with health providers, most felt it 
would have a positive impact by allowing care providers to 
respond rapidly in a more informed way. Objective data 
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provision, participants felt, would increase trust between GPs 
and their patients. Participants also felt that it would open up 
conversations, allow for better-targeted consultations which 
were backed up by a better picture of what was actually 
happening rather than relying or patients’ subjective memories. 
Not all participants felt so positively. Some articulated concerns 
that such data might lead to a power dynamic where patients 
feel “told off” by their GPs. Others worried about 
depersonalisation. 
“…the risk is that they could just use the data 
and not … see how the patient was face to face, 
that would be a risk but then that probably 
depends on both the patient and the practitioner 
so … there’s always a risk of becoming slightly 
more anonymous as a patient I guess, if there’s 
more, if someone relies more on just data.” 
SIT001IF, 54 yrs. 
Participants highlighted the importance of healthcare providers 
maintaining a two-way conversation with their patients that 
explored their feelings and worked around issues rather than 
automated responses to data.  
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On healthcare resources, a few participants recognised this sort 
of technology as having a potential for impact but were split 
over whether this would be positive or negative. On the basis 
of the current cost of the devices, some participants noted how 
challenging it could prove for the NHS to provide such a service. 
For other participants, however, there was a potential for 
benefit by reducing GP appointments, hospital appointments, 
unnecessary treatment escalations and emergency department 
and hospital admissions. One participant did note that such 
“efficacy” would need to be evidenced. 
One participant linked the technology to public health 
messaging recommending greater self-management practices 
in the management of chronic conditions and the push towards 
increasingly personalised medicine.  
“Even part of this is you're monitoring an 
individual, you're not making assumptions 
based on a population … I think that’s the way 
it’s going and I'm all for personalised medicine 
because what will work for you will not work for 
me but I think we’re a bit away from that at the 
moment.” SIT003IF, 47 yrs.   
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For some participants, the impact – either experienced or 
potential – was great enough for them to foresee its potential 
for the wider asthma community. Most participants described 
themselves as already adherent but felt that it would be 
advantageous for people with asthma to have access to their 
own data.  
“I could see it just being really useful long term 
and I think everybody should have a device and 
everybody should be able to see their 
information…”  SIT008CF, 44 yrs. 
 
6.5. Discussion 
6.5.1. Summary of study findings 
At the final visit of a pilot study using EMDs as part of an 
adherence intervention, study participants discussed their 
experiences with the Smartinhaler™, how these experiences 
were in the context of their experiences with asthma and 
asthma treatment and how those experiences shaped their 
perceptions of digital inhaler technology as well as its potential 
for future use in routine clinical practice. Participants described 
how they contextualised their asthma from the (at times) belief-
altering perspective of their recent experience of exacerbation, 
which was both an “eye opener” and a motivator to 
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maintain/regain control. They explained that they generally felt 
in control of and responsible for their asthma, and that 
healthcare teams could be contributors to this. For them, 
symptom control was generally defined in terms of a reliance 
on reliever inhalers or symptoms which led to frustration and 
limitation.  
Similarly, they described how their perception of inhaler efficacy 
was tied to their previous experiences, whether a reduction in 
interval symptoms and increase in peak flow or a perceived 
increase in symptom burden despite reported ongoing inhaler 
use. Necessity was based on past experiences, generally of 
what had happened or (fear/lack of fear with regards to what 
could happen) in the absence of preventer medication. 
Participants also described the reassurance supplied by the 
presence of their reliever inhaler and discomfort with reliance 
on treatment. They described frustration where they perceived 
changes to their medication to be arbitrary. Participants 
described their patterns of inhaler use and the factors that 
affected those patterns, particularly highlighting the power of 
habit formation and routine in addition to the role of past 
experiences. They also described perceived unwanted attention 
from public inhaler use and a desire to keep their condition 
hidden. 
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Participants generally found the Smartinhalers™ acceptable, 
although for some this was a balance between issues such as 
their physical characteristics. They were largely in agreement 
that they preferred their EMDs to be subtle and non-intrusive 
(whatever their opinion of the size of the Smartinhaler™ 
device). There was some frustration around technical issues 
such as connectivity and data reliability. They placed a high 
value on ease of use (simplicity, in-app guidance, ease of 
replacement, ease of charging). Intervention participants 
variably found the in-app feedback helpful. Many participants 
described some level of impact, whether this was increased 
awareness of their condition, its importance, their ongoing 
symptom status or behaviours. This was sometimes dependent 
on baseline factors such as pre-study adherence and perceived 
drug efficacy. A few participants described engagement with 
clinical teams and varying responses from cynicism to interest 
and changes in management.  
Participants generally felt desirability of a Smartinhaler™ 
system would be dependent on its potential for impact and had 
ideas for improving its physical characteristics, additional app 
features (without doing away with its simplicity), integrated 
data collection of environmental factors, physiological markers 
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(both automated from other mHealth systems and user-
determined) and uses including enhanced self-monitoring.  
They were mostly unconcerned about data sharing so long as it 
was on a need-to-know basis, for user benefit and 
anonymised/secure. Most participants were open to additional 
data sharing, fewer were open to integration with other systems 
including wearables and fewer (albeit still the majority of 
participants) were open to the use of GPS tracking. Some 
participants were more vociferous in voicing their discomfort 
with proposals, others more subtle – potentially projecting their 
discomfort onto “some/other people”. Participants could see 
ways in which Smartinhaler™ technology could enhance their 
asthma care, but not many were happy for it to replace face-
to-face conversations altogether. Participants felt that feedback 
should be in partnership with users rather than done to users 
by healthcare professionals as they wanted to be empowered 
to understand their condition. They saw this technology slotting 
into primary care due to relationships they had already built 
with primary care providers and their role in management. They 
felt that EMDs should be issued for long enough to gather a 
holistic picture of the user’s asthma. They were generally 
optimistic that, particularly where data are used as stated, that 
this would improve communication with their clinicians. 
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Participants foresaw both positive and negative implications 
(usually in terms of cost) for wider impact. 
6.5.2. Contextualising this study 
Previous work 
This study provides important insight into user perspectives 
from the point of view of an interventional study of adherence, 
a view only obtained by one other study thus far (184) despite 
some 30 years of adherence research (152). Unique to this 
study, however, is its understanding of how “control group” 
users in the context of non-covert monitoring interacted with 
their devices. This is key in understanding the effect a hands-
off approach to EMD use may have in the clinical setting. Also 
novel is the presence of user (rather than clinician/researcher) 
perspectives on how such devices may be deployed in the 
future. 
This study carries echoes of what has been seen before. As in 
the study from Stewart et al., participants were highly 
motivated to avoid experiencing repeat exacerbation or 
symptom deterioration (186). Participants were often optimistic 
about the role of healthcare professionals and potential role for 
EMDs in aiding in this endeavour. There was a high level of EMD 
desirability as found by Howard et al. (185) and, as noted by 
Foster et al. (184), this often persisted in the face of technical 
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malfunction. Some found the EMDs contributed to their ability 
to self-monitor and thus take ownership over their asthma. 
Some also found that it facilitated conversations around their 
medication regime in a similar way to that anticipated by 
participants in the study by Howard et al. (185) and discussed 
by participants in the study by Foster et al. (184). Also similar 
to the study by Foster et al. (184), participants found the EMDs 
to be effective reminders for inhaler use, even where the 
reminder alarms had not been activated and discussed how it 
had improved their preventer use, helped maintain routines, 
and changed their attitude towards various self-management 
behaviours. This supports its highlighting of the importance of 
habit formation. 
As found by all three papers, however, these benefits were not 
universal. There were varying levels of acceptability of the 
devices’ appearance and their potential to attract unwanted 
attention and therefore decrease inhaler use; although in this 
study, this was more around reliever use. Participants also drew 
links between baseline medication use, perceptions about 
medications, perceptions about asthma and EMD impact. 
Participants expressed concerns about data sharing and about 
the risk of depersonalisation in the face of their own data. 
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The in-depth interviews from the current study, however, go 
further, exploring participants’ beliefs about both their asthma 
and their medication in greater depth. This is key. Farnesi et al. 
note that, “…even when well-intentioned, attempts to persuade 
patients to adhere to biomedical treatments may prove futile if 
they fail to fit with the patient’s beliefs, expectations, and 
needs” (207). As Foster et al. noted, there were some beliefs 
that EMD provision only altered if it led to direct conversation 
with patients’ clinical team (184). It would therefore stand to 
reason that participants with poor adherence behaviours prior 
to the study who perceive greater impact do so because they 
already have beliefs which are congruous with increased 
adherence and an understanding of the role EMDs play in 
enhancing these may provide a mechanism of action.  
The sample in the other adult qualitative study, whilst being 
individuals with uncontrolled asthma, were not necessarily 
individuals with recent or frequent exacerbations. The current 
study, therefore sheds greater light on the strength of 
motivation the desire to avoid recurrence of negative asthma 
experiences provides to an intervention. It provides greater 
detail over precisely what individuals wished to avoid (activity 
limitation as well as, reliance on acute reliever medication use 
and unanticipated service use (186)). It also highlights that 
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participants are not only concerned about adverse effects from 
their inhalers. Beliefs of non-efficacy appeared to be important 
demotivation in a few participants that would require separate 
targeting.  
Participants expressing such beliefs also reported periods of not 
engaging with this study. This is in keeping with findings from 
other adherence studies where, despite EMDs resulting in 
overall increased adherence, a subset of patients showed either 
persistent poor adherence or disengagement including reported 
device loss and damage (69, 99, 112). This group of individuals 
(high baseline risk, self-confessed poor disease control and 
beliefs which both work to demotivate adherence and prove 
resistant to simple interventions) is at increased risk of poor 
outcomes (12). Unfortunately, they are also at risk of being 
excluded from the evidence for inhaler technology adherence 
interventions by virtue of being more likely to disengage from 
studies and more resistant to interventions. Interestingly, a 
recent observational study of fractional exhaled nitric oxide 
FENO suppression excluded patients who were shown not to be 
adherent during a one week run-in period (112). Already, EMD-
based interventions as they stand do not work for this group, 
as demonstrated by the studies above.   
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Whilst not by any means over-simplifying the complexity of 
these individuals (some of whom have refractory disease which 
plays into their poor adherence (99) and others of whom may 
have complex concomitant psychosocial circumstances or 
comorbidities) participants themselves suggest potential 
avenues of engaging with regular preventer inhaler use and 
doing so via inhaler technology. Thus, even though inhaler 
technology alone cannot answer these complex problems (184), 
it may be part of a multifaceted, holistic solution.  
Informing application of behavioural change models in asthma 
adherence 
Elements of all behaviour-change perspectives are relevant to 
EMD interventions. They are engaged in behaviour change on 
the basis that ICS has been evidenced to improve asthma 
control (biomedical), use social learning to establish and 
maintain new behaviours, can be used to acknowledge the 
rationality of beliefs undergirding poor adherence by providing 
evidence at an individual level of the benefit of regular ICS 
adherence, providing new experiences to alter old cognitive 
representations as demonstrated by Foster et al. (184), and 
facilitate communication with clinical teams. Current research 
on who they should be deployed in suggests that, for impact, 
users require a certain level of motivation – potentially, as 
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demonstrated in this study, recent exacerbation or experience 
of deteriorating control leading to functional limitation, 
increased medication requirements or unscheduled service use.  
Participants’ emphasis of beliefs, perceptions and, in particular, 
the memories of the experiences and emotions that shaped 
them appear to support the validity of a self-regulatory model 
for behaviour change in asthma, even beyond Horne’s 
necessity-concerns framework (59). The data also suggest that 
harnessing these experiences and emotions at a personal level 
may be a significantly powerful motivator for change. Some of 
those beliefs are well-elucidated in the health belief model, 
particularly susceptibility and seriousness. Importantly, 
however, in describing factors which led to them adhering to 
their medication as prescribed, participants emphasised routine 
and habit formation, a finding echoed by Foster et al. (184), an 
element more in keeping with a social learning perspective but 
which may also fit well into the action-planning part of the self-
regulatory model. Such paradigmatic integration is in line with 
Leventhal’s own aims in promoting a self-regulatory framework 
(190). Whilst self-efficacy was less directly emphasised, 
participants’ clarity on their sense of responsibility for and 
control over their condition (and, where control) was absent, 
their desire to regain control suggests that individuals with 
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asthma do want to feel empowered to control their own disease. 
As Stewart et al. demonstrate, there is a risk that EMDs can 
work contrary to this (186). There is therefore likely to be 
benefit in considering the theoretical basis of how they are 
deployed so that this is not the case. 
Future applications for inhaler technology 
This is believed to be the first study that has explored in depth 
the unique and expert perspective of individuals who have 
experienced EMD as an intervention to improve adherence in 
asthma in understanding how proposed future uses of EMDs 
interventions and ethical issues related to this were received. 
Other studies have explored such themes in less depth (185, 
186), with individuals who have not used EMDs as an 
intervention and therefore lack the expertise of experience in 
this area (208) or more narrowly in relation to EMDs as they 
exist in their current form and use (184).  
The current study went beyond desirability to understanding 
potential for impact as based on participants’ own experience, 
both with a basic app and an app with in-app data and 
associated feedback. It also examined where it would fit into 
services, how such uses would be perceived by the individuals 
who could be affected by them, what platform integration could 
look like and how useful individuals with asthma actually 
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perceive this to be. This is particularly timely in the light of NHS 
England’s requirement for adherence to be evidenced 
objectively before treatment escalation to biological therapy 
(34) and the anecdotal increasing use of EMDs in that process. 
It is also timely as work is already apace testing integration of 
EMDs with other mHealth inputs, including several suggested 
by participants in this study (209, 210).  
Also timely is this study’s sounding of participant views on data 
ethics, particularly in light of recent controversies (211). As 
interest in mHealth rises, so important questions need to be 
answered. Who safeguards the interventions and their effects 
on individuals, whether this is in the form of information and its 
evidence base (212, 213), the human factors effects which may 
be yet unknown (214) or data security and confidentiality (215) 
as highlighted by the DeepMind controversy (211)? On a wider 
scale, what effects will such technologies have on health equity, 
on health infrastructures and on the boundaries between 
commodification and the human right to health (214, 215)? In 
the qualitative tradition, this study pushes to the fore the voices 
of the individuals for whom these issues will have the greatest 
relevance. By acknowledging the centrality of the patient role 
in their own self-management, it utilises these user perceptions 
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and experiences to inform potential implications for EMD 
interventions as part of future clinical care.  
6.5.3. Applying this work to future intervention practice 
Unsurprisingly for such a heterogeneous condition, this study 
demonstrates significant heterogeneity of baseline experiences 
and beliefs. Individuals who entered the study used these 
experiences and beliefs to construct stories which helped them 
make sense of their asthma and its treatment. These stories 
seemed to motivate (or demotivate) habit formation which led 
to adherent or poorly-adherent inhaler use behaviours. Using a 
self-regulatory framework, the aim of EMD interventions is 
twofold. As a simple intervention, they can assist individuals 
who have stories consistent with adherence behaviours which 
increase their asthma control and decrease their asthma risk 
(equivalent to Leventhal’s cognitive representations (190)) to 
take actions in line with those beliefs. The primary action 
identified by this study is habit formation. The second aim is to, 
where needed, work with individuals to modify stories which do 
not motivate behaviours that lead to increased asthma control 
and decreased asthma risk. Discussed below is a framework to 
practice approach drawn from this interpretation of the data. 
Page | 331  
 
Targetable beliefs and story modification 
The data presented in this study suggest that, within the stories 
that individuals have constructed about their condition from 
their perceptions, experiences and emotions – whether its 
aetiology, their symptoms, its effect on them or their 
medications – lie key targetable beliefs. Thus, overarching 
stories may not be fully concordant or fully discordant with 
adherent behaviour. Rather, they may demonstrate a balance 
of adherence-concordant beliefs set on a scale against 
adherence-discordant beliefs. Resultant behaviour would 
depend, as it appeared to from our data, on which beliefs 
weighed more heavily. Similarly, Scherman and Löwhagen 
found that medication behaviours depended on which belief-
forming experiences achieved dominance (216), as illustrated 
by Figure 6-2.  
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Figure 6-2: Stories are constructed from a balance of concordant-discordant beliefs 
 
Individuals’ perceptions and beliefs around both their asthma 
and its treatment have consistently been shown to interact with 
their self-management behaviours (trigger avoidance, lifestyle 
and adherence) (183). Evidence also suggests that self-
management behaviours will be most effectively influenced 
when clinicians take the time to engage with beliefs, inviting 
their patients into “a shared understanding of how the disease 
manifests itself in a specific patient” (207), rather than simply 
dictating the terms of reference (183, 207). This was just as 
much the case where discordant habits were leading to harm, 
as individuals did not always automatically relate their 
symptoms and limitation to poor symptom control or self-
management behaviours (207).  
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Examples of key targetable discordant beliefs from this study 
include: 
- The belief that asthma is not a serious condition. Studies 
have shown that the understanding of asthma as a 
serious condition is fundamental for participant 
engagement in their intervention (184) and associated 
with higher levels of concordant treatment necessity 
beliefs (182).  
- An individual’s belief that they are not themselves 
susceptible to serious asthma. In this study, this belief 
was targeted by the use of asthma control and quality of 
life questionnaires and the awareness of their reliever use 
resulting from knowing their inhaler use was being 
monitored. This was reported by both intervention and 
control participants. In one study, participants recalled 
their objective data challenging previously-held 
perceptions of their own adherence, again, helping them 
to understand their susceptibility (184), likely to in a 
similar way to which participants in this study described 
their EMD as helping them to be more regular users. 
- The belief that preventer inhaler use is unrelated to 
asthma symptoms. Foster et al. demonstrated how EMD 
provision led to experiences which helped users to link 
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their regular preventer use with improved asthma control 
(184). 
- The belief that inhaler use is embarrassing and results in 
unwarranted attention. Some studies show an association 
between such feelings (the fear of increased attention 
stemming from their asthma, embarrassment, unease 
with public inhaler use) and lower levels of adherence 
(182).  Whilst in our study response was mixed, for some 
participants the novelty of the inhalers gave them 
confidence to engage with them in public in a way in 
which they previously had not. 
- The belief that overuse of their reliever is necessary. A 
couple of participants in this study attempted reduction of 
excessive reliever use in response to seeing their data 
showing that the process had challenged their beliefs 
around how often they truly needed their reliever inhaler. 
For some individuals, simple provision of an EMD-based 
intervention will be enough to tip the scale in favour of their 
more concordant beliefs. Those who do not respond can be 
stratified out and receive targeted intervention. This would 
ensure that no patient is left behind without leading to the 
expense of undeliverable, complex interventions targeted at 
people who do not need them. 
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Habit formation and adherence behaviours  
Most individuals in this study reported themselves (some 
confidently, some less confidently) as using their preventer 
inhaler religiously or regularly with occasional missed doses or 
overuse. This suggested a belief, at least, that preventer 
inhalers should be used regularly, even when participants (often 
apologetically) admitted that they were not. Participants were 
also keen to exert control over their condition and felt a sense 
of responsibility to do so. These participants also discussed 
partnering with their clinical teams to achieve personal agency 
over their condition. That these participants were not 
necessarily universally adherent would suggest that beliefs 
alone are not enough to influence behaviour. This prominence 
of habit formation is in line with the findings of Foster et al. in 
their qualitative study of experiences with EMDs (184). 
Data from this study suggests key parts of habit-formation 
include: 
- Visual cues (seeing their preventer on their bedside table 
or by their toothbrush for example) 
- Auditory cues (reminder alarms, important others) 
- Routine (e.g. timing preventer inhaler use with other key 
daily routines) 
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Data from this study also suggests that EMDs may stimulate 
habit formation through: 
- The awareness of being monitored, emphasised by in-app 
feedback and device characteristics such as the LED flash 
at data upload and device novelty 
- Reminder alarm function activation (auditory cue, 
reducing habit loss when there is a change of routine) 
- The ability to check whether a dose has been missed (also 
reducing habit loss when there is a change of routine) 
This may be enhanced by other forms of feedback to keep the 
user engaged. 
Suggested model to inform practice 
Based on both previous literature and work presented by this 
study, an integration of what is known into a working model is 
suggested (Figure 6-3). This proposes that behavioural 
interventions work by targeting specific beliefs which are 
amenable to change as well as by stimulating habit formation 
in order to see the desired behavioural outcome.  
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Figure 6-3: Proposed Beliefs - Habits - Behaviours Model 
 
For some individuals, beliefs may not need to be targeted 
directly – simple reminders leading to habit formation and 
reinforcing concordant beliefs may be enough. For others, 
without a more complex intervention to target beliefs, habit 
formation (and consequently, behaviour change) will not be 
attained. Even here, however, successful modification of beliefs 
will only lead to modification of behaviour if habit formation is 
reinforced as well. 
6.5.4. The future of EMDs 
It has been stated that, “attempts aiming at enhancing asthma 
control should combine strategies targeting the individual 
diagnosed, the health care organisation, and community” 
(207). In this study, EMDs were described as having a level of 
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impact in all three spheres. Perhaps most exciting was how 
participants saw the future of EMDs. Research in this field is still 
young and has almost exclusively focused on the impact of EMD 
technologies on asthma control through improving adherence. 
However, as Farnesi et al. noted, “…patients viewed asthma 
management and control to provide more comprehensive 
assistance regarding behavioural changes to be implemented…” 
(207). Participants in this study were similarly curious about the 
potential for an integrated inhaler technology platform to inform 
their lifestyle choices around exercise and safety in exercise, 
around trigger avoidance and increasing awareness of the risk 
that particulate air pollutants pose to people with airways 
disease as well as information on the weather and pollen. More 
practically, they wanted an opportunity to be able to integrate 
this with their current status – symptoms, questionnaires and 
physiological markers – in order to both self-monitor and better 
inform their healthcare providers. This desire for better-
informed, more personalised care and information has been 
noted to come from the desire individuals with asthma have to 
have a greater sense of control over their condition: i.e. 
“knowledge is power” (217). 
Exploration of these future avenues may contribute to more 
than just patient engagement. With the growing interest both 
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within the asthma community (218, 219) and the public 
imagination (220) of air pollution, for example, it may be that 
these less studied features prove important in improving 
asthma control in the future. EMD technology may offer 
solutions to the resource strapping of recent years that has 
made time an increasingly unavailable commodity and affected 
continuity of care. By providing clinicians with tailored 
information, they allow for delivery of personalised care 
supported by personalised information which is validated and 
available to users at the touch of a button and takes into 
account their current status, environmental factors, 
physiological markers as well as inhaler use.  
Finally, users are clear that they want data to enhance, not 
replace, interaction with healthcare teams. They are clear that 
they want their data to be secure, they want to be fully informed 
of what it is being used for and they want control over what 
they share and whom they share it with. Finally, they are clear 
that they expect integration between their primary and 
secondary care teams. This should be accounted for in service 
delivery. 
6.5.5. Strengths and limitations  
This study explores much-needed and previously neglected 
research into user perspectives on EMDs. It offers novel work, 
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particularly in terms of future use of EMDs. Participants were 
asked to hypothesize based on their experiences into potential 
implications in the future. The findings from this are important 
(and, to this investigator’s knowledge, an equivalent has not 
been attempted before). This is a major strength of the study. 
Whilst acknowledging the nature of this part of the interview as 
extrapolative rather than based in experience, it is still superior 
as a source of information to the research and scientific 
community conducting such extrapolations on the behalf of 
their patients.  
In addition to the transferability and novelty of its findings, 
strengths of this study included the duration of time participants 
were provided with an EMD.  A six month duration allowed 
participants significant exposure to the EMD and reduced the 
novelty effect, such that experiences were perhaps more 
reflective than a shorter study of what effect such devices used 
in clinical practice would potentially have. This study also 
involved a sample that had significant experience of asthma 
morbidity, providing a rich source of information with regards 
to experiences of asthma. Finally, this study’s use of 
behavioural change theory has further focused data into an 
implementable strategy for care. 
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This study shares the limitations of most studies in generalising 
findings. This is particularly the case from its qualitative nature 
as well as in terms of demographics – the study sample was 
overwhelmingly female and Caucasian, for example. Findings 
are therefore the perceptions and experiences of this unique 
group of individuals. However, they offer valuable and novel 
insights and perspectives that can inform not only future digital 
inhaler interventions but also inform clinician approach to their 
patients. This is strengthened by the fact many of the base 
findings are supported by research in this field. Whilst these 
findings cannot be generalised per se, the themes drawn out 
and the model developed are transferable to other asthma 
populations.  
Some of the experiences participants were asked about were 
from prior to study entry. It is inevitable that, for at least some 
participants, these experiences will have been modified by 
various aspects of participation in the study. However, this risk 
was balanced against the need to minimise emphasis on 
adherence at the start of the study. Such an emphasis may 
have resulted in a Hawthorne Effect (143) on behaviour by 
emphasising themes around medication and control. It is also 
noted that participants were also asked to discuss their 
experiences and perspectives immediately the study closed, 
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reducing the opportunity for them to have time to process and 
contextualise their experiences. As discussed in the 
methodology, however, the benefit of maintaining engagement 
and minimising memory bias was judged to outweigh this. 
 
6.6. Conclusion: Incorporating patient experiences and 
perspectives into future technology delivery 
Inhaler technology has shown promise in improving adherence 
but has less evidence in showing that this leads to improvement 
in clinical outcomes. This may be in part due to interventions 
which assume individuals with poor medication adherence are 
a homogenous group. There is also a risk that studies continue 
to exclude (or fail to show benefit in) individuals with complex 
underlying causes for their poor adherence who are potentially 
at high risk of poor outcomes. 
This study proposes a targetable beliefs/habit formation model, 
which may help researchers and clinicians deploy inhaler 
technology in a way that is more effective in terms of clinical 
outcomes and that also benefits individuals with more complex 
needs. It further proposes a willingness for a more integrated, 
platform-based approach which may help clinicians target not 
only adherence but various elements of overall asthma care. 
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This study also suggests a general optimism from individuals 
with asthma for the potential of inhaler technology to have both 
personal and wider impact. There are, however, rules of 
engagement, particularly related to usability, reliability, data 
security and data access. Manufacturers, researchers and 
service providers would do well to pay attention to these if EMDs 
are to have the impact they are capable of.
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Chapter 7: Inhaler technology: 
translating from clinical trials to routine 
use 
7.1. Findings of the thesis 
This thesis set out to investigate the effectiveness of electronic 
monitoring devices (EMDs) in the monitoring of adherence and 
delivery of interventions. It also set out to understand the 
implications of this for their routine clinical use.  
A meta-analysis of studies using EMD-derived adherence found 
that electronically monitored individuals with asthma actuated 
64.3% (95% CI 57.1-71.5%) of puffs prescribed. This estimate 
is higher than that found in previous reviews incorporating 
various methods of adherence monitoring (46, 50), likely 
reflecting selection bias and observation effect (see Chapter 2). 
The review also found that interventional studies saw an 
improvement in adherence (i.e. proportion of prescribed doses 
actuated) of 12.7% (95% CI 6.1 – 19.3%), suggesting that 
EMDs are a good measure of change in adherence. However, 
there were also a wide variety adherence definitions. What 
devices actually measured and how this was reported differed 
across sample populations. This review also found differences 
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between technological features of different devices and device 
accuracy. These were all judged to be factors which could affect 
development of effective interventions and, ultimately, EMD use 
in clinical practice.  
In its second review, this thesis also confirmed that EMD-based 
interventions improved adherence. However, it found that the 
gains in adherence did not consistently translate into 
improvement in clinical outcomes. This was despite established 
evidence that good adherence to inhaled corticosteroid (ICS) 
results in better clinical outcomes (31, 32).  
As part of a pilot study of an EMD-based intervention, 130 
devices were tested. As 12% of devices failed both in pre-study 
and post-study testing, this thesis concluded that quality control 
remained a barrier to widespread clinical uptake. The causes of 
the device failures largely related to the device casing-inhaler 
fit.  
The thesis centred on a pilot study isolating feedback as an 
EMD-based adherence intervention. It found that the 
intervention group actuated 11% more of their prescribed 
inhaled corticosteroid (ICS) doses, although this was not 
statistically significant (p=0.319). It also found a difference in 
the proportion of individuals who took their ICS inhaler on 
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average ≥75% of the time. This approached significance 
(p=0.056). A follow-up power calculation suggested that a 
sample of 340 would be required to see a statistically significant 
difference in adherence between groups. This may indicate that 
the effect of feedback alone may not be enough to justify the 
use of EMDs in clinical practice. 
There was no evidence of improvement in clinical outcomes but 
there was a trend towards an increase in exacerbation rate in 
the intervention group (p=0.069), suggesting that the 
relationship between adherence and outcomes may not be as 
simple as previously thought. Finally, adherence in the control 
group changed over time, suggesting that there may have been 
an observation (Hawthorne) effect i.e. the control group’s 
adherence was increased by imminent past and imminent 
future face-to-face study visits. 
Finally, user experiences of participating in an EMD-based 
intervention, their perspectives on EMDs and their perspectives 
on potential future uses of EMDs were investigated. Findings 
from this qualitative study demonstrated that, while users were 
open to a role for EMDs in asthma care, this was not 
unconditional. They wanted to see evidence of impact. For 
some, this would involve greater reliability, for others 
integration with other avenues of data and clinical care. Users 
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were generally clear that they expected their data to be 
anonymised and secure, that they expected access to their data 
and that they expected to be empowered to understand their 
data. They expected their data to form a part of (but not 
replace) clinical reviews. Participants valued a sense of control 
over their condition. They saw a role for EMDs in helping with 
this including by supporting their adherence behaviours and 
giving them access to reliever data to help them monitor their 
symptoms. They also thought positively about potential future 
platform integration (e.g. with wearable health devices).  
7.2. An ideal study: from pilot to real-world  
A key aim from the pilot study was to investigate feasibility of 
a fully-powered randomised controlled trial (RCT). Both the 
systematic review of electronically monitored adherence and 
the review of EMD-based adherence intervention further 
highlighted important study design considerations that should 
be incorporated into future interventional EMD studies. Based 
on the findings of this thesis, proposals for the ideal 
interventional study are detailed below. 
7.2.1. Target population of an ideal EMD-based interventional study 
Only two studies have shown a clear improvement in clinical 
outcomes from the use of an EMD-based intervention. These 
were both in children who had recently exacerbated (69, 71). 
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Questionnaire-defined asthma control alone was insufficient in 
highlighting the at-risk populations most likely to benefit from 
adherence intervention (Table 3-4). Thus an ideal study would 
enrich for poor asthma control as measured by recent 
exacerbation, ideally within the three months preceding the 
study.  
Both of the reviews in this thesis found that baseline adherence 
had not been routinely reported. Where it was reported, it had 
been measured in different ways. The pilot study noted that a 
high baseline adherence may have masked any adherence 
gains or, perhaps more importantly, made a threshold 
improvement in clinical outcomes unattainable. Adherence 
interventions, by definition, are best targeted at individuals with 
poor baseline adherence. Identifying these individuals and 
retaining them in a study is likely to be challenging, however 
future studies of adherence must find ways of identifying 
individuals at risk of poor adherence and enriching for it. In its 
systematic review, this thesis challenges the idea of a run-in 
period as an effective measurement of baseline adherence. 
Measurement using pharmacy records and/or adherence 
questionnaires may help identify individuals who are more likely 
to benefit from adherence intervention instead. 
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Whilst there is no consistent evidence for the independent role 
of socioeconomic status in adherence, studies suggest that it 
cannot be ignored (53, 100, 118). Similar to socioeconomic 
status (221), certain ethnic minorities are known to have poorer 
asthma outcomes (222-227). Potential mechanisms for both 
socioeconomic status and ethnicity include out of pocket costs 
of medicines (228, 229), low health literacy impacting beliefs 
and behaviours (230) and beliefs about health and medicines 
(56, 60). Despite this, many studies have been shown by this 
thesis not to report socioeconomic status or ethnicity. Where 
reported, studies – including the pilot study presented here – 
with a small ethnic minority proportion have been unable to 
address barriers unique to this at-risk population. An ideal study 
would identify these at-risk populations and analyse data such 
that effective interventions can be tailored to their needs.   
It may be that individuals with evidence of airway inflammation 
may benefit more substantially from improved adherence than 
individuals with poor adherence and no evidence of current 
airways inflammation. An ideal study would therefore include a 
subgroup of these individuals to aid future understanding.  
7.2.2. Sample size for an ideal EMD-based interventional study 
Chapter 3 describes how previous studies of EMD-based 
interventions have used sample sizes of anything between 20 
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and 330 participants to power for an adherence effect size of 
10-15% for a variety of interventions in more than one 
demographic. The pilot study presented in this thesis suggests 
the need for a larger sample size. In it, the intervention group 
had an overall mean study adherence of 70.7% and the control 
group a mean adherence of 59.4%. Using this effect size of 
11.3%, a sample size of 340 would be required (alpha <0.05, 
power = 0.9) for the difference in adherence to be significant 
(see Chapter 5). A loss to follow-up rate of 17% suggests over-
recruitment allowing up to 20% loss to follow-up could be 
needed.  
Power calculations for clinical outcomes were less commonly 
reported by interventional studies reviewed by this thesis. 
Where they were reported, sample sizes varied between 76 
participants for a 0.5 point difference in ACQ and 188 
participants for a 1.5 point difference in in ACT™. No published 
EMD-based adherence intervention studies have been powered 
on exacerbation reduction as yet. In children, a significant 
reduction in exacerbations was seen in a sample size of 89 and 
in adults, an unadjusted signal was seen in a sample size of 
129. These were both for EMD-based adherence reminder 
interventions.  
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Drawing both adherence and clinical outcomes together, an 
overall sample size of 425 participants is suggested (340 with 
over-recruitment to account for a 20% attrition rate). This 
would be larger than any EMD-based interventional studies to 
date, positioning it to be powered for both adherence and 
exacerbation reduction.  
7.2.3. Interventional arm of an ideal EMD-based study 
The main brands of EMD device now in use collect date and time 
stamps and this should continue to be the minimum 
requirement. There is no evidence for devices collecting more 
information (i.e. presence of inhalation, quality of technique) 
and no device on the market currently has the ability to provide 
biological feedback in the mode of real time continuous glucose 
monitoring (rtCGM) systems. Nevertheless, it stands to reason 
that such devices may, by engaging users in their own care and 
reducing alert fatigue, have a greater impact than devices 
measuring date and time stamps alone and not providing 
feedback directly to users.  
This thesis suggests that device accuracy is more important 
both to device users than and for study integrity than what 
devices are capable of doing (see Chapter 4, Chapter 6). An 
ideal study would prioritise devices with validation data showing 
good accuracy and allocate time and resources to device testing 
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before, during and after usage. An ideal study also needs to 
maintain clear avenues of communication between the study 
team, device manufacturers and inhaler manufacturers in order 
to allow emerging issues in device design or accuracy to be 
addressed during the course of the study. At least one member 
of the study team should have had experience using such 
devices, either in the context of research or clinically to 
minimise time lost in the testing phase due to lack of familiarity.   
Whilst the pilot study suggests the possibility that feedback 
alone may be less effective than other methods of intervention, 
this thesis notes that studies combining reminders with 
feedback have tended to see their intervention group maintain 
a higher level of adherence. In contrast, studies using 
reminders only have tended to see a decline in adherence in 
their intervention groups. Whilst a large study of adherence as 
described above would be powered for feedback alone (with an 
expected effect size of 11%), combining feedback with 
automated reminders is likely to increase intervention impact 
and, consequently, effectiveness. A potentially greater 
distinction between control and intervention groups than that 
observed in the pilot study would increase the possibility that a 
difference in clinical outcomes between the groups may be 
observed.  
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In planning a study intervention, the ideal study would propose 
a mechanism for identifying participants who do not respond to 
the EMD-based intervention. It would then have a standardised 
way of assessing for common beliefs based on current evidence 
which are preventing formation of adherence habits and target 
them. Interventions to address such beliefs are likely to be 
more complex and not required in all participants. As 
incorporating them into an ideal study is likely to be 
challenging, the characteristics of participants identified as 
standing to benefit from more complex interventions could be 
collated and described to support future work in the area.  
Participants discussed the desire to see EMD-based 
interventions link in with data which gives them a sense of 
control over their asthma, such as trigger data. Incorporating 
such data is likely to maintain study engagement and may also 
provide initial data in this area. Much of these data can be 
provided using already-available apps in smartphones.  
7.2.4. Control arm of an ideal EMD-based study 
EMD-based adherence studies are difficult to control, 
particularly where monitoring is not covert. Whilst this thesis 
suggests blinding may not be essential to show EMD impact on 
adherence, it also suggests that inherent study biases such as 
a lack of blinding may lessen an intervention’s effect size by 
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increasing control group adherence. Furthermore, a Hawthorne 
effect may lead to EMD provision and study visits having an 
impact on some participants. Again, any resultant increase in 
control group adherence from this could lead to a reduced 
intervention effect size.  
Separately, because in an EMD-based intervention, the EMD is 
also the mode of measurement, lack of engagement may also 
lead to loss of study data. In the pilot study, five of the six 
participants lost to follow-up belonged to the control arm of the 
study. It may be that participants who are at higher risk of 
disengaging from the study process are also at higher risk of 
disengaging from health services and self-management 
practices. Loss of engagement of participants who are more 
likely to be poorly adherent could also lead to a reduced effect 
size.  
In an ideal study, the control group would not receive any input 
beyond usual care from a medical or research team with the 
exception of EMD provision and outcome data collection. Data 
should be collected with as light a touch as possible. User 
perspectives presented in this study suggest a possibility that 
engagement may be maintained by using the EMD as a platform 
for integrating other mHealth data. Collection of non-relevant 
electronic data such as heart rate might encourage continued 
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use of the electronic device in participants who may otherwise 
have disengaged and whose data may have consequently been 
lost.  
7.2.5. Outcome measurement in an ideal EMD-based interventional 
study 
Adherence should be defined as the proportion of ICS doses 
prescribed which have been taken. This should have a dosing 
time separation of at least 6 hours and be capped at 100% per 
dosing period. Overuse should also be reported. Feedback to 
users should distinguish between doses taken after midnight 
and doses taken on waking. Dosing effectiveness (e.g. quality 
of technique) should be investigated as a secondary outcome 
as, whilst it is intuitive that this would be superior to date-time 
measurement only, there is as yet no evidence to confirm this.  
This thesis has noted that, whilst an improvement in adherence 
of 13% is estimated across RCTs, effect sizes of this magnitude 
have not led to much significant change in clinical outcomes. 
Much of this ideal study design assumes that the issue has been 
poorly targeted, overly-heterogeneous sample selection and a 
lack of clarity of interventions. However it is also possible that 
the magnitude of effect size generally seen and powered for 
here is not large enough to see the sorts of improvements 
required. A subgroup analysis of individuals who do show a 
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response in adherence should therefore be assessed for 
translation of this response into clinical outcomes. Similarly, a 
subgroup analysis of individuals who have shown a response in 
clinical outcomes (if this occurs) should also be reviewed. These 
subgroups should be assessed for characteristics (e.g. degree 
of change in adherence, baseline asthma control and 
behavioural characteristics) which they might hold in common 
and might inform whom such an intervention should be targeted 
at in clinical practice. 
In addition to adherence, an ideal study would be powered for 
asthma exacerbations. These should be measured in terms of 
clinical symptoms and systemic steroid use. Other markers of 
deteriorating control or airways inflammation such as peak 
flow/forced expiratory volume in one second (FEV1), serum 
eosinophilia or fractional exhaled nitric oxide (FENO) may also 
be of use in quantifying the clinical response to improved 
adherence. FENO has already successfully been used to 
distinguish adherence from non-adherence (112). Subjective 
asthma control should be measured using derivatives of the 
Asthma Control Questionnaire (ACQ) and Asthma Control Test 
(ACT™).  
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7.3. Electronic monitoring technology beyond asthma 
Electronic adherence monitoring has been identified as holding 
promise beyond asthma. One such area is hypertension, which 
bears similarity to asthma as a largely asymptomatic disease 
with significant consequences for poor control resulting from 
poor treatment adherence (231, 232). Early systematic review 
suggested potential value in EMD-based or EMD-supported 
interventions, particularly for individuals identified as having 
‘drug-resistant hypertension’ (231). With only a few exceptions 
(233, 234), these studies were largely noted to be of short 
duration and low quality (231). Challenges which may bear 
significance in the asthma setting included the clinical relevance 
of observed changes in adherence (41, 233), the importance of 
targeting interventions at specific populations in order to see an 
improvement in adherence (235) and overcoming the 
Hawthorne effect (235, 236).  
Another area which may be more indicative of the ultimate goal 
for these systems may be to develop an asthma equivalent to 
intermittently scanned continuous glucose monitoring (isCGM), 
also known as flash glucose monitoring. This system integrates 
sensor technology with mHealth to reduce the need for 
recurrent skin pricks compared to traditional blood glucose 
monitoring (237-239) reducing costs related to blood glucose 
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monitoring (240). It potentially reduces the risk of alarm fatigue 
compared to real-time continuous glucose monitoring (rtCGM) 
systems (239), as well as reducing periods of hypoglycaemia 
(237, 238) with their associated healthcare costs. All this whilst 
achieving a similar level of blood glucose control to blood 
glucose monitors (239).  
These principles – integration of biomarker measurement with 
accessible interpretation leading to clinically impactful 
behaviour change – are not yet available in asthma, although 
some systems are approaching this (112). For EMDs, there 
remains a need to demonstrate to users the benefits of inhaler 
use and to communicate this in real-time in a way that effects 
behaviour change. A major challenge is that the benefits of ICS 
adherence occur over time and there are few specific 
biomarkers, other than peak flow, that are easily measurable 
outside of the clinical setting. Potential advances may include 
integration of environmental sensors to show more personalised 
benefit (209) or with other biomarkers such as FENO should its 
cost become less prohibitive in the future.  
7.4. Implications for future research 
This thesis highlights key challenges in study design including 
selection of individuals likely to benefit from intervention, 
measurement of baseline adherence, heterogeneity of 
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intervention and outcome measurement and issues with 
regards to EMD accuracy. It highlights the fact that these design 
challenges are not merely academic. Rather, they are likely to 
be important factors in the lack of consistent clinical outcomes 
data from studies in this field.  
There is a risk that adherence studies continue to be designed 
with no attention to either historic design flaws or patient 
perspectives, resulting in more data which still lacks definitive 
evidence of clinical effect, particularly in adults. An ideal study 
is described, but even with many of the design flaws identified 
by this thesis addressed and more effective interventions 
incorporating real-time reminders, feedback and targeted 
behavioural change proposed, it is unlikely that such a study 
would immediately pave the way to widespread uptake in 
clinical practice. Careful considerations such as cost-benefit 
analyses, data management and device accuracy are required 
and are discussed further below.  
Modern life is ever-increasingly connected, ever-increasingly 
digitised. This has been described as the ‘internet of things’, 
where not just computers and smart phones but home 
appliances, televisions and cars are part of this intangible 
network. There is a certain inevitability that this will extend to 
solutions in healthcare.  
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Technological development continues apace, outstripping the 
speed of traditional modes of evidence-gathering. Such a 
situation presents a real risk that a window of opportunity for 
employing  health technologies, including digital inhaler 
technology, for actual patient benefit will subsequently be lost 
(152). Future research assessing the benefits of adherence 
technologies should therefore seek to incorporate as much as is 
feasible and practical from the considerations presented by this 
thesis with the aim of impacting clinical outcomes i.e. control 
and exacerbations.  
Beyond this, this thesis presents a case for asking new 
questions and seeking new ways to answer them. As 
interviewed participants discussed the importance to them of 
maintaining a sense of power over their condition, the utility of 
increased awareness and the centrality of both beliefs and 
habits highlight not only potential mechanisms for improving 
adherence but also ways of engaging individuals in their own 
chronic disease management. It highlights the reality that, for 
a sizeable proportion of those individuals at greatest risk, a 
different approach to the one-size-fits-all interventions of the 
past is desperately needed in the same way that severe asthma 
management is now personalised and specific. 
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Studies until now have targeted adherence as upstream of 
outcomes but have rarely found ways to parse and measure 
outcomes which are upstream of adherence. Understanding this 
has been key to the success of digital monitoring in diabetes, 
where the outcome measure of interest became blood glucose 
monitoring frequency and measures of patient satisfaction, 
allowing their widespread real-world adoption and for clinical 
benefits such as reductions in HbA1c and glycaemic 
emergencies to be observed (241-243). 
In summary, this thesis suggests that, unless the appropriate 
population is engaged, appropriate interventions are used and, 
where required, more complex interventions are targeted 
according to an individual’s behavioural ‘phenotype’ (including 
past experiences, underlying beliefs and current habits), EMD-
based adherence studies are unlikely to see consistent 
improvements in clinical outcomes. New ways of assessing 
successful outcomes may also need to be employed if inhaler 
technologies in the long-term are to have any more usefulness 
than that of a digital gadget. 
7.5. Implications for future use and for clinical practice 
This thesis finds that there is currently inadequate evidence to 
suggest the use of EMD-based adherence interventions in 
clinical practice, particularly for adults. If the evidence for EMD-
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based adherence interventions can be strengthened, however, 
it does suggest the cohort likely to benefit will be those with 
poor baseline adherence, recent exacerbation and non-
adherence which is amenable to simple intervention. Of 
concern, however, there are individuals who have more 
complex behavioural needs and who have been highlighted to 
be at particular risk of poor outcomes (12). That some studies 
note a small group of individuals who, even when exposed to a 
successful intervention, appear resistant to change their 
behaviours suggests that these individuals may not respond to 
simple interventions (69, 99). 
This thesis did not include a health economic analysis. EMDs 
used purely to increase adherence are expensive (6, 154). 
Interviews conducted in Chapter 6 made it clear that not all 
consumers are willing to bear the brunt of the cost. Direct-to-
consumer sales models may thus exacerbate already-existing 
socioeconomically-driven health inequalities in asthma, but 
without strong evidence to support healthcare-wide adoption, 
this may be the model for the foreseeable future. Financial costs 
are not the only costs to consider. Incorporation of these 
devices into normal inhaler devices carries an environmental 
cost, as highlighted by some interviewed participants. Privacy 
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is another potential cost which, if these technologies are not 
carefully implemented, risks being a significant concern. 
The 21st Century has already demonstrated the dangers of 
assuming that the ethics of the digital space will evolve in a way 
that is beneficial to the individual. Whilst individuals may be 
happy to share much of their personal data in the current digital 
age, scandals such as the Facebook/Cambridge Analytica 
scandal and the Google DeepMind controversy demonstrate 
that general consent cannot be assumed and is not limitless. 
Healthcare data is sensitive and may place individuals in 
vulnerable position.  
Participants in this thesis have indicated that trust is key and 
that the purpose for which data is to be used and the 
organisations which will have access to and oversight of their 
data are important considerations. Once these have been made 
clear and appropriate protective measures are in place, many 
have no objections to data use and sharing. However such good 
will must not be exploited and this important issue which faces 
society as a whole cannot be ignored by researchers, clinicians 
or other stakeholders in this field. Privacy and the ethics of 
digital health data is an area into which careful research and 
investment are urgently needed. 
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The question of adherence monitoring as the sole use for EMDs 
may itself become obsolete. Cheaper ways of encouraging 
increased cumulative ICS exposure in the context of poor 
adherence, such as use of ICS/LABA (long-acting beta agonist) 
as reliever in mild asthma (24, 97, 244) and increased ICS dose 
during exacerbations (6, 245) are already gaining traction. The 
future use of these devices may therefore rely on their ability 
to anticipate the future of the digital space in asthma. Beyond 
adherence, this could include devices which have the potential 
to be integrated into self-management education, disease 
monitoring and control as well as treatment escalation and 
response. These uses will require the employment of qualitative 
research findings, such as those presented in this thesis, in 
order to understand more clearly what patients with asthma 
and their clinicians want from technology. It will also require 
the presentation of data outputs in ways that are interpretable 
for users with asthma, as well as standardised and clinically 
useful for their clinicians.  
Finally, these devices are only as useful as their data outputs 
are reliable. A major issue highlighted by this thesis was the 
significant failure rates of devices, both in Chapter 2 which 
reviewed previous literature, and in Chapter 4 where in-house 
validity testing was conducted. This is particularly an issue 
Page | 365  
 
where devices are employed to assist in treatment decisions. 
Clinicians in the real-world cannot be expected to conduct 
quality assurance processes. As the technology advances, it is 
expected that new models with greater capabilities will be 
produced. Ways of rapidly validating these models routinely and 




Smartinhaler™-like technologies and platforms hold significant 
promise; however, this promise remains unfulfilled. Current 
data suggests that this may not simply be due to a true absence 
of clinical effect. Study design factors and factors which may 
mediate between adherence and clinical outcomes may also be 
responsible. Considerations for EMD translation into clinical 
practice include reliability, consistent demonstration of clinical 
effect and output of accessible, meaningful data for both users 
and clinicians. 
Even more importantly, this thesis presents a pressing need to 
target interventions at individuals at greatest risk, who stand to 
benefit the most from using these technologies. As more simple 
interventions (such as maintenance and reliever therapy) 
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challenge the role of inhaler technology, the future may lie in 
its ability to integrate multiple platforms to engage the 
individuals for whom usual care is not preventing morbidity or 
mortality.  
This thesis concludes that, as they stand, the evidence for using 
Smartinhaler™-like technologies in clinical practice to improve 
adherence is inadequate. It furthermore concludes that they 
should only be used as adherence measures where local quality 
control procedures are feasible. 
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Appendix A: List of abbreviations 
ACQ Asthma Control Questionnaire 
ACT™ Asthma Control Test™ 
 
AE Asthma education 
app Application 
AQLQ Asthma quality of life questionnaire 
ASK Adherence Starts with Knowledge questionnaire 
ATS American Thoracic Society 
AVR Audio-visual reminder 
BDP Beclometasone diproprionate 
BMQ Beliefs About Medication Questionnaire 
BTS British Thoracic Society 
C-ACT Children’s Asthma Control Test 
CARAT Control of allergic rhinitis and asthma test 
CENTRAL Cochrane Central Register of Controlled Trials 
CES-D Centre for Epidemiological Studies Depression 
Scale 
CG Control group 
CI Confidence interval 
CINAHL Cumulative Index of Nursing and Allied Health 
Literature 
COPD Chronic obstructive pulmonary disease 
DAL Diskus Adherence Logger 
Doser CT Doser Clinical Trials Version 
ED Emergency department 
EMD Electronic monitoring device 
EMI Electronic monitoring of the intake of inhalation 
medication 
ERS European Respiratory Society 
FENO Fractional exhaled nitric oxide 
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FEV1 Forced expiratory volume in one second 
GINA Global initiative for asthma 
GP General practitioner 
GPS Global positioning system 
HADS Hospital anxiety and depression score 
HIV Human immunodeficiency virus 
ICS Inhaler corticosteroid 
ID Identity 
IEEE Institute of Electrical and Electronics Engineers 
IG Intervention group 
IgE Immunoglobulin E 
INCA Inhaler Compliance Assessment 
IPQ Illness Perception Questionnaire 
IQR Interquartile range 
IRF Inhaler reminders and feedback 
isCGM Intermittently scanned continuous glucose 
monitoring 
ISRCTN International Standard Randomised Controlled 
Trial Number 
ITT Intention to treat 
LABA Long-acting beta agonist 
LED Light-emitting diode 
MARS Medication Adherence Report Scale 
MARS-A Medication Adherence Report Scale for Asthma 
MART Maintenance and reliever therapy 
MDI Metered dose inhaler 
MEDLINE Medical Literature Analysis and Retrieval System 
Online 
mHealth Mobile health 
MID Minimally important difference 
MMAS Morisky Medication Adherence Scale 
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NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NRAD National Review of Asthma Deaths 
NRRD Nottingham Respiratory Research Database 
NRRU Nottingham Respiratory Research Unit 
OCS Oral corticosteroids 
PAD Personalised adherence discussion 
PAQLQ Paediatric asthma quality of life questionnaire 
PDC Proportion of days covered 
PEF Peak expiratory flow rate 
PRISMA Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses 
PS Problem solving approach 
RCT Randomised controlled trial 
ROI Republic of Ireland 
rtCGM Real-time continuous glucose monitoring 
SABA Short-acting beta agonist 
SD Standard deviation 
SES Socioeconomic status 
SIGN Scottish Intercollegiate Guidelines Network 
SMD Standardised mean difference 
SMS Short message service 
TIC Turbuhaler Inhalation Computer 
TX Texas 
U-BIOPRED Unbiased Biomarkers in Prediction of Respiratory 
Disease Outcomes 
UC Usual care 
USA United States of America 
USB Universal Serial Bus 
WHO World Health Organisation 
WMD Weighted mean difference 
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document. 
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Non-adherence with inhaled pharmacotherapy, generally 
manifesting as inhaled corticosteroid (ICS) underuse or short-
acting beta agonist (SABA) overuse1, is a well-recognised 
barrier to adequate control of asthma. As such, it has been 
linked with increased exacerbation rates2, hospitalisations3 and 
deaths4. Guidelines advise the assessment of adherence as part 
of routine asthma care, particularly when considering an 
escalation of therapy5, 6.  
Different modes of assessing adherence include prescription 
refill counting, canister weighing, dose meter counting and, 
more recently, the introduction of electronic monitoring with 
remote feedback. To our knowledge, there has not yet been a 
systematic review examining the current evidence base for 
these different modes of assessing adherence.  
Treatment modalities are advancing to increase the availability 
of niche, expensive therapies such as monoclonal antibodies 
and bronchial thermoplasty, with the potential for a greater side 
effect profile. This is occurring as the plateau in asthma death 
rates point to continuing concerns with the standards of basic 
care provided7. Consequently, it is more essential than ever to 
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ensure that patients with asthma obtain the maximum possible 
benefit from the evidence-based care they already receive. It is 
also important that healthcare professionals involved in asthma 
care are able to assess adherence effectively, both to avert 
adverse outcomes for their patients and to inform safe, effective 
management for ongoing care. 
Rationale 
This systematic review examines the evidence base for current 
modes of assessing adherence to inhaled corticosteroids, 
including novel electronic means. Although other reviews8 have 
assessed different methods individually, none has sought to 
systematically review all known objective methods as we are 
attempting to. It is therefore hoped that this will inform ongoing 
conversations around what constitutes accurate, effective, and 
good quality assessment which is feasible in the day-to-day 
clinical environment, so proving a useful tool for the healthcare 
providers in asthma.  
Objectives 
Study 1: A systematic review of electronically monitored 
adherence in clinical trials  
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1. To determine electronic monitoring methods for assessing 
adherence to inhaled corticosteroid therapy in adult asthma 
used in the literature. 
2. To determine the rate of ICS adherence found in the 
literature using electronically monitored adherence. 
3. To describe criteria used to analyse and report the 
effectiveness of these methods where effectiveness includes 
accuracy, reliability, change in self-management behaviours or 
change in clinical outcomes. 
4. To attempt to describe some universal criteria for 
analysing and reporting effectiveness of electronic monitoring 
methods of assessing adherence to inhaled corticosteroid 
therapy in asthma. 
Study 2: A systematic review of current methods of objectively 
assessing inhaler adherence in adults with asthma 
1. To determine objective methods of assessing adherence 
to inhaled corticosteroid therapy in adult asthma used in the 
literature. 
2. To determine the effectiveness of these methods when 
compared with the standard method at the time. 
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3. To describe criteria used to analyse and report the 
effectiveness of these methods where effectiveness includes 
accuracy, reliability, change in self-management behaviours or 
change in clinical outcomes. 
4. To attempt to describe some universal criteria for 
analysing and reporting effectiveness of methods of assessing 




Randomised controlled trials, quasi-experimental studies and 
cohort studies will be included. 
Adherence may be studied as part of a broader intervention. 
Consequently, any study where the effectiveness of a method 
of assessing adherence has been considered will be included.  
Studies will be limited to those with human participants. 
Participants 
Studies will be included where the study population have been 
pre-defined as adults having asthma of any severity. This 
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review will be limited to adults as management will differ 
significantly when clinicians deal with adults as opposed to 
dealing with the child/parent and adolescent dynamics. 
Interventions 
Any objective (i.e. not self-reported or physician-reported) 
method of assessing adherence to inhaled therapy including 
(but not limited to) integrated inhaler device dose counters, 
prescription assessment, canister weighing and electronic 
monitoring. 
Comparators 
Comparators may include other objective methods of assessing 
adherence or subjective methods of assessing adherence or no 
assessment of adherence.  
Outcomes 
Outcomes of accuracy of methods of assessing adherence, 
change in self-management behaviours or change in clinical 
outcomes may be reported. 
Identification of studies 
Electronic searches 
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Studies will be identified from the Cochrane Central Register of 
Controlled Trials (CENTRAL), MEDLINE group of databases, 
EMBASE, Web of Science, SCOPUS, CINAHL, PsychINFO and 
IEEE Xplore. 
Any unpublished studies where data collection and analysis is 
complete will be searched for using clinicaltrials.gov, 
BioMedCentral ISRCTN Registry and OpenGrey.  
Literature from 1950 onwards will be searched.  
The following search terms will be used: 
1. exp Asthma/ OR Asthma*.mp.  
2. (exp Nebulizers and Vaporizers/) OR (exp Asthma/dt) 
OR Inhal* OR Aerosol* OR Nebuli*  
AND 
(exp Patient Compliance/) OR Adher* OR Complian* OR 
Co?operat* OR Concord* OR Non?adher* OR Non?complian* 
OR Non?concord* OR Under?complian* OR Over?complian* 
OR Monitor*  
OR 
3. EMD OR Smartinhaler OR SmartTrack OR SmartTouch 
OR Nebulizer Chrono* OR Doser* OR Propeller OR MDILog OR 
Canister weigh* OR Prescription count* OR Refill count* OR 
Dose count*  
 
Data Collection and Analysis 
Study Selection 
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Search Results 
Two independent reviewers (IA and TM) will inspect citations 
retrieved from the searches and identify relevant abstracts for 
further screening as denoted by the eligibility criteria detailed 
above. Discrepancies will be discussed with the third reviewer 
(DS) who will make the final decision on inclusion/exclusion. 
Further Screening 
Two independent reviewers (IA and TM) will examine identified 
abstracts to assess further for fulfilment of the eligibility criteria 
and relevance to the study question. Where abstracts are not 
obtainable, the full article will be obtained instead. 
Disagreements will be discussed with the third reviewer (DS) 
who will make the final decision on inclusion/exclusion. 
Full Text 
Full texts will be obtained by the investigation team. IA will 
examine identified full texts for eligibility. TM will examine a 
10% sample to check that there is agreement.  Disagreements 
will be discussed with the third reviewer (DS) who will make the 
final decision on inclusion/exclusion. Where full texts are 
unavailable, it will be demonstrated that investigators made 
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every reasonable effort to obtain them and reasons for the 
unavailability will be documented. 
Data Extraction and Management 
Data Management 
Data will be managed using the Covidence online system 
(www.covidence.org, © 2017 Covidence, Melbourne). 
Data Collection 
Data will be extracted onto pre-designed forms which will be 
tested with a sample of papers for usability. 
Extraction will be performed by two reviewers. A third reviewer 
will also data extract 10% of included studies for validation 
purposes.   
Outcome measures 
Primary outcome 
Objectively monitored adherence rates in available data. 
Suggested gold standard method of assessing inhaler 
adherence in adults with asthma. 
Secondary outcomes 
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1. Comparative effectiveness of different methods of 
assessing adherence compared to standard at the time 
or drawn from this study.  
a. Mean or median difference between 
assessed method of adherence and gold 
standard method at the time (if applicable, 
gold standard previously reported or 
reported from the study results). 
b. Sensitivity and/or specificity reported for 
detection of (lack of) adherence. 
c. Positive and/or negative predictive values 
reported for detection of (lack of) 
adherence. 
d. Any other measure of accuracy. 





2. Any reported change in self-management behaviour 
(including adherence). 
3. Any reported change in clinical outcomes. 
4. Suggested characteristics of a gold standard method of 
assessing adherence. 
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Quality Assessment 
Risk of Bias 
Risk of bias will be assessed and reported descriptively using 
the Cochrane Collaboration’s tool for assessing risk of bias. The 
tool has been adapted by the study team to account for risk of 
bias in observational studies. 
Assessment of Heterogeneity 
Heterogeneity will be described at the following levels: 
1. The method used to assess adherence. 
2. The method used to analyse effectiveness. 
3. The standard against which effectiveness was 
assessed. 
4. How effectiveness was reported. 
5. The context of the study.  
Data Synthesis and Statistical Analysis 
It is not anticipated that it will be possible to perform a meta-
analysis of methods of assessing adherence in this review due 
to the anticipated small number of studies in this field and the 
multiple methods of assessment which are heterogeneous in 
their nature as well as their modes of measurement and 
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reporting. Instead, a narrative synthesis will be provided based 
on the context of assessment of adherence, the mode of 
assessment of adherence, the suitability of that mode for the 
context in which it was provided, the effectiveness of that mode 
(whether as denoted by studies using it or by a means of 
assessing effectiveness derived from this review) and whether 
there is enough evidence to recommend its use in routine 
clinical practice. 
Potential outcomes for a future meta-analysis may be 
suggested should common themes occur.  
Subgroup Analysis 
This review will also separately analyse the primary outcome in 
the following groups known to be poorly adherent: 
• Ethnic minorities 
• Low socioeconomic status 
• “Difficult” asthma (poorly controlled, severe or 
resistant) 
Any randomised trials directly comparing two or more methods 
of assessing adherence and any trials directly comparing two or 
more methods of assessing adherence will also be analysed 
separately. 
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Any studies judged as “high quality” will be analysed separately. 
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Appendix C: Pilot study protocol  
Clinical Investigation Title:  
IMPROVING ASTHMA TREATMENT USING INHALER TECHNOLOGY 
  
Short Study Title:  
INHALER TECHNOLOGY STUDY 
 
A 2-arm feasibility study to assess whether inhaler electronic monitoring and 
feedback technology is patient-friendly and cost effective in three main areas of 
asthma care: inhaler adherence, treatment decisions, and the prediction and 
prevention of asthma exacerbations.  
 This protocol has regard for the HRA guidance 
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SIGNATURE PAGE 
The undersigned confirm that the following protocol has been agreed and accepted and that 
the Chief Investigator agrees to conduct the study in compliance with the approved protocol 
and will adhere to the principles outlined in the Declaration of Helsinki, the Sponsor’s SOPs, 
and other regulatory requirement. 
I agree to ensure that the confidential information contained in this document will not be 
used for any other purpose other than the evaluation or conduct of the investigation without 
the prior written consent of the Sponsor 
I also confirm that I will make the findings of the study publically available through publication 
or other dissemination tools without any unnecessary delay and that an honest accurate and 
transparent account of the study will be given; and that any discrepancies from the study as 
planned in this protocol will be explained. 
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This CIP describes the Inhaler Technology Study clinical investigation and provides 
information about procedures for entering participants.  Every care was taken in its drafting, 
but corrections or amendments may be necessary. These will be circulated to investigators in 
the clinical investigation team.  Problems relating to this clinical investigation should be 
referred, in the first instance, to the Chief Investigator.  
 
This clinical investigation will adhere to the principles outlined in the NHS Research 
Governance Framework for Health and Social Care (2nd edition). It will be conducted in 


















Date Issued Author(s) of 
Changes 




1.1 21/11/16 Ireti Adejumo Inclusion of REC 
number 
Draft timeline update 
Updates of version 
number and date  
7 (SA3) 1.2 24/08/17 Ireti Adejumo  Title page: 
Inclusion of ISRCTN 
number  
7 (SA3) 1.2 24/08/17 Ireti Adejumo Pg 21 (Section 9): 




7 (SA3) 1.2 24/08/17 Ireti Adejumo Pg 23 (Section 10.1); 
Pg 27 (Section 12.3) 
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Recruitment 
broadened to include 
respiratory wards, 
Accident and 
Emergency and poster 
display throughout 
NUH sites. 
7 (SA3) 1.2 24/08/17 Ireti Adejumo Pg 47 (Appendix 1): 
Draft study 
timeline/target dates 
changed to reflect 
study start December 
2016  
8 (SA4) 1.3 16/10/17 Ireti Adejumo Addition of 
SmartTurbo™ device 
10 (SA5) 1.4 22/03/18 Ireti Adejumo Pg 23 (Section 10.1) 
and Pg 27 (Section 
12.3) addition of GP 
PIC and research sites 
as sites for consent 
and study procedures 
10 (SA5) 1.4 22/03/18 Ireti Adejumo Pg 26 (Section 11.1) 
broadening research 
sites to East Midlands 
Primary Care CRN 
10 (SA5) 1.4 22/03/18 Ireti Adejumo Pg 47 (Appendix 1): 
Study extension 
10 (SA5) 1.4 22/03/18 Ireti Adejumo Reformatting 
document for Word 
2016 and addition of 
new abbreviations to 
list. 
11 (SA6) 1.5 09/11/18 Ireti Adejumo Pg 23: recruitment 
broadened 
11 (SA6) 1.5 09/11/18 Ireti Adejumo Pg 27: recruitment 
broadened 
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Asthma Control Test 
Asthma Control Questionnaire 
CI Chief Investigator 
CIP Clinical Investigation Plan 
CRF Case Report Form 
CRN Clinical Research Network 
CT Clinical Trial 
CTA Clinical Trial Authorisation 
EC Ethics Committee (see REC) 
GCP Good Clinical Practise 
GP General Practitioner 
GTAC Gene Therapy Advisory Committee 
IB Investigator Brochure 
ICF Informed Consent Form 
ICH International Conference of Harmonisation 
IEC Independent Ethics Committee 
IMP Investigational Medicinal Products 
IRB Independent Review Board 
MHRA Medicinal Health Research Authority 
NHS National Health Service 
NRES National Research Ethics Service 
PI Principle Investigator 
PIC Participant Identification Centre 
PIS Participant Information Sheet 
R&I Research & Innovation 
REC 
SABA 
Research Ethics Committee 
Short Acting Beta Agonist (s) 
SAE Serious Adverse Event 
SAR Serious Adverse Reaction 
SmPC/SPC Summary of Products Characteristics 
SOP Standard Operating Procedure 
SUSAR Suspected Unexpected Serious Adverse Reactions 
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CLINICAL INVESTIGATION SUMMARY 
Clinical Investigation 
Title 




Clinical Phase 4 
Clinical investigation 
Design 
2-arm feasibility study using inhaler technology to monitor inhaler use in 
participants with asthma:  
A) monitored with no feedback to participants (control);  




Age 18 to 65 inclusive; physician diagnosis of asthma for at least 12 
months; prescribed ICS therapy; on BTS Step 2 to 5 treatment; asthma 
attack requiring systemic corticosteroids in the previous 12 months 
Planned Sample Size This is a feasibility study of 50 patients (25 each to active and control).  
We also aim to engage approximately 30 of these patients (15 from 
active and 15 from control) in qualitative evaluation. 
Number of Participants 50 and 30 of these in qualitative interviews. 
Follow-up Duration 6 months 
Planned Clinical 
investigation Period 
Overall 3 years study duration from approval to include 18 months 
recruitment and ; 6 months participation per patient 
Primary Objective We will assess whether the use of Inhaler Technology to monitor and 
feedback on patterns of medication use can improve preventer inhaler 
adherence and reduce reliever inhaler overuse. 
Secondary Objectives We will assess whether Inhaler Technology is patient friendly and cost 
effective, aid with asthma treatment decisions, and with the prediction 
and prevention of asthma exacerbations 
Primary End points Adherence (preventer treatment): The mean percentage of prescribed 
doses taken daily over the study period  
i.e. If 2 of 4 prescribed doses taken on day 1, this is 50%; calculate this 
daily for duration of study period and then average [Sum daily % 
adherence and divide by number of days of treatment] [as per Foster 
JACI 2014] 
Reliever Use: The number of days with >16 actuations/day of 
Salbutamol taken in a 24-hour period 
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Rationale: in a prior study, we used >16 actuations as a threshold of 
SABA use at which self-management plans recommended medical 
review [Patel TLRM 2013] 
Secondary End points Improving asthma treatment 
Studying patient factors for over/under treatment. 
Assess adherence with standard care asthma treatment. 
Identify need for stepping up/ down treatment based on inhaler use 
versus symptoms. 
Assess capability of technology in real world patients with asthma. 
Patient feedback and healthcare utilisation 
Design system of feedback to patients and assess its ease of use, 
uptake and feasibility. 
Identify triggers for asthma review and treatment change. 
Compare costs of Inhaler Technology regime with current costs of 
routine asthma management. 
To calculate power needed for design of definitive exacerbation 
prediction study using this technology 
Device Name SmartTouch™ 
SmartTurbo™ 
Manufacturer Name Smartinhaler™ by Adherium 
Principle Intended Use To monitor inhaler use and send data wirelessly to Smartinhaler™ apps 
and software.  
Length of Time the 
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The development of new asthma inhalers embedded with technology enabling automated 
capture of real time data allows us to explore patterns of inhaler use and to relate this to other 
important factors related with asthma control, rather than relying upon time consuming and 
laborious measures such as peak flow, questionnaires and prescription counting to determine 
asthma treatment, symptom control and compliance. New data that can be captured include 
time of activation and number of activations. When an electronic monitoring inhaler is 
combined with a smart phone the place of activation can also be obtained allowing other data 
streams to be collated, including weather, temperature, pollution exposure, traffic exposure, 
pollen/fungal exposure and patterns of viral infection in the environment. 
Recent studies have studied the use of mobile phone-enhanced asthma self-
management(246) and the use of inhaler technology-based medication reminders and 
feedback in primary care asthma patients(68).  In both studies, participants were selected on 
the basis of having poorly-controlled asthma (defined by ACQ or ACT), but approximately two-
thirds had mild asthma (Step 0-2(246)) or had not required a course of oral corticosteroids in 
the prior 12 months(68). In both studies, interventions involved intensive (twice-daily) 
recording or reminders. Results showed no significant improvements in asthma control 
compared to the usual-care groups. From these studies, it may be concluded that the 
application of technology to clinical practice is limited by practicality (need for intensive data 
collection or feedback) and cost effectiveness (selection of a broad range of participants with 
predominantly mild asthma, in whom the occurrence of attacks requiring the greatest 
healthcare resource is relatively uncommon). At present, the evidence suggests that the use 
of inhaler technology-based feedback may not be cost effective or practical to implement when 
applied to patients with predominantly mild, poorly controlled asthma.  The generalizability of 
these findings are limited by the use of self-report (rather than electronic monitoring) to 
measure medication use(246) and the high-intensity reminders and adherence feedback 
processes(68).   
However, adherence to inhaled corticosteroids (ICS) was improved by the use of inhaler 
technology(68). This suggests that cost-effectiveness may be improved in the sub-group of 
patients most at risk of healthcare utilisation [patients with prior recent severe exacerbations], 
if the cost of the use of technology is balanced by a reduction in healthcare utilisation based 
on severe exacerbations. This may be possible if a link can be demonstrated between 
improved inhaler adherence using inhaler technology and reduced asthma attacks, in patients 
at-risk of these events. This is important because it is already well-recognised that poor 
adherence to asthma treatments commonly occurs in patients with difficult asthma3.    With 
the availability of new biological treatments for severe asthma on the horizon, evidence of 
optimisation of adherence to inhaled therapy in patients with moderate to severe asthma will 
be crucial prior to prescription of these expensive novel agents. This point is emphasised in a 
recent editorial4 of an anti-IL5 Mepoluzimab study5, in which there was a 50% reduction in 
severe exacerbations in the placebo group. This is likely partly attributable to improved 
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adherence to inhalers because of involvement in a clinical trial, illustrating the concept that 
improvements in inhaler adherence in this at-risk patient group can help to improve asthma 
outcomes. 
The hypothesis is that the use of Inhaler Technology to measure both preventer and reliever 
medication use and guide patient feedback improves adherence and potentially clinical 
outcomes (asthma control and exacerbations), and is cost-effective, when used in asthma 
patients with recent asthma attacks in a practical, real-world setting. 
We will recruit 50 patients with mild to severe asthma and issue them with Electronic monitors 
for both short acting beta agonists (SABA) and inhaled corticosteroids (ICS) and follow them 
for six months.  
We will assess whether this technology is patient friendly and cost effective in three main 
areas of asthma care; adherence, treatment decisions, and the prediction and prevention of 
asthma exacerbations. We intend to improve adherence, treatment decision making and 
patient self-management. 
 
RATIONALE FOR CURRENT STUDY 
Adherence 
Adherence is a key issue in asthma. Studies have shown that patients over-report use of ICS; 
one study found that the median use of ICS reported by patients in their diaries was 95%, 
whereas the median actual use was 58% and more than 90% of patients exaggerated their 
ICS use6. Adherence with ICS therapy is associated with lower mortality rate in asthma7, 
whereas reliance on SABAs is associated with increased mortality8. The recent National 
Review of Asthma Deaths (NRAD) report published in May 20149 highlighted that on average, 
80% of patients who died of asthma over a 1-year period in the UK had been prescribed less 
than 1 preventer inhaler per month. In addition, this study9 found that almost 40% of patients 
who died of asthma had been prescribed more than one reliever inhaler per month. 
We will compare prescribed SABA and ICS use with actual treatment use and explore factors 
for under- and over-use. 
 
Treatment Decisions 
In the UK 80% of patients with a diagnosis of asthma are managed solely in primary care 
where both the diagnosis and decision to increase or decrease treatment is based upon self-
reported asthma symptoms. Treatment decisions are made at regular reviews conducted by 
a nurse or doctor. This system of assessment leaves little flexibility in a highly heterogeneous 
disease10, and treatment is often not stepped down quickly or appropriately11.  
We will assess whether electronic inhaler data capture can identify patients requiring more 
frequent reviews or treatment change and enable proactive self-management. 
Exacerbation Prediction 
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Predicting asthma exacerbations (attacks) is a key goal in asthma research. We will assess 
whether electronic monitoring technology can be combined with other data sources to build a 
complete enough picture to begin to understand exacerbation triggers in real-time.  
 
 
Inhaler Monitoring Device 
The Smartinhaler (SmartTouch™/SmartTurbo™) range of electronic monitors will be used to 
record the use of inhalers by participants in the study. The monitors are manufactured by 
Adherium Limited, Auckland, New Zealand (http://adherium.com/). Please see the attached 
product data information sheet provided by the manufacturer for technical specifications 
Appendix 2. The device will fit around the patient’s existing inhaler, and will record the date 
and time of each actuation. Data is regularly and automatically transferred, via Bluetooth 
connection, to the Smartinhaler App™ or Smartinhaler Lite App™ on the patient’s internet-
enabled phone. The phone will be installed with the appropriate app at the first study visit. The 
app manages the transfer of data. The actuation use data is then transferred from the phone 
to a secure website-based database, via the internet, using WiFi connection or the internet 
connection via mobile phone. Investigators can then remotely view and download data from 
the website. 
 
The devices are compatible with the following MDIs: Fostair® (beclomethasone/formoterol), 
Seretide® (fluticasone/salmeterol), Ventolin® (salbutamol), Salamol® (salbutamol). They are 
also compatible with the following Turbohalers: Symbicort® (budesonide/formoterol), 
Bricanyl® (terbutaline) and Pulmicort® (budesonide). 
 
The manufacturer advises us that the devices are CE marked and for this clinical investigation 
SmartTouch™/SmartTurbo™ will be used in accordance to their directions for use.  
 
The manufacturer will provide technical support throughout the study. Initial training on the 
use of the device can be provided by the manufacturer. Dr Shaw and Dr Patel both have 
experience with the use of this type of electronic monitoring technology from previously-
conducted studies.  
 
 




The hypothesis is that the use of electronic monitoring technology to measure both preventer 
and reliever medication use and to help provide patient feedback improves inhaler adherence 
and potentially clinical outcomes (asthma control and exacerbations) when used in asthma 




To assess the utility of electronic monitor-guided care on exacerbation prediction and patient 
acceptability of use. Cost effectiveness established if scalable from qualitative work. (i.e. 
barriers to adoption)  
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1. Preventer use: The mean percentage of prescribed doses taken daily over the study 
period  
i.e. If 2 of 4 prescribed doses taken on day 1, this is 50%; calculate this daily for duration 
of study period and then average [Sum daily % adherence and divide by number of days 
of treatment](68) 
2. Reliever Use: The number of days with >16 actuations/day of Salbutamol taken in a 
24-hour period. 
Rationale: in a prior study, we used >16 actuations as a threshold of SABA use at which 




Secondary Outcomes: medication use (Categorised by preventer and reliever medication) 
1. Number of days of preventer non-adherence (0 actuations per 24 hours) [expressed 
as a rate: number of days/days of treatment]  
2. Number of days of 100% preventer adherence (when all prescribed doses taken) 
3. Mean % of prescribed preventer dose taken daily by month (month 1 to 6) 
4. Number of days of overuse of preventer treatment (when more than daily prescribed 
doses taken i.e. >2 or >4/day) – this is likely to occur in a subset of patients who 
perceive symptom relief with LABAs and use their combination inhaler for relief or 
alternatively make up for missed doses  
5. Mean daily ICS (preventer) dose (total number of actuations over study period 
multiplied by dose per actuation) divided by number of days of treatment exposure. 
6. Overuse of SABA (reliever): Number of days of >24 and >32 actuations of salbutamol 
in a 24 hour period 
7. Number of days of zero SABA use (reliever) 
8. Derive power calculation for full study, based on adherence 
 
Secondary outcomes: clinical control 
1. Number of exacerbations (treatment with systemic corticosteroids for asthma or 
antibiotics)  
2. FEV1 (spirometry) 
3. Asthma Control Test (ACT) Score 
4. Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) 
 
 
Secondary outcomes: treatment decisions 
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1. Patient views/attitudes to monitoring/ feedback* 
2. Understand patient factors around using devices* 
3. Ease of use/ patient acceptability* 
4. Studying the utility of differing thresholds for feedback (e.g. ICS adherence of <75% 
or <80%; salbutamol thresholds based on number of days of at least one salbutamol 
actuation or maximal daily number of actuations) 
5. Study practicality of data feedback processes 
6. Episodes where advice provided to seek GP/clinical review based on monitoring 
data; and, episodes when participants actually sought review subsequently  
* assessed via interview at final visit.   
 
CLINICAL INVESTIGATION DESIGN 
The study is collaboration between experts in asthma, statistics and human factors and builds 
upon previous work in this area performed by the investigators. The work will take 3 years, 
which includes 18 months patient recruitment for a six month study. 
 
 
Recruitment and Consent 
We will initially recruit from our severe asthma service clinic and general respiratory clinics, 
respiratory wards, acute admissions wards and Accident and Emergency across NUH 
Trust. We will also recruit via the Nottingham Respiratory Research Unit database of research 
volunteers, and utilising primary care PIC and research sites in both Nottingham City and 
County areas, as well as putting posters up in public places, at the University of Nottingham 
and around Nottingham University Hospitals NHS Trust.  We will recruit 50 patients at 
BTS Step 2-5. 
 
Patients aged 18-65 inclusive will be initially approached by a healthcare professional in clinic, 
or via a letter (if patients have signed up to the NRRU approved database), or through primary 
care PIC sites (through posters). Potential participants will have the opportunity to read an 
information sheet and given time before consenting to the study. Current best practice for 
clinical studies will be followed. Patients must have a doctor diagnosis of asthma for 12 months 
and be prescribed an inhaled corticosteroid. All patients will require access to their own 
internet-access enabled mobile phone.  
 
Once recruited, patients will be assessed at the dedicated clinical studies unit within the 
Nottingham Respiratory Research Unit, or at their local GP practice where this is a PIC or 
research site, at a time convenient to the patient. A brief clinical history will be taken. Asthma 
control will be assessed by Asthma Control Test (ACT) questionnaire and treatment continued 
as per current guidelines. Asthma Quality of Life will be measured by the mini Asthma Quality 
of Life Questionnaire (mini AQLQ).  Spirometry with reversibility will be undertaken according 
to a standardised protocol. Baseline data on asthma phenotype will be collected from the 
patient’s medical record where available (e.g. prior eosinophilia, Skin prick test results, 
exhaled nitric oxide, IgE). Randomisation will occur and the electronic monitors will then be 
fitted to the inhaler. Inhaler technique will be checked and patients issued with contact details 
for the study team. 
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Patients will be allocated to one of two groups in order to study the effects of being monitored 
and having feedback.  Establishing these differential effects will be crucial in understanding 
any future impact of Inhaler Technology.  The groups will be as follows: 
 
Group A: (control) a monitored group where patients have their dosing monitored but have 
no feedback on inhaler usage  
 
Group B: (active) a feedback group where inhaler usage is openly monitored, and with 




In the control group, participants will be informed that they have been provided an inhaler 
that can measure medication use over the study period and allow this information to be 
studied alongside symptoms as measured by ACT. In order to obtain medication use data in 
an unbiased format, participants will not be told that their inhalers can record patterns of 
medication use. The Smartinhaler Lite™ smartphone application which they will have 
installed will not provide access to their own adherence data. 
This method involves minimal risk to the patient, because we are just recording/observing 
current usual inhaler use. Because treatment use may be affected by knowledge of being 
monitored, this method benefits from allowing the most accurate method to measure 
medication use in the control group. In prior similar situations where the (minimal) risk of 
covert monitoring has been outweighed by the benefit of unbiased data collection, ethics 
approval has been obtained [Foster JACI 20142, page e1, ‘Electronic inhaler monitoring’: 
patients in the control group were told that the monitors were to ‘help keep track of patient’s 
asthma control’ and the monitors were not labelled by their commercial name]. At the final 
study visit, patients will be informed of the recording capabilities of the monitors, provided 
with a summary of their adherence data and have the opportunity to discuss this with a 




In the active group, feedback will be given by an investigator (research nurse or PhD student) 
via a phone call every 4 weeks if adherence is outside pre-set thresholds based on the results 
of the inhaler tracking over the prior study month. The phone call will include a discussion of 
adherence data, and advice to contact the patient’s GP/nurse in the setting of worsening 
asthma. The format below will be used as a guide during feedback: 
 
 ‘Your preventer inhaler has been used for less than half the recommended number 
of doses over the past 4 weeks. This could lead to your asthma getting worse or 
not being as well controlled as possible.’  And/or 
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  ‘Your reliever inhaler has been used often during at least one week recently. This 
could mean that you asthma is not being as well controlled as possible’.  
 
A copy of the adherence data will be sent to the GP if clinical review is suggested.  
 




All Patients will be seen at visit 1 (week 0, baseline) and at visit 7 (week 24, end of study), 
giving a total of 2 visits to site per patient.   
 
All patients will complete follow-up questionnaires every 4 weeks i.e. Visit 2-6 (Weeks - 4,8,12, 
and 20) remotely (e.g. by telephone call, email, or online web-based survey). Questionnaires 
will include the ACT and mini AQLQ and questions on changes to treatment will be asked.  If 
a participant does not return the questionnaire data, then they will be contacted via 
phone/text/email to remind them to complete this. 
 
All patients will be advised to seek help from their GP if they suffer from poor control. In the 
event of an asthma emergency, patients will seek urgent care as per usual, via 999, the GP 
or Emergency Department. 
 
CLINICAL INVESTIGATION POPULATION 
Number of Participants 
50 participants, sites Nottingham Respiratory Research Unit and East Midlands primary 
care CRN, 24 months recruitment time for a 6 month person follow-up time. 
 
Inclusion Criteria 
 Age18-65 inclusive 
 Use of systemic corticosteroids for worsening asthma (or an increase from baseline 
dose in patients on long-term oral corticosteroids) in the prior 12 months [i.e. at least 
one asthma exacerbation requiring additional systemic corticosteroid in the prior 12 
months] patient reported.  
 Doctor’s diagnosis of asthma for at least 12 months 
 On BTS step 2-5 treatment via MDI [monitoring devices to be utilised in the study are 
compatible with MDI inhalers] 
 Use of own internet-enabled and compatible mobile phone 
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 Participant is willing and able to give informed consent for participation in the clinical 
investigation. 
 Able (in the Investigators opinion) and willing to comply with all clinical investigation 
requirements. 
 Willing to allow his or her General Practitioner and consultant, if appropriate, to be 
notified of participation in the clinical investigation. 
 
Exclusion Criteria 
 Diagnosis of COPD or onset of symptoms after the age of 40 in patients with ≥10 
Pack Year History of smoking 
 Other clinically significant coexisting respiratory disease e.g. fibrosis, bronchiectasis 
 No personal mobile smartphone 
 Patients on maintenance and reliever therapy (‘SMART’ or ‘Fostair® MART’) 
 Any other significant disease or disorder which, in the opinion of the Investigator, 
may either put the participants at risk because of participation in the clinical 
investigation, or may influence the result of the clinical investigation, or the 
participant’s ability to participate in the clinical investigation. 
 
PARTICIPANT SELECTION AND ENROLMENT 
SCREENING FOR ELIGIBLE PARTICIPANTS 
Demographics 
The date of birth, gender, smoking and asthma and clinical history in keeping with the 
inclusion/exclusion criteria will be recorded.  
 
Medical History 
Details of any history of disease or surgical interventions in the following systems will be 
recorded: asthma and general medical. 
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All prescription medication will be recorded.   
 
Trial / study configuration 
Single centre study, but GP practices may act as Patient Identification Centre sites as they 
may display a poster advertising the study as will the University of Nottingham campus.  
 
Recruitment 
The study will be conducted by the Nottingham Respiratory Research Unit at Nottingham City 
Hospital. Patients will be recruited from clinics, existing volunteer databases, NUH (and 
specifically respiratory wards and Accident and Emergency) and primary care PIC and 
research sites or University of Nottingham. Recruitment posters will be displayed in public 
places. Visits will be conducted at the Respiratory Research Unit or at participating primary 




The participant must personally sign and date the latest approved version of the informed 
consent form before any study procedures are performed. 
Written participant information sheets and Informed consent forms will be presented to the 
participants detailing no less than: the exact nature of the clinical investigation; the implications 
and constraints of the clinical investigation plan; the known side effects and any risks involved 
in taking part.  It will be clearly stated that the participant is free to withdraw from the clinical 
investigation at any time for any reason without prejudice to future care, and with no obligation 
to give the reason for withdrawal. 
 
The participant will be allowed as much time as wished to consider the information and the 
opportunity to question the Investigator, their GP or other independent parties to decide 
whether they will participate in the clinical investigation.  Written Informed Consent will then 
be obtained by means of participant dated signature and dated signature of the person who 
presented and obtained the informed consent. The person who obtained the consent must be 
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suitably qualified and experienced, and have been authorised to do so by the Chief/Principal 
Investigator. A copy of the signed Informed Consent and accompanying participant 
information sheet will be given to the participants and a copy filed in the medical notes.  The 
original signed form will be retained within the Investigator Site File.  
 
The investigator will inform the participant of any relevant information that becomes available 
during the course of the study, and will discuss with them whether they wish to continue with 
the study. If applicable they will be asked to sign revised consent forms. If the Consent Form 
is amended during the study, the investigator shall follow all applicable regulatory 
requirements pertaining to approval of the amended Consent Form by the REC and use of the 
amended form (including for on-going participants). 
 
Specific  
To obtain objective medication use data in the control group (Group A), participants will not 
be told of the exact capabilities of the monitor to record patterns of medication use. This 
approach has received ethical approval previously(68). The process of consent will follow the 
published guidance about blinding of device studies and ethics for randomised trials of non-
pharmacological interventions, as per Boutron et al13: 
‘Blinding participants to study hypotheses could also be proposed when the comparator is an 
active control treatment of the same nature or different nature by use of a modified Zelen 
design. Such design is a two-stage procedure, in which patients are asked to provide consent 
for an observational study in the first stage. Then patients are randomized to the experimental 
treatment and the control arm, and in the second stage are asked to provide a second consent 
for treatment.’ 
The process will be as follows: 
1. Potentially eligible participants will be informed that the study is investigating the use 
of technology in asthma and that this involves use of an inhaler that will ‘help keep 
track of asthma control’(68). Participants will be blinded to detailed study hypotheses 
and outcomes.  
2. Eligible patients will be consented and then randomised. 
3. Patients randomised to the control group will continue as per Group A; patients 
randomised to groups B will be provided further information about the active arm and 
will then be asked to sign an additional consent form.  
 
The NPSA has provided guidance on the practice of withholding information in medical 
research (http://www.hra.nhs.uk/documents/2013/09/ige-paper-deception-in-medical-
research.pdf). Withholding information may be permissible if: 
1. ‘no other research method would suffice’ 
2. The subject is not exposed to anything other than ‘minimal risk’ 
3. Debriefing occurs at the end of the study 
4. The rationale for the planned withholding of information is clearly justified and 
supported by scientific expert review.   
5. This study meets the above requirements. 
 
Randomisation and Blinding 
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Feedback of medication use 
 
ICS low-adherence: Low adherence defined as more than 14 days (i.e. 15 days or more) 
[over the preceding 4 weeks] on which there was less than 50% ICS adherence per day 
[Suissa NEJM7: ‘The rate of death from asthma among users of inhaled corticosteroids as 
compared with nonusers was reduced by about 50% with the use of more than six canisters 
per year i.e. >6 canisters over 12 months, >50% adherence]. 
 
Reliever use:  ≥ average 6 actuations of salbutamol per day during any one week over the 
preceding 4 weeks [i.e. categorise the preceding 1 month into 4 one-week windows and 
calculate the average daily salbutamol use for each of these 4 windows]. Average daily 
salbutamol use is a significant predictor for future severe asthma exacerbations14.  In 
comparison to a patient with no salbutamol use over 2 weeks, a patient using an average of 
six inhalations of salbutamol per day has twice the odds for a severe asthma exacerbation in 
the next 6 months14.  6 inhalations of salbutamol per day equates to approximately one 
canister of salbutamol per month, which is associated with twice the odds of death or near 
death compared to no salbutamol use15. 
 
ACT scores will be collected but this data will not be used to determine feedback calls. This 
information will be analysed as an outcome of the study to determine the relationship 
between ACT score, medication use and feedback options.  
 
Qualitative data 
Research methods will include surveys and interviews with patients. 
 
Semi-structured interviews will be arranged at the end of the 6 month period with the sub-
sample of patients who provided consent to take part at the point of recruitment. 
Approximately 30 patients will be interviewed (15 active, 15 control). Should more patients 
provide consent than required, we will purposively sample patients to ensure varying levels 
of adherence (both observed and subjective as measured by an adherence questionnaire 
such as the Medical Adherence Report Scale – Asthma or ‘MARS-A’) and varying ACT 
scores are included.  
 
Semi-structured interviews will be conducted either face-to-face or via telephone. To 
minimise study burden, we will strive to coincide face-to-face interviews with the final visit.  
 
The semi-structured interview guide will explore patients’ views of the device, including the 
ease of use, social acceptance, portability, practicality and aesthetics. The guide will cover 
topics around what patients thought about being monitored, data sharing and communication 
and feedback related to the monitoring. It will also ask about how views on being ‘tracked via 
GPS’ for future projects. Finally, the guide will also consider areas for improvement, 
particularly with regards to how the device, communication and feedback could be improved 
to increase patient engagement.  
 
We will continue to recruit until we reach saturation of new opinions and themes being 
generated from each group of patients.  
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Qualitative Data Analysis 
Interviews will be digitally audio-recorded and transcribed verbatim. This will be carried out, 
in the first instance, by the PhD student under the supervision of Dr Manpreet Bains 
(associate professor of health research University of Nottingham). A proportion may also be 
carried out by a university approved external transcription service.  Data will be stored and 
managed using NVivo® software. Following receipt of the transcripts, the researchers will 
ensure all personal identifiers are removed and that transcripts are accurate. Participants will 
be assigned a code that will only identify the group they represent (active, control). Data 
generated from the interviews will then be analysed (by the PhD student and Dr Manpreet 
Bains) using the framework approach17 which is a hierarchical, matrix based method 
developed for applied or policy-relevant research which allows focused interrogation of data. 
The framework approach will allow the research team to map whether there are 
differences/similarities according to the individuals sampled (active, control, adherence 
level). Data will be coded using inductive approaches, where the familiarisation stage will 
enable the identification of themes and sub-themes. Data will then be indexed according to 
the identified themes and sub-themes. Themes and sub-themes will then be discussed 
between the research team, which will allow clarification of the final framework. Using 
NVivo® software, data will then be charted according to each theme to synthesise the data 
and aid interpretation. Extracts from interviews will be included in the charts. 
 
Study outcome measures  
Patients will have 6 months follow-up in the study. For all patients, individual feedback 
regarding patterns of medication use will be provided in summary format at study 
completion, with an opportunity to discuss with the study research nurse or PhD student. 
Participant reimbursement 
£20 (total) per participant will be provided to cover the cost of data charges/text 
messages/phone calls, and for travel.  
 
Withdrawal of Participants 
Any patient is able to withdraw from the study at any point. For patients who withdraw prior 
to study completion, a final close-out visit will be requested with the patient.  The data 
collected so far will still be used in the final analysis of the study.  Participants who lose 
mental capacity during the study will be withdrawn, but their data collected up to that point 






SmartTouch™, CE Marked 
SmartTurbo™, CE Marked 
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Adherium, Suites 205-206, 8 Commerce Street, Auckland 1010, New Zealand 
 
MARKETING AUTHORISATION HOLDER 
Adherium, Suites 205-206, 8 Commerce Street, Auckland 1010, New Zealand 
 
Device Accountability 
Inhaled medication for asthma 
Patients will continue on their usual prescribed inhaled preventer and reliever medication.  
Electronic monitoring of MDI use has an established track record in clinical studies2,16. 
Monitoring of use of other inhaler devices is less well established.  Patients who use MDI 
inhalers only will therefore be recruited.  Patients will obtain replacement inhalers from their 
usual primary/secondary care doctors. At the first visit, patients will be shown how to fit the 
monitoring device to their inhaler and will be provided with information regarding this and care 
of the monitor. Patients will transfer their electronic monitor onto any new inhalers during the 
trial. Patients will be offered telephone support at any point during the study for monitor 
problems, including but not restricted to, problems with transfer onto new inhalers, damage, 
loss, malfunction.  For monitors that are lost, replacements will be provided and this will be 
recorded as an outcome for the study. Patients will be provided several electronic monitors 
each to account for multiple inhalers. If a patient’s inhaled therapy changes during study 
participation (for instance, due to a step-up in therapy), this data will be recorded at the 4 
weekly data collection via phone/text/email.  
Electronic Monitor Quality Control Process 
All monitors will be tested pre commencement of study for correct functioning prior to being 
used in the trial and will undergo a within-trial Quality Control process, in keeping with prior 
recommendations16. 
Malfunctioning monitors will be replaced and a process will be implemented whereby these 
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CLINICAL INVESTIGATION ASSESSMENTS 
 
 






Visit type  Run in Site visit Telephone call  Site visit 






Information sheet given X    
Information sheet discussed X X   
Informed consent  X   
Determine eligibility  X   
Randomisation  X   
Medical / asthma History  X   
ACT, mini AQLQ  X X X 
Spirometry and reversibility  X  X 
Fit electronic monitors  X   
Check inhaler technique  X   
Review written asthma plan (if already in 
place)/provide plan 
 X   
Provide information on electronic 
monitors 
 X   
Discuss feedback methods depending 
on group 
 X   
Letter to GP  X X (a) X 
Download data from monitors   X X 
Collect self-reported data on asthma 
exacerbations, change in asthma 
treatment, scheduled or unscheduled 
healthcare visits for asthma 
  X X 
Self-reported Adverse Event and 
Serious Adverse Event data  [respiratory 
events] 
  X X 
Review of adherence data, debriefing to 
all groups and letter to GP 
   X 
Perform semi-structured interview with 
selected participants  
   X 
Adherence questionnaire e.g. MARS-A 
(b) 
   X 
(a) If applicable: see section 10.1 – applies only to active monitoring group (Group B) 




Inhaler Technology Study 
Sponsor Reference Number: 14RM008 
IRAS ID: 193750 
Date and Version No: Final Version 1.5 09 Nov 2018 
 CONFIDENTIAL  Page 433 of 497 
 
 
Source documents are original documents, data, and records from which participants’ Case 
Report Form data are obtained.  These include, but are not limited to, hospital records (from 
which medical history and previous and concurrent medication may be summarised into the 
CRF), clinical and office charts, laboratory and pharmacy records, diaries, microfiches, 
radiographs, and correspondence. 
CRF entries will be considered source data if the CRF is the site of the original recording 
(e.g., there is no other written or electronic record of data). In this clinical investigation the 
CRF will be used as the source document for all study information required and collected.  
 
All documents will be stored safely in confidential conditions.  On all clinical investigation-
specific documents, other than the signed consent, the participant will be referred to by the 




Description of Statistical Methods 
This is a feasibility study and is planned to help inform the potential conduct a future larger 
definitive trial. 
Statistics: This is a feasibility study. For the primary outcome, a non-parametric distribution is 
anticipated. Appropriate non-parametric tests, such as the Mann Whitney test, will be used.  
Mixed-model analysis will be used to examine patterns of change with time. Health economic 
analysis will be performed. 
 
THE NUMBER OF PARTICIPANTS 
50 
 
THE LEVEL OF STATISTICAL SIGNIFICANCE  
P<0.05 
 
PROCEDURE FOR ACCOUNTING FOR MISSING, UNUSED AND SPURIOUS DATA 
The quality control processes detailed above should minimise the quantity of missing or 
spurious data.  Please see p.34 under Medical Devices section for details.  
 
PROCEDURES FOR REPORTING ANY DEVIATIONS(S) FROM THE ORIGINAL 
STATISTICAL PLAN 
To be reported in the final report. Any deviations from the Statistical Analysis Plan will be 
documented within the Trial Master File and will be reported in the final report, along with the 
justification for these deviations.  
 
INCLUSION IN ANALYSIS 
All randomised participants will be included within the analysis. 
 
SAFETY REPORTING 
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Adverse Event (AE) 
 
An AE or adverse event is: 
Any untoward medical occurrence in a patient or other clinical investigation participant taking 
part in a clinical investigation of a medical device, which does not necessarily have to have a 
causal relationship with the device under investigation.  
 
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom or disease temporally associated with the use of the device, 
whether or not considered related to the device. 
 
Adverse Device Effect (ADE) 
 
All untoward and unintended responses to the medical device.  
The phrase "responses to a medical device" means that a causal relationship between the 
device under investigation and an AE is at least a reasonable possibility, i.e., the relationship 
cannot be ruled out. 
 
All cases judged by either the reporting medically qualified professional or the sponsor as 
having a reasonable suspected causal relationship to the device qualifies as a device effect.   
 
This also includes any event resulting from insufficiencies or inadequacies in the instruction 
for use or deployment of the device and includes any event that is a result of a user error.  
 
Serious Adverse Event (SAE) 
 
SAE is an adverse event that  
 
 Led to death  
 Led to foetal distress, foetal death or congenital abnormality or birth defect.  
 Led to serious deterioration in the health of the subject that:  
 
 Resulted in a life-threatening illness or injury 
o NOTE: The term "life-threatening" in the definition of "serious" refers to an 
event in which the participant was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it 
were more severe. 
 Resulted in a permanent impairment of a body structure or a body function  
 Required in-patient hospitalisation or prolongation of existing hospitalisation  
 Resulted in medical or surgical intervention to prevent permanent impairment to a 
body structure or a body function  
 Other important medical events* 
o *Other events that may not result in death, are not life threatening, or do not 
require hospitalisation, may be considered a serious adverse event when, 
based upon appropriate medical judgement, the event may jeopardise the 
patient and may require medical or surgical intervention to prevent one of the 
outcomes listed above 
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To ensure no confusion or misunderstanding of the difference between the terms "serious" 
and "severe", which are not synonymous, the following note of clarification is provided: 
 
The term "severe" is often used to describe the intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); the event itself, however, may be of relatively 
minor medical significance (such as severe headache).  This is not the same as "serious," 
which is based on patient/event outcome or action criteria usually associated with events that 
pose a threat to a participant's life or functioning.  Seriousness (not severity) serves as a guide 
for defining regulatory reporting obligations. 
 
Serious Adverse Device Effects (SADE) 
 
A serious adverse device effect (SADE) is any untoward medical occurrence seen in a patient 
that can be attributed wholly or partly to the device which resulted in any of the characteristics 
or led to characteristics of a serious adverse event.  
 
SADE is also any event that may have led to these consequences if suitable action had not 
been taken or intervention had not been made or if circumstances have been less opportune.  
 
All cases judged by either the reporting medically qualified professional or the sponsor.  
 
Unanticipated Serious Adverse Device Effect (USADE) 
 
Any serious adverse device effect on health or safety or any life-threatening problem or death 
caused by, or associated with a device, if that effect, problem, or death was not previously 
identified in nature, severity or degree of incidence in the investigational plan or application 
(including a supplementary plan or application), or any other unanticipated serious problem 
associated with a device that related to the rights, safety or welfare of the subject. 
 
Reporting of AEs 
 
All AEs occurring during the clinical investigation observed by the investigator or reported by 
the participant, whether or not attributed to the device under investigation will be recorded on 
the CRF as specified in the clinical investigation plan.  All ADEs will be recorded in the CRF.  
 
The following information will be recorded: description, date of onset and end date, severity, 
assessment of relatedness to device, other suspect drug or device and action taken.  Follow-
up information should be provided as necessary.  
 
The relationship of AEs to the device will be assessed by a medically qualified investigator or 
the sponsor/manufacturer and will be followed up until resolution or the event is considered 
stable.  
 
All ADE that result in a participant’s withdrawal from the clinical investigation or are present at 
the end of the clinical investigation, should be followed up until a satisfactory resolution occurs. 
 
AE data relating to respiratory events/conditions will be collected at scheduled patient 
visits/contacts via participant self-report and by using standard questions: ‘Have you had any 
asthma or breathing-related problems since the last contact?’; ‘Is there anything new about 
your asthma or breathing that you wish to discuss?’ 
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ADE data will be collected at scheduled patient visits/contacts via participant self-report and 
by using standard questions: ‘Have you had any problems with the inhaler device?’ 
  
 
Reporting Procedures for all SAEs/ SADEs/ USADEs 
 
For studies of CE marked devices:  
All SAE/SADE/USADEs will be reported to the sponsor/legal representative and manufacture 
and NUH R&I within one working day of the investigator team becoming aware of them.  
 
All SAEs must be reported to R&I within one working day of discovery or notification of the 
event.   
Reporting to the MHRA, where required, will be done in liaison with the Chief Investigator and 
the Manufacturer.  
 
The Manufacturer has a legal obligation to report all events that need to be reported to the 
Nominated Competent Authority immediately (without any unjustifiable delay) after a link is 
established between the event and the device, but no more than: 
 
 2 days following the awareness of the event for Serious Public Health Threat. 
 10 days following awareness of the event for Death or unanticipated serious 
deterioration in health. 





In addition to the expedited reporting above, the CI shall submit once a year throughout the 
clinical investigation or on request a Safety Report to R&I, and the Research Ethics 
Committee. 
 
CLINICAL INVESTIGATION MANAGEMENT  
Clinical Investigation Management Group 
The following group will meet monthly to monitor progress of study.   
Dominick Shaw – Chief Investigator 
Mitesh Patel – co-investigator 
Research Nursing Team – screening, consent, patient visits, follow-up 
PhD student - screening, consent, patient visits, follow-up 
 
Inspection of Records 
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Investigators and institutions involved in the clinical investigation will permit clinical 
investigation related monitoring and audits on behalf of the sponsor and regulatory 
inspection(s).  In the event of an audit or monitoring, the Investigator agrees to allow the 
representatives of the sponsor direct access to all clinical investigation records and source 
documentation. In the event of regulatory inspection, the Investigator agrees to allow 




A risk assessment will be performed by the Sponsor to determine if monitoring is required and 
if so, at what level.  
 
Clinical Investigation Monitoring 
A Research Project Manager from Nottingham University Hospitals will visit the Investigator 
site prior to the start of the clinical investigation and during the course of the clinical 
investigation if required, in accordance with the monitoring plan. Monitoring will be performed 
according to ICH GCP. Data will be evaluated for compliance with the clinical investigation 
plan and accuracy in relation to source documents. Following written standard operating 
procedures, the monitors will verify that the clinical investigation is conducted and data are 
generated, documented and reported in compliance with the clinical investigation plan, GCP 
and the applicable regulatory requirements.  
GOOD CLINICAL PRACTICE 
 
DECLARATION OF HELSINKI  
The Investigator will ensure that this clinical investigation is conducted in full conformity with 
the current revision of the Declaration of Helsinki (last amended October 2000, with additional 
footnotes added 2002 and 2004). 
 
ICH GUIDELINES FOR GCP 
The Investigator will ensure that this clinical investigation is conducted in full conformity with 
relevant regulations and with the ICH Guidelines for Good Clinical Practice 
(CPMP/ICH/135/95) July 1996. 
 
APPROVALS 
The clinical investigation plan, informed consent form, participant information sheet and any 
proposed advertising material will be submitted to an appropriate Research Ethics Committee 
(REC), the Health Research Authority (HRA) and host institution(s) for written approval, where 
necessary.   
 
The Investigator will submit and, where necessary, obtain approval from the above parties for 
all substantial amendments to the original approved documents.    
 
PARTICIPANT CONFIDENTIALITY 
The clinical investigation staff will ensure that the participants’ anonymity is maintained.  The 
participants will be identified only by initials and a participants ID number on the CRF and any 
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electronic database.  All documents will be stored securely and only accessible by clinical 
investigation staff and authorised personnel. The clinical investigation will comply with the 
Data Protection Act which requires data to be anonymised as soon as it is practical to do so.   
 
Data Handling and Record Keeping 
 
The participants will be identified by a clinical investigation specific participant number and/or 
code in any database.  The name and any other identifying detail will NOT be included in any 
clinical investigation data electronic file.  
Interview data will be held on audio interview files and documents showing the transcribed 
recordings. A hard copy of data from the interviews will be kept securely in a locked filing 
cabinet within Clinical Sciences Building (University of Nottingham) for a period determined 
by the sponsor. Electronic files (including audio files) will be held securely on password 




CLINICAL INVESTIGATION CONDUCT RESPONSIBILITITES 
Clinical Investigation Plan Amendments 
Amendments to the clinical investigation plan must be submitted to the Sponsor for review 
before submitting to the appropriate REC, HRA and local R&I for approval. 
 
Clinical Investigation Plan Violations, Deviations and Serious Breaches 
The CI will not implement any deviation from the clinical investigation plan without agreement 
from the Sponsor, except where necessary to eliminate an immediate hazard to clinical 
investigation participants. 
In the event that the CI needs to deviate from the clinical investigation plan, the nature of and 
reasons for the deviation will be recorded in the CRF and notified to the Sponsor using the 
appropriate Deviation Form according to NUH SOP-RES-017. If this necessitates a 
subsequent clinical investigation plan amendment, this will be submitted to the Sponsor for 
approval and then to the appropriate REC, Health Research Authority and local NHS R&I for 
review and approvals as appropriate. It is Sponsor policy that waivers to the clinical 
investigation plan will not be approved. 
In the event that a serious breach of GCP is suspected, this will be reported to the Sponsor 
immediately. Refer to SOP-RES-017 “Non-Compliance and Serious Breach Reporting”. 
 
Clinical Investigation Record Retention 
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All clinical investigation documentation will be kept for 10 years from the clinical 
investigation plan defined end of clinical investigation point. When the minimum 
retention period has elapsed, clinical investigation documentation will not be destroyed 
without permission from the sponsor. 
 
End of Clinical Investigation 
 
The end of clinical investigation is defined as the last participant’s last visit.   
The Investigators and/or the clinical investigation steering committee and/or the co-sponsor(s) 
have the right at any time to terminate the clinical investigation for clinical or administrative 
reasons.  
 
The end of the clinical investigation will be reported to the REC within 90 days, or 15 days if 
the clinical investigation is terminated prematurely.  The Investigators will inform participants 
of the premature clinical investigation closure and ensure that the appropriate follow up is 
arranged for all participants involved. 
 
A summary report of the clinical investigation will be provided to the REC within 1 year of the 
end of the clinical investigation. 
 
Insurance and Indemnity 
 
NHS bodies are legally liable for the negligent acts and omissions of their employees. If you 
are harmed whilst taking part in a clinical investigation as a result of negligence on the part of 
a member of the clinical investigation team this liability cover would apply.  
Non-negligent harm is not covered by the NHS indemnity scheme. The Nottingham University 
Hospitals NHS Trust, therefore, cannot agree in advance to pay compensation in these 
circumstances. In exceptional circumstances an ex-gratia payment may be offered.   
 
Funding 
GSK have provided funding for the study. 
 
 
REPORTING, PUBLICATIONS AND NOTIFICATIONS OF RESULTS 
 
Authorship Policy 
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Ownership of the data arising from this clinical investigation resides with the sponsor, 
Nottingham University Hospitals.  On completion of the clinical investigation, the clinical 
investigation data will be analysed and tabulated, and a clinical investigation report will be 
prepared in accordance with ICH guidelines.  
 
Publication 
The report will be submitted to a peer-reviewed journal. 
PEER REVIEW 
This study has been peer reviewed by experts from: 
University of Nottingham (Professor of Epidemiology) 
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Appendix D: Patient information and consent 
Participant Information Sheet (MAIN) 
Version: 2.3 Date: 11th June 2018 
 
Study Title: Improving asthma treatment using inhaler technology 
 





You are being invited to take part in a research study. Before you decide 
whether or not to take part, it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the 
following information carefully, and discuss it with friends or family if you 
wish.  
 
PART 1 tells you the purpose of this study and what will happen to you if 
you take part. 
 
PART 2 gives you more detailed information about the conduct of the study. 
 
Ask us if there is anything that is not clear, or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
2. What is the purpose of the study? 
Although we aim to keep asthma symptoms controlled, lung function at its 
best and to reduce adverse effects from medicines, these aims are not 
always achievable. One way to better understand why this happens is by 
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Our aim is to involve 50 patients, all of whom have had at least one asthma 
attack in the past year. Each patient will be involved for 6 months and will 
be asked questions about their asthma. There are only 2 planned visits, 
either to the Nottingham Respiratory Research Unit or to your GP surgery if 
this has been agreed; one at the start and one at the end of the study. During 
the rest of the 6 months, the study team will keep in touch with you by phone, 
email or text message. The study is based at Nottingham University 
Hospitals NHS Trust. 
 
3. Why have I been chosen? 
You have been chosen because you have been diagnosed with asthma, are 
prescribed a preventer (steroid) inhaler for your asthma, and have had at 
least one asthma attack in the past year where you have needed tablet 
steroids (or more than your usual dose if you already take tablet steroids 
every day). You will also already be using a mobile phone that can connect 
to the Internet (for example, to check your email or to use Facebook). 
 
4. Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form to confirm that you understand what is involved when taking 
part in this study. If you decide to take part you are free to leave the study 
at any time and without giving a reason.  If you withdraw, unless you object, 
we will still keep records relating to the treatment given to you, as this is 
valuable to the study.  A decision to withdraw at any time, or a decision not 
to take part, will not affect the quality of care you receive 
 
5.  What will happen to me if I take part? 
If after reading this information sheet and talking to a member of the 
research team, you would like to take part in this study, you will be seen at 
Nottingham City Hospital in the Nottingham Research Respiratory Unit (or 
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at your GP surgery if this has been agreed) and asked to sign a consent 
form to give us permission to involve you in the study.  
This first visit takes about 1 hour and the following will take place: 
 
a. Information about your asthma: we will ask you about your 
asthma history and also look at your medical records from the 
hospital and your GP (where possible) to get as much information 
about your asthma as possible 
b. Questionnaires: you will fill out questionnaires on your current 
asthma symptoms (every 4 weeks) and your medications 
c. Spirometry: we will measure the amount of air that you can 
breathe out. You will be asked to blow as hard as you can into a 
tube which is connected to a recording device and repeat this 
several times. We will then give you 4 puffs of salbutamol, wait 15 
minutes and ask you to repeat the test. You may have to withhold 
some of your usual inhalers a few hours before this test, but we will 
let you know in advance (you may have done this test before at 
your GP practice).  
d. New inhalers casings provided: To allow us to collect information 
about your asthma, you will be provided with new inhaler casings 
that clip around your current preventer and reliever inhalers. The 
casings help tell us how well controlled your asthma is. The casings 
link up to your mobile phone and send this information back to us 
via the internet. We will show you how to swap over the casings 
onto your new inhalers that you use during the study. 
e. Inhaler technique and asthma action plan: we will provide you 
with a written asthma action plan and check your inhaler technique.  
 
Your participation in the study lasts for 6 months. After this first visit, you will 
complete a questionnaire about your asthma, and the new casings once 
every month and we will contact you (by text, email or phone) to remind you 
if needed. Otherwise, you can go about your daily life as usual. We will make 
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an appointment to see you at Nottingham City Hospital or at your GP surgery 
at the end of the study. This final visit will take about 1 hour. We will measure 
your spirometry (as above), find out how your asthma has been over the 
past 6 months and collect your inhaler casings. We will also discuss how 
you felt about using the new casings. 
 
You may also be asked at the end of the study if you would like to take part 
in an interview with one of our research team, where you will be asked about 
your experience in the trial. This conversation will be audio recorded so the 
research team can concentrate on what you are saying without having to 
take notes. Interviews will then be transcribed anonymously. Anonymised 
quotes from these transcriptions may be used publications generated from 
this study. 
We will give you contact details for our research team in case you have any 
questions over the 6 months.    
 
6. What do I have to do?  
You should carry on as normal; this study should not affect your lifestyle and 
you should continue to take your normal medication as per usual. 
 
The day-to-day care of your asthma with remain in the hands of your 
General Practitioner (GP).  If during the study you have an asthma attack, 
you should go to see your GP, or go to an out-of-hours clinic/call 111 or the 
hospital emergency department (ED) and seek medical care - you will 
receive the same care and treatment as you would do if you were not 
involved in the study.  Your asthma action plan will also provide you with 
guidance as to when to seek help or start a course of tablet steroids for your 
asthma 
 
7.  What is the drug / treatment that is being tested? 
We are not testing any drugs in this study – you will continue to use your 
usual current inhaled preventer and reliever asthma treatments.  
 
 
Page | 449  
 
IRAS ID: 193750   NUH03004S 
14RM008 Inhaler Technology Study PIS (Main) 





8. What are the alternatives for diagnosis or treatment? 
If you choose not to take part in the study, your care will not be affected and 
you will continue to be treated as per usual. 
 
9. What are other possible disadvantages and risks of taking part? 
Performing spirometry can make you feel light-headed and short of breath, 
but the test is generally very safe. 
If you do decide to take part in the study, you must report any problems you 
have to your study nurse or doctor. There is also a contact number given at 
the end of this information sheet for you to phone if you become worried at 
any time. In the unlikely event of an emergency occurring during the conduct 
of the study, we may contact your nominated next of kin. 
If you notice any problems with the inhaler casings or if any become lost, we 
will give you contact details for our team so that we can repair/replace them.   
 
10. What are the possible benefits of taking part?  
We cannot promise the study will help you, but it is hoped that we will be 
able to learn about asthma attacks and medication use. This will allow us to 
better understand and plan future care for people with asthma.  
 
11. What happens when the research study stops? 
We will review your progress in the 6 months of the study with you at your 
final study visit.  We intend to publish the results in a scientific respiratory 
journal. A summary of the results will be available to you should you wish.  
The device is for research purposes only at present and will therefore not 
be available to you after the study has finished.  
 
12. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to 
speak with the researchers who will do their best to answer your question.  
If you remain unhappy and wish to complain formally, you can do this 
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through the NHS Complaints Procedure.  Details can be obtained from the 
hospital or you can contact PALS (Patient Advice and Liaison Service) 
telephone 0800 183 0204. 
 
In the unlikely event that something does go wrong and you are harmed 
during the research study there are no special compensation arrangements.  
If you are harmed and this is due to someone’s negligence then you may 
have grounds for a legal action for compensation but you may have to pay 
your legal costs.  The normal National Health Service complaints 
mechanisms will still be available to you. 
 
13.  Will travel expenses and phone data charges be reimbursed? 
Yes, mileage/travel allowance will be available. You will also receive an 
allowance for phone data charges (maximum £20 allowance overall for 6 
months). 
 
14. Will my taking part in this study be kept confidential? 
Yes.  All the information about your participation in this study will be kept 
confidential.  Details are included in Part 2. 
 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 
before making any decision. 
 
PART 2 
15.  What if new information becomes available? 
Sometimes during the course of a clinical trial, new information becomes 
available. If this  
happens, we will tell you about it and discuss with you whether you want to 
or should continue in the study. If you decide to withdraw, we will make 
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arrangements for your care to continue. If you decide to continue in the study 
you will be asked to sign an updated consent form. 
 
On receiving new information, we might consider it to be in your best 
interests to withdraw you from the study. If so, we will explain the reasons 
and arrange for your care to continue. 
 
If the study is stopped for any other reason, you will be told why and 
your continuing care will be arranged. 
 
16. What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time but we will use the data 
collected up to your withdrawal. We will also need to collect the inhaler 
casings that we have provided you.  
 
17. Will my part in this study be kept confidential? 
If you consent to take part in this study, the records obtained while you are 
in this study as well as related health records will remain strictly confidential 
at all times. The information will be held securely on paper and electronically 
at your treating hospital and at Nottingham University Hospitals NHS Trust 
under the provisions of the General Data Protection Regulation. Your name 
will not be passed to anyone else outside the research team or the sponsor, 
who is not involved in the trial. You will be allocated a trial number, which 
will be used as a code to identify you on all trial forms. 
 
If you withdraw consent from further study treatment, unless you object, your 
data and samples will remain on file and will be included in the final study 
analysis. 
 
Your records will be available to people authorised to work on the trial but 
may also need to be made available to people authorised by the Research 
Sponsor, which is the organisation responsible for ensuring that the study is 
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carried out correctly. A copy of your consent form may be sent to the 
Research Sponsor during the course of the study. By signing the consent 
form you agree to this access for the current study and any further research 
that may be conducted in relation to it, even if you withdraw from the current 
study.  
 
The information collected about you may also be shown to authorised 
people from the UK Regulatory Authority and Independent Ethics 
Committee; this is to ensure that the study is carried out to the highest 
possible scientific standards.  All will have a duty of confidentiality to 
you as a research participant. 
 
In line with Good Clinical Practice guidelines, at the end of the study, your 
data will be securely archived for a minimum of 15 years. Arrangements for 
confidential destruction will then be made.  
 
With your permission on the Consent form, your GP (and other doctors who 
may be treating you) will be notified that you are taking part in this study. 
 
18. Use of your personal data in research 
Nottingham University Hospitals NHS Trust is the sponsor for this study 
based in the United Kingdom. We will be using information from you and/or 
your medical records in order to undertake this study and will act as the data 
controller for this study. This means that we are responsible for looking after 
your information and using it properly. Nottingham University Hospitals NHS 
Trust will keep identifiable information about you until study closure. 
Your rights to access, change or move your information are limited, as we 
need to manage your information in specific ways in order for the research 
to be reliable and accurate. If you withdraw from the study, we will keep the 
information about you that we have already obtained. To safeguard your 
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You can find out more about how we use your information www.nuh.nhs.uk. 
 
Nottingham Respiratory Research Unit (NRRU, which is a part of 
Nottingham University Hospitals NHS Trust) and the East Midlands Primary 
Care Network (PCRN) will collect information from you and/or your medical 
records for this research study in accordance with our instructions. 
 
Nottingham Respiratory Research Unit and the East Midlands PCRN will 
use your name, date of birth, NHS number and contact details to contact 
you about the research study, and make sure that relevant information about 
the study is recorded for your care, and to oversee the quality of the study. 
Individuals from Nottingham University Hospitals NHS Trust and regulatory 
organisations may look at your medical and research records to check the 
accuracy of the research study. The NRRU and East Midlands PCRN will 
pass these details to Nottingham University Hospitals NHS Trust (the study 
Sponsor) along with the information collected from you and/or your medical 
records. The only people in Nottingham University Hospitals NHS Trust who 
will have access to information that identifies you will be people who need 
to contact you for the purpose of study oversight or audit the data collection 
process. The people who analyse the information will not be able to identify 
you and will not be able to find out your name, NHS number or contact 
details. 
 
The NRRU and East Midlands PCRN will keep identifiable information about 
you from this study until study closure. 
 
Data collected during the study may be transferred for the purpose of 
processing, analysis, etc to associated researchers within/outside the 
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Your asthma control data will be stored on a password-protected website. 
The website will not contain any identifiable information about you and will 
use a code that is only known to researchers.  
 
If you are willing to participate in the final interview, anonymous quotes taken 
from this interview may be published. Neither the transcriptions of this 
interview nor any of these quotes will contain any identifiable information 
about you. 
 
19.  Informing your General Practitioner (GP) 
With your permission on the Consent Form, your GP (and other doctors who 
may be treating you) will be notified that you are taking part in this study. 
Your GP (and other doctors who may be treating you) will also be provided 
information on your progress at the end of the study. 
If you take a course of steroids for your asthma, either in tablet or liquid form 
or into your veins in hospital, then we would like you to make a note of the 
date this treatment started together with how many days you were treated 
for; you will be asked about this at each study vists This is so that we can 
keep a record of when your asthma has been troublesome.  We will ask for 
your permission on the Consent Form to obtain further information about 
your health from the hospital or GP records.  To make sure that we have all 
the information we need about the attack, we will need to contact the health 
service provider involved to check the medical details. 
 
20.  What will happen to any samples I give? 
We are not taking any samples. 
 
21. Will any Genetic testing be done? 
No. 
 
22. What will happen to the results of this clinical trial? 
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The results of the study will be available after it finishes and will usually be 
published in a medical journal or be presented at a scientific conference. 
The data will be anonymous and none of the patients involved in the trial will 
be identified in any report or publication.  
 
Should you wish to see the results, or the publication, please ask your study 
doctor.  
 
23. Who is organising and funding this clinical trial? 
The Nottingham University Hospitals NHS Trust will act a sponsor the 
research.  GlaxoSmithKline has provided funding for the study.  
 
24. Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people 
called a Research Ethics Committee, to protect your safety, rights, well-
being and dignity.  This study has been reviewed and given a favourable 
opinion by the NHS by London Central Research Ethics Committee. 
 
The study has also been reviewed and approved by the Research & 
Innovation department of Nottingham University Hospitals NHS Trust. 
 
25. Contact for further information 
You are encouraged to ask any questions you wish, before, during or after 
your treatment. If you have any questions about the study, please speak to 
your study nurse or doctor, who will be able to provide you with up to date 
information about the intervention involved. If you wish to read the research 
on which this study is based, please ask your study nurse or doctor. If you 
require any further information or have any concerns while taking part in the 
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If you decide you would like to take part then please read and sign the 
consent form. You will be given a copy of this information sheet and the 
consent form to keep. A copy of the consent form will be filed in your patient 
notes, one will be filed with the study records and one may be sent to the 
Research Sponsor. 
 
You can have more time to think this over if you are at all unsure. 
 




26. Contact Details 
Doctor 
Name Dr Ireti Adejumo 
Tel. Number: 0115 82 31935 
 
Research/Specialist Nurses 
Name Mrs Norma Thompson   Name: Miss Clair Parrish 
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Participant Information Sheet (Group B) 
Version: 2.3 Date: 11th June 2018 
 
Study Title: Improving asthma treatment using inhaler technology 
 
Principal Investigator: Dr Dominick Shaw 
 
You are receiving this information sheet because you have previously 
consented to take part in the study “Improving asthma treatment using inhaler 
technology”. Participation in this study involves randomisation into one of two 
groups: This randomisation was done by a computer, equivalent to picking 
names out of a hat.  
 
You have been randomly selected to be in the Group B  
 
Group B 
This means that every 4 weeks the researcher will contact you by phone, email 
or text message to give you feedback on your medication use, which is 
measured via the inhaler casings.  You will also get feedback on how well your 
asthma is controlled. The Researcher may advise you to seek care from your 
GP if your asthma is not well-controlled.  
 
Please refer back to the previous information sheet you were provided (Version 
2.3 dated 11th June 2018) as well as the information provided in this sheet to 
inform your decision of whether or not you want to continue to take part in the 
study.  
 
If you any further questions please speak to the researcher or research nurse.  
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Dr Ireti Adejumo        Tel. Number: 0115 82 31935 
 
Research/Specialist Nurses:  
Mrs Norma Thompson        Tel. Number: 0115 82 31315 
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Participant Consent Form (Main) 
Version:   2.3  Date: 11th June 2018 
 
Improving asthma treatment using inhaler technology 
Principal Investigator: Dr Dominick Shaw 
 
Patient Study ID: …..………………..  Initials: ………………  
  
Patient initial each box 
1. I confirm that I have read and understand the information 
sheet version 2.3 dated 11th June 2018 for the above study 
and have had the opportunity to ask questions.  
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time without my medical care or legal 
rights being affected. 
 
3. I understand that my medical records may be looked at by 
authorised individuals from the Sponsor for the study and the 
UK Regulatory Authority in order to check that the study is 
being carried out correctly.  
 
4. I understand that even if I withdraw from the above study, the 
data collected from me will be used in analysing the results of 
the trial, unless I specifically withdraw consent for this.  
 
5. I consent to the storage including electronic, of personal 
information for the purposes of this study. I understand that 
any information that could identify me will be kept strictly 
confidential and that no personal information will be included 
in the study report or other publication. 
 
6. I agree that my GP, or any other doctor treating me, will be 
notified of my participation in this study and will be contacted 
if there are any concerns about my health.  
 
7. I agree to allow researchers to view my medical records (for 
example, GP or hospital records) to collect information that is 
related to my asthma or this study.   
 
8. I consent to medication use data being stored on a password-
protected website, which may be hosted outside England.  
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_______________________________    ______________  




Patient’s signature  
   
 
 
_______________________________    ______________  




   
 
 
Original to be retained and filed in the site file, 1 copy to patient, 1 copy to be filed in 
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Improving asthma treatment using inhaler technology 
Principal Investigator: Dr Dominick Shaw 
 
Patient Study ID: …..………………..  Initials: ………………  
  
Patient initial each box 
1. I confirm that I have read and understand the information sheet 
version (B) 2.3 dated 11th June 2018 for the above study and 
have had the opportunity to ask questions.  
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time without my medical care or legal 
rights being affected. 
 
3. I understand that my medical records may be looked at by 
authorised individuals from the Sponsor for the study and the 
UK Regulatory Authority in order to check that the study is 
being carried out correctly.  
 
4. I understand that even if I withdraw from the above study, the 
data collected from me will be used in analysing the results of 
the trial, unless I specifically withdraw consent for this.  
 
5. I consent to the storage including electronic, of personal 
information for the purposes of this study. I understand that 
any information that could identify me will be kept strictly 
confidential and that no personal information will be included 
in the study report or other publication. 
 
6. I agree that my GP, or any other doctor treating me, will be 
notified of my participation in this study and will be contacted 
if there are any concerns about my health.  
 
7. I agree to allow researchers to view my medical records (for 
example, GP or hospital records) to collect information that is 
related to my asthma or this study. 
 
8. I consent to medication use data from my inhaler being stored 
on a password-protected website, which may be hosted 
outside England.  
9. I agree to my inhaler medication use being sent to researchers. 
I understand that I     may be contacted to discuss my asthma. 
11. I agree to take part in the study 
 
 
Participant Consent Form (B) 
Version:   2.3      Date:      11th June 2018 
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_______________________________    ______________  
Name of the patient (Print)    date   
  
_______________________________ 
Patient’s signature  
   
 
 
_______________________________    ______________  





Original to be retained and filed in the site file, 1 copy to patient, 1 copy to be filed in 
patient’s notes  
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Participant Consent Form 
(Qualitative Interview) 
Version:   1.2  Date: 11th June 2018 
 
Improving asthma treatment using inhaler technology 
Principal Investigator: Dr Dominick Shaw 
 
Research Fellow: Dr Ireti Adejumo 
 
 
Patient Study ID: …..………………..  Initials: ………………  
  
Patient initial each box 
1. I confirm that I have read and understand the information 
sheet version 2.3 dated 11th June 2018 for the above 
study and have had the opportunity to ask questions.  
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time without my medical care 
or legal rights being affected. 
 
3. I consent to participate in the ‘qualitative interview’ part of 
this study. 
 
4. I understand that this will involve an audio recording of the 
interview and that this recording will be kept for use in the 
study.  
 
5. I understand that the audio recording of the interview will 
not use any personal identifiers to identify me.  
 
6. I understand that the audio recording of the interview may 





_______________________________    ______________  
Name of the patient (Print)    date   
  
_______________________________ 
Patient’s signature  
   
 
_______________________________    ______________  
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Original to be retained and filed in the site file, 1 copy to patient, 1 copy to be filed in 
patient’s notes  
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Appendix E: Semi-structured interview guide 
The interview guide 
 
Semi-Structured Interview Guide 
1. Introduction 
Explain the purpose of the interview in general: 
‘We would like to hear how you felt about: 
- Your participation in the Smartinhaler™ study 
- Your views on the device 
- Your views on the collection of personal electronic data from your Smartinhaler™ 
- Your views on the collection of personal electronic data from your mobile phone.’ 
Check consent form has been signed and check still happy to take part. 
1. Give statement on confidentiality, right to withdraw consent, recording 
of the interview: 
‘We would like to reassure you that all data relating to yourself will be kept 
strictly confidential by the research team. The recording of this interview and 
any quotes used in study reports will not identify you in any way. Your 
participation is entirely voluntary and you are free to stop the interview at any 
time without giving a reason.We will retain any information collected to this 
point unless you specify otherwise.’ 
2. Ask if the participant has any questions before starting the interview. 
3. Explain that the interview will last between 30 and 45 minutes. 
 
 






Discussion of baseline asthma control 
1. Tell me about your asthma – how is it normally? – how does it affect 
you? 
2. How long have you had asthma for? How has it been treated over the 
years? 
3. To what extent do you feel you’re in control of your asthma? 
a. How often you’re getting symptoms 
b. The effect it’s having on your life 
c. The number of times you’re needing to see your GP/go to hospital 
4. What did you think of your inhalers prior to enrolling in the study? 
a. Did you feel you needed them? 
b. How effective were they for your asthma? 
c. According to your prescription, how regularly was your preventer inhaler 
meant to be used? 
d. How regularly did you use your preventer? Explore. 
e. Did you use any prompts to remember to use your preventer (e.g. 
phone alarms, calendar reminders)? 
f. How did you feel about using them publicly? 
 
Exploration of baseline health beliefs 
1. How important do you feel it is to take your preventer inhaler regularly? 
a. If I made the statement “Regular use of your inhalers as prescribed is 
crucial to preventing your asthma from getting worse or flaring up,” would 
you find yourself able to agree or would you have to disagree? 
b. What makes you feel this way? 
2. How important do you feel it is to take your other asthma medication 
regularly? 
a. What makes you feel this way? 
3. Smartinhaler™ Experience 
Discussion opening 
1. Can you share your general thoughts on the device you have been 
using? 
a. What did you think of it? 
b. How did it compare to using your inhaler without the device? 
c. How easy was it to carry around? Is this any different to your normal 
inhaler? 
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3. Smartinhaler™ Experience 
Exploration of perceived impact on inhaler usage 
subsequent to being informed of monitoring 
1. To what extent do you think your participation in the study impacted 
the use of your inhaler? 
a. Did it impact how regularly you used your preventer? 
b. Did it impact how regularly you used your reliever? 
c. Do you feel it changed how you used your inhalers in any other way? 
d. Do you feel it changed how important you feel taking your preventer 
regularly is? 
2. I asked earlier whether you used any prompts before to remind you to 
use your inhalers. 
a. Did you find you used any prompts during the study? 
b. Did you find yourself more or less in need of those prompts during the 
study? 
Discussion of response to feedback 
1. Can you tell me about any feedback you received? 
a. Through the smartphone app? 
b. From your GP/practice nurse? 
c. From your hospital clinician? 
d. From any other sources? 
2. How did the feedback make you feel? 
3. How useful was the feedback? 
4. How clear was the feedback? 
5. Can you suggest any ways in which the provision of the feedback could 
be improved? 
Discussion of effect of participation on other aspects of 
self-management. 
1. To what extent has participation in the study helped with how well your 
asthma has been controlled? 
a. How often you’re getting symptoms 
b. The effect it’s having on your life 
c. The number of times you’re needing to see your GP/go to hospital 
2. To what extent has participation in the study helped with how well you 
have been able to take control of your asthma? 








3. Smartinhaler™ Experience 
Exploration of reaction to monitoring 
1. What were you told about the device when it was given to you? 
2. Were you aware that the way you used the inhaler was being 
monitored? 
a. If yes: what do you think was being monitored? 
i. What did you think about this? How did it make you feel? 
ii. If you hadn’t been aware you were being monitored, would that 
change how you feel now? 
iii. To what extent did knowing you were being monitored change the 
way used your inhaler? 
b. If no: what do you think might have been monitored? 
i. Explain monitoring took place 
ii. Explain what was monitored 
iii. ‘How do you feel about this?’ 
iv. If you had been aware ……… was being monitored, would that change 
how you feel now? 
4. Data Capture 
1. If, in the future, we started monitoring inhalers like we did with you, 
who, in your opinion, should be responsible for keeping an eye on the 
data? 
a. E.g. You? Your GP/practice nurse? The hospital? 
b. What makes you feel this way? 
2. Where do you feel that healthcare-related data like this should be 
stored? (NB these are NOT your medical records) 
a. E.g. on the company’s database? On a GP or hospital database? 
3. If, in the future, we started monitoring inhalers like we did with you, 
who, in your opinion, should be responsible for providing the feedback? 
a. E.g. Your GP/practice nurse? The hospital? A dedicated lay service? 
b. How should it be provided? (text, email, web link, phone call etc) 
4. Who do you feel has the ultimate responsibility for your asthma at the 
moment? 
a. Who should have/would you like to have responsibility for it? 








4. Data Capture 
5. How would you feel about data on how you use your inhaler being 
linked to data on your asthma triggers (local pollen levels, for example)? 
a. How would you feel about the use of location tracking via GPS to 
increase the accuracy of this? 
b. Do you feel there is a possibility this could be used to help with your 
asthma? 
6. How would you feel about linking information from fitness or healthcare 
apps you already use or might use in the future to give us more 
information relevant to your asthma? 
7. Is there anything else you feel we could collect data on that might help 
us get a better idea of the factors involved in what makes your asthma 
easy/hard to control? 
8. Is there any type of data capture (information on your asthma that we 
could collect using technology) that makes you nervous? 
9. Who do you think should or shouldn’t have access to this sort of data? 
5. Future applications 
1. Would you consider using a Smartinhaler™ regularly? 
a. What are the main reasons you think/don’t think so? 
2. How would you feel if your GP or consultant provided you with a 
Smartinhaler™ permanently/for a short period of time? 
3. How do you think your GP or consultant might use the data obtained 
from it? 
4. How would you feel if your GP or consultant/another healthcare 
professional/a nonhealthcare professional: 
a. Discussed the data they had obtained from it with you? 
b. Asked you to change something based on this data? 
c. Carried out an emergency intervention based on this data? 
d. Used it to monitor your response to treatment? 
5. How often do you think these discussions should take place? E.g. 
monthly, as and when needed 
6. How would you feel if this information was shared with other members 
of your healthcare team? 
7. How would you feel about this data being used to inform what 
treatment you are/are not prescribed? 
a. For example, we may consider using them to tell us if people can start 
newer medications for asthma in the future. How would you feel about 
them being used in this way? 
b. If Smartinhalers™ were to be used in this way, do you think they would 
impact the way your GPs interact with you? E.g. your annual asthma 
review 
i. If so, how? If not, why? 
ii. How do you feel about this? 
 
 






6. Smartinhaler™ going forward 
1. Can you think of any ways in which the Smartinhaler™ could be 
designed differently? 
a. Is there anything in the design of the device that: 
i. Could be improved? 
ii. Would make it easier to use? 
iii. Would make you more likely to want to use it? 
b. Is there anything in the design of the app that: 
i. Could be improved? 
ii. Would make it easier to use? 
iii. Would make you more likely to want to use it? 
2. How would you feel if there was no casing at all and the Smartinhaler™ 
was just part of your inhaler? 
3. Would you ever consider purchasing a Smartinhaler™ for use yourself? 
Why/why not? 
4. How much do you think the Smartinhaler™ costs? 
a. What do you think about the cost? 
b. How does this affect whether you would consider purchasing one? 
5. Can you think of anything else the Smartinhaler™ might add 
a. To your current care? 
b. To the way we manage asthma in general? 
7. Closing Remarks 
1. Is there anything that we haven’t talked about that is important to you 
and that 
you’d like to add? 
2. Do you have any questions for me? 
3. Thank the participant for their time. 
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